

Health and Labour Sciences Research Grants 2015
Research on Regulatory Science of Pharmaceuticals and Medical Devices:
(H27-Iyaku A-Ippan-001)

2015 Nationwide General Population Survey on Drug Use in Japan

Principal Investigator: Takuya SHIMANE
Department of Drug Dependence Research,
National Institute of Mental Health,
National Center of Neurology and Psychiatry

March 2017

Annual Report
2015 Nationwide General Population Survey on
Drug Use in Japan

2015 Nationwide General Population Survey on Drug Use in Japan

Principal Investigator: Takuya SHIMANE (National Center of Neurology and Psychiatry)
Research Collaborators: Megumi OMAGARI (National Center of Neurology and Psychiatry),
Kiyoshi WADA (Saitama Psychiatric Medical Center), and
Dongmei QIU (National Center of Neurology and Psychiatry)

Abstract

[Objective] This survey was conducted to examine the current situation of drug use, including alcohol, tobacco, and medications, in Japan. The findings will be provided as basic data for a drug abuse prevention strategy. This survey is the only monitoring survey on drug use conducted for the general population in Japan. Since the first nationwide survey in 1995, this series of surveys has been conducted every other year, and this survey is the 11th one.

[Methods] A total of 5,000 individuals aged 15–64 years were sampled from the Basic Resident Register using a two-stage stratified random sampling method (number of survey spots: 350). A self-administered questionnaire (anonymous) was handed out to each individual selected and was then collected from September to October 2015. The study protocol was reviewed and approved by the Ethics Committee of the National Center of Neurology and Psychiatry.

[Results] The questionnaires were collected from a total of 3,085 respondents (response rate: 61.7%). The following findings were obtained from valid responses from a total of 3,076 individuals (52.3% of which were females, with a mean age of 43.3 years):

1. The lifetime prevalence of new psychoactive substance (NPS) use decreased from 0.4% (2013) to 0.3% (2015), and the past-year prevalence decreased from 0.1% (2013) to 0% (2015).
 2. The number of individuals in the population with lifetime use of NPSs decreased from approximately 400,000 (2013) to 310,000 (2015).
 3. The proportion of respondents having knowledge of harmful effects of NPSs increased from 61.5% (2013) to 85.8% (2015), with 56.9% of respondents having knowledge of Japan's regulations for designated substances and measures to prevent NPS use.
 4. The lifetime prevalence of drug use was 1.5% for organic solvents, 1.0% for cannabis, 0.5% for methamphetamine, 0.1% for MDMA, 0.1% for cocaine, 0.3% for NPSs, and 2.4% for any drug. The rate for heroin was within the range of statistical errors.
 5. The mean age of drug users was 47.9 years for organic solvents, 41.3 years for cannabis, 44.1 years for methamphetamine, 40.0 years for MDMA, 45.4 years for cocaine, 45.7 years for heroin, 40.8 years for NPSs, and 45.5 years for any drug.
-

-
6. The number of individuals in the population with lifetime drug use was approximately 1.38 million for organic solvents, 0.95 million for cannabis, 0.50 million for methamphetamine, 0.12 million for cocaine, 0.12 million for MDMA, and 0.31 million for NPSs. All these figures decreased from those of 2013.
 7. In general, the number of individuals in the population who have ever had someone try to tempt them with illegal drugs was also decreasing, except for methamphetamine (increasing from approximately 0.93 million to 0.94 million) and MDMA (increasing from approximately 0.42 million to 0.58 million).
 8. The past-year prevalence of analgesic use increased from 34.3% (1995) to 62.9% (2015). The rate of chronic use of analgesics (≥ 3 times/week) increased from 1.6% (1999) to 2.5% (2015).
 9. The past-year prevalence of hypnotic use increased between 1995 (4.0%) and 2007 (7.7%), followed by a decrease, and then by a re-increase in 2015 (6.1%). Similarly, the rate of chronic use of hypnotics reached its peak in 2007 (2.7%) and subsequently decreased in 2011 (1.9%), but it increased again in 2015 (2.9%).

[Discussion] The number of respondents with lifetime use of NPSs decreased, and the past-year prevalence of the use of such was 0%. Behind this may lie the expansion of designated substances (2,297 substances as of May 2015) and the reinforcement of regulations regarding such designated substances (including orders of scientific testing, sales suspension, and advertisement suspension), which eliminated shops and websites selling NPSs and led to reduced opportunities for obtaining NPSs. The social issue regarding NPSs is considered to be calming down. However, approximately 20% of respondents answered that NPSs are “available,” suggesting the necessity of continuous measures to prevent NPS abuse.

Based on the estimated number of individuals in the population with lifetime drug use, the use of organic solvents, cannabis, methamphetamine, cocaine, and MDMA have all decreased from the 2013 survey. It should be noted, however, that the number of individuals in the population who have ever had someone try to tempt them with illegal drugs is increasing both for methamphetamine and MDMA.

A. Objective

As shown in the Fourth Five-Year Drug Abuse Prevention Strategy (2013), the annual number of persons arrested for methamphetamine-related crimes is more than 10,000, and the proportion of repeat methamphetamine offenders has been more than 60%. Also, as indicated in “Emergency Countermeasures to Eradicate New Psychoactive Substance Abuse (2014),” in recent years the widespread use of new psychoactive substances (NPSs) sold as “legal herbs” has been leading to the continual occurrence of crimes and serious fatal traffic accidents caused by abusers, posing a significant social problem.

As the issue of drug abuse is constantly in flux along with the times and with social change, measures against drug abuse should be in line with actual conditions. For this purpose, a monitoring survey to understand the actual circumstances of drug abuse and dependence over time is necessary. In addition, the fact where not only illegal drugs, including narcotics and methamphetamine, but also some medications are subject to abuse requires the monitoring of the use of medications as well as illegal drugs.

This survey is the only monitoring survey on drug use conducted on the general population in Japan. The history of general population surveys on drug use dates back to the 1990s. Such were conducted in Ichikawa City, Chiba Prefecture (n = 1,100) in 1992, in the Tokyo and Osaka areas (n = 3,000) in 1993, and in the Tokyo, Osaka, and Kita-Kyushu areas (n = 3,300) in 1994. This survey was conducted as the first nationwide survey in 1995, followed by surveys conducted every two years. To date, a total of 11 surveys,

including this report, have been conducted.

The findings from the study will be provided as basic data for the drug abuse prevention strategy in Japan. They will also be useful for the evaluation of various drug abuse prevention strategies and the process of planning for future countermeasures. Furthermore, it should be emphasized that the study findings can be used as basic data for the consideration of the proper use of alcohol, tobacco, and medications.

When considering the trend of drug abuse in recent years, abuse of NPSs cannot be ignored. According to a Nationwide Mental Hospital Survey on Drugrelated Psychiatric Disorders (from September to October in 2014), among patients who had used any drug in the past one year, NPS abusers accounted for the largest portion, exceeding that of methamphetamine abusers. To deal with the social issue regarding NPSs, the scope of designated substances was expanded (2,297 substances as of May 2015), and the minister of the Ministry of Health, Labour and Welfare and prefectural governors were granted the right to issue orders for scientific testing and the suspension of sales and/or advertisement to manufacturers (revised in December 2014), under the *Law on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices* (the former *Pharmaceutical Law*).

These measures have led to the elimination of NPS dealers, and it is expected that the number of NPS abusers is decreasing. Yet, no evidence of such a decrease in abusers has been obtained. In this report, we particularly focused on the trend of NPS abuse.

B. Methods

1. Target population and sampling

Sample size: 5,000 individuals (number of survey spots: 350)

Sampling method: Two-stage stratified random sampling method

Duration of survey: From September 10 to October 4, 2015

Sampling: In this study, a total of 5,000 individuals aged 15–64 years living in Japan were sampled using a two-stage stratified random sampling method. The sampling method is outlined as follows.

1) All 47 prefectures of Japan were divided into the following 11 geographic areas:

- ① Hokkaido area: Hokkaido
- ② Tohoku area: Aomori, Iwate, Miyagi, Akita, Yamagata, and Fukushima
- ③ Kanto area: Ibaraki, Tochigi, Gunma, Saitama, Chiba, Tokyo, and Kanagawa
- ④ Hokuriku area: Niigata, Toyama, Ishikawa, and Fukui
- ⑤ Tōsan area: Yamanashi, Nagano, and Gifu
- ⑥ Tokai area: Shizuoka, Aichi, and Mie
- ⑦ Kinki area: Shiga, Kyoto, Osaka, Hyogo, Nara, and Wakayama
- ⑧ Chūgoku area: Tottori, Shimane, Okayama, Hiroshima, and Yamaguchi
- ⑨ Shikoku area: Tokushima, Kagawa, Ehime, and Kochi
- ⑩ Kita-Kyūshū area: Fukuoka, Saga, Nagasaki, and Oita
- ⑪ Minami-Kyūshū area: Kumamoto, Miyazaki, Kagoshima, and Okinawa

2) Each of the 11 areas was further stratified into five community sizes with a total of 65 strata (Table A).

- ① Large cities: 23 wards of Tokyo metropolitan, Yokohama City, Kawasaki City, Kyoto City, Chiba City,

Nagoya City, Osaka City, Saitama City, Shizuoka City, Kobe City, Hiroshima City, Kita-Kyūshū City, and other ordinance-designated cities (a total of 21 strata)

- ② Cities with a population of ≥ 0.2 million (11 strata in total)
- ③ Cities with a population of ≥ 0.1 million (11 strata in total)
- ④ Cities with a population of < 0.1 million (11 strata in total)
- ⑤ Suburban districts (11 strata)

A “city” refers to a geographical area as per the implementation of the granting of city status as of April 1, 2015. The classification of community sizes based on population size was performed according to the *Basic Resident Register Population Handbook* based on the Basic Resident Register as of January 1, 2014 (population of individuals aged 15–64 years: 80,038,406).

3) The 5,000 individuals sampled were distributed to each of the above 65 strata proportional to the population density so as to have 10–16 samples per survey spot.

4) The survey spots selected to conduct the 2010 National Census were used as a primary sampling unit, and survey spots (enumeration districts) were selected according to the following procedures.

- If the number of survey spots (enumeration districts) within each stratum was 1, one spot was randomly selected using a random number table.
- If the number of survey spots (enumeration districts) was ≥ 2 , the sampling interval was calculated, and survey spots (enumeration districts) were randomly selected using equal-interval sampling. The procedure of selecting survey spots (enumeration districts) is referred to as the “first

stage.”

Sampling interval = (Sum of the population aged 15–64 years for each stratum at the time of conducting the national census) / (Number of survey spots calculated for each stratum)

5) During the selection of survey spots, the sequence of municipalities was arranged within each stratum according to the municipality codes used for the conduct of the 2010 National Census.

6) After calculating the sampling interval, the target population for each survey spot (enumeration district) was randomly selected from the Basic Resident Register or the pollbook using equal-interval sampling. The procedure of selecting the target population from each survey spot (enumeration district) is referred to as the “second stage.”

Sampling interval = (Population aged 15–64 years for each survey spot at the time of conducting the national census) / (Number of samples selected from each enumeration district for each stratum)

2. Methods of survey and ethical considerations

Each individual selected using the above-mentioned procedures was informed of the conduct of the survey in advance via postcard. Trained staffs visited each individual in his/her home to explain the survey both in writing and orally. When there was more than one member in a household, the staff made direct explanation to the subject. After obtaining consent, the staff selected the date and time for the collection of the questionnaire with the individual, and gave him/her an envelope containing the questionnaire and a ballpoint pen. A few days later, the staff

collected the questionnaire. Before being collected, the envelope was to be sealed by the respondent to ensure that the staff was unable to see the content during the collection. If the respondent and his/her family were not home at the time of visit, the staff left a notice in the mailbox and came back at different days and times.

The questionnaire was to be anonymous and self-administered, containing no personally identifiable questions. It included a description to explain that the subject can voluntarily choose whether to respond to the survey or not. The study protocol was reviewed and approved by the Ethics Committee of the National Center of Neurology and Psychiatry (approval number: A2014-149).

3. Survey items

The survey items consisted of the following four parts.

1) Basic demographics: Sex, age, occupation, final academic background, time spent on the Internet, etc.

2) Alcohol and/or tobacco use: Lifetime use, age of first use, past-year use, past 30-day use, etc.

3) Medications: Past-year use of analgesics, tranquilizers, and/or hypnotics; how obtained; reason for use; past 30-day use (name of the medications used); etc.

4) Drug use: Knowledge on and/or perception of drug abuse/dependence, presence or absence of peer abusers, accessibility (on a scale of four levels from “completely inaccessible” to “easily accessible”), experience of having someone try to tempt them with drugs, use experience, type of the NPS used (e.g., herbal), hospital visit associated with NPS use, etc.

4. Statistical analysis

Statistical analysis consisted of the following 12 parts.

- 1) Prevalence of drug use: For each drug, the prevalence was calculated for lifetime use, experience of having someone try to tempt them with the drug, accessibility, and the presence of peer drug users. Of the four response categories on the Likert scale for accessibility, responses of “barely accessible” and “easily accessible” were reclassified as “accessible.” The prevalence was also calculated for analgesics, tranquilizers, hypnotics, and alcohol and/or tobacco use (Tables 1–6)
- 2) Cross tabulation for basic demographics (Tables 7–11)
- 3) Cross tabulation for alcohol and/or tobacco use (Tables 12–16)
- 4) Cross tabulation for the medications use (Tables 17–21)
- 5) Cross tabulation for analgesic use (Tables 22–26)
- 6) Cross tabulation for tranquilizer use (Tables 27–31)
- 7) Cross tabulation for hypnotic use (Tables 32–36)
- 8) Cross tabulation for knowledge on and/or perception of drug abuse (Tables 37–41)
- 9) Cross tabulation for NPSs use (Tables 42–46)
- 10) Cross tabulation for presence of peer drug users and the experience of having someone try to tempt them with drugs (Tables 47–51)
- 11) Cross tabulation for drug accessibility (Tables 52–56)
- 12) Cross tabulation for drug use experience (Tables 57–61)
- 13) Monitoring of trend changes (Figures

2–33 and Tables 62–69)

In the cross tabulation for the above-mentioned items 2–12, cross tabulation with each item was conducted in terms of residence area (11 areas), sex, age group (15 to 64 [here in after, “teens” refers to those aged 15 to 19, and “60s” refers to those aged 60 to 64]), occupation (seven categories), and drug use experience (yes/no). For the detection of significant differences, Pearson’s chi-square test was used for categorical variables, and a t-test and one-way analysis of variance (ANOVA) were used for a two-group and a three or more-group comparisons of continuous variables, respectively. For items such as lifetime prevalence, estimates (point and interval estimates), which were adjusted based on the total number of survey spots included in each stratum and in the population aged 15 years or older in each survey spot, were calculated. In the text, tables, and figures included in the report, these figures are shown as “estimates” as applicable.

C. Results

1. Response rate

Valid questionnaires were collected from 3,085 out of 5,000 targeted individuals (response rate: 61.7%). There were 1,915 individuals who did not respond to the survey. Overall, the most common reason for not responding to the survey was refusal (45.8%), followed by temporary absence (31.3%), and change of home address (10.9%).

The reasons for not responding to the survey are shown in Table B by sex. The proportion of individuals who refused to respond (refusal rate) was higher in women (49.1%) than in men (42.9%), and the

proportion of those who have changed address was higher in men (13.2%) than in women (8.2%). The reasons for not responding to the survey are shown in Table C by age group. The proportion of individuals who refused to respond (refusal rate) was highest in those in their 60s (63.2%) among all age groups, and such proportion was lowest in those in their 20s (31.5%). The proportion of individuals who were temporarily absent was highest in those in their 20s (38.7%) and lowest in those in their 60s (18.9%). Also, the proportion of individuals who have changed address was highest in those in their 20s (18.1%) and lowest in people in their 60s (5.7%). The reasons for not responding to the survey are shown in Table D by geographic area. The proportions of individuals who refused to respond (refusal rate) were high in those from the Hokuriku (61.2%) and Tokai (58.7%) areas, and such proportions were low in individuals from the Shikoku (35.0%) and Tōhoku (35.7%) areas. The proportions of individuals who were temporarily absent were high in those from the Kanto (37.2%), Tōhoku (35.7%), and Kinki (35.6%) areas, and such proportions were low in individuals from the Chūgoku (14.6%) and Kinki-Kyūshū (17.2%) areas.

Figure 1 shows the change in response rate (1995–2015). In 1995, when the study was initiated, the response rate was 78.9%. It stayed in the 70% range until 2003, but decreased to the 60% range after 2005. In 2007 and 2013, the response rate further decreased to the 50% range, but it returned to the 60% range in this survey.

Responses were considered valid if the respondent answered to at least 40 out of a total of 76 questions. A total of 3,076

respondents met these criteria and were thus included in the analysis population of the study. The questionnaire contains 52 questions (Questions 1–52). If questions asked for each type of drugs (Questions 47–50) are considered independent questions, however, the total number of questions will be 76.

2. Basic demographics

The results regarding the basic demographics of the respondents are presented in Tables 7–11. Responses were obtained from all 47 prefectures of Japan, with the highest proportion of responses being obtained from the Kanto area (30.8%). Of all the respondents, 52.3% and 47.7% were women and men, respectively, and the mean age was 43.3 years. The most common age group was 40s (24.4%), followed by 50s (22.6%) and 30s (18.0%). The most common occupation was “full-time employee” (45.7%), followed by “housewife” (14.2%) and “non-full-time employee” (12.8%). The most common final academic background was “high school” (38.6%), followed by “junior college/university” (30.2%) and “vocational school” (13.2%). The most common cellular phone owned was “smartphone” (68.1%), with only 2.7% of respondents having no cellular phone. Time spent on the Internet (not for work) given by the highest proportion of respondents was <1 hour (25.6%), but some respondents spend ≥ 5 hours (13.8%).

3. Alcohol and/or tobacco use

The results regarding alcohol and/or tobacco use are presented in Tables 6 and 12–16. For alcohol use, the lifetime prevalence was 93.8%, the past-year

prevalence was 80.2%, and the past 30-day prevalence was 67.0% (all these figures being estimates). The past 30-day prevalence was high in the Minami-Kyushu area (70.9%) with the lowest in the Chugoku area (61.3%). The past 30-day prevalence was higher in men (75.0%) than in women (59.7%). The past 30-day prevalence was highest in those in their 20s (76.7%). By occupation, the said prevalence was highest in workers engaged in “self-employed business” (79.4%), and by classification by time spent on the Internet, the prevalence was highest in the group of “1 to <2 hours” (72.0%).

For tobacco use, the lifetime prevalence was 59.8%, the past-year prevalence was 26.2%, and the past 30-day prevalence was 23.2% (all these figures being estimates). The past 30-day prevalence was highest in the Hokkaido area (33.6%) and lowest in the Tōhoku area (21.3%). As with alcohol use, the past 30-day prevalence was higher in men (37.9%) than in women (11.8%). The past 30-day prevalence was highest in those in their 30s (29.1%). By occupation, as with alcohol use, the said prevalence was highest in workers engaged in “self-employed business” (36.3%), and by time spent on the Internet, the prevalence was highest in the group of “zero” (31.2%).

4. Medications use

The results regarding the use of household medicines and medications are presented in Tables 17–21. The most common household medicine was “cold medicine” (71.3%), followed by “gastrointestinal medicine” (55.6%) and “antipyretic analgesic” (55.3%). The most common medications used within the past year was “cold medicine” (64.7%), followed

by “antipyretic analgesic” (63.0%) and “gastrointestinal medicine” (37.1%).

5. Analgesic use

The results regarding analgesic use are shown in Tables 5 and 22–26. For analgesics use, the past-year prevalence was 62.9%, the past 30-day prevalence was 26.9%, and the rate of chronic use (defined as \geq three times a week) was 2.3% (all these figures being estimates). The rate of chronic use was highest in the Shikoku area (4.5%) and low in the Hokkaido (1.5%) and Tokai (1.5%) areas. The said rate was higher in women (3.0%) than in men (2.0%). The age group with the highest rate was 60s (3.6%). For occupation, the rate was high in the groups of “other” (5.1%) and “housewife” (3.4%). By time spent on the Internet, the rate was highest in the group responding “zero” (3.3%).

The most common source of analgesics was “pharmacies/drugstores” (39.3%), followed by “clinics/hospitals” (25.7%) and “household medicines” (12.9%). “Friends/acquaintances” (0.9%) or “romantic partners” (0.1%) were not common. Common reasons for the use of analgesics included “headache” (39.5%) and “menstrual pain” (10.9%), and no respondent selected “recreation (pleasure).”

6. Tranquilizer use

The results regarding tranquilizer use are shown in Tables 5 and 27–31. For tranquilizer use, the past-year prevalence was 5.6%, the past 30-day prevalence was 4.2%, and the rate of chronic use (defined as \geq three times a week) was 3.0% (all these figures being estimates). The rate of chronic use was highest in the Shikoku area (5.7%) and low in the Hokuriku (1.3%)

and Tousan (1.3%) areas. The rate of chronic use was higher in women (3.4%) than in men (2.8%). The rate was highest in the age group of 60s (4.0%). For occupation, the rate was highest in the group of “unemployed” (12.3%). By time spent on the Internet, the said rate was highest in the group of “zero” (5.1%).

The most common source of tranquilizers was “clinics/hospitals” (4.4%). “friends” (0.1%) was not common, and no respondent selected “romantic partners.” The most common reason for the use of tranquilizers was “to eliminate anxiety” (3.2%), followed by “to improve insomnia” (2.2%) and “to reduce stress” (1.5%). Only one respondent selected “recreation (pleasure)” (0.03%).

7. Hypnotic use

The results regarding hypnotic use are presented in Tables 5 and 32–36.

For hypnotic use, the past-year prevalence was 6.1%, the past 30-day prevalence was 4.3%, and the rate of chronic use (defined as \geq three times a week) was 2.8% (all these figures being estimates). The rate of chronic use was highest in the Hokkaido area (3.8%) and low in the Hokuriku area (0.6%). The rate of chronic use was higher in women (3.4%) than in men (2.4%). The age group with the highest rate was 60s (5.1%), and the occupation with the highest rate was “unemployed” (11.2%). By time spent on the Internet, the rate of chronic use was highest in the group responding “zero” (5.1%).

The most common source of hypnotics was “clinics/hospitals” (4.5%). “friends” (0.1%) was not common, and no respondent selected “romantic partners.” “To improve insomnia” (5.1%) was a common reason for

the use of hypnotics, and only one respondent selected “recreation (pleasure)” (0.03%).

8. Knowledge on and/or perception of drug abuse

The results regarding knowledge on and/or perception of drug abuse are presented in Tables 37–41. Common familiar harmful effects associated with drug abuse included drug dependence (97.9%), hallucinations (96.0%), delusion (92.3%), flashbacks (78.5%), cannabis-induced hallucinations/delusion (78.0%), cannabis-induced amotivational syndrome (60.8%), and methamphetamine-induced hallucinations/delusion (89.9%).

The common view on cannabis use was mostly “under no situation should it be used” (82.7%), but a few respondents answered that “it is not necessary to legally prohibit” (1.2%). Similarly, the common view on methamphetamine use was mostly “under no situation should it be used” (89.9%), but a few respondents answered that “it is an individual freedom and should not be legally prohibited” (0.7%).

9. New psychoactive substances (NPSs)

The results regarding NPSs are shown in Tables 1 and 42–46. The lifetime prevalence of NPS use was 0.4% (adjusted value: 0.3%), and no respondent used any NPS within the past year. Types of NPSs used included herbal (0.3%), powder (0.2%), and liquid (0.1%). No hospital visit associated with NPS use was observed.

The lifetime prevalence was highest in the Hokkaido area (1.5%), whereas it was 0% in the Tohoku, Hokuriku, and Tousan areas. The lifetime prevalence was higher

in men (0.5%) than in women (0.2%). By age, the rate was highest in the age group of 30–39 (0.7%). For occupation, it was highest in the group of “Full-time employee” (0.5%), and by time spent on the Internet, the rate was highest in those responding “≥5 hours” (0.9%).

The harmful effects of NPSs and the regulations regarding designated substances were known to 85.8% and 56.9% of the respondents, respectively. While there were almost no differences in the proportion of respondents familiar with the harmful effects of NPSs in terms of sex, age group, or residence area, the proportion of respondents familiar with the harmful effects of NPSs was slightly low in unemployed respondents (76.5%).

On the other hand, the proportion of respondents familiar with the regulations for designated substances was higher in men (61.9%) than in women (52.3%), and it increased with age (49.1% for teens and 62.6% for those who were in their 60s). The proportion of respondents familiar with the regulations for designated substances was highest in the Kita Kyushu area (60.7%), whereas it was low in the Shikoku area (50.0%). By occupation, the proportion was high in the group of “self-employed business” (66.5%), whereas it was low in the group of “student” (46.9%). The most common answer to a question on the perceived number of NPS users was “increasing (57.2%),” followed by “do not know” (35.5%), “not changing” (5.8%), and “decreasing” (1.1%).

10. Drug use (presence of peer drug users and the experience of ever having someone try to tempt them with drugs)

The results regarding drug use (presence

of peer drug users and the experience of ever having someone try to tempt them with drugs) are shown in Tables 2, 4, and 47–51. The proportion of respondents who have ever had someone try to tempt them with illegal drugs was 2.4% for organic solvents, 2.0% for cannabis, 1.0% for methamphetamine, 0.6% for MDMA, 0.2% for cocaine, 0.2% for heroin, 0.6% for NPSs, and 4.1% for any drug (all these figures being adjusted values).

The proportion of respondents who have ever had someone try to tempt them with NPSs was highest in the Hokkaido area (3.1%) and higher in men (0.7% [adjusted value]) than in women (0.5% [adjusted value]). That proportions were highest in the age group of 30–39 (1.4%), the group of “non-full-time employee” (1.0%), and the group of “2 to <3 hours” (1.1%).

The proportion of respondents with a peer drug abuser was 4.5% for organic solvents, 2.7% for cannabis, 2.5% for methamphetamine, 1.4% for MDMA, 1.3% for cocaine, 1.2% for heroin, 1.6% for NPSs, and 5.9% for any drug (all these figures being adjusted values).

The proportion of respondents with a peer NPS abuser was highest in the Chugoku area (3.1%) and higher in men (2.1%) than in women (1.0%). The age groups with high proportions were 20–29 and 30–39 (2.4% each). By occupation, the proportion was highest in the group of “self-employed business” (2.4%), and by time spent on the Internet, it was highest in those responding “3 to <5 hours” (2.5%).

11. Drug use (accessibility)

The results regarding drug use (accessibility) are shown in Tables 3 and 52–56. The proportion of respondents who

answered that drugs were accessible (combined with “barely accessible” and “easily accessible”) was 52.4% for organic solvents, 14.6% for cannabis, 13.1% for methamphetamine, 13.0% for MDMA, 11.5% for cocaine, 11.1% for heroin, 21.8% for NPSs, and 53.5% for any drug (all these figures being adjusted values).

The proportion of respondents who answered that NPSs were accessible was high in the Kanto area (25.0%), higher in men (22.2%) than in women (18.2%), higher in those in their 30s (24.1%) than those in their 60s (11.2%), and higher in students (23.2%) than those who were unemployed (13.4%). By time spent on the Internet, the said proportion was highest in the group of “≥5 hours” (25.3%).

12. Drug use (use experience)

The results regarding drug use (use experience) are presented in Tables 1 and 57–61 and Table E. The lifetime prevalence (i.e., the proportion of respondents who have used an illegal drug at least once) was 1.5% for organic solvents, 1.0% for cannabis, 0.5% for methamphetamine, 0.1% for MDMA, 0.1% for cocaine, 0.3% for NPSs, and 2.4% for any drug (all these figures being adjusted values). The proportion for heroin was within the range of statistical errors. The mean age of drug users was 47.9 years for organic solvents, 41.3 years for cannabis, 44.1 years for methamphetamine, 40.0 years for MDMA, 45.4 years for cocaine, 45.7 years for heroin, 40.8 years for NPSs, and 45.5 years for any drug.

The past-year prevalence of drug use was 0.1% for organic solvents, 0.1% for cannabis, 0.0% for methamphetamine, 0.0% for MDMA, 0.0% for cocaine, 0.0% for

heroin, 0.0% for NPSs, and 0.1% for any drug.

13. Monitoring of trend changes

Changes in the past-year prevalence of alcohol use over time are shown in Figures 2 and 3 and Table 62. The past-year prevalence of alcohol use has been decreasing (85.0%, 81.9%, and 79.8% for 2011, 2013, and 2015, respectively). Particularly, the decrease in the past-year prevalence of alcohol use is significant in teens. The past-year prevalence of alcohol use in teens reached its peak in 2007 (50.6%) and subsequently decreased to 25.2% in 2015.

Changes in the lifetime prevalence of tobacco use over time are shown in Figures 4 and 5. After reaching its peak in 2009 (66.4%), the lifetime prevalence of tobacco use decreased to 65.0%, 64.0%, and 59.8%, in 2011, 2013, and 2015, respectively. Especially, the decrease in the lifetime prevalence of tobacco use is significant in those in their 20s. The lifetime prevalence of tobacco use in those in their 20s reached its peak in 2001 (71.2%) and subsequently decreased to 42.9% in 2015.

Changes in the past-year prevalence of tobacco use over time are shown in Figures 6 and 7 and Table 62. The past-year prevalence of tobacco use has been gradually decreasing from 2001 (36.0%) to 2015 (26.9%). It has been decreasing in all age groups except for teens, whose past-year prevalence increased from 2013 (2.6%) to 2015 (4.5%).

Changes in analgesic use over time are shown in Figures 8 and 9 and Table 63. The past-year prevalence of analgesic use has been increasing every year in both men and women. Overall, it increased from

34.3% (1995) to 62.9% (2015). The chronic use of analgesics (\geq three times a week) has also been increasing in both men and women. Overall, it increased from 1.6% (1999) to 2.5% (2015).

Changes in tranquilizer use over time are shown in Figures 10 and 11 and Table 63. After reaching its peak in 2007, the past-year prevalence of tranquilizer use has been decreasing in both men and women. The chronic use of tranquilizers slightly increased to 2.6%, 2.9%, and 3.1% in 1999, 2013, and 2015, respectively.

Changes in hypnotic use over time are shown in Figures 12 and 13 and Table 63. The past-year prevalence of hypnotic use increased between 1995 (4.0%) and 2007 (7.7%), followed by a decrease in 2011 (5.6%), and then by a re-increase in 2015 (6.1%). Similarly, the rate of chronic use of hypnotics reached its peak in 2007 (2.7%) and subsequently decreased in 2011 (1.9%), but it increased again in 2015 (2.9%).

Changes in views on cannabis use over time are shown in Figures 14 and 15. The figure shown is the sum of the proportion of respondents who answered that “a little use should be allowed although legally prohibited” or “it is an individual freedom and should not be legally prohibited” (i.e., those who accept cannabis use). Overall, this has been decreasing (2.9%, 2.8%, 2.4%, and 1.5% in 2009, 2011, 2013, and 2015, respectively). It has been decreasing in all age groups, with no increase from 2013 to 2015 in any of these age groups.

Changes in views on methamphetamine use over time are shown in Figures 16 and 17. The figure shown is the sum of the proportion of respondents who answered that “a little use should be allowed although legally prohibited” or “it is an

individual freedom and should not be legally prohibited” (i.e., those who accept methamphetamine use). Overall, it has been decreasing (1.7%, 1.4%, 0.9%, and 0.8% in 2009, 2011, 2013, and 2015, respectively). It decreased in those in their 20s, 50s, and 60s from 2013 to 2015, whereas it increased in teens and those in their 30s.

Changes over time in the proportion of respondents with a peer drug abuser within the past year are shown in Figure 18. The proportion increased from 2013 to 2015 for all drugs.

Changes in drug accessibility over time are shown in Figure 19. The figure shown is the sum of the proportion of respondents who answered that drugs were “barely accessible” or “easily accessible.” Although little change in drug accessibility was observed over time, NPS accessibility (20.1%), which was investigated for the first time in this survey, was the second most common next to organic solvents (51.5%). Figures 20–31 show changes in the accessibility of each drug over time by age group.

Figure 32 and Tables 64 and 65 show changes over time in the lifetime experience of having someone try to tempt them with illegal drugs. While the lifetime experience of having someone try to tempt them with illegal drugs has generally remained unchanged, it increased from 2013 to 2015 only for methamphetamine (0.9% \rightarrow 1.0%) and MDMA (0.4% \rightarrow 0.6%).

Figure 33 and Tables 67 and 68 show changes in the lifetime prevalence of drug abuse over time. The lifetime prevalence of NPS abuse decreased from 0.4% (2013) to 0.3% (2015). The lifetime prevalence of drug abuse also decreased for organic

solvents (1.9% → 1.5%), cannabis (1.1% → 1.0%), and MDMA (0.3% → 0.1%). No change was observed for methamphetamine and cocaine.

14. Estimated population with drug use

Table 65 shows changes in the population of individuals with lifetime experience of having someone try to tempt them with illegal drugs. This is an estimate of the number of people who have had someone try to tempt them with illegal drugs in Japan, and it was 2.29 million for organic solvents, 1.91 million for cannabis, 0.94 million for methamphetamine, 0.16 million for heroin, 0.20 million for cocaine, 0.58 million for MDMA, and 0.52 million for NPSs (all figures approximate). As compared with 2013, the estimate increased only for methamphetamine (~0.93 → ~0.94 million) and MDMA (~0.42 → ~0.58 million) and decreased for other drugs.

Table 68 shows changes in the population of individuals with lifetime experience of drug use. This is an estimate of the number of people with the experience of illegal drug use in Japan, and it was 1.38 million for organic solvents, 0.95 million for cannabis, 0.50 million for methamphetamine, 0.12 million for cocaine, 0.12 million for MDMA, and 0.31 million for NPSs (all figures approximate). As compared with the 2013 survey, the estimate decreased for all these drugs.

D. Discussion

1. Summary of the 2015 survey

Although the response rate decreased to the 50% range in the 2013 survey, it increased back to 61.7% in this survey. Behind this rise in the response rate may

lie an increase in residents' awareness of drug abuse as brought about by media coverage on the social issue regarding "NPS-related accidents," including the runaway car accident in Ikebukuro, Tokyo (2014). Still, the response rate has remained low compared to the rate seen at the initial conduct of the study. To avoid a further drop in the response rate, it is necessary to continue to patiently explain to target individuals the detailed purposes and necessity of the study, and to solicit their understanding. At any rate, we would like to express our gratitude to the 3,085 respondents in 47 prefectures of Japan for their understanding and cooperation regarding the survey.

One of objectives of this study is to understand the actual circumstances of drug abuse in Japan. To approach this goal from a variety of angles, we aimed to play a "role of dictionary." In other words, we tried to obtain a picture of the current situation of drug abuse via analyzation not only by sex and age group but also by other different variables, including residence area, occupation, and educational background. In addition, this study has been conducted every other year since 1995 as a series of "monitoring surveys." Over the years, all these surveys have been conducted using the same sampling and study methods, which allows us to monitor the trend of drug abuse. In addition to the trend of drug abuse, a wide range of health-related information, including data on the use of alcohol, tobacco, and medications has been collected, which can be used as basic data for the consideration of related health issues. It is a tremendous amount of data, and it is impossible to discuss all of them; but we will discuss

some of important issues below.

2. Trend regarding new psychoactive substances (NPSs)

The lifetime prevalence of NPS use decreased from 0.4% (2013) to 0.3% (2015), and the past-year prevalence decreased from 0.1% (2013) to 0% (2015). Our estimates suggest that the number of individuals in the population with lifetime experience of NPS use is approximately 0.31 million, showing a decrease from the figure of the 2013 survey (approximately 0.40 million). It is likely that this decrease and the absence of past-year users are related to the recent inaccessibility of NPSs itself. In December 2014, The *Law on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices* (the former *Pharmaceutical Law*) was revised, and the minister of the Ministry of Health, Labour and Welfare and prefectural governors were granted the right to issue orders for scientific testing and the suspension of sales and/or advertisements to manufacturers. Since then, drug retail outlets known as “head shops” and websites selling drugs on the Internet have apparently been eliminated. This strengthening of the regulations on NPSs may have been effective to a certain degree, contributing to the decrease in the accessibility of NPSs. This may have resulted in the disappearance of past-year users. These results suggest that the social issue regarding NPSs is calming down.

The proportion of respondents having knowledge of harmful effects of NPSs increased from 61.5% (2013) to 85.8% (2015), with 56.9% of respondents having knowledge of Japan’s regulations for

designated substances as measures to prevent NPS use. It is speculated that this increase in knowledge has resulted from media coverage of NPS-related crimes, anti-drug abuse activities led by each local government, and education for the prevention of drug abuse as provided by schools, through all of which the harmful effects of NPSs became more widely recognized by the general population. As for familiarity with the regulations for designated substances, this survey revealed that more than half of the general population were familiar with such regulations, although the future trend needs to be monitored because this was assessed for the first time in this survey.

Despite the increased awareness of the harmful effects of NPSs and the decrease in NPS users, the accessibility of NPSs is still higher than that of other drugs. The proportion of respondents who answered that drugs were “available” exceeded 20%, indicating that these respondents see NPSs as more accessible drugs compared with methamphetamine and cannabis. Continuous measures to prevent NPS use are required. Especially, the proportion of respondents who answered that NPSs were “available” was high in those spending ≥ 5 hours on the Internet, warranting an ongoing strengthening of the measures against websites selling drugs on the Internet.

3. Trend regarding illegal drugs

Based on the estimated number of individuals in the population with lifetime drug use, the use of organic solvents, cannabis, methamphetamine, cocaine, and MDMA have all decreased from the 2013 survey. It should be noted, however, that

the number of individuals in the population who had ever had someone try to tempt them with illegal drugs is increasing both for methamphetamine and MDMA. The majority of the respondents were obviously conscious of methamphetamine use, with nearly 90% of respondents answering that “under no situation should it be used.” However, it is also true that there were a small number of respondents who answered that “a little use should be allowed although legally prohibited” or “it is an individual freedom and not necessary to legally prohibit,” namely we would call the “accepters.” The increase in the proportion of accepters in young respondents, including teens and those in their 30s, from 2013 to 2015 suggests that there is a need to further enhance preventative measures against drug abuse targeting the younger generation.

As for MDMA, on the other hand, the amount seized has been decreasing in recent years, indicating that opportunities for abuse are decreasing. The future trend should be carefully monitored.

4. Trend regarding analgesic/hypnotic use


The survey showed that opportunities for using analgesics and hypnotics are clearly increasing. The past-year prevalence of analgesic use was 62.9%, the highest figure ever. While the past-year prevalence of hypnotic use reached its peak in 2007 and then decreased, this survey revealed that it is increasing again.

Some analgesics and hypnotics have dependence-forming potential. Such dependence-forming medications include

opioid analgesics (e.g., tramadol) and benzodiazepines. It is known that there some patients abuse or heavily depend on benzodiazepines. The Nationwide Mental Hospital Survey on Drugrelated Psychiatric Disorders has reported that etizolam, flunitrazepam, and triazolam are often abused. This study, in which the use of drugs \geq three times a week was defined as “chronic use,” showed that the chronic use of analgesics and hypnotics has also obviously been increasing.—It is difficult to predict the risk of drug abuse/dependence in drug users from the frequency of drug use. However, there is a certain proportion of individuals who use drugs having dependency-forming potential. It is therefore continuously important for physicians and pharmacists to promote the “proper use” of these drugs.

E. Conclusion

The number of respondents with lifetime use of NPSs decreased, and the past-year prevalence of their use was 0%. Behind this may lie the reinforcement of the regulations for designated substances (including orders for scientific testing and suspension of sales and/or advertisements) to eliminate shops and websites selling NPSs, which led to reduced opportunities for obtaining NPSs. In addition, the social issue regarding NPSs is considered to be calming down. However, approximately 20% of respondents answered that NPSs are “available,” suggesting the necessity of continuous measures to prevent NPS abuse.



Map of Japan (All 47 prefectures of Japan were divided into the 11 geographic areas)

Table A. Number of samples and number of survey spot by each strata

	Large cities						Cities with a population of ≥ 0.2 million	Cities with a population of ≥ 0.1 million	Cities with a population of < 0.1 million	Suburban districts	Total
	23 wards of Tokyo metropolitan	Yokohama City	Kawasaki City and Kyoto City,	Chiba City, Nagoya City and Osaka City	Saitama City, Shizuoka City, Kobe City, Hiroshima City and Kita-Kyushu City	Other ordinance-designated cities					
Hokkaido area						79 (5)	23 (2)	34 (3)	36 (3)	37 (3)	209 (16)
Tohoku area						44 (3)	91 (6)	44 (3)	106 (7)	64 (5)	349 (24)
Kanto area	382 (26)	151 (10)	61 (4)	38 (3)	51 (4)	29 (2)	408 (29)	311 (21)	225 (15)	75 (5)	1731 (119)
Hokuriku area						31 (2)	62 (4)	23 (2)	72 (5)	16 (1)	204 (14)
Tosan area							40 (3)	41 (3)	78 (5)	33 (3)	192 (14)
Tokai area				90 (6)	27 (2)	31 (2)	124 (8)	110 (7)	98 (7)	33 (3)	513 (35)
Kinki area			56 (4)	107 (7)	61 (4)	33 (3)	257 (18)	101 (7)	154 (10)	44 (3)	813 (56)
Chugoku area					47 (3)	27 (2)	63 (4)	69 (5)	54 (4)	21 (2)	281 (20)
Shikoku area							60 (4)	20 (2)	45 (3)	23 (2)	148 (11)
Kita-Kyushu area					37 (3)	62 (4)	66 (5)	36 (3)	89 (6)	39 (3)	329 (24)
Minami-Kyushu area						29 (2)	53 (4)	40 (3)	70 (5)	39 (3)	231 (17)
Total	382 (26)	151 (10)	117 (8)	235 (16)	223 (16)	365 (25)	1247 (87)	829 (59)	1027 (70)	424 (33)	5000 (350)

*Upper data is number of samples, lower data is number of survey spot




Fig1. The change in response rate (1995–2015)

Table B. The reasons for not responding to the survey by sex

	Men		Women		Total	
Change of home address	134	13.2%	74	8.2%	208	10.9%
Long term absence	50	4.9%	28	3.1%	78	4.1%
Temporary absence	306	30.1%	293	32.6%	599	31.3%
Unknown address	33	3.3%	17	1.9%	50	2.6%
Refusal	435	42.9%	442	49.1%	877	45.8%
Answered by families	11	1.1%	9	1.0%	20	1.0%
Other reasons	46	4.5%	37	4.1%	83	4.3%
Total	1015	100.0%	900	100.0%	1,915	100.0%

Table C. The reasons for not responding to the survey by age group

	10s		20s		30s		40s	
Change of home address	14	13.1%	65	18.1%	49	13.4%	39	8.0%
Long term absence	3	2.8%	18	5.0%	13	3.5%	20	4.1%
Temporary absence	22	20.6%	139	38.7%	129	35.1%	168	34.6%
Unknown address	1	0.9%	12	3.3%	12	3.3%	15	3.1%
Refusal	60	56.1%	113	31.5%	153	41.7%	220	45.4%
Answered by families	1	0.9%	1	0.3%	2	0.5%	6	1.2%
Other reasons	6	5.6%	11	3.1%	9	2.5%	17	3.5%
Total	107	100.0%	359	100.0%	367	100.0%	485	100.0%

	50s		60s		Total	
Change of home address	29	7.9%	12	5.7%	208	10.9%
Long term absence	16	4.4%	8	3.8%	78	4.1%
Temporary absence	101	27.7%	40	18.9%	599	31.3%
Unknown address	6	1.6%	4	1.9%	50	2.6%
Refusal	197	54.0%	134	63.2%	877	45.8%
Answered by families	6	1.6%	4	1.9%	20	1.0%
Other reasons	10	2.7%	10	4.7%	83	4.3%
Total	365	100.0%	212	100.0%	1,915	100.0%

“10s” refers to those aged 15 to 19, and “60s” refers to those aged 60 to 64.

Table D. The reasons for not responding to the survey by geographic area

	Hokkaido		Tohoku		Kanto		Hokuriku		Tousan		Tokai	
Change of home address	3	3.8%	9	9.3%	65	8.3%	6	12.2%	8	19.0%	15	8.2%
Long term absence	7	9.0%	7	7.2%	29	3.7%	1	2.0%	1	2.4%	6	3.3%
Temporary absence	23	29.5%	16	16.5%	291	37.2%	10	20.4%	15	35.7%	46	25.0%
Unknown address	2	2.6%	3	3.1%	22	2.8%	1	2.0%	3	7.1%	2	1.1%
Refusal	39	50.0%	56	57.7%	340	43.4%	30	61.2%	15	35.7%	108	58.7%
Answered by families	1	1.3%	1	1.0%	4	0.5%	0	0.0%	0	0.0%	4	2.2%
Other reasons	3	3.8%	5	5.2%	32	4.1%	1	2.0%	0	0.0%	3	1.6%
Total	78	100.0%	97	100.0%	783	100.0%	49	100.0%	42	100.0%	184	100.0%

	Kinki		Chugoku		Shikoku		Kita-Kyusyu		Minami-Kyusyu		Total	
Change of home address	39	10.6%	19	21.3%	13	21.7%	23	23.2%	8	12.1%	208	10.9%
Long term absence	10	2.7%	5	5.6%	1	1.7%	6	6.1%	5	7.6%	78	4.1%
Temporary absence	131	35.6%	13	14.6%	17	28.3%	17	17.2%	20	30.3%	599	31.3%
Unknown address	8	2.2%	2	2.2%	5	8.3%	2	2.0%	0	0.0%	50	2.6%
Refusal	152	41.3%	44	49.4%	21	35.0%	41	41.4%	31	47.0%	877	45.8%
Answered by families	6	1.6%	2	2.2%	2	3.3%	0	0.0%	0	0.0%	20	1.0%
Other reasons	22	6.0%	4	4.5%	1	1.7%	10	10.1%	2	3.0%	83	4.3%
Total	368	100.0%	89	100.0%	60	100.0%	99	100.0%	66	100.0%	1,915	100.0%

Table 1. Lifetime Prevalence of Drug Use by Drug (n = 3076)

(%)

	Prevalence of drug use (lifetime)							
	Organic solvents	Cannabis	Methamph etamine	MDMA	Cocaine	Heroin	NPSs	Any drug
Total	1.6 (1.5)	1.1 (1.0)	0.5 (0.5)	0.2 (0.1)	0.2 (0.1)	0.1 (-)	0.4 (0.3)	2.5 (2.4)
Residence area								
Hokkaido	1.5	3.1	1.5	0.8	0.8	0.0	1.5	4.6
Tohoku	1.2	0.4	0.0	0.0	0.0	0.0	0.0	1.6
Kanto	1.5	1.6	0.7	0.1	0.3	0.3	0.2	2.6
Hokuriku	1.9	0.0	0.0	0.0	0.0	0.0	0.0	1.9
Tousan	0.7	1.3	0.7	0.0	0.0	0.0	0.0	1.3
Tokai	2.7	1.2	0.9	0.0	0.3	0.0	0.3	3.0
Kinki	1.4	1.4	0.2	0.5	0.0	0.0	0.5	2.9
Chugoku	2.1	0.5	0.5	0.5	0.0	0.0	0.5	3.1
Shikoku	0.0	0.0	0.0	0.0	0.0	0.0	1.1	1.1
Kita-Kyusyu	1.3	0.9	0.4	0.4	0.0	0.0	0.4	1.3
Minami-Kyusyu	2.4	0.0	0.0	0.0	0.0	0.0	0.6	3.0
Sex								
Men	2.3 (2.1)	1.9 (1.6)	1.0 (1.0)	0.3 (0.2)	0.3 (0.3)	0.2 (-)	0.5 (0.5)	4.0 (3.6)
Women	0.9 (0.8)	0.4 (0.4)	0.1 (-)	0.1 (-)	0.0 (-)	0.0 (-)	0.2 (-)	1.2 (1.2)
Age group								
10s	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
20s	0.8	1.0	0.0	0.0	0.0	0.0	0.5	2.1
30s	1.1	2.0	0.9	0.5	0.2	0.0	0.7	2.7
40s	2.4	1.5	0.8	0.3	0.4	0.4	0.3	3.1
50s	1.9	1.3	0.6	0.1	0.1	0.0	0.4	3.3
60s	1.9	0.0	0.2	0.0	0.0	0.0	0.0	1.9
Occupation								
Self-employed business	2.8	2.8	1.2	0.4	0.4	0.4	0.4	5.6
Full-time employee	1.6	1.1	0.6	0.1	0.2	0.1	0.5	2.6
Non-full-time employee	2.0	2.0	0.0	0.0	0.0	0.0	0.3	3.6
Student	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Housewife (househusband)	0.7	0.0	0.0	0.2	0.0	0.0	0.2	1.1
Unemployed	3.4	1.7	1.7	0.6	0.6	0.6	0.0	3.4
Other	1.4	1.4	0.7	0.7	0.0	0.0	0.7	2.2
No response/unknown	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Final academic background								
Junior high school	9.3	5.7	4.1	1.0	1.5	1.0	3.1	11.9
High school	2.0	0.6	0.4	0.2	0.1	0.0	0.3	2.9
Vocational school	1.2	1.7	0.5	0.0	0.2	0.2	0.2	2.2
Junior college/university	0.2	0.9	0.1	0.2	0.0	0.0	0.1	1.1
Graduate school	0.0	1.5	0.0	0.0	0.0	0.0	0.0	1.5
Other	0.0	6.3	0.0	0.0	0.0	0.0	0.0	6.3
In school	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
No response/unknown	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Time spent on the Internet								
None	1.6	0.0	0.0	0.0	0.0	0.0	0.0	1.6
<1 hour	2.3	1.3	0.8	0.3	0.1	0.1	0.5	3.2
1 to <2 hours	1.1	1.2	0.5	0.2	0.0	0.0	0.2	2.6
2 to <3 hours	1.3	1.3	0.4	0.0	0.2	0.0	0.2	2.2
3 to <5 hours	0.9	0.9	0.3	0.3	0.3	0.3	0.3	1.6
≥5 hours	1.9	1.9	0.9	0.5	0.5	0.2	0.9	3.3
No response/unknown	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

The values in parentheses for the total and sex are estimates, and “-” represents within the range of statistical “10s” refers to those aged 15 to 19, and “60s” refers to those aged 60 to 64.

Time spent on the Internet: Average hours spent per day not for work

Table 2. Experience of ever having try to tempt with illegal drugs (n = 3076)

(%)

	Experience of ever having try to tempt illegal drugs (lifetime)							
	Organic solvents	Cannabis	Methamp hetamine	MDMA	Cocaine	Heroin	NPSs	Any drug
Total	2.6 (2.4)	2.1 (2.0)	1.0 (1.0)	0.7 (0.6)	0.3 (0.2)	0.2 (0.2)	0.5 (0.6)	4.3 (4.1)
Residence area								
Hokkaido	3.1	3.8	1.5	2.3	0.8	0.0	3.1	7.6
Tohoku	2.4	2.4	0.4	0.8	0.0	0.0	0.4	4.0
Kanto	3.1	3.1	1.4	0.7	0.5	0.4	0.7	5.5
Hokuriku	2.6	0.0	0.0	0.0	0.0	0.0	0.0	2.6
Tousan	1.3	2.0	1.3	0.0	0.0	0.0	0.0	2.7
Tokai	4.3	1.8	1.5	0.6	0.0	0.0	0.0	5.5
Kinki	1.8	1.8	0.5	0.2	0.0	0.0	0.2	3.2
Chugoku	1.0	1.0	1.0	0.0	0.5	0.5	0.5	2.6
Shikoku	4.5	1.1	1.1	1.1	0.0	0.0	0.0	4.5
Kita-Kyusyu	1.7	0.9	0.4	0.9	0.4	0.4	0.4	1.7
Minami-Kyusyu	2.4	1.2	1.2	1.2	0.0	0.0	0.6	3.6
Sex								
Men	3.6 (3.4)	2.9 (2.9)	1.3 (1.2)	0.8 (0.7)	0.4 (0.4)	0.3 (0.3)	0.5 (0.7)	5.5 (5.2)
Women	1.7 (1.6)	1.3 (1.2)	0.7 (0.8)	0.5 (0.5)	0.1 (-)	0.1 (-)	0.6 (0.5)	3.2 (3.1)
Age group								
10s	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
20s	2.6	3.1	0.5	0.5	0.3	0.0	0.8	6.0
30s	5.1	4.9	2.5	2.0	0.2	0.2	1.4	8.0
40s	3.5	2.3	0.8	0.7	0.5	0.5	0.4	4.7
50s	1.9	1.0	0.9	0.1	0.1	0.0	0.3	3.0
60s	0.8	0.2	0.6	0.2	0.2	0.2	0.0	1.7
Occupation								
Self-employed business	4.0	3.2	0.8	0.8	0.8	0.8	0.4	5.2
Full-time employee	3.4	2.1	1.3	0.9	0.1	0.1	0.6	4.7
Non-full-time employee	2.0	3.6	1.0	0.5	0.8	0.5	1.0	5.3
Student	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.4
Housewife (househusband)	1.1	0.9	1.1	0.5	0.0	0.0	0.5	3.2
Unemployed	3.4	2.2	1.1	1.1	0.6	0.6	0.0	5.0
Other	2.9	2.2	0.0	0.0	0.0	0.0	0.7	5.1
No response/unknown	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Final academic background								
Junior high school	11.9	6.2	4.6	3.1	1.0	1.0	1.5	13.9
High school	3.5	2.0	1.2	0.6	0.3	0.2	0.7	5.3
Vocational school	2.7	2.5	1.2	0.7	0.5	0.5	0.5	3.9
Junior college/university	0.6	1.6	0.3	0.3	0.1	0.0	0.3	2.4
Graduate school	0.0	1.5	0.0	0.0	0.0	0.0	0.0	1.5
Other	0.0	6.3	0.0	6.3	0.0	0.0	0.0	6.3
In school	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.4
No response/unknown	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Time spent on the Internet								
None	1.2	0.2	0.5	0.0	0.0	0.0	0.2	1.9
<1 hour	3.0	2.0	1.0	0.8	0.5	0.4	0.5	4.1
1 to <2 hours	2.2	2.6	0.9	0.6	0.2	0.2	0.3	4.9
2 to <3 hours	3.1	2.4	0.9	0.9	0.2	0.0	1.1	5.1
3 to <5 hours	2.5	2.8	0.9	0.9	0.3	0.3	0.0	4.1
≥5 hours	3.8	2.4	1.9	0.7	0.2	0.2	0.9	5.4
No response/unknown	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

“10s” refers to those aged 15 to 19, and “60s” refers to those aged 60 to 64.

Table 3. Drug Accessibility by Drug (n = 3076)

(%)

	Drug accessibility							
	Organic solvents	Cannabis	Methamp hetamine	MDMA	Cocaine	Heroin	NPSs	Any drug
Total	51.5 (52.4)	14.1 (14.6)	12.7 (13.1)	12.8 (13.0)	11.1 (11.5)	10.5 (11.1)	20.1 (21.8)	52.6 (53.5)
Residence area								
Hokkaido	43.5	18.3	11.5	12.2	9.9	9.2	20.6	45.8
Tohoku	48.8	15.6	14.0	14.0	11.2	10.8	18.8	49.6
Kanto	55.9	17.8	15.7	15.5	14.1	13.8	25.0	57.0
Hokuriku	45.5	5.8	6.5	6.5	5.2	5.2	15.6	50.0
Tousan	46.0	5.3	5.3	6.7	4.7	4.7	8.0	46.7
Tokai	51.8	12.8	11.9	12.8	10.4	9.8	22.0	52.4
Kinki	51.6	12.7	11.3	11.8	9.0	8.1	18.6	52.5
Chugoku	56.0	12.6	14.1	11.5	11.5	10.5	18.8	56.5
Shikoku	48.9	12.5	11.4	12.5	9.1	9.1	19.3	48.9
Kita-Kyusyu	47.6	14.4	13.5	14.4	13.1	12.2	18.3	48.0
Minami-Kyusyu	47.9	10.9	10.3	10.3	10.3	9.1	13.9	49.1
Sex								
Men	61.8	14.8	12.7	13.1	11.1	10.8	22.2	62.8
Women	42.1	13.4	12.7	12.6	11.1	10.3	18.2	43.3
Age group								
10s	32.4	18.5	17.6	15.3	16.2	15.8	20.3	33.8
20s	43.5	20.4	17.8	16.0	16.2	15.2	23.0	45.3
30s	51.4	19.0	16.5	17.2	13.7	13.2	24.1	52.8
40s	58.6	13.6	12.6	14.1	10.9	10.5	22.4	59.5
50s	55.5	10.6	10.1	10.2	8.9	8.1	19.0	56.5
60s	49.9	7.0	5.9	5.9	4.9	4.9	11.2	50.1
Occupation								
Self-employed business	64.1	12.9	11.7	12.9	10.1	10.1	20.6	64.5
Full-time employee	57.8	14.6	12.4	12.7	10.9	10.4	21.7	58.8
Non-full-time employee	48.0	16.8	16.0	17.0	13.5	12.9	23.1	49.7
Student	35.8	19.9	18.8	16.2	18.1	17.3	23.2	37.3
Housewife (househusband)	41.7	9.4	8.7	9.2	6.9	6.0	13.5	42.7
Unemployed	44.7	10.1	10.6	9.5	8.4	7.8	13.4	45.8
Other	44.9	12.3	11.6	11.6	11.6	10.9	18.8	45.7
No response/unknown	50.0	0.0	25.0	0.0	0.0	0.0	0.0	50.0
Final academic background								
Junior high school	49.0	17.5	16.0	18.0	14.9	14.4	20.6	49.5
High school	50.7	12.4	11.4	11.9	9.7	8.9	18.4	51.4
Vocational school	52.0	14.8	13.3	12.1	11.1	11.1	18.0	52.7
Junior college/university	56.1	13.6	11.9	12.4	10.2	9.8	21.5	57.6
Graduate school	78.8	15.2	12.1	13.6	10.6	9.1	33.3	80.3
Other	31.3	12.5	6.3	12.5	6.3	6.3	18.8	37.5
In school	35.8	19.9	18.8	16.2	18.1	17.3	23.2	37.3
No response/unknown	25.0	0.0	0.0	0.0	0.0	0.0	0.0	25.0
Time spent on the Internet								
None	39.2	8.9	9.1	8.4	7.7	7.2	11.7	39.9
<1 hour	53.7	12.2	10.0	10.0	9.3	8.5	18.8	54.9
1 to <2 hours	51.9	13.3	11.4	12.3	9.6	9.4	21.1	53.0
2 to <3 hours	55.0	17.1	15.7	15.3	14.4	13.7	22.4	56.3
3 to <5 hours	51.3	15.9	15.0	16.6	13.4	12.8	23.4	52.2
≥5 hours	56.5	19.9	18.7	18.2	15.1	14.4	25.3	57.4
No response/unknown	31.3	6.3	6.3	6.3	6.3	6.3	6.3	31.3

Drug accessibility: The proportion of respondents who answered that drug were “barely accessible” or “easily accessible” when a question about drug accessibility was asked on a scale of four levels.

“10s” refers to those aged 15 to 19, and “60s” refers to those aged 60 to 64.

Table 4. Rate of Having a Close Drug Abuser by Drug (n = 3076)

(%)

	Rate of having a close drug abuser							
	Organic solvents	Cannabis	Methamp hetamine	MDMA	Cocaine	Heroin	NPSs	Any drug
Total	4.5 (4.5)	2.8 (2.7)	2.6 (2.5)	1.4 (1.4)	1.2 (1.3)	1.1 (1.2)	1.5 (1.6)	6.0 (5.9)
Residence area								
Hokkaido	3.1	6.1	3.8	3.1	0.8	0.8	2.3	8.4
Tohoku	4.4	2.8	2.4	1.2	1.6	1.2	2.0	4.8
Kanto	4.6	2.3	2.0	0.8	0.8	0.9	1.4	5.9
Hokuriku	5.2	2.6	1.9	1.3	0.6	0.6	0.6	5.8
Tousan	2.7	3.3	3.3	2.7	2.7	2.7	2.7	4.7
Tokai	6.4	3.4	3.4	2.4	1.8	1.5	1.8	7.6
Kinki	2.9	2.9	2.3	0.7	0.7	0.7	1.1	5.4
Chugoku	6.3	3.1	3.7	2.1	2.6	2.6	3.1	7.9
Shikoku	9.1	2.3	5.7	2.3	1.1	1.1	1.1	11.4
Kita-Kyusyu	3.1	1.7	2.2	0.9	0.4	0.9	0.9	3.9
Minami-Kyusyu	3.0	2.4	1.8	1.2	1.2	0.6	0.6	4.2
Sex								
Men	5.7	3.8	3.0	1.8	1.6	1.5	2.1	7.5
Women	3.4	1.9	2.2	0.9	0.7	0.8	1.0	4.7
Age group								
10s	2.7	2.7	2.3	2.3	2.3	1.8	1.8	3.2
20s	3.9	3.9	2.1	1.3	1.3	1.3	2.4	6.5
30s	5.8	4.5	2.7	2.2	1.3	1.3	2.4	9.0
40s	5.1	2.4	3.6	0.8	0.7	0.7	0.9	6.5
50s	3.7	1.9	2.3	1.4	1.3	1.3	1.4	4.2
60s	4.2	1.9	1.7	0.8	1.1	1.1	0.8	5.3
Occupation								
Self-employed business	8.9	7.3	4.0	2.8	2.4	2.0	2.4	10.9
Full-time employee	5.0	2.5	2.3	1.3	1.0	0.9	1.7	6.3
Non-full-time employee	4.3	3.0	3.0	1.3	1.3	1.8	1.5	6.6
Student	3.0	3.3	2.6	2.6	2.6	2.2	2.2	3.7
Housewife (househusband)	2.5	0.9	1.6	0.7	0.2	0.2	0.7	3.9
Unemployed	3.4	2.2	2.8	0.6	0.6	0.6	0.6	5.6
Other	1.4	2.9	2.9	0.7	1.4	1.4	0.7	3.6
No response/unknown	25.0	0.0	25.0	0.0	0.0	0.0	0.0	25.0
Final academic background								
Junior high school	10.3	7.2	7.7	3.1	2.1	2.1	3.1	13.4
High school	4.6	2.2	2.6	1.1	1.0	0.8	1.3	5.8
Vocational school	5.4	3.4	2.0	0.7	0.5	0.5	0.7	6.9
Junior college/university	3.0	2.2	1.7	1.2	1.1	1.3	1.7	5.0
Graduate school	6.1	4.5	3.0	3.0	1.5	1.5	1.5	9.1
Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
In school	3.0	3.3	2.6	2.6	2.6	2.2	2.2	3.7
No response/unknown	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Time spent on the Internet								
None	4.4	1.9	3.3	0.9	1.2	1.2	0.9	5.6
<1 hour	4.1	2.5	2.8	1.6	1.6	1.5	1.9	6.0
1 to <2 hours	4.3	1.8	1.8	0.6	0.6	0.5	0.6	5.2
2 to <3 hours	4.7	3.5	2.2	1.3	1.1	1.1	1.8	6.9
3 to <5 hours	4.1	3.4	2.8	2.5	1.9	1.9	2.5	5.3
≥5 hours	5.7	4.5	2.8	1.7	0.7	0.9	1.9	7.6
No response/unknown	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Rate of having a close drug abuser: The proportion of respondents knowing anybody who uses or has used illegal drugs around them.

Table 5. Prevalence of the Use of Analgesics, Tranquilizers, and/or Hypnotics (n = 3076)

(%)

	Analgesics			Tranquilizers			Hypnotics		
	Past-year use	Past 30-day use	Chronic use	Past-year use	Past 30-day use	Chronic use	Past-year use	Past 30-day use	Chronic use
Total	63.0 (62.9)	26.7 (26.9)	2.5 (2.3)	6.0 (5.6)	4.3 (4.2)	3.1 (3.0)	6.2 (6.1)	4.4 (4.3)	2.9 (2.8)
Residence area									
Hokkaido	73.3	30.5	1.5	8.4	7.6	4.6	9.9	6.9	3.8
Tohoku	60.4	19.2	2.8	6.0	5.2	2.8	5.2	5.2	2.8
Kanto	63.2	27.5	2.7	7.2	5.5	4.0	7.4	5.3	3.4
Hokuriku	62.3	24.7	3.9	3.2	1.9	1.3	4.5	2.6	0.6
Tousan	58.7	24.0	2.7	5.3	2.7	1.3	6.0	4.0	3.3
Tokai	66.2	29.9	1.5	4.0	3.4	2.1	4.0	2.7	1.8
Kinki	58.1	26.2	2.3	6.1	3.6	2.9	6.1	4.5	3.4
Chugoku	58.6	24.6	2.1	4.7	2.6	2.1	5.2	3.1	2.1
Shikoku	71.6	29.5	4.5	8.0	4.5	5.7	6.8	3.4	3.4
Kita-Kyusyu	64.6	27.1	2.6	3.9	2.6	2.2	5.2	3.9	2.6
Minami-Kyusyu	66.7	29.1	1.8	7.3	4.8	3.6	6.1	3.6	3.0
Sex									
Men	53.0 (53.1)	15.4 (15.3)	2.0 (1.9)	4.6 (4.2)	3.5 (3.3)	2.8 (2.7)	5.0 (5.2)	3.7 (3.6)	2.4 (2.3)
Women	72.0 (71.9)	36.9 (37.5)	3.0 (2.7)	7.2 (6.9)	5.0 (5.0)	3.4 (3.2)	7.2 (7.0)	5.0 (4.9)	3.4 (3.2)
Age group									
10s	57.2	24.8	0.0	3.2	1.8	1.4	1.8	0.5	0.0
20s	62.6	28.0	1.8	5.8	3.4	2.1	3.7	2.4	1.3
30s	70.3	32.7	1.6	5.1	3.6	2.7	4.5	3.4	2.7
40s	66.4	28.6	2.7	6.7	4.3	3.5	7.1	4.8	2.9
50s	63.0	25.3	3.5	6.2	4.9	3.5	7.6	5.5	3.3
60s	51.8	18.2	3.6	7.2	6.1	4.0	8.7	6.8	5.1
Occupation									
Self-employed business	56.9	16.9	2.0	4.8	3.6	2.8	2.8	2.4	2.0
Full-time employee	63.5	25.4	2.3	4.6	2.8	2.0	5.2	3.5	2.0
Non-full-time employee	67.8	29.4	3.3	5.1	3.8	3.0	4.6	3.0	2.0
Student	56.1	26.2	0.0	2.6	1.5	0.7	1.5	0.4	0.0
Housewife (househusband)	71.6	38.1	3.4	7.6	6.0	3.4	8.9	6.0	3.7
Unemployed	48.0	20.1	2.8	19.6	15.6	12.3	17.3	13.4	11.2
Other	60.9	22.5	5.1	8.7	7.2	5.8	12.3	11.6	8.0
No response/unknown	50.0	25.0	0.0	25.0	25.0	25.0	25.0	25.0	25.0
Final academic background									
Junior high school	56.2	21.6	6.2	9.8	8.2	6.2	9.3	7.2	5.7
High school	63.8	27.1	2.8	6.1	4.4	3.4	7.1	4.6	3.0
Vocational school	70.4	31.0	3.4	6.9	4.2	3.2	7.4	5.9	4.4
Junior college/university	63.3	25.6	1.8	5.6	4.1	2.7	5.2	4.0	2.3
Graduate school	53.0	24.2	0.0	6.1	4.5	4.5	7.6	6.1	4.5
Other	50.0	25.0	6.3	12.5	12.5	0.0	6.3	6.3	0.0
In school	56.1	26.2	0.0	2.6	1.5	0.7	1.5	0.4	0.0
No response/unknown	25.0	25.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Time spent on the Internet									
None	49.7	17.2	3.3	7.7	6.3	5.1	8.2	7.0	5.1
<1 hour	61.2	24.9	2.8	6.6	5.2	3.6	6.7	4.9	3.3
1 to <2 hours	65.9	27.0	1.7	5.4	3.4	2.8	6.2	4.5	2.2
2 to <3 hours	69.6	33.0	3.1	5.3	3.3	2.9	5.1	3.3	2.4
3 to <5 hours	68.4	29.1	2.5	5.0	3.8	1.6	4.7	3.1	1.9
≥5 hours	65.2	30.7	1.9	5.4	3.3	2.1	5.2	2.8	2.4
No response/unknown	31.3	18.8	0.0	6.3	6.3	0.0	12.5	0.0	0.0

Rate of having a close drug abuser: The proportion of respondents knowing anybody who uses or has used illegal drugs around them.

Chronic use: The proportion of respondents who have used any analgesic, tranquilizer, or hypnotic ≥three times a week.

“10s” refers to those aged 15 to 19, and “60s” refers to those aged 60 to 64.

Table 6. Prevalence of Alcohol and/or Tobacco Use (n = 3076)

(%)

	Alcohol and/or tobacco use					
	Alcohol use			Tobacco use		
	Lifetime prevalence	Past-year prevalence	Past 30-day prevalence	Lifetime prevalence	Past-year prevalence	Past 30-day prevalence
Total	93.4 (93.8)	79.8 (80.2)	67.0 (67.0)	59.8 (59.8)	26.9 (26.2)	24.3 (23.2)
Residence area						
Hokkaido	96.9	84.7	67.9	77.9	36.6	33.6
Tohoku	92.0	77.2	65.2	59.2	29.6	28.4
Kanto	92.8	81.3	69.7	60.7	26.4	23.7
Hokuriku	96.1	86.4	68.8	66.9	29.2	26.6
Tousan	94.0	80.0	64.0	55.3	22.0	21.3
Tokai	95.4	78.0	67.4	57.3	27.1	23.5
Kinki	93.9	76.7	63.6	55.7	24.4	21.7
Chugoku	89.5	77.0	61.3	56.5	26.7	23.6
Shikoku	98.9	79.5	61.4	67.0	31.8	29.5
Kita-Kyusyu	91.3	79.9	68.1	59.0	24.5	22.7
Minami-Kyusyu	91.5	79.4	70.9	55.2	27.3	22.4
Sex						
Men	93.7 (94.2)	84.4 (84.6)	75.0 (74.9)	76.2 (75.0)	40.9 (40.2)	37.9 (36.8)
Women	93.0 (93.4)	75.6 (76.1)	59.7 (59.7)	44.8 (45.8)	14.1 (13.3)	11.8 (10.6)
Age group						
10s	36.0	25.2	14.9	6.8	4.5	2.7
20s	97.1	90.3	76.7	42.9	26.7	23.0
30s	98.6	83.9	70.0	68.7	32.7	29.1
40s	98.8	85.9	71.9	67.6	30.9	28.4
50s	97.7	81.7	70.4	67.9	28.8	26.5
60s	96.2	79.5	67.4	63.2	21.6	19.9
Occupation						
Self-employed business	97.6	89.1	79.4	79.0	38.3	36.3
Full-time employee	98.9	89.7	78.1	69.1	33.8	30.8
Non-full-time employee	97.7	82.5	66.2	58.6	23.4	20.8
Student	50.2	41.3	31.0	8.9	4.4	1.8
Housewife (househusband)	95.9	69.3	52.5	46.6	12.2	10.8
Unemployed	92.2	67.6	59.2	65.9	32.4	29.6
Other	94.9	79.0	61.6	67.4	29.0	24.6
No response/unknown	100.0	75.0	25.0	50.0	50.0	50.0
Final academic background						
Junior high school	92.3	75.3	60.8	77.8	53.6	51.5
High school	97.6	84.1	71.6	67.3	33.5	30.4
Vocational school	98.0	83.5	67.7	65.5	26.1	23.9
Junior college/university	98.5	84.3	71.8	59.6	21.4	18.8
Graduate school	100.0	89.4	81.8	48.5	9.1	7.6
Other	87.5	81.3	68.8	62.5	12.5	12.5
In school	50.2	41.3	31.0	8.9	4.4	1.8
No response/unknown	75.0	62.5	37.5	37.5	12.5	12.5
Time spent on the Internet						
None	91.8	68.8	55.5	57.1	33.1	31.2
<1 hour	97.0	84.3	71.4	64.5	24.0	21.6
1 to <2 hours	93.8	81.7	72.0	61.8	26.2	21.9
2 to <3 hours	91.4	78.7	66.5	57.6	27.5	25.5
3 to <5 hours	90.3	81.9	62.5	54.1	25.0	23.4
≥5 hours	92.0	80.1	67.6	57.4	27.9	25.1
No response/unknown	93.8	56.3	43.8	50.0	25.0	25.0

“10s” refers to those aged 15 to 19, and “60s” refers to those aged 60 to 64.

Table 7. Basic demographics by Residence Area (n = 3076)

	Residence area											
	Hokkaido		Tohoku		Kanto		Hokuriku		Tousan		Tokai	
	n = 131	n = 250	n = 948	n = 154	n = 150	n = 328	n	(%)	n	(%)	n	(%)
Sex												
Men	65	(49.6)	114	(45.6)	466	(49.2)	83	(53.9)	71	(47.3)	157	(47.9)
Women	66	(50.4)	136	(54.4)	482	(50.8)	71	(46.1)	79	(52.7)	171	(52.1)
Age group												
10s	9	(6.9)	16	(6.4)	82	(8.6)	11	(7.1)	7	(4.7)	15	(4.6)
20s	16	(12.2)	41	(16.4)	129	(13.6)	14	(9.1)	14	(9.3)	44	(13.4)
30s	29	(22.1)	30	(12.0)	158	(16.7)	28	(18.2)	27	(18.0)	81	(24.7)
40s	28	(21.4)	49	(19.6)	255	(26.9)	42	(27.3)	36	(24.0)	69	(21.0)
50s	28	(21.4)	55	(22.0)	191	(20.1)	36	(23.4)	39	(26.0)	83	(25.3)
60s	21	(16.0)	59	(23.6)	133	(14.0)	23	(14.9)	27	(18.0)	36	(11.0)
Mean age (year)	43.36		44.85		42.27		44.21		45.60		42.69	
Occupation												
Self-employed business	6	(4.6)	30	(12.0)	67	(7.1)	8	(5.2)	16	(10.7)	29	(8.8)
Full-time employee	61	(46.6)	106	(42.4)	429	(45.3)	91	(59.1)	77	(51.3)	159	(48.5)
Non-full-time employee	13	(9.9)	34	(13.6)	125	(13.2)	20	(13.0)	22	(14.7)	34	(10.4)
Student	11	(8.4)	17	(6.8)	96	(10.1)	13	(8.4)	8	(5.3)	25	(7.6)
Housewife (househusband)	28	(21.4)	24	(9.6)	130	(13.7)	10	(6.5)	21	(14.0)	54	(16.5)
Unemployed	7	(5.3)	25	(10.0)	55	(5.8)	8	(5.2)	1	(.7)	15	(4.6)
Other	5	(3.8)	14	(5.6)	46	(4.9)	4	(2.6)	5	(3.3)	12	(3.7)
No response/unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Final academic background												
Junior high school	13	(9.9)	23	(9.2)	52	(5.5)	12	(7.8)	4	(2.7)	19	(5.8)
High school	43	(32.8)	129	(51.6)	309	(32.6)	69	(44.8)	56	(37.3)	143	(43.6)
Vocational school	24	(18.3)	26	(10.4)	132	(13.9)	25	(16.2)	26	(17.3)	31	(9.5)
Junior college/university	38	(29.0)	46	(18.4)	311	(32.8)	35	(22.7)	54	(36.0)	102	(31.1)
Graduate school	1	(.8)	4	(1.6)	40	(4.2)	0	(.0)	1	(.7)	5	(1.5)
Other	1	(.8)	4	(1.6)	7	(.7)	0	(.0)	0	(.0)	2	(.6)
In school	11	(8.4)	17	(6.8)	96	(10.1)	13	(8.4)	8	(5.3)	25	(7.6)
No response/unknown	0	(.0)	1	(.4)	1	(.1)	0	(.0)	1	(.7)	1	(.3)
Cellular phone												
Smartphone	82	(62.6)	148	(59.2)	679	(71.6)	98	(63.6)	97	(64.7)	232	(70.7)
Conventional cellular phone	44	(33.6)	91	(36.4)	259	(27.3)	54	(35.1)	52	(34.7)	95	(29.0)
PHS	0	(.0)	2	(.8)	14	(1.5)	1	(.6)	0	(.0)	3	(.9)
Other	0	(.0)	2	(.8)	5	(.5)	0	(.0)	2	(1.3)	1	(.3)
None	3	(2.3)	12	(4.8)	24	(2.5)	5	(3.2)	3	(2.0)	6	(1.8)
No response/unknown	2	(1.5)	1	(.4)	2	(.2)	0	(.0)	0	(.0)	2	(.6)
Time spent on the Internet												
None	17	(13.0)	42	(16.8)	96	(10.1)	26	(16.9)	29		37	(11.3)
<1 hour	35	(26.7)	70	(28.0)	222	(23.4)	36	(23.4)	53	(35.3)	90	(27.4)
1 to <2 hours	27	(20.6)	42	(16.8)	213	(22.5)	40	(26.0)	22	(14.7)	67	(20.4)
2 to <3 hours	22	(16.8)	31	(12.4)	146	(15.4)	22	(14.3)	20	(13.3)	44	(13.4)
3 to <5 hours	13	(9.9)	35	(14.0)	109	(11.5)	15	(9.7)	10	(6.7)	37	(11.3)
≥5 hours	15	(11.5)	29	(11.6)	159	(16.8)	14	(9.1)	15	(10.0)	52	(15.9)
No response/unknown	2	(1.5)	1	(.4)	3	(.3)	1	(.6)	1	(.7)	1	(.3)

“10s” refers to those aged 15 to 19, and “60s” refers to those aged 60 to 64.

Table 7. Basic demographics by Residence Area (n = 3076) continued

	Residence area										P-value		
	Kinki		Chugoku		Shikoku		Kita-Kyusyu		Minami-			Total	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)		n	(%)
Sex													0.714
Men	194	(43.9)	91	(47.6)	43	(48.9)	103	(45.0)	79	(47.9)	1,466	(47.7)	
Women	248	(56.1)	100	(52.4)	45	(51.1)	126	(55.0)	86	(52.1)	1,610	(52.3)	
Age group													0.003
10s	29	(6.6)	18	(9.4)	4	(4.5)	16	(7.0)	15	(9.1)	222	(7.2)	
20s	51	(11.5)	18	(9.4)	11	(12.5)	27	(11.8)	17	(10.3)	382	(12.4)	
30s	72	(16.3)	27	(14.1)	18	(20.5)	51	(22.3)	32	(19.4)	553	(18.0)	
40s	109	(24.7)	54	(28.3)	24	(27.3)	54	(23.6)	31	(18.8)	751	(24.4)	
50s	108	(24.4)	41	(21.5)	20	(22.7)	44	(19.2)	50	(30.3)	695	(22.6)	
60s	73	(16.5)	33	(17.3)	11	(12.5)	37	(16.2)	20	(12.1)	473	(15.4)	
Mean age (year)	44.14		44.08		43.05		42.68		42.87		43.30		0.089
Occupation													<0.001
Self-employed business	39	(8.8)	13	(6.8)	5	(5.7)	25	(10.9)	10	(6.1)	248	(8.1)	
Full-time employee	157	(35.5)	98	(51.3)	51	(58.0)	102	(44.5)	75	(45.5)	1,406	(45.7)	
Non-full-time employee	65	(14.7)	25	(13.1)	8	(9.1)	28	(12.2)	20	(12.1)	394	(12.8)	
Student	39	(8.8)	21	(11.0)	4	(4.5)	21	(9.2)	16	(9.7)	271	(8.8)	
Housewife (househusband)	88	(19.9)	20	(10.5)	12	(13.6)	25	(10.9)	24	(14.5)	436	(14.2)	
Unemployed	29	(6.6)	7	(3.7)	5	(5.7)	12	(5.2)	15	(9.1)	179	(5.8)	
Other	23	(5.2)	7	(3.7)	3	(3.4)	14	(6.1)	5	(3.0)	138	(4.5)	
No response/unknown	2	(.5)	0	(.0)	0	(.0)	2	(.9)	0	(.0)	4	(.1)	
Final academic background													<0.001
Junior high school	37	(8.4)	5	(2.6)	8	(9.1)	14	(6.1)	7	(4.2)	194	(6.3)	
High school	162	(36.7)	77	(40.3)	35	(39.8)	83	(36.2)	80	(48.5)	1,186	(38.6)	
Vocational school	58	(13.1)	32	(16.8)	11	(12.5)	23	(10.0)	18	(10.9)	406	(13.2)	
Junior college/university	140	(31.7)	54	(28.3)	27	(30.7)	81	(35.4)	41	(24.8)	929	(30.2)	
Graduate school	4	(.9)	2	(1.0)	3	(3.4)	4	(1.7)	2	(1.2)	66	(2.1)	
Other	1	(.2)	0	(.0)	0	(.0)	0	(.0)	1	(.6)	16	(.5)	
In school	39	(8.8)	21	(11.0)	4	(4.5)	21	(9.2)	16	(9.7)	271	(8.8)	
No response/unknown	1	(.2)	0	(.0)	0	(.0)	3	(1.3)	0	(.0)	8	(.3)	
Cellular phone													
Smartphone	303	(68.6)	128	(67.0)	62	(70.5)	155	(67.7)	111	(67.3)	2,095	(68.1)	0.065
Conventional cellular phone	137	(31.0)	63	(33.0)	23	(26.1)	66	(28.8)	52	(31.5)	936	(30.4)	0.220
PHS	2	(.5)	2	(1.0)	2	(2.3)	2	(.9)	4	(2.4)	32	(1.0)	0.372
Other	4	(.9)	0	(.0)	1	(1.1)	5	(2.2)	2	(1.2)	22	(.7)	0.247
None	15	(3.4)	4	(2.1)	1	(1.1)	6	(2.6)	3	(1.8)	82	(2.7)	0.546
No response/unknown	1	(.2)	1	(.5)	1	(1.1)	2	(.9)	0	(.0)	12	(.4)	0.405
Time spent on the Internet													0.009
None	75	(17.0)	23	(12.0)	10	(11.4)	39	(17.0)	35		429	(13.9)	
<1 hour	104	(23.5)	53	(27.7)	19	(21.6)	63	(27.5)	43	(26.1)	788	(25.6)	
1 to <2 hours	90	(20.4)	41	(21.5)	21	(23.9)	52	(22.7)	34	(20.6)	649	(21.1)	
2 to <3 hours	74	(16.7)	28	(14.7)	19	(21.6)	24	(10.5)	21	(12.7)	451	(14.7)	
3 to <5 hours	44	(10.0)	15	(7.9)	9	(10.2)	22	(9.6)	11	(6.7)	320	(10.4)	
≥5 hours	53	(12.0)	30	(15.7)	9	(10.2)	27	(11.8)	20	(12.1)	423	(13.8)	
No response/unknown	2	(.5)	1	(.5)	1	(1.1)	2	(.9)	1	(.6)	16	(.5)	

“10s” refers to those aged 15 to 19, and “60s” refers to those aged 60 to 64.

Table 8. Basic demographics by Sex (n = 3076)

	Sex						P-value
	Men		Women		Total		
	n = 1466		n = 1610		n = 3076		
	n	(%)	n	(%)	n	(%)	
Residence area							0.714
Hokkaido	65	(4.4)	66	(4.1)	131	(4.3)	
Tohoku	114	(7.8)	136	(8.4)	250	(8.1)	
Kanto	466	(31.8)	482	(29.9)	948	(30.8)	
Hokuriku	83	(5.7)	71	(4.4)	154	(5.0)	
Tosan	71	(4.8)	79	(4.9)	150	(4.9)	
Tokai	157	(10.7)	171	(10.6)	328	(10.7)	
Kinki	194	(13.2)	248	(15.4)	442	(14.4)	
Chugoku	91	(6.2)	100	(6.2)	191	(6.2)	
Shikoku	43	(2.9)	45	(2.8)	88	(2.9)	
Kita-Kyusyu	103	(7.0)	126	(7.8)	229	(7.4)	
Minami-Kyusyu	79	(5.4)	86	(5.3)	165	(5.4)	
Age group							0.697
10s	111	(7.6)	111	(6.9)	222	(7.2)	
20s	169	(11.5)	213	(13.2)	382	(12.4)	
30s	271	(18.5)	282	(17.5)	553	(18.0)	
40s	356	(24.3)	395	(24.5)	751	(24.4)	
50s	328	(22.4)	367	(22.8)	695	(22.6)	
60s	231	(15.8)	242	(15.0)	473	(15.4)	
Mean age (year)	43.45		43.16		43.30		0.558
Occupation							<0.001
Self-employed business	179	(12.2)	69	(4.3)	248	(8.1)	
Full-time employee	913	(62.3)	493	(30.6)	1,406	(45.7)	
Non-full-time employee	91	(6.2)	303	(18.8)	394	(12.8)	
Student	132	(9.0)	139	(8.6)	271	(8.8)	
Housewife (househusband)	1	(.1)	435	(27.0)	436	(14.2)	
Unemployed	94	(6.4)	85	(5.3)	179	(5.8)	
Other	56	(3.8)	82	(5.1)	138	(4.5)	
No response/unknown	0	(.0)	4	(.2)	4	(.1)	
Final academic background							<0.001
Junior high school	116	(7.9)	78	(4.8)	194	(6.3)	
High school	567	(38.7)	619	(38.4)	1,186	(38.6)	
Vocational school	137	(9.3)	269	(16.7)	406	(13.2)	
Junior college/university	450	(30.7)	479	(29.8)	929	(30.2)	
Graduate school	51	(3.5)	15	(.9)	66	(2.1)	
Other	10	(.7)	6	(.4)	16	(.5)	
In school	132	(9.0)	139	(8.6)	271	(8.8)	
No response/unknown	3	(.2)	5	(.3)	8	(.3)	
Cellular phone							
Smartphone	984	(67.1)	1,111	(69.0)	2,095	(68.1)	0.466
Conventional cellular phone	475	(32.4)	461	(28.6)	936	(30.4)	0.072
PHS	20	(1.4)	12	(.7)	32	(1.0)	0.221
Other	11	(.8)	11	(.7)	22	(.7)	0.895
None	40	(2.7)	42	(2.6)	82	(2.7)	0.898
No response/unknown	5	(.3)	7	(.4)	12	(.4)	0.677
Time spent on the Internet							0.040
None	178	(12.1)	251	(15.6)	429	(13.9)	
<1 hour	372	(25.4)	416	(25.8)	788	(25.6)	
1 to <2 hours	332	(22.6)	317	(19.7)	649	(21.1)	
2 to <3 hours	232	(15.8)	219	(13.6)	451	(14.7)	
3 to <5 hours	145	(9.9)	175	(10.9)	320	(10.4)	
≥5 hours	200	(13.6)	223	(13.9)	423	(13.8)	
No response/unknown	7	(.5)	9	(.6)	16	(.5)	

“10s” refers to those aged 15 to 19, and “60s” refers to those aged 60 to 64.

Table 9. Basic demographics by Age Group (n = 3076)

	Age group												P-value		
	10s		20s		30s		40s		50s		60s			Total	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)		n	(%)
Residence area															
Hokkaido	9	(4.1)	16	(4.2)	29	(5.2)	28	(3.7)	28	(4.0)	21	(4.4)	131	(4.3)	0.003
Tohoku	16	(7.2)	41	(10.7)	30	(5.4)	49	(6.5)	55	(7.9)	59	(12.5)	250	(8.1)	
Kanto	82	(36.9)	129	(33.8)	158	(28.6)	255	(34.0)	191	(27.5)	133	(28.1)	948	(30.8)	
Hokuriku	11	(5.0)	14	(3.7)	28	(5.1)	42	(5.6)	36	(5.2)	23	(4.9)	154	(5.0)	
Tousan	7	(3.2)	14	(3.7)	27	(4.9)	36	(4.8)	39	(5.6)	27	(5.7)	150	(4.9)	
Tokai	15	(6.8)	44	(11.5)	81	(14.6)	69	(9.2)	83	(11.9)	36	(7.6)	328	(10.7)	
Kinki	29	(13.1)	51	(13.4)	72	(13.0)	109	(14.5)	108	(15.5)	73	(15.4)	442	(14.4)	
Chugoku	18	(8.1)	18	(4.7)	27	(4.9)	54	(7.2)	41	(5.9)	33	(7.0)	191	(6.2)	
Shikoku	4	(1.8)	11	(2.9)	18	(3.3)	24	(3.2)	20	(2.9)	11	(2.3)	88	(2.9)	
Kita-Kyusyu	16	(7.2)	27	(7.1)	51	(9.2)	54	(7.2)	44	(6.3)	37	(7.8)	229	(7.4)	
Minami-Kyusyu	15	(6.8)	17	(4.5)	32	(5.8)	31	(4.1)	50	(7.2)	20	(4.2)	165	(5.4)	
Sex															
Men	111	(50.0)	169	(44.2)	271	(49.0)	356	(47.4)	328	(47.2)	231	(48.8)	1,466	(47.7)	0.697
Women	111	(50.0)	213	(55.8)	282	(51.0)	395	(52.6)	367	(52.8)	242	(51.2)	1,610	(52.3)	
Occupation															
Self-employed business	1	(.5)	8	(2.1)	23	(4.2)	58	(7.7)	98	(14.1)	60	(12.7)	248	(8.1)	<0.001
Full-time employee	6	(2.7)	206	(53.9)	329	(59.5)	422	(56.2)	315	(45.3)	128	(27.1)	1,406	(45.7)	
Non-full-time employee	5	(2.3)	49	(12.8)	60	(10.8)	114	(15.2)	105	(15.1)	61	(12.9)	394	(12.8)	
Student	207	(93.2)	62	(16.2)	1	(.2)	1	(.1)	0	(.0)	0	(.0)	271	(8.8)	
Housewife (househusband)	0	(.0)	21	(5.5)	94	(17.0)	99	(13.2)	105	(15.1)	117	(24.7)	436	(14.2)	
Unemployed	2	(.9)	24	(6.3)	20	(3.6)	28	(3.7)	31	(4.5)	74	(15.6)	179	(5.8)	
Other	1	(.5)	12	(3.1)	24	(4.3)	29	(3.9)	39	(5.6)	33	(7.0)	138	(4.5)	
No response/unknown	0	(.0)	0	(.0)	2	(.4)	0	(.0)	2	(.3)	0	(.0)	4	(.1)	
Final academic background															
Junior high school	4	(1.8)	19	(5.0)	26	(4.7)	47	(6.3)	34	(4.9)	64	(13.5)	194	(6.3)	<0.001
High school	11	(5.0)	111	(29.1)	188	(34.0)	293	(39.0)	336	(48.3)	247	(52.2)	1,186	(38.6)	
Vocational school	0	(.0)	61	(16.0)	95	(17.2)	116	(15.4)	89	(12.8)	45	(9.5)	406	(13.2)	
Junior college/university	0	(.0)	119	(31.2)	214	(38.7)	269	(35.8)	223	(32.1)	104	(22.0)	929	(30.2)	
Graduate school	0	(.0)	5	(1.3)	24	(4.3)	19	(2.5)	9	(1.3)	9	(1.9)	66	(2.1)	
Other	0	(.0)	4	(1.0)	2	(.4)	5	(.7)	2	(.3)	3	(.6)	16	(.5)	
In school	207	(93.2)	62	(16.2)	1	(.2)	1	(.1)	0	(.0)	0	(.0)	271	(8.8)	
No response/unknown	0	(.0)	1	(.3)	3	(.5)	1	(.1)	2	(.3)	1	(.2)	8	(.3)	
Cellular phone															
Smartphone	200	(90.1)	371	(97.1)	484	(87.5)	553	(73.6)	363	(52.2)	124	(26.2)	2,095	(68.1)	<0.001
Conventional cellular phone	11	(5.0)	18	(4.7)	81	(14.6)	204	(27.2)	312	(44.9)	310	(65.5)	936	(30.4)	<0.001
PHS	0	(.0)	2	(.5)	5	(.9)	13	(1.7)	8	(1.2)	4	(.8)	32	(1.0)	0.161
Other	1	(.5)	3	(.8)	5	(.9)	3	(.4)	4	(.6)	6	(1.3)	22	(.7)	0.361
None	10	(4.5)	0	(.0)	5	(.9)	12	(1.6)	20	(2.9)	35	(7.4)	82	(2.7)	<0.001
No response/unknown	0	(.0)	0	(.0)	3	(.5)	1	(.1)	4	(.6)	4	(.8)	12	(.4)	0.212
Time spent on the Internet															
None	5	(2.3)	9	(2.4)	17	(3.1)	52	(6.9)	145	(20.9)	201	(42.5)	429	(13.9)	<0.001
<1 hour	16	(7.2)	40	(10.5)	127	(23.0)	223	(29.7)	237	(34.1)	145	(30.7)	788	(25.6)	
1 to <2 hours	44	(19.8)	76	(19.9)	135	(24.4)	194	(25.8)	139	(20.0)	61	(12.9)	649	(21.1)	
2 to <3 hours	56	(25.2)	81	(21.2)	102	(18.4)	110	(14.6)	78	(11.2)	24	(5.1)	451	(14.7)	
3 to <5 hours	49	(22.1)	81	(21.2)	70	(12.7)	77	(10.3)	30	(4.3)	13	(2.7)	320	(10.4)	
≥5 hours	51	(23.0)	95	(24.9)	100	(18.1)	92	(12.3)	61	(8.8)	24	(5.1)	423	(13.8)	
No response/unknown	1	(.5)	0	(.0)	2	(.4)	3	(.4)	5	(.7)	5	(1.1)	16	(.5)	

"10s" refers to those aged 15 to 19, and "60s" refers to those aged 60 to 64.

Table 10. Basic demographics by Occupation (n = 3076)

	Occupation									
	Self-employed		Full-time		Non-full-time		Student		Housewife	
	n = 248		n = 1406		n = 394		n = 271		n = 436	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Residence area										
Hokkaido	6	(2.4)	61	(4.3)	13	(3.3)	11	(4.1)	28	(6.4)
Tohoku	30	(12.1)	106	(7.5)	34	(8.6)	17	(6.3)	24	(5.5)
Kanto	67	(27.0)	429	(30.5)	125	(31.7)	96	(35.4)	130	(29.8)
Hokuriku	8	(3.2)	91	(6.5)	20	(5.1)	13	(4.8)	10	(2.3)
Tousan	16	(6.5)	77	(5.5)	22	(5.6)	8	(3.0)	21	(4.8)
Tokai	29	(11.7)	159	(11.3)	34	(8.6)	25	(9.2)	54	(12.4)
Kinki	39	(15.7)	157	(11.2)	65	(16.5)	39	(14.4)	88	(20.2)
Chugoku	13	(5.2)	98	(7.0)	25	(6.3)	21	(7.7)	20	(4.6)
Shikoku	5	(2.0)	51	(3.6)	8	(2.0)	4	(1.5)	12	(2.8)
Kita-Kyusyu	25	(10.1)	102	(7.3)	28	(7.1)	21	(7.7)	25	(5.7)
Minami-Kyusyu	10	(4.0)	75	(5.3)	20	(5.1)	16	(5.9)	24	(5.5)
Sex										
Men	179	(72.2)	913	(64.9)	91	(23.1)	132	(48.7)	1	(.2)
Women	69	(27.8)	493	(35.1)	303	(76.9)	139	(51.3)	435	(99.8)
Age group										
10s	1	(.4)	6	(.4)	5	(1.3)	207	(76.4)	0	(.0)
20s	8	(3.2)	206	(14.7)	49	(12.4)	62	(22.9)	21	(4.8)
30s	23	(9.3)	329	(23.4)	60	(15.2)	1	(.4)	94	(21.6)
40s	58	(23.4)	422	(30.0)	114	(28.9)	1	(.4)	99	(22.7)
50s	98	(39.5)	315	(22.4)	105	(26.6)	0	(.0)	105	(24.1)
60s	60	(24.2)	128	(9.1)	61	(15.5)	0	(.0)	117	(26.8)
Mean age (year)	51.19		43.10		45.71		18.16		48.83	
Final academic background										
Junior high school	26	(10.5)	71	(5.0)	24	(6.1)	0	(.0)	31	(7.1)
High school	102	(41.1)	547	(38.9)	185	(47.0)	0	(.0)	201	(46.1)
Vocational school	39	(15.7)	210	(14.9)	53	(13.5)	0	(.0)	58	(13.3)
Junior college/university	74	(29.8)	523	(37.2)	125	(31.7)	0	(.0)	141	(32.3)
Graduate school	5	(2.0)	47	(3.3)	5	(1.3)	0	(.0)	2	(.5)
Other	1	(.4)	7	(.5)	1	(.3)	0	(.0)	2	(.5)
In school	0	(.0)	0	(.0)	0	(.0)	271	(100.0)	0	(.0)
No response/unknown	1	(.4)	1	(.1)	1	(.3)	0	(.0)	1	(.2)
Cellular phone										
Smartphone	131	(52.8)	1,040	(74.0)	258	(65.5)	250	(92.3)	257	(58.9)
Conventional cellular phone	113	(45.6)	392	(27.9)	137	(34.8)	12	(4.4)	157	(36.0)
PHS	7	(2.8)	17	(1.2)	1	(.3)	0	(.0)	4	(.9)
Other	0	(.0)	8	(.6)	0	(.0)	0	(.0)	4	(.9)
None	8	(3.2)	9	(.6)	6	(1.5)	10	(3.7)	19	(4.4)
No response/unknown	1	(.4)	4	(.3)	2	(.5)	0	(.0)	3	(.7)
Time spent on the Internet										
None	46	(18.5)	131	(9.3)	64	(16.2)	5	(1.8)	97	(22.2)
<1 hour	68	(27.4)	395	(28.1)	95	(24.1)	24	(8.9)	130	(29.8)
1 to <2 hours	49	(19.8)	341	(24.3)	82	(20.8)	48	(17.7)	79	(18.1)
2 to <3 hours	29	(11.7)	221	(15.7)	52	(13.2)	67	(24.7)	48	(11.0)
3 to <5 hours	24	(9.7)	125	(8.9)	46	(11.7)	62	(22.9)	34	(7.8)
≥5 hours	29	(11.7)	186	(13.2)	53	(13.5)	65	(24.0)	46	(10.6)
No response/unknown	3	(1.2)	7	(.5)	2	(.5)	0	(.0)	2	(.5)

Table 10. Basic demographics by Occupation (n = 3076)continued

	Occupation								P-value
	Unemployed		Other		Unknown		Total		
	n = 179		n = 138		n = 4		n = 3076		
	n	(%)	n	(%)	n	(%)	n	(%)	
Residence area									<0.001
Hokkaido	7	(3.9)	5	(3.6)	0	(.0)	131	(4.3)	
Tohoku	25	(14.0)	14	(10.1)	0	(.0)	250	(8.1)	
Kanto	55	(30.7)	46	(33.3)	0	(.0)	948	(30.8)	
Hokuriku	8	(4.5)	4	(2.9)	0	(.0)	154	(5.0)	
Tousan	1	(.6)	5	(3.6)	0	(.0)	150	(4.9)	
Tokai	15	(8.4)	12	(8.7)	0	(.0)	328	(10.7)	
Kinki	29	(16.2)	23	(16.7)	2	(50.0)	442	(14.4)	
Chugoku	7	(3.9)	7	(5.1)	0	(.0)	191	(6.2)	
Shikoku	5	(2.8)	3	(2.2)	0	(.0)	88	(2.9)	
Kita-Kyusyu	12	(6.7)	14	(10.1)	2	(50.0)	229	(7.4)	
Minami-Kyusyu	15	(8.4)	5	(3.6)	0	(.0)	165	(5.4)	
Sex									<0.001
Men	94	(52.5)	56	(40.6)	0	(.0)	1,466	(47.7)	
Women	85	(47.5)	82	(59.4)	4	(100.0)	1,610	(52.3)	
Age group									<0.001
10s	2	(1.1)	1	(.7)	0	(.0)	222	(7.2)	
20s	24	(13.4)	12	(8.7)	0	(.0)	382	(12.4)	
30s	20	(11.2)	24	(17.4)	2	(50.0)	553	(18.0)	
40s	28	(15.6)	29	(21.0)	0	(.0)	751	(24.4)	
50s	31	(17.3)	39	(28.3)	2	(50.0)	695	(22.6)	
60s	74	(41.3)	33	(23.9)	0	(.0)	473	(15.4)	
Mean age (year)	49.38		48.12		44.75		43.30		<0.001
Final academic background									<0.001
Junior high school	26	(14.5)	16	(11.6)	0	(.0)	194	(6.3)	
High school	90	(50.3)	61	(44.2)	0	(.0)	1,186	(38.6)	
Vocational school	21	(11.7)	23	(16.7)	2	(50.0)	406	(13.2)	
Junior college/university	36	(20.1)	30	(21.7)	0	(.0)	929	(30.2)	
Graduate school	3	(1.7)	4	(2.9)	0	(.0)	66	(2.1)	
Other	2	(1.1)	3	(2.2)	0	(.0)	16	(.5)	
In school	0	(.0)	0	(.0)	0	(.0)	271	(8.8)	
No response/unknown	1	(.6)	1	(.7)	2	(50.0)	8	(.3)	
Cellular phone									
Smartphone	79	(44.1)	77	(55.8)	3	(75.0)	2,095	(68.1)	<0.001
Conventional cellular phone	77	(43.0)	48	(34.8)	0	(.0)	936	(30.4)	<0.001
PHS	2	(1.1)	1	(.7)	0	(.0)	32	(1.0)	<0.001
Other	3	(1.7)	7	(5.1)	0	(.0)	22	(.7)	<0.001
None	23	(12.8)	7	(5.1)	0	(.0)	82	(2.7)	<0.001
No response/unknown	0	(.0)	1	(.7)	1	(25.0)	12	(.4)	<0.001
Time spent on the Internet									<0.001
None	50	(27.9)	35	(25.4)	1	(25.0)	429	(13.9)	
<1 hour	39	(21.8)	36	(26.1)	1	(25.0)	788	(25.6)	
1 to <2 hours	28	(15.6)	22	(15.9)	0	(.0)	649	(21.1)	
2 to <3 hours	19	(10.6)	14	(10.1)	1	(25.0)	451	(14.7)	
3 to <5 hours	18	(10.1)	11	(8.0)	0	(.0)	320	(10.4)	
≥5 hours	25	(14.0)	19	(13.8)	0	(.0)	423	(13.8)	
No response/unknown	0	(.0)	1	(.7)	1	(25.0)	16	(.5)	

Table 11. Basic demographics by Drug Use Experience (n = 3076)

	Drug use experience								P-value
	Lifetime experience		No lifetime experience		Unknown		Total		
	n = 78		n = 2940		n = 58		n = 3076		
	n	(%)	n	(%)	n	(%)	n	(%)	
Residence area									0.798
Hokkaido	6	(7.7)	120	(4.1)	5	(8.6)	131	(4.3)	
Tohoku	4	(5.1)	239	(8.1)	7	(12.1)	250	(8.1)	
Kanto	25	(32.1)	909	(30.9)	14	(24.1)	948	(30.8)	
Hokuriku	3	(3.8)	149	(5.1)	2	(3.4)	154	(5.0)	
Tousan	2	(2.6)	144	(4.9)	4	(6.9)	150	(4.9)	
Tokai	10	(12.8)	312	(10.6)	6	(10.3)	328	(10.7)	
Kinki	13	(16.7)	420	(14.3)	9	(15.5)	442	(14.4)	
Chugoku	6	(7.7)	180	(6.1)	5	(8.6)	191	(6.2)	
Shikoku	1	(1.3)	86	(2.9)	1	(1.7)	88	(2.9)	
Kita-Kyusyu	3	(3.8)	223	(7.6)	3	(5.2)	229	(7.4)	
Minami-Kyusyu	5	(6.4)	158	(5.4)	2	(3.4)	165	(5.4)	
Sex									<0.001
Men	58	(74.4)	1374	(46.7)	34	(58.6)	1466	(47.7)	
Women	20	(25.6)	1566	(53.3)	24	(41.4)	1610	(52.3)	
Age group									0.101
10s	0	(.0)	219	(7.4)	3	(5.2)	222	(7.2)	
20s	8	(10.3)	368	(12.5)	6	(10.3)	382	(12.4)	
30s	15	(19.2)	530	(18.0)	8	(13.8)	553	(18.0)	
40s	23	(29.5)	718	(24.4)	10	(17.2)	751	(24.4)	
50s	23	(29.5)	655	(22.3)	17	(29.3)	695	(22.6)	
60s	9	(11.5)	450	(15.3)	14	(24.1)	473	(15.4)	
Mean age (year)	45.51		43.16		47.05		43.30		0.041
Occupation									0.014
Self-employed business	14	(17.9)	227	(7.7)	7	(12.1)	248	(8.1)	
Full-time employee	36	(46.2)	1345	(45.7)	25	(43.1)	1406	(45.7)	
Non-full-time employee	14	(17.9)	375	(12.8)	5	(8.6)	394	(12.8)	
Student	0	(.0)	268	(9.1)	3	(5.2)	271	(8.8)	
Housewife (househusband)	5	(6.4)	422	(14.4)	9	(15.5)	436	(14.2)	
Unemployed	6	(7.7)	169	(5.7)	4	(6.9)	179	(5.8)	
Other	3	(3.8)	130	(4.4)	5	(8.6)	138	(4.5)	
No response/unknown	0	(.0)	4	(.1)	0	(.0)	4	(.1)	
Final academic background									<0.001
Junior high school	23	(29.5)	162	(5.5)	9	(15.5)	194	(6.3)	
High school	34	(43.6)	1128	(38.4)	24	(41.4)	1186	(38.6)	
Vocational school	9	(11.5)	393	(13.4)	4	(6.9)	406	(13.2)	
Junior college/university	10	(12.8)	904	(30.7)	15	(25.9)	929	(30.2)	
Graduate school	1	(1.3)	64	(2.2)	1	(1.7)	66	(2.1)	
Other	1	(1.3)	13	(.4)	2	(3.4)	16	(.5)	
In school <input type="checkbox"/>	0	(.0)	268	(9.1)	3	(5.2)	271	(8.8)	
No response/unknown	0	(.0)	8	(.3)	0	(.0)	8	(.3)	
Cellular phone									<0.001
Smartphone	56	(71.8)	2011	(68.4)	28	(48.3)	2095	(68.1)	<0.001
Conventional cellular phone	21	(26.9)	892	(30.3)	23	(39.7)	936	(30.4)	<0.001
PHS	2	(2.6)	27	(.9)	3	(5.2)	32	(1.0)	<0.001
Other	1	(1.3)	19	(.6)	2	(3.4)	22	(.7)	<0.001
None	2	(2.6)	77	(2.6)	3	(5.2)	82	(2.7)	<0.001
No response/unknown	0	(.0)	9	(.3)	3	(5.2)	12	(.4)	<0.001
Time spent on the Internet									0.010
None	7	(9.0)	403	(13.7)	19	(32.8)	429	(13.9)	
<1 hour	25	(32.1)	751	(25.5)	12	(20.7)	788	(25.6)	
1 to <2 hours	17	(21.8)	622	(21.2)	10	(17.2)	649	(21.1)	
2 to <3 hours	10	(12.8)	434	(14.8)	7	(12.1)	451	(14.7)	
3 to <5 hours	5	(6.4)	313	(10.6)	2	(3.4)	320	(10.4)	
≥5 hours	14	(17.9)	402	(13.7)	7	(12.1)	423	(13.8)	
No response/unknown	0	(.0)	15	(.5)	1	(1.7)	16	(.5)	

Table 12. Alcohol and/or Tobacco Use by Residence area (n=3076)

	Residence area											
	Hokkaido		Tohoku		Kanto		Hokuriku		Tousan		Tokai	
	n=131	n=250	n=948	n=154	n=150	n=328	n	(%)	n	(%)	n	(%)
Lifetime alcohol use												
Yes	127	(96.9)	230	(92.0)	880	(92.8)	148	(96.1)	141	(94.0)	313	(95.4)
Age at first alcohol use												
Never	4	(3.1)	20	(8.0)	65	(6.9)	6	(3.9)	9	(6.0)	15	(4.6)
≤9 years old	8	(6.1)	7	(2.8)	46	(4.9)	4	(2.6)	8	(5.3)	9	(2.7)
10–11 years old	3	(2.3)	2	(.8)	17	(1.8)	4	(2.6)	4	(2.7)	7	(2.1)
12–13 years old	6	(4.6)	2	(.8)	26	(2.7)	4	(2.6)	4	(2.7)	11	(3.4)
14–15 years old	16	(12.2)	10	(4.0)	46	(4.9)	12	(7.8)	7	(4.7)	24	(7.3)
16–17 years old	23	(17.6)	33	(13.2)	138	(14.6)	19	(12.3)	13	(8.7)	40	(12.2)
18–19 years old	40	(30.5)	79	(31.6)	316	(33.3)	55	(35.7)	44	(29.3)	95	(29.0)
≥ 20 years old	30	(22.9)	96	(38.4)	289	(30.5)	49	(31.8)	61	(40.7)	123	(37.5)
Age unknown	1	(.8)	1	(.4)	2	(.2)	1	(.6)	0	(.0)	4	(1.2)
Age at the start of chronic alcohol use												
Never	4	(3.1)	19	(7.6)	66	(7.0)	6	(3.9)	8	(5.3)	15	(4.6)
≤9 years old	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
10–11 years old	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
12–13 years old	1	(.8)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
14–15 years old	1	(.8)	1	(.4)	2	(.2)	1	(.6)	0	(.0)	4	(1.2)
16–17 years old	5	(3.8)	7	(2.8)	26	(2.7)	3	(1.9)	1	(.7)	6	(1.8)
18–19 years old	26	(19.8)	47	(18.8)	156	(16.5)	28	(18.2)	24	(16.0)	64	(19.5)
≥ 20 years old	83	(63.4)	163	(65.2)	622	(65.6)	103	(66.9)	104	(69.3)	204	(62.2)
Age unknown	11	(8.4)	12	(4.8)	74	(7.8)	13	(8.4)	12	(8.0)	35	(10.7)
Past-year alcohol use												
Yes	111	(84.7)	193	(77.2)	771	(81.3)	133	(86.4)	120	(80.0)	256	(78.0)
Number of days of alcohol use within the past 30 days												
0 day	41	(31.3)	87	(34.8)	286	(30.2)	48	(31.2)	53	(35.3)	107	(32.6)
1–2 days	20	(15.3)	49	(19.6)	164	(17.3)	26	(16.9)	25	(16.7)	65	(19.8)
3–5 days	17	(13.0)	22	(8.8)	130	(13.7)	9	(5.8)	15	(10.0)	35	(10.7)
6–9 days	15	(11.5)	6	(2.4)	73	(7.7)	10	(6.5)	12	(8.0)	23	(7.0)
10–19 days	12	(9.2)	19	(7.6)	88	(9.3)	10	(6.5)	12	(8.0)	23	(7.0)
20–29 days	17	(13.0)	32	(12.8)	104	(11.0)	24	(15.6)	19	(12.7)	38	(11.6)
Every day	8	(6.1)	35	(14.0)	102	(10.8)	27	(17.5)	13	(8.7)	37	(11.3)
Frequency unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Lifetime tobacco use												
Yes	102	(77.9)	148	(59.2)	575	(60.7)	103	(66.9)	83	(55.3)	188	(57.3)
Age at first tobacco use												
Never	26	(19.8)	99	(39.6)	364	(38.4)	51	(33.1)	64	(42.7)	136	(41.5)
≤9 years old	1	(.8)	1	(.4)	9	(.9)	0	(.0)	2	(1.3)	0	(.0)
10–11 years old	0	(.0)	5	(2.0)	4	(.4)	0	(.0)	2	(1.3)	4	(1.2)
12–13 years old	4	(3.1)	5	(2.0)	19	(2.0)	5	(3.2)	1	(.7)	8	(2.4)
14–15 years old	13	(9.9)	12	(4.8)	54	(5.7)	7	(4.5)	7	(4.7)	23	(7.0)
16–17 years old	16	(12.2)	29	(11.6)	114	(12.0)	22	(14.3)	11	(7.3)	36	(11.0)
18–19 years old	31	(23.7)	47	(18.8)	162	(17.1)	23	(14.9)	31	(20.7)	52	(15.9)
≥20 years old	37	(28.2)	49	(19.6)	209	(22.0)	44	(28.6)	28	(18.7)	65	(19.8)
Age unknown	0	(.0)	0	(.0)	4	(.4)	2	(1.3)	1	(.7)	0	(.0)
Age at the start of chronic tobacco use												
Never	26	(19.8)	98	(39.2)	364	(38.4)	50	(32.5)	64	(42.7)	137	(41.8)
≤9 years old	0	(.0)	0	(.0)	1	(.1)	0	(.0)	0	(.0)	0	(.0)
10–11 years old	0	(.0)	1	(.4)	1	(.1)	0	(.0)	0	(.0)	0	(.0)
12–13 years old	0	(.0)	0	(.0)	3	(.3)	0	(.0)	0	(.0)	2	(.6)
14–15 years old	4	(3.1)	6	(2.4)	19	(2.0)	4	(2.6)	3	(2.0)	4	(1.2)
16–17 years old	4	(3.1)	14	(5.6)	57	(6.0)	11	(7.1)	4	(2.7)	21	(6.4)
18–19 years old	24	(18.3)	36	(14.4)	127	(13.4)	23	(14.9)	24	(16.0)	43	(13.1)
≥20 years old	44	(33.6)	64	(25.6)	249	(26.3)	45	(29.2)	33	(22.0)	81	(24.7)
Age unknown	26	(19.8)	27	(10.8)	118	(12.4)	20	(13.0)	19	(12.7)	37	(11.3)
Past-year tobacco use												
Yes	48	(36.6)	74	(29.6)	250	(26.4)	45	(29.2)	33	(22.0)	89	(27.1)
Number of days of tobacco use within the past 30 days												
0 day	86	(65.6)	177	(70.8)	717	(75.6)	113	(73.4)	116	(77.3)	249	(75.9)
1–2 days	1	(.8)	5	(2.0)	5	(.5)	0	(.0)	0	(.0)	2	(.6)
3–5 days	1	(.8)	2	(.8)	5	(.5)	1	(.6)	1	(.7)	1	(.3)
6–9 days	1	(.8)	1	(.4)	1	(.1)	0	(.0)	0	(.0)	1	(.3)
10–19 days	2	(1.5)	0	(.0)	8	(.8)	3	(1.9)	2	(1.3)	2	(.6)
20–29 days	3	(2.3)	2	(.8)	9	(.9)	2	(1.3)	2	(1.3)	3	(.9)
Every day	36	(27.5)	61	(24.4)	197	(20.8)	35	(22.7)	27	(18.0)	68	(20.7)
Frequency unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)

Respondents with “no response/unknown” are not included. For age at the start of chronic alcohol use, respondents not having reached the stage of chronic alcohol use are included in “age unknown.” For age at the start of chronic tobacco use, respondents not having reached the stage of chronic tobacco use are included in “age unknown.”

Table 12. Alcohol and/or Tobacco Use by Residence area (n=3076) continued

	Residence area										p-value		
	Kinki		Chugoku		Shikoku		Kita-Kyusyu		Minami-			Total	
	n=442		n=191		n=88		n=229		n=165			n=3076	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	
Lifetime alcohol use													0.032
Yes	415	(93.9)	171	(89.5)	87	(98.9)	209	(91.3)	151	(91.5)	2,872	(93.4)	
Age at first alcohol use													0.001
Never	27	(6.1)	18	(9.4)	1	(1.1)	19	(8.3)	14	(8.5)	198	(6.4)	
≤9 years old	24	(5.4)	6	(3.1)	1	(1.1)	16	(7.0)	4	(2.4)	133	(4.3)	
10–11 years old	10	(2.3)	1	(.5)	3	(3.4)	8	(3.5)	2	(1.2)	61	(2.0)	
12–13 years old	15	(3.4)	7	(3.7)	1	(1.1)	9	(3.9)	5	(3.0)	90	(2.9)	
14–15 years old	20	(4.5)	11	(5.8)	8	(9.1)	8	(3.5)	11	(6.7)	173	(5.6)	
16–17 years old	44	(10.0)	25	(13.1)	13	(14.8)	22	(9.6)	10	(6.1)	380	(12.4)	
18–19 years old	128	(29.0)	48	(25.1)	23	(26.1)	71	(31.0)	52	(31.5)	951	(30.9)	
≥ 20 years old	170	(38.5)	73	(38.2)	37	(42.0)	75	(32.8)	67	(40.6)	1,070	(34.8)	
Age unknown	4	(.9)	0	(.0)	1	(1.1)	0	(.0)	0	(.0)	14	(.5)	
Age at the start of chronic alcohol use													0.050
Never	26	(5.9)	19	(9.9)	1	(1.1)	19	(8.3)	14	(8.5)	197	(6.4)	
≤9 years old	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
10–11 years old	2	(.5)	0	(.0)	0	(.0)	0	(.0)	1	(.6)	3	(.1)	
12–13 years old	1	(.2)	0	(.0)	1	(1.1)	0	(.0)	0	(.0)	3	(.1)	
14–15 years old	0	(.0)	2	(1.0)	0	(.0)	3	(1.3)	1	(.6)	15	(.5)	
16–17 years old	7	(1.6)	2	(1.0)	2	(2.3)	1	(.4)	4	(2.4)	64	(2.1)	
18–19 years old	68	(15.4)	20	(10.5)	18	(20.5)	45	(19.7)	23	(13.9)	519	(16.9)	
≥ 20 years old	289	(65.4)	124	(64.9)	56	(63.6)	139	(60.7)	110	(66.7)	1,997	(64.9)	
Age unknown	48	(10.9)	23	(12.0)	10	(11.4)	21	(9.2)	12	(7.3)	271	(8.8)	
Past-year alcohol use													0.072
Yes	339	(76.7)	147	(77.0)	70	(79.5)	183	(79.9)	131	(79.4)	2,454	(79.8)	
Number of days of alcohol use within the past 30 days													0.171
0 day	160	(36.2)	73	(38.2)	34	(38.6)	71	(31.0)	48	(29.1)	1,008	(32.8)	
1–2 days	73	(16.5)	27	(14.1)	11	(12.5)	34	(14.8)	32	(19.4)	526	(17.1)	
3–5 days	52	(11.8)	26	(13.6)	9	(10.2)	33	(14.4)	17	(10.3)	365	(11.9)	
6–9 days	37	(8.4)	7	(3.7)	4	(4.5)	15	(6.6)	10	(6.1)	212	(6.9)	
10–19 days	33	(7.5)	11	(5.8)	7	(8.0)	21	(9.2)	20	(12.1)	256	(8.3)	
20–29 days	43	(9.7)	26	(13.6)	10	(11.4)	27	(11.8)	18	(10.9)	358	(11.6)	
Every day	43	(9.7)	20	(10.5)	13	(14.8)	26	(11.4)	20	(12.1)	344	(11.2)	
Frequency unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
Lifetime tobacco use													0.002
Yes	246	(55.7)	108	(56.5)	59	(67.0)	135	(59.0)	91	(55.2)	1,838	(59.8)	
Age at first tobacco use													0.136
Never	190	(43.0)	81	(42.4)	28	(31.8)	91	(39.7)	74	(44.8)	1,204	(39.1)	
≤9 years old	5	(1.1)	2	(1.0)	0	(.0)	3	(1.3)	0	(.0)	23	(.7)	
10–11 years old	7	(1.6)	0	(.0)	1	(1.1)	1	(.4)	1	(.6)	25	(.8)	
12–13 years old	12	(2.7)	4	(2.1)	1	(1.1)	3	(1.3)	3	(1.8)	65	(2.1)	
14–15 years old	26	(5.9)	6	(3.1)	11	(12.5)	14	(6.1)	9	(5.5)	182	(5.9)	
16–17 years old	47	(10.6)	23	(12.0)	10	(11.4)	24	(10.5)	16	(9.7)	348	(11.3)	
18–19 years old	62	(14.0)	34	(17.8)	20	(22.7)	33	(14.4)	26	(15.8)	521	(16.9)	
≥20 years old	85	(19.2)	38	(19.9)	16	(18.2)	56	(24.5)	36	(21.8)	663	(21.6)	
Age unknown	2	(.5)	1	(.5)	0	(.0)	1	(.4)	0	(.0)	11	(.4)	
Age at the start of chronic tobacco use													0.444
Never	190	(43.0)	81	(42.4)	28	(31.8)	91	(39.7)	73	(44.2)	1,202	(39.1)	
≤9 years old	0	(.0)	0	(.0)	0	(.0)	1	(.4)	0	(.0)	2	(.1)	
10–11 years old	0	(.0)	0	(.0)	1	(1.1)	0	(.0)	0	(.0)	3	(.1)	
12–13 years old	3	(.7)	0	(.0)	0	(.0)	1	(.4)	2	(1.2)	11	(.4)	
14–15 years old	10	(2.3)	4	(2.1)	4	(4.5)	4	(1.7)	4	(2.4)	66	(2.1)	
16–17 years old	20	(4.5)	14	(7.3)	7	(8.0)	14	(6.1)	10	(6.1)	176	(5.7)	
18–19 years old	63	(14.3)	29	(15.2)	19	(21.6)	31	(13.5)	22	(13.3)	441	(14.3)	
≥20 years old	103	(23.3)	45	(23.6)	19	(21.6)	59	(25.8)	38	(23.0)	780	(25.4)	
Age unknown	47	(10.6)	16	(8.4)	9	(10.2)	25	(10.9)	15	(9.1)	359	(11.7)	
Past-year tobacco use													0.653
Yes	108	(24.4)	51	(26.7)	28	(31.8)	56	(24.5)	45	(27.3)	827	(26.9)	
Number of days of tobacco use within the past 30 days													0.635
0 day	345	(78.1)	144	(75.4)	62	(70.5)	174	(76.0)	127	(77.0)	2,310	(75.1)	
1–2 days	3	(.7)	2	(1.0)	0	(.0)	2	(.9)	0	(.0)	20	(.7)	
3–5 days	1	(.2)	1	(.5)	0	(.0)	1	(.4)	1	(.6)	15	(.5)	
6–9 days	0	(.0)	0	(.0)	1	(1.1)	1	(.4)	0	(.0)	6	(.2)	
10–19 days	2	(.5)	1	(.5)	1	(1.1)	0	(.0)	2	(1.2)	23	(.7)	
20–29 days	9	(2.0)	0	(.0)	0	(.0)	6	(2.6)	4	(2.4)	40	(1.3)	
Every day	81	(18.3)	41	(21.5)	24	(27.3)	42	(18.3)	30	(18.2)	642	(20.9)	
Frequency unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	

Respondents with “no response/unknown” are not included. For age at the start of chronic alcohol use, respondents not having reached the stage of chronic alcohol use are included in “age unknown.” For age at the start of chronic tobacco use, respondents not having reached the stage of chronic tobacco use are included in “age unknown.”

Table 13. Alcohol and/or Tobacco Use by Sex (n = 3076)

	Sex						P-value
	Men		Women		Total		
	n = 1466		n = 1610		n = 3076		
	n	(%)	n	(%)	n	(%)	
Lifetime alcohol use							0.448
Yes	1,374	(93.7)	1,498	(93.0)	2,872	(93.4)	
Age at first alcohol use							<0.001
Never	90	(6.1)	108	(6.7)	198	(6.4)	
≤9 years old	67	(4.6)	66	(4.1)	133	(4.3)	
10–11 years old	35	(2.4)	26	(1.6)	61	(2.0)	
12–13 years old	57	(3.9)	33	(2.0)	90	(2.9)	
14–15 years old	107	(7.3)	66	(4.1)	173	(5.6)	
16–17 years old	242	(16.5)	138	(8.6)	380	(12.4)	
18–19 years old	507	(34.6)	444	(27.6)	951	(30.9)	
≥ 20 years old	353	(24.1)	717	(44.5)	1,070	(34.8)	
Age unknown	6	(.4)	8	(.5)	14	(.5)	
Age at the start of chronic alcohol use							<0.001
Never	89	(6.1)	108	(6.7)	197	(6.4)	
≤9 years old	0	(.0)	0	(.0)	0	(.0)	
10–11 years old	0	(.0)	3	(.2)	3	(.1)	
12–13 years old	3	(.2)	0	(.0)	3	(.1)	
14–15 years old	11	(.8)	4	(.2)	15	(.5)	
16–17 years old	41	(2.8)	23	(1.4)	64	(2.1)	
18–19 years old	325	(22.2)	194	(12.0)	519	(16.9)	
≥ 20 years old	888	(60.6)	1,109	(68.9)	1,997	(64.9)	
Age unknown	106	(7.2)	165	(10.2)	271	(8.8)	
Past-year alcohol use							<0.001
Yes	1,237	(84.4)	1,217	(75.6)	2,454	(79.8)	
Number of days of alcohol use within the past 30 days							<0.001
0 day	363	(24.8)	645	(40.1)	1,008	(32.8)	
1–2 days	201	(13.7)	325	(20.2)	526	(17.1)	
3–5 days	159	(10.8)	206	(12.8)	365	(11.9)	
6–9 days	105	(7.2)	107	(6.6)	212	(6.9)	
10–19 days	143	(9.8)	113	(7.0)	256	(8.3)	
20–29 days	234	(16.0)	124	(7.7)	358	(11.6)	
Every day	258	(17.6)	86	(5.3)	344	(11.2)	
Frequency unknown	0	(.0)	0	(.0)	0	(.0)	
Lifetime tobacco use							<0.001
Yes	1,117	(76.2)	721	(44.8)	1,838	(59.8)	
Age at first tobacco use							<0.001
Never	343	(23.4)	861	(53.5)	1,204	(39.1)	
≤9 years old	13	(.9)	10	(.6)	23	(.7)	
10–11 years old	19	(1.3)	6	(.4)	25	(.8)	
12–13 years old	45	(3.1)	20	(1.2)	65	(2.1)	
14–15 years old	134	(9.1)	48	(3.0)	182	(5.9)	
16–17 years old	242	(16.5)	106	(6.6)	348	(11.3)	
18–19 years old	334	(22.8)	187	(11.6)	521	(16.9)	
≥20 years old	325	(22.2)	338	(21.0)	663	(21.6)	
Age unknown	5	(.3)	6	(.4)	11	(.4)	
Age at the start of chronic tobacco use							<0.001
Never	344	(23.5)	858	(53.3)	1,202	(39.1)	
≤9 years old	0	(.0)	2	(.1)	2	(.1)	
10–11 years old	3	(.2)	0	(.0)	3	(.1)	
12–13 years old	7	(.5)	4	(.2)	11	(.4)	
14–15 years old	58	(4.0)	8	(.5)	66	(2.1)	
16–17 years old	120	(8.2)	56	(3.5)	176	(5.7)	
18–19 years old	326	(22.2)	115	(7.1)	441	(14.3)	
≥20 years old	456	(31.1)	324	(20.1)	780	(25.4)	
Age unknown	147	(10.0)	212	(13.2)	359	(11.7)	
Past-year tobacco use							<0.001
Yes	600	(40.9)	227	(14.1)	827	(26.9)	
Number of days of tobacco use within the past 30 days							<0.001
0 day	904	(61.7)	1,406	(87.3)	2,310	(75.1)	
1–2 days	11	(.8)	9	(.6)	20	(.7)	
3–5 days	13	(.9)	2	(.1)	15	(.5)	
6–9 days	4	(.3)	2	(.1)	6	(.2)	
10–19 days	17	(1.2)	6	(.4)	23	(.7)	
20–29 days	31	(2.1)	9	(.6)	40	(1.3)	
Every day	480	(32.7)	162	(10.1)	642	(20.9)	
Frequency unknown	0	(.0)	0	(.0)	0	(.0)	

Respondents with “no response/unknown” are not included. For age at the start of chronic alcohol use, respondents not having reached the stage of chronic alcohol use are included in “age unknown.” For age at the start of chronic tobacco use, respondents not having reached the stage of chronic tobacco use are included in “age unknown.”

Table 14. Alcohol and/or Tobacco Use by Age group (n=3076)

	Age group												p-value		
	10s		20s		30s		40s		50s		60s			Total	
	n=222	n=382	n=553	n=751	n=695	n=473	n=3076	n (%)	n (%)	n (%)	n (%)	n (%)		n (%)	
Lifetime alcohol use													<0.001		
Yes	80 (36.0)	371 (97.1)	545 (98.6)	742 (98.8)	679 (97.7)	455 (96.2)	2,872 (93.4)								
Age at first alcohol use													<0.001		
Never	142 (64.0)	10 (2.6)	8 (1.4)	8 (1.1)	14 (2.0)	16 (3.4)	198 (6.4)								
≤9 years old	11 (5.0)	19 (5.0)	25 (4.5)	30 (4.0)	32 (4.6)	16 (3.4)	133 (4.3)								
10–11 years old	8 (3.6)	5 (1.3)	9 (1.6)	15 (2.0)	21 (3.0)	3 (0.6)	61 (2.0)								
12–13 years old	12 (5.4)	10 (2.6)	20 (3.6)	25 (3.3)	18 (2.6)	5 (1.1)	90 (2.9)								
14–15 years old	12 (5.4)	25 (6.5)	53 (9.6)	44 (5.9)	29 (4.2)	10 (2.1)	173 (5.6)								
16–17 years old	14 (6.3)	36 (9.4)	79 (14.3)	113 (15.0)	90 (12.9)	48 (10.1)	380 (12.4)								
18–19 years old	20 (9.0)	102 (26.7)	167 (30.2)	249 (33.2)	254 (36.5)	159 (33.6)	951 (30.9)								
≥ 20 years old	0 (0)	173 (45.3)	190 (34.4)	265 (35.3)	231 (33.2)	211 (44.6)	1,070 (34.8)								
Age unknown	3 (1.4)	1 (0.3)	2 (0.4)	1 (0.1)	4 (0.6)	3 (0.6)	14 (0.5)								
Age at the start of chronic alcohol use													<0.001		
Never	141 (63.5)	11 (2.9)	8 (1.4)	7 (0.9)	15 (2.2)	15 (3.2)	197 (6.4)								
≤9 years old	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)								
10–11 years old	1 (0.5)	0 (0)	1 (0.2)	0 (0)	1 (0.1)	0 (0)	3 (0.1)								
12–13 years old	0 (0)	1 (0.3)	2 (0.4)	0 (0)	0 (0)	0 (0)	3 (0.1)								
14–15 years old	2 (0.9)	3 (0.8)	2 (0.4)	3 (0.4)	2 (0.3)	3 (0.6)	15 (0.5)								
16–17 years old	8 (3.6)	11 (2.9)	21 (3.8)	15 (2.0)	4 (0.6)	5 (1.1)	64 (2.1)								
18–19 years old	27 (12.2)	66 (17.3)	93 (16.8)	131 (17.4)	142 (20.4)	60 (12.7)	519 (16.9)								
≥ 20 years old	1 (0.5)	280 (73.3)	388 (70.2)	552 (73.5)	455 (65.5)	321 (67.9)	1,997 (64.9)								
Age unknown	41 (18.5)	10 (2.6)	38 (6.9)	41 (5.5)	75 (10.8)	66 (14.0)	271 (8.8)								
Past-year alcohol use													<0.001		
Yes	56 (25.2)	345 (90.3)	464 (83.9)	645 (85.9)	568 (81.7)	376 (79.5)	2,454 (79.8)								
Number of days of alcohol use within the past 30 days													<0.001		
0 day	188 (84.7)	89 (23.3)	165 (29.8)	210 (28.0)	206 (29.6)	150 (31.7)	1,008 (32.8)								
1–2 days	16 (7.2)	115 (30.1)	113 (20.4)	126 (16.8)	92 (13.2)	64 (13.5)	526 (17.1)								
3–5 days	8 (3.6)	78 (20.4)	73 (13.2)	93 (12.4)	74 (10.6)	39 (8.2)	365 (11.9)								
6–9 days	4 (1.8)	48 (12.6)	52 (9.4)	51 (6.8)	36 (5.2)	21 (4.4)	212 (6.9)								
10–19 days	3 (1.4)	28 (7.3)	51 (9.2)	66 (8.8)	71 (10.2)	37 (7.8)	256 (8.3)								
20–29 days	2 (0.9)	16 (4.2)	57 (10.3)	111 (14.8)	107 (15.4)	65 (13.7)	358 (11.6)								
Every day	0 (0)	8 (2.1)	41 (7.4)	93 (12.4)	109 (15.7)	93 (19.7)	344 (11.2)								
Frequency unknown	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)								
Lifetime tobacco use													<0.001		
Yes	15 (6.8)	164 (42.9)	380 (68.7)	508 (67.6)	472 (67.9)	299 (63.2)	1,838 (59.8)								
Age at first tobacco use													<0.001		
Never	205 (92.3)	217 (56.8)	171 (30.9)	233 (31.0)	217 (31.2)	161 (34.0)	1,204 (39.1)								
≤9 years old	0 (0)	1 (0.3)	3 (0.5)	11 (1.5)	7 (1.0)	1 (0.2)	23 (0.7)								
10–11 years old	0 (0)	3 (0.8)	7 (1.3)	6 (0.8)	8 (1.2)	1 (0.2)	25 (0.8)								
12–13 years old	1 (0.5)	7 (1.8)	20 (3.6)	22 (2.9)	13 (1.9)	2 (0.4)	65 (2.1)								
14–15 years old	6 (2.7)	22 (5.8)	49 (8.9)	57 (7.6)	36 (5.2)	12 (2.5)	182 (5.9)								
16–17 years old	3 (1.4)	26 (6.8)	79 (14.3)	93 (12.4)	103 (14.8)	44 (9.3)	348 (11.3)								
18–19 years old	3 (1.4)	40 (10.5)	78 (14.1)	118 (15.7)	165 (23.7)	117 (24.7)	521 (16.9)								
≥20 years old	0 (0)	63 (16.5)	141 (25.5)	198 (26.4)	139 (20.0)	122 (25.8)	663 (21.6)								
Age unknown	2 (0.9)	2 (0.5)	3 (0.5)	3 (0.4)	1 (0.1)	0 (0)	11 (0.4)								
Age at the start of chronic tobacco use													<0.001		
Never	205 (92.3)	217 (56.8)	169 (30.6)	234 (31.2)	217 (31.2)	160 (33.8)	1,202 (39.1)								
≤9 years old	0 (0)	1 (0.3)	0 (0)	1 (0.1)	0 (0)	0 (0)	2 (0.1)								
10–11 years old	0 (0)	1 (0.3)	0 (0)	2 (0.3)	0 (0)	0 (0)	3 (0.1)								
12–13 years old	0 (0)	0 (0)	4 (0.7)	5 (0.7)	2 (0.3)	0 (0)	11 (0.4)								
14–15 years old	2 (0.9)	12 (3.1)	22 (4.0)	22 (2.9)	4 (0.6)	4 (0.8)	66 (2.1)								
16–17 years old	3 (1.4)	10 (2.6)	54 (9.8)	59 (7.9)	37 (5.3)	13 (2.7)	176 (5.7)								
18–19 years old	2 (0.9)	35 (9.2)	82 (14.8)	86 (11.5)	156 (22.4)	80 (16.9)	441 (14.3)								
≥20 years old	0 (0)	71 (18.6)	143 (25.9)	229 (30.5)	180 (25.9)	157 (33.2)	780 (25.4)								
Age unknown	8 (3.6)	34 (8.9)	75 (13.6)	104 (13.8)	93 (13.4)	45 (9.5)	359 (11.7)								
Past-year tobacco use													<0.001		
Yes	10 (4.5)	102 (26.7)	181 (32.7)	232 (30.9)	200 (28.8)	102 (21.6)	827 (26.9)								
Number of days of tobacco use within the past 30 days													<0.001		
0 day	213 (95.9)	292 (76.4)	390 (70.5)	534 (71.1)	509 (73.2)	372 (78.6)	2,310 (75.1)								
1–2 days	0 (0)	8 (2.1)	6 (1.1)	2 (0.3)	1 (0.1)	3 (0.6)	20 (0.7)								
3–5 days	1 (0.5)	1 (0.3)	4 (0.7)	5 (0.7)	4 (0.6)	0 (0)	15 (0.5)								
6–9 days	0 (0)	3 (0.8)	0 (0)	2 (0.3)	0 (0)	1 (0.2)	6 (0.2)								
10–19 days	1 (0.5)	5 (1.3)	5 (0.9)	4 (0.5)	4 (0.6)	4 (0.8)	23 (0.7)								
20–29 days	1 (0.5)	4 (1.0)	10 (1.8)	9 (1.2)	10 (1.4)	6 (1.3)	40 (1.3)								
Every day	3 (1.4)	67 (17.5)	136 (24.6)	191 (25.4)	165 (23.7)	80 (16.9)	642 (20.9)								
Frequency unknown	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)								

“10s” refers to those aged 15 to 19, and “60s” refers to those aged 60 to 64.

Respondents with “no response/unknown” are not included. For age at the start of chronic alcohol use, respondents not having reached the stage of chronic alcohol use are included in “age unknown.” For age at the start of chronic tobacco use, respondents not having reached the stage of chronic tobacco use are included in “age unknown.”

Table 15. Alcohol and/or Tobacco Use by Occupation (n=3076)

	Occupation									
	Self-employed		Full-time		Non-full-time		Student		Housewife	
	n=248		n=1406		n=394		n=271		n=436	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Lifetime alcohol use										
Yes	242	(97.6)	1,391	(98.9)	385	(97.7)	136	(50.2)	418	(95.9)
Age at first alcohol use										
Never	5	(2.0)	14	(1.0)	8	(2.0)	135	(49.8)	16	(3.7)
≤9 years old	9	(3.6)	66	(4.7)	19	(4.8)	14	(5.2)	11	(2.5)
10–11 years old	9	(3.6)	25	(1.8)	7	(1.8)	7	(2.6)	6	(1.4)
12–13 years old	8	(3.2)	48	(3.4)	7	(1.8)	13	(4.8)	10	(2.3)
14–15 years old	18	(7.3)	93	(6.6)	18	(4.6)	13	(4.8)	19	(4.4)
16–17 years old	46	(18.5)	209	(14.9)	35	(8.9)	19	(7.0)	42	(9.6)
18–19 years old	81	(32.7)	477	(33.9)	138	(35.0)	36	(13.3)	118	(27.1)
≥ 20 years old	70	(28.2)	468	(33.3)	161	(40.9)	31	(11.4)	208	(47.7)
Age unknown	1	(.4)	5	(.4)	0	(.0)	3	(1.1)	4	(.9)
Age at the start of chronic alcohol use										
Never	5	(2.0)	14	(1.0)	8	(2.0)	134	(49.4)	17	(3.9)
≤9 years old	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
10–11 years old	1	(.4)	0	(.0)	0	(.0)	1	(.4)	0	(.0)
12–13 years old	1	(.4)	2	(.1)	0	(.0)	0	(.0)	0	(.0)
14–15 years old	3	(1.2)	7	(.5)	0	(.0)	2	(.7)	1	(.2)
16–17 years old	3	(1.2)	31	(2.2)	5	(1.3)	6	(2.2)	9	(2.1)
18–19 years old	57	(23.0)	298	(21.2)	50	(12.7)	29	(10.7)	47	(10.8)
≥ 20 years old	160	(64.5)	968	(68.8)	293	(74.4)	58	(21.4)	307	(70.4)
Age unknown	17	(6.9)	85	(6.0)	37	(9.4)	40	(14.8)	54	(12.4)
Past-year alcohol use										
Yes	221	(89.1)	1,261	(89.7)	325	(82.5)	112	(41.3)	302	(69.3)
Number of days of alcohol use within the past 30 days										
0 day	50	(20.2)	307	(21.8)	133	(33.8)	186	(68.6)	205	(47.0)
1–2 days	32	(12.9)	260	(18.5)	72	(18.3)	40	(14.8)	68	(15.6)
3–5 days	23	(9.3)	175	(12.4)	54	(13.7)	22	(8.1)	50	(11.5)
6–9 days	14	(5.6)	110	(7.8)	27	(6.9)	14	(5.2)	32	(7.3)
10–19 days	24	(9.7)	139	(9.9)	38	(9.6)	3	(1.1)	28	(6.4)
20–29 days	42	(16.9)	223	(15.9)	36	(9.1)	4	(1.5)	27	(6.2)
Every day	62	(25.0)	191	(13.6)	34	(8.6)	1	(.4)	24	(5.5)
Frequency unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Lifetime tobacco use										
Yes	196	(79.0)	971	(69.1)	231	(58.6)	24	(8.9)	203	(46.6)
Age at first tobacco use										
Never	48	(19.4)	422	(30.0)	158	(40.1)	245	(90.4)	227	(52.1)
≤9 years old	4	(1.6)	12	(.9)	3	(.8)	1	(.4)	1	(.2)
10–11 years old	5	(2.0)	16	(1.1)	2	(.5)	0	(.0)	1	(.2)
12–13 years old	7	(2.8)	39	(2.8)	4	(1.0)	1	(.4)	7	(1.6)
14–15 years old	22	(8.9)	107	(7.6)	17	(4.3)	5	(1.8)	13	(3.0)
16–17 years old	48	(19.4)	199	(14.2)	36	(9.1)	2	(.7)	24	(5.5)
18–19 years old	51	(20.6)	273	(19.4)	78	(19.8)	5	(1.8)	62	(14.2)
≥20 years old	58	(23.4)	320	(22.8)	90	(22.8)	8	(3.0)	94	(21.6)
Age unknown	1	(.4)	5	(.4)	1	(.3)	2	(.7)	1	(.2)
Age at the start of chronic tobacco use										
Never	48	(19.4)	422	(30.0)	158	(40.1)	245	(90.4)	226	(51.8)
≤9 years old	0	(.0)	1	(.1)	1	(.3)	0	(.0)	0	(.0)
10–11 years old	1	(.4)	2	(.1)	0	(.0)	0	(.0)	0	(.0)
12–13 years old	4	(1.6)	4	(.3)	0	(.0)	0	(.0)	0	(.0)
14–15 years old	6	(2.4)	44	(3.1)	3	(.8)	2	(.7)	4	(.9)
16–17 years old	21	(8.5)	108	(7.7)	13	(3.3)	1	(.4)	15	(3.4)
18–19 years old	59	(23.8)	240	(17.1)	58	(14.7)	2	(.7)	41	(9.4)
≥20 years old	70	(28.2)	402	(28.6)	102	(25.9)	4	(1.5)	86	(19.7)
Age unknown	35	(14.1)	170	(12.1)	54	(13.7)	15	(5.5)	57	(13.1)
Past-year tobacco use										
Yes	95	(38.3)	475	(33.8)	92	(23.4)	12	(4.4)	53	(12.2)
Number of days of tobacco use within the past 30 days										
0 day	154	(62.1)	964	(68.6)	310	(78.7)	263	(97.0)	388	(89.0)
1–2 days	4	(1.6)	8	(.6)	3	(.8)	1	(.4)	0	(.0)
3–5 days	1	(.4)	13	(.9)	0	(.0)	0	(.0)	1	(.2)
6–9 days	0	(.0)	2	(.1)	0	(.0)	1	(.4)	1	(.2)
10–19 days	1	(.4)	10	(.7)	5	(1.3)	0	(.0)	1	(.2)
20–29 days	5	(2.0)	20	(1.4)	6	(1.5)	1	(.4)	1	(.2)
Every day	79	(31.9)	380	(27.0)	68	(17.3)	2	(.7)	43	(9.9)
Frequency unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)

Respondents with “no response/unknown” are not included. For age at the start of chronic alcohol use, respondents not having reached the stage of chronic alcohol use are included in “age unknown.” For age at the start of chronic tobacco use, respondents not having reached the stage of chronic tobacco use are included in “age unknown.”

Table 15. Alcohol and/or Tobacco Use by Occupation (n=3076) continued

	Occupation						p-value		
	Unemployed		Other		Unknown			Total	
	n	(%)	n	(%)	n	(%)		n	(%)
Lifetime alcohol use								<0.001	
Yes	165	(92.2)	131	(94.9)	4	(100.0)	2,872	(93.4)	
Age at first alcohol use								<0.001	
Never	13	(7.3)	7	(5.1)	0	(.0)	198	(6.4)	
≤9 years old	6	(3.4)	8	(5.8)	0	(.0)	133	(4.3)	
10–11 years old	2	(1.1)	5	(3.6)	0	(.0)	61	(2.0)	
12–13 years old	2	(1.1)	2	(1.4)	0	(.0)	90	(2.9)	
14–15 years old	5	(2.8)	7	(5.1)	0	(.0)	173	(5.6)	
16–17 years old	17	(9.5)	12	(8.7)	0	(.0)	380	(12.4)	
18–19 years old	53	(29.6)	47	(34.1)	1	(25.0)	951	(30.9)	
≥ 20 years old	79	(44.1)	50	(36.2)	3	(75.0)	1,070	(34.8)	
Age unknown	1	(.6)	0	(.0)	0	(.0)	14	(.5)	
Age at the start of chronic alcohol use								<0.001	
Never	12	(6.7)	7	(5.1)	0	(.0)	197	(6.4)	
≤9 years old	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
10–11 years old	1	(.6)	0	(.0)	0	(.0)	3	(.1)	
12–13 years old	0	(.0)	0	(.0)	0	(.0)	3	(.1)	
14–15 years old	1	(.6)	1	(.7)	0	(.0)	15	(.5)	
16–17 years old	4	(2.2)	6	(4.3)	0	(.0)	64	(2.1)	
18–19 years old	22	(12.3)	16	(11.6)	0	(.0)	519	(16.9)	
≥ 20 years old	114	(63.7)	93	(67.4)	4	(100.0)	1,997	(64.9)	
Age unknown	23	(12.8)	15	(10.9)	0	(.0)	271	(8.8)	
Past-year alcohol use								<0.001	
Yes	121	(67.6)	109	(79.0)	3	(75.0)	2,454	(79.8)	
Number of days of alcohol use within the past 30 days								<0.001	
0 day	72	(40.2)	53	(38.4)	2	(50.0)	1,008	(32.8)	
1–2 days	27	(15.1)	26	(18.8)	1	(25.0)	526	(17.1)	
3–5 days	21	(11.7)	20	(14.5)	0	(.0)	365	(11.9)	
6–9 days	8	(4.5)	7	(5.1)	0	(.0)	212	(6.9)	
10–19 days	14	(7.8)	10	(7.2)	0	(.0)	256	(8.3)	
20–29 days	17	(9.5)	9	(6.5)	0	(.0)	358	(11.6)	
Every day	19	(10.6)	13	(9.4)	0	(.0)	344	(11.2)	
Frequency unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
Lifetime tobacco use								<0.001	
Yes	118	(65.9)	93	(67.4)	2	(50.0)	1,838	(59.8)	
Age at first tobacco use								<0.001	
Never	59	(33.0)	43	(31.2)	2	(50.0)	1,204	(39.1)	
≤9 years old	1	(.6)	1	(.7)	0	(.0)	23	(.7)	
10–11 years old	1	(.6)	0	(.0)	0	(.0)	25	(.8)	
12–13 years old	3	(1.7)	4	(2.9)	0	(.0)	65	(2.1)	
14–15 years old	13	(7.3)	5	(3.6)	0	(.0)	182	(5.9)	
16–17 years old	23	(12.8)	15	(10.9)	1	(25.0)	348	(11.3)	
18–19 years old	28	(15.6)	24	(17.4)	0	(.0)	521	(16.9)	
≥20 years old	49	(27.4)	43	(31.2)	1	(25.0)	663	(21.6)	
Age unknown	0	(.0)	1	(.7)	0	(.0)	11	(.4)	
Age at the start of chronic tobacco use								<0.001	
Never	58	(32.4)	43	(31.2)	2	(50.0)	1,202	(39.1)	
≤9 years old	0	(.0)	0	(.0)	0	(.0)	2	(.1)	
10–11 years old	0	(.0)	0	(.0)	0	(.0)	3	(.1)	
12–13 years old	1	(.6)	2	(1.4)	0	(.0)	11	(.4)	
14–15 years old	3	(1.7)	4	(2.9)	0	(.0)	66	(2.1)	
16–17 years old	14	(7.8)	4	(2.9)	0	(.0)	176	(5.7)	
18–19 years old	23	(12.8)	18	(13.0)	0	(.0)	441	(14.3)	
≥20 years old	61	(34.1)	53	(38.4)	2	(50.0)	780	(25.4)	
Age unknown	16	(8.9)	12	(8.7)	0	(.0)	359	(11.7)	
Past-year tobacco use								<0.001	
Yes	58	(32.4)	40	(29.0)	2	(50.0)	827	(26.9)	
Number of days of tobacco use within the past 30 days								<0.001	
0 day	125	(69.8)	104	(75.4)	2	(50.0)	2,310	(75.1)	
1–2 days	2	(1.1)	2	(1.4)	0	(.0)	20	(.7)	
3–5 days	0	(.0)	0	(.0)	0	(.0)	15	(.5)	
6–9 days	1	(.6)	1	(.7)	0	(.0)	6	(.2)	
10–19 days	4	(2.2)	2	(1.4)	0	(.0)	23	(.7)	
20–29 days	3	(1.7)	4	(2.9)	0	(.0)	40	(1.3)	
Every day	43	(24.0)	25	(18.1)	2	(50.0)	642	(20.9)	
Frequency unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	

Respondents with “no response/unknown” are not included. For age at the start of chronic alcohol use, respondents not having reached the stage of chronic alcohol use are included in “age unknown.” For age at the start of chronic tobacco use, respondents not having reached the stage of chronic tobacco use are included in “age unknown.”

Table 16. Alcohol and/or Tobacco Use by Drug use experience (n=3076)

	Drug use experience								p-value
	Lifetime		No lifetime		Unknown		Total		
	n=78	n=2940	n=58	n=3076	n	(%)	n	(%)	
Lifetime alcohol use									0.050
Yes	78	(100.0)	2741	(93.2)	53	(91.4)	2872	(93.4)	
Age at first alcohol use									<0.001
Never	0	(.0)	194	(6.6)	4	(6.9)	198	(6.4)	
≤9 years old	8	(10.3)	125	(4.3)	0	(.0)	133	(4.3)	
10–11 years old	4	(5.1)	56	(1.9)	1	(1.7)	61	(2.0)	
12–13 years old	10	(12.8)	79	(2.7)	1	(1.7)	90	(2.9)	
14–15 years old	16	(20.5)	153	(5.2)	4	(6.9)	173	(5.6)	
16–17 years old	20	(25.6)	352	(12.0)	8	(13.8)	380	(12.4)	
18–19 years old	15	(19.2)	917	(31.2)	19	(32.8)	951	(30.9)	
≥20 years old	4	(5.1)	1046	(35.6)	20	(34.5)	1070	(34.8)	
Age unknown	1	(1.3)	13	(.4)	0	(.0)	14	(.5)	
Age at the start of chronic alcohol use									<0.001
Never	0	(.0)	193	(6.6)	4	(6.9)	197	(6.4)	
≤9 years old	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
10–11 years old	0	(.0)	3	(.1)	0	(.0)	3	(.1)	
12–13 years old	2	(2.6)	1	(0.03)	0	(.0)	3	(.1)	
14–15 years old	4	(5.1)	10	(.3)	1	(1.7)	15	(.5)	
16–17 years old	10	(12.8)	54	(1.8)	0	(.0)	64	(2.1)	
18–19 years old	29	(37.2)	478	(16.3)	12	(20.7)	519	(16.9)	
≥20 years old	31	(39.7)	1933	(65.7)	33	(56.9)	1997	(64.9)	
Age unknown	2	(2.6)	262	(8.9)	7	(12.1)	271	(8.8)	
Past-year alcohol use									0.001
Yes	72	(92.3)	2341	(79.6)	41	(70.7)	2454	(79.8)	
Number of days of alcohol use within the past 30 days									0.001
0 day	15	(19.2)	972	(33.1)	21	(36.2)	1008	(32.8)	
1–2 days	6	(7.7)	513	(17.4)	7	(12.1)	526	(17.1)	
3–5 days	11	(14.1)	350	(11.9)	4	(6.9)	365	(11.9)	
6–9 days	5	(6.4)	205	(7.0)	2	(3.4)	212	(6.9)	
10–19 days	7	(9.0)	243	(8.3)	6	(10.3)	256	(8.3)	
20–29 days	18	(23.1)	331	(11.3)	9	(15.5)	358	(11.6)	
Every day	16	(20.5)	320	(10.9)	8	(13.8)	344	(11.2)	
Frequency unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
Lifetime tobacco use									<0.001
Yes	77	(98.7)	1725	(58.7)	36	(62.1)	1838	(59.8)	
Age at first tobacco use									<0.001
Never	1	(1.3)	1182	(40.2)	21	(36.2)	1204	(39.1)	
≤9 years old	4	(5.1)	19	(.6)	0	(.0)	23	(.7)	
10–11 years old	6	(7.7)	18	(.6)	1	(1.7)	25	(.8)	
12–13 years old	10	(12.8)	55	(1.9)	0	(.0)	65	(2.1)	
14–15 years old	21	(26.9)	157	(5.3)	4	(6.9)	182	(5.9)	
16–17 years old	24	(30.8)	318	(10.8)	6	(10.3)	348	(11.3)	
18–19 years old	7	(9.0)	504	(17.1)	10	(17.2)	521	(16.9)	
≥20 years old	5	(6.4)	643	(21.9)	15	(25.9)	663	(21.6)	
Age unknown	0	(.0)	11	(.4)	0	(.0)	11	(.4)	
Age at the start of chronic tobacco use									<0.001
Never	1	(1.3)	1180	(40.1)	21	(36.2)	1202	(39.1)	
≤9 years old	1	(1.3)	1	(0.03)	0	(.0)	2	(.1)	
10–11 years old	2	(2.6)	1	(0.03)	0	(.0)	3	(.1)	
12–13 years old	8	(10.3)	3	(.1)	0	(.0)	11	(.4)	
14–15 years old	13	(16.7)	52	(1.8)	1	(1.7)	66	(2.1)	
16–17 years old	24	(30.8)	151	(5.1)	1	(1.7)	176	(5.7)	
18–19 years old	18	(23.1)	411	(14.0)	12	(20.7)	441	(14.3)	
≥20 years old	9	(11.5)	755	(25.7)	16	(27.6)	780	(25.4)	
Age unknown	2	(2.6)	351	(11.9)	6	(10.3)	359	(11.7)	
Past-year tobacco use									<0.001
Yes	46	(59.0)	757	(25.7)	24	(41.4)	827	(26.9)	
Number of days of tobacco use within the past 30 days									<0.001
0 day	34	(43.6)	2239	(76.2)	37	(63.8)	2310	(75.1)	
1–2 days	1	(1.3)	18	(.6)	1	(1.7)	20	(.7)	
3–5 days	1	(1.3)	13	(.4)	1	(1.7)	15	(.5)	
6–9 days	0	(.0)	6	(.2)	0	(.0)	6	(.2)	
10–19 days	2	(2.6)	21	(.7)	0	(.0)	23	(.7)	
20–29 days	1	(1.3)	37	(1.3)	2	(3.4)	40	(1.3)	
Every day	39	(50.0)	587	(20.0)	16	(27.6)	642	(20.9)	
Frequency unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	

Respondents with “no response/unknown” are not included. For age at the start of chronic alcohol use, respondents not having reached the stage of chronic alcohol use are included in “age unknown.” For age at the start of chronic tobacco use, respondents not having reached the stage of chronic tobacco use are included in “age unknown.”

Table17. Medications use by Residence area (n=3076)

	Residence area											
	Hokkaido		Tohoku		Kanto		Hokuriku		Tousan		Tokai	
	n=131		n=250		n=948		n=154		n=150		n=328	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Household medicines												
None	14	(10.7)	34	(13.6)	107	(11.3)	11	(7.1)	19	(12.7)	35	(10.7)
Cold medicines	101	(77.1)	179	(71.6)	672	(70.9)	122	(79.2)	111	(74.0)	229	(69.8)
Antipyretic analgesics	73	(55.7)	127	(50.8)	529	(55.8)	85	(55.2)	79	(52.7)	192	(58.5)
Drugs for rhinitis (allergy drugs)	39	(29.8)	79	(31.6)	313	(33.0)	44	(28.6)	53	(35.3)	106	(32.3)
Motion sickness drugs	22	(16.8)	35	(14.0)	155	(16.4)	27	(17.5)	17	(11.3)	48	(14.6)
Gastrointestinal medicines	77	(58.8)	143	(57.2)	533	(56.2)	102	(66.2)	84	(56.0)	185	(56.4)
Laxatives	25	(19.1)	41	(16.4)	134	(14.1)	27	(17.5)	25	(16.7)	51	(15.5)
Cough medicines	27	(20.6)	55	(22.0)	196	(20.7)	35	(22.7)	30	(20.0)	78	(23.8)
Chinese herbal medicines	18	(13.7)	35	(14.0)	139	(14.7)	26	(16.9)	28	(18.7)	55	(16.8)
Vitamin supplements	25	(19.1)	40	(16.0)	191	(20.1)	25	(16.2)	25	(16.7)	57	(17.4)
Other supplements	29	(22.1)	60	(24.0)	234	(24.7)	37	(24.0)	27	(18.0)	82	(25.0)
Other	3	(2.3)	9	(3.6)	25	(2.6)	10	(6.5)	5	(3.3)	6	(1.8)
No response/unknown	2	(1.5)	2	(.8)	6	(.6)	0	(.0)	0	(.0)	2	(.6)
Medicinal drugs used within the past year												
None	4	(3.1)	26	(10.4)	69	(7.3)	10	(6.5)	13	(8.7)	23	(7.0)
Cold medicines	92	(70.2)	165	(66.0)	635	(67.0)	100	(64.9)	97	(64.7)	208	(63.4)
Antipyretic analgesics	96	(73.3)	151	(60.4)	599	(63.2)	96	(62.3)	88	(58.7)	217	(66.2)
Drugs for rhinitis (allergy drugs)	32	(24.4)	72	(28.8)	315	(33.2)	42	(27.3)	42	(28.0)	100	(30.5)
Motion sickness drugs	10	(7.6)	14	(5.6)	66	(7.0)	13	(8.4)	7	(4.7)	19	(5.8)
Gastrointestinal medicines	56	(42.7)	93	(37.2)	369	(38.9)	57	(37.0)	51	(34.0)	113	(34.5)
Laxatives	23	(17.6)	29	(11.6)	80	(8.4)	20	(13.0)	17	(11.3)	37	(11.3)
Cough medicines	26	(19.8)	48	(19.2)	204	(21.5)	23	(14.9)	23	(15.3)	57	(17.4)
Chinese herbal medicines	23	(17.6)	26	(10.4)	150	(15.8)	17	(11.0)	30	(20.0)	41	(12.5)
Vitamin supplements	24	(18.3)	31	(12.4)	176	(18.6)	20	(13.0)	24	(16.0)	49	(14.9)
Other supplements	24	(18.3)	55	(22.0)	222	(23.4)	33	(21.4)	32	(21.3)	68	(20.7)
Other	12	(9.2)	24	(9.6)	73	(7.7)	14	(9.1)	8	(5.3)	25	(7.6)
No response/unknown	2	(1.5)	1	(.4)	3	(.3)	0	(.0)	0	(.0)	1	(.3)

For household medicines and drugs used within the past year, vitamin supplements are not included in "other supplements," and "gastrointestinal medicines" include antifatulents and antidiarrheics.

Table 17. Medications use by Residence area (n=3076) continued

	Residence area										p-value		
	Kinki		Chugoku		Shikoku		Kita-Kyusyu		Minami-			Total	
	n=442	n=191	n=88	n=229	n=165	n=3076	n	(%)	n	(%)		n	(%)
Household medicines													
None	66	(14.9)	21	(11.0)	9	(10.2)	38	(16.6)	27	(16.4)	381	(12.4)	0.250
Cold medicines	318	(71.9)	146	(76.4)	61	(69.3)	151	(65.9)	102	(61.8)	2192	(71.3)	0.066
Antipyretic analgesics	234	(52.9)	109	(57.1)	52	(59.1)	125	(54.6)	96	(58.2)	1701	(55.3)	0.808
Drugs for rhinitis (allergy drugs)	149	(33.7)	55	(28.8)	28	(31.8)	57	(24.9)	49	(29.7)	972	(31.6)	0.634
Motion sickness drugs	86	(19.5)	30	(15.7)	16	(18.2)	28	(12.2)	16	(9.7)	480	(15.6)	0.262
Gastrointestinal medicines	231	(52.3)	107	(56.0)	40	(45.5)	123	(53.7)	86	(52.1)	1711	(55.6)	0.267
Laxatives	85	(19.2)	43	(22.5)	13	(14.8)	29	(12.7)	22	(13.3)	495	(16.1)	0.237
Cough medicines	91	(20.6)	54	(28.3)	20	(22.7)	46	(20.1)	27	(16.4)	659	(21.4)	0.559
Chinese herbal medicines	77	(17.4)	30	(15.7)	15	(17.0)	35	(15.3)	21	(12.7)	479	(15.6)	0.872
Vitamin supplements	87	(19.7)	32	(16.8)	12	(13.6)	34	(14.8)	26	(15.8)	554	(18.0)	0.672
Other supplements	100	(22.6)	45	(23.6)	21	(23.9)	53	(23.1)	34	(20.6)	722	(23.5)	0.877
Other	13	(2.9)	4	(2.1)	1	(1.1)	10	(4.4)	2	(1.2)	88	(2.9)	0.329
No response/unknown	1	(.2)	2	(1.0)	0	(.0)	1	(.4)	0	(.0)	16	(.5)	0.635
Medicinal drugs used within the past year													
None	40	(9.0)	21	(11.0)	5	(5.7)	19	(8.3)	16	(9.7)	246	(8.0)	0.147
Cold medicines	270	(61.1)	113	(59.2)	55	(62.5)	150	(65.5)	105	(63.6)	1990	(64.7)	0.215
Antipyretic analgesics	257	(58.1)	112	(58.6)	63	(71.6)	148	(64.6)	110	(66.7)	1937	(63.0)	0.019
Drugs for rhinitis (allergy drugs)	127	(28.7)	44	(23.0)	22	(25.0)	56	(24.5)	47	(28.5)	899	(29.2)	0.062
Motion sickness drugs	33	(7.5)	17	(8.9)	7	(8.0)	14	(6.1)	17	(10.3)	217	(7.1)	0.332
Gastrointestinal medicines	161	(36.4)	68	(35.6)	32	(36.4)	79	(34.5)	63	(38.2)	1142	(37.1)	0.420
Laxatives	57	(12.9)	24	(12.6)	8	(9.1)	14	(6.1)	18	(10.9)	327	(10.6)	0.016
Cough medicines	73	(16.5)	32	(16.8)	13	(14.8)	50	(21.8)	30	(18.2)	579	(18.8)	0.143
Chinese herbal medicines	68	(15.4)	29	(15.2)	13	(14.8)	41	(17.9)	24	(14.5)	462	(15.0)	0.113
Vitamin supplements	77	(17.4)	25	(13.1)	13	(14.8)	36	(15.7)	33	(20.0)	508	(16.5)	0.156
Other supplements	94	(21.3)	40	(20.9)	19	(21.6)	45	(19.7)	40	(24.2)	672	(21.8)	0.565
Other	49	(11.1)	18	(9.4)	8	(9.1)	23	(10.0)	8	(4.8)	262	(8.5)	0.178
No response/unknown	0	(.0)	2	(1.0)	1	(1.1)	0	(.0)	0	(.0)	10	(.3)	0.153

For household medicines and drugs used within the past year, vitamin supplements are not included in "other supplements," and "gastrointestinal medicines" include antiflatulents and antidiarrheics.

Table 18. Medications use by Sex (n = 3076)

	Sex						P-value
	Men		Women		Total		
	n = 1466		n = 1610		n = 3076		
	n	(%)	n	(%)	n	(%)	
Household medicines							
None	212	(14.5)	169	(10.5)	381	(12.4)	0.002
Cold medicines	1031	(70.3)	1161	(72.1)	2192	(71.3)	0.309
Antipyretic analgesics	681	(46.5)	1020	(63.4)	1701	(55.3)	<0.001
Drugs for rhinitis (allergy drugs)	446	(30.4)	526	(32.7)	972	(31.6)	0.216
Motion sickness drugs	196	(13.4)	284	(17.6)	480	(15.6)	0.003
Gastrointestinal medicines	824	(56.2)	887	(55.1)	1711	(55.6)	0.379
Laxatives	165	(11.3)	330	(20.5)	495	(16.1)	<0.001
Cough medicines	303	(20.7)	356	(22.1)	659	(21.4)	0.319
Chinese herbal medicines	214	(14.6)	265	(16.5)	479	(15.6)	0.188
Vitamin supplements	247	(16.8)	307	(19.1)	554	(18.0)	0.145
Other supplements	306	(20.9)	416	(25.8)	722	(23.5)	0.003
Other	38	(2.6)	50	(3.1)	88	(2.9)	0.346
No response/unknown	10	(.7)	6	(.4)	16	(.5)	0.233
Medicinal drugs used within the past year							
None	142	(9.7)	104	(6.5)	246	(8.0)	0.003
Cold medicines	923	(63.0)	1067	(66.3)	1990	(64.7)	0.129
Antipyretic analgesics	777	(53.0)	1160	(72.0)	1937	(63.0)	<0.001
Drugs for rhinitis (allergy drugs)	379	(25.9)	520	(32.3)	899	(29.2)	<0.001
Motion sickness drugs	75	(5.1)	142	(8.8)	217	(7.1)	<0.001
Gastrointestinal medicines	537	(36.6)	605	(37.6)	1142	(37.1)	0.647
Laxatives	65	(4.4)	262	(16.3)	327	(10.6)	<0.001
Cough medicines	228	(15.6)	351	(21.8)	579	(18.8)	<0.001
Chinese herbal medicines	161	(11.0)	301	(18.7)	462	(15.0)	<0.001
Vitamin supplements	202	(13.8)	306	(19.0)	508	(16.5)	<0.001
Other supplements	270	(18.4)	402	(25.0)	672	(21.8)	<0.001
Other	124	(8.5)	138	(8.6)	262	(8.5)	0.733
No response/unknown	6	(.4)	4	(.2)	10	(.3)	0.434

For household medicines and drugs used within the past year, vitamin supplements are not included in “other supplements,” and “gastrointestinal medicines” include antifoam agents and antidiarrheals.

Table 19. Medications use by Age group (n=3076)

	Age group												p-value		
	10s		20s		30s		40s		50s		60s			Total	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)		n	(%)
Household medicines															
None	40	(18.0)	54	(14.1)	61	(11.0)	80	(10.7)	81	(11.7)	65	(13.7)	381	(12.4)	0.008
Cold medicines	133	(59.9)	266	(69.6)	407	(73.6)	542	(72.2)	502	(72.2)	342	(72.3)	2192	(71.3)	0.004
Antipyretic analgesics	100	(45.0)	201	(52.6)	319	(57.7)	448	(59.7)	403	(58.0)	230	(48.6)	1701	(55.3)	<0.001
Drugs for rhinitis (allergy drugs)	73	(32.9)	116	(30.4)	174	(31.5)	263	(35.0)	223	(32.1)	123	(26.0)	972	(31.6)	0.012
Motion sickness drugs	70	(31.5)	56	(14.7)	78	(14.1)	148	(19.7)	91	(13.1)	37	(7.8)	480	(15.6)	<0.001
Gastrointestinal medicines	94	(42.3)	176	(46.1)	278	(50.3)	432	(57.5)	436	(62.7)	295	(62.4)	1711	(55.6)	<0.001
Laxatives	45	(20.3)	55	(14.4)	68	(12.3)	109	(14.5)	134	(19.3)	84	(17.8)	495	(16.1)	0.001
Cough medicines	51	(23.0)	65	(17.0)	108	(19.5)	150	(20.0)	172	(24.7)	113	(23.9)	659	(21.4)	0.006
Chinese herbal medicines	25	(11.3)	47	(12.3)	93	(16.8)	127	(16.9)	120	(17.3)	67	(14.2)	479	(15.6)	0.020
Vitamin supplements	30	(13.5)	56	(14.7)	107	(19.3)	139	(18.5)	137	(19.7)	85	(18.0)	554	(18.0)	0.038
Other supplements	36	(16.2)	62	(16.2)	125	(22.6)	174	(23.2)	192	(27.6)	133	(28.1)	722	(23.5)	<0.001
Other	3	(1.4)	3	(.8)	10	(1.8)	24	(3.2)	30	(4.3)	18	(3.8)	88	(2.9)	0.001
No response/unknown	4	(1.8)	3	(.8)	2	(.4)	2	(.3)	1	(.1)	4	(.8)	16	(.5)	0.040
Medicinal drugs used within the past year															
None	30	(13.5)	40	(10.5)	41	(7.4)	44	(5.9)	47	(6.8)	44	(9.3)	246	(8.0)	0.003
Cold medicines	134	(60.4)	260	(68.1)	394	(71.2)	504	(67.1)	425	(61.2)	273	(57.7)	1990	(64.7)	<0.001
Antipyretic analgesics	127	(57.2)	239	(62.6)	389	(70.3)	499	(66.4)	438	(63.0)	245	(51.8)	1937	(63.0)	<0.001
Drugs for rhinitis (allergy drugs)	81	(36.5)	115	(30.1)	168	(30.4)	234	(31.2)	201	(28.9)	100	(21.1)	899	(29.2)	0.002
Motion sickness drugs	42	(18.9)	32	(8.4)	31	(5.6)	54	(7.2)	39	(5.6)	19	(4.0)	217	(7.1)	<0.001
Gastrointestinal medicines	54	(24.3)	121	(31.7)	188	(34.0)	291	(38.7)	289	(41.6)	199	(42.1)	1142	(37.1)	<0.001
Laxatives	17	(7.7)	44	(11.5)	41	(7.4)	75	(10.0)	87	(12.5)	63	(13.3)	327	(10.6)	0.016
Cough medicines	46	(20.7)	76	(19.9)	110	(19.9)	141	(18.8)	112	(16.1)	94	(19.9)	579	(18.8)	0.324
Chinese herbal medicines	21	(9.5)	58	(15.2)	99	(17.9)	118	(15.7)	104	(15.0)	62	(13.1)	462	(15.0)	0.071
Vitamin supplements	23	(10.4)	61	(16.0)	98	(17.7)	130	(17.3)	121	(17.4)	75	(15.9)	508	(16.5)	0.158
Other supplements	23	(10.4)	57	(14.9)	117	(21.2)	171	(22.8)	184	(26.5)	120	(25.4)	672	(21.8)	<0.001
Other	3	(1.4)	12	(3.1)	29	(5.2)	69	(9.2)	86	(12.4)	63	(13.3)	262	(8.5)	<0.001
No response/unknown	0	(.0)	0	(.0)	1	(.2)	2	(.3)	3	(.4)	4	(.8)	10	(.3)	0.252

"10s" refers to those aged 15 to 19, and "60s" refers to those aged 60 to 64.

For household medicines and drugs used within the past year, vitamin supplements are not included in "other supplements," and "gastrointestinal medicines" include antifatulents and antidiarrheics.

Table 20. Medications use by Occupation (n=3076)

	Occupation									
	Self-employed		Full-time		Non-full-time		Student		Housewife	
	n=248		n=1406		n=394		n=271		n=436	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Household medicines										
None	38	(15.3)	159	(11.3)	36	(9.1)	47	(17.3)	46	(10.6)
Cold medicines	169	(68.1)	1,021	(72.6)	298	(75.6)	169	(62.4)	325	(74.5)
Antipyretic analgesics	125	(50.4)	767	(54.6)	258	(65.5)	125	(46.1)	274	(62.8)
Drugs for rhinitis (allergy drugs)	73	(29.4)	457	(32.5)	137	(34.8)	90	(33.2)	135	(31.0)
Motion sickness drugs	32	(12.9)	193	(13.7)	80	(20.3)	79	(29.2)	72	(16.5)
Gastrointestinal medicines	152	(61.3)	791	(56.3)	230	(58.4)	119	(43.9)	255	(58.5)
Laxatives	45	(18.1)	179	(12.7)	84	(21.3)	53	(19.6)	85	(19.5)
Cough medicines	58	(23.4)	280	(19.9)	97	(24.6)	60	(22.1)	100	(22.9)
Chinese herbal medicines	50	(20.2)	213	(15.1)	65	(16.5)	31	(11.4)	79	(18.1)
Vitamin supplements	45	(18.1)	263	(18.7)	71	(18.0)	41	(15.1)	76	(17.4)
Other supplements	64	(25.8)	314	(22.3)	101	(25.6)	42	(15.5)	131	(30.0)
Other	10	(4.0)	31	(2.2)	13	(3.3)	3	(1.1)	24	(5.5)
No response/unknown	0	(.0)	7	(.5)	1	(.3)	4	(1.5)	2	(.5)
Medicinal drugs used within the past year										
None	28	(11.3)	87	(6.2)	27	(6.9)	38	(14.0)	31	(7.1)
Cold medicines	142	(57.3)	958	(68.1)	259	(65.7)	171	(63.1)	286	(65.6)
Antipyretic analgesics	141	(56.9)	893	(63.5)	267	(67.8)	152	(56.1)	312	(71.6)
Drugs for rhinitis (allergy drugs)	58	(23.4)	419	(29.8)	132	(33.5)	101	(37.3)	127	(29.1)
Motion sickness drugs	15	(6.0)	82	(5.8)	29	(7.4)	48	(17.7)	35	(8.0)
Gastrointestinal medicines	102	(41.1)	528	(37.6)	160	(40.6)	71	(26.2)	166	(38.1)
Laxatives	22	(8.9)	110	(7.8)	56	(14.2)	21	(7.7)	75	(17.2)
Cough medicines	44	(17.7)	250	(17.8)	78	(19.8)	54	(19.9)	101	(23.2)
Chinese herbal medicines	38	(15.3)	197	(14.0)	65	(16.5)	29	(10.7)	89	(20.4)
Vitamin supplements	35	(14.1)	238	(16.9)	64	(16.2)	35	(12.9)	81	(18.6)
Other supplements	60	(24.2)	307	(21.8)	95	(24.1)	27	(10.0)	115	(26.4)
Other	22	(8.9)	108	(7.7)	32	(8.1)	5	(1.8)	53	(12.2)
No response/unknown	1	(.4)	5	(.4)	1	(.3)	0	(.0)	1	(.2)

For household medicines and drugs used within the past year, vitamin supplements are not included in “other supplements,” and “gastrointestinal medicines” include antitflatulents and antidiarrheics.

Table 20. Medications use by Occupation (n=3076) continued

	Occupation								p-value
	Unemployed		Other		Unknown		Total		
	n=179		n=138		n=4		n=3076		
	n	(%)	n	(%)	n	(%)	n	(%)	
Household medicines									
None	34	(19.0)	21	(15.2)	0	(.0)	381	(12.4)	0.003
Cold medicines	110	(61.5)	97	(70.3)	3	(75.0)	2,192	(71.3)	0.002
Antipyretic analgesics	75	(41.9)	74	(53.6)	3	(75.0)	1,701	(55.3)	<0.001
Drugs for rhinitis (allergy drugs)	44	(24.6)	36	(26.1)	0	(.0)	972	(31.6)	0.134
Motion sickness drugs	11	(6.1)	13	(9.4)	0	(.0)	480	(15.6)	<0.001
Gastrointestinal medicines	87	(48.6)	75	(54.3)	2	(50.0)	1,711	(55.6)	0.005
Laxatives	23	(12.8)	24	(17.4)	2	(50.0)	495	(16.1)	<0.001
Cough medicines	32	(17.9)	32	(23.2)	0	(.0)	659	(21.4)	0.274
Chinese herbal medicines	24	(13.4)	16	(11.6)	1	(25.0)	479	(15.6)	0.104
Vitamin supplements	27	(15.1)	30	(21.7)	1	(25.0)	554	(18.0)	0.536
Other supplements	31	(17.3)	37	(26.8)	2	(50.0)	722	(23.5)	0.001
Other	3	(1.7)	4	(2.9)	0	(.0)	88	(2.9)	0.018
No response/unknown	2	(1.1)	0	(.0)	0	(.0)	16	(.5)	0.279
Medicinal drugs used within the past year									
None	25	(14.0)	10	(7.2)	0	(.0)	246	(8.0)	<0.001
Cold medicines	82	(45.8)	91	(65.9)	1	(25.0)	1,990	(64.7)	<0.001
Antipyretic analgesics	86	(48.0)	84	(60.9)	2	(50.0)	1,937	(63.0)	<0.001
Drugs for rhinitis (allergy drugs)	29	(16.2)	32	(23.2)	1	(25.0)	899	(29.2)	0.001
Motion sickness drugs	2	(1.1)	6	(4.3)	0	(.0)	217	(7.1)	<0.001
Gastrointestinal medicines	61	(34.1)	53	(38.4)	1	(25.0)	1,142	(37.1)	0.043
Laxatives	19	(10.6)	23	(16.7)	1	(25.0)	327	(10.6)	<0.001
Cough medicines	21	(11.7)	31	(22.5)	0	(.0)	579	(18.8)	0.138
Chinese herbal medicines	23	(12.8)	20	(14.5)	1	(25.0)	462	(15.0)	0.084
Vitamin supplements	21	(11.7)	33	(23.9)	1	(25.0)	508	(16.5)	0.177
Other supplements	27	(15.1)	39	(28.3)	2	(50.0)	672	(21.8)	<0.001
Other	29	(16.2)	13	(9.4)	0	(.0)	262	(8.5)	<0.001
No response/unknown	2	(1.1)	0	(.0)	0	(.0)	10	(.3)	0.649

For household medicines and drugs used within the past year, vitamin supplements are not included in “other supplements,” and “gastrointestinal medicines” include antifoam agents and antidiarrheals.

Table 21. Medications use by Drug use experience (n=3076)

	Drug use experience								p-value
	Lifetime		No lifetime		Unknown		Total		
	n=78	n=2940	n=58	n=3076	n	(%)	n	(%)	
Household medicines									
None	8	358	15	381	(10.3)	(12.2)	(25.9)	(12.4)	0.024
Cold medicines	52	2,108	32	2,192	(66.7)	(71.7)	(55.2)	(71.3)	0.043
Antipyretic analgesics	49	1,633	19	1,701	(62.8)	(55.5)	(32.8)	(55.3)	0.004
Drugs for rhinitis (allergy drugs)	24	936	12	972	(30.8)	(31.8)	(20.7)	(31.6)	0.334
Motion sickness drugs	9	467	4	480	(11.5)	(15.9)	(6.9)	(15.6)	0.224
Gastrointestinal medicines	43	1,637	31	1,711	(55.1)	(55.7)	(53.4)	(55.6)	0.856
Laxatives	13	476	6	495	(16.7)	(16.2)	(10.3)	(16.1)	0.610
Cough medicines	22	628	9	659	(28.2)	(21.4)	(15.5)	(21.4)	0.322
Chinese herbal medicines	10	462	7	479	(12.8)	(15.7)	(12.1)	(15.6)	0.698
Vitamin supplements	16	535	3	554	(20.5)	(18.2)	(5.2)	(18.0)	0.085
Other supplements	18	697	7	722	(23.1)	(23.7)	(12.1)	(23.5)	0.234
Other	3	83	2	88	(3.8)	(2.8)	(3.4)	(2.9)	0.817
No response/unknown	1	15	0	16	(1.3)	(.5)	(.0)	(.5)	0.553
Medicinal drugs used within the past year									
None	4	232	10	246	(5.1)	(7.9)	(17.2)	(8.0)	<0.001
Cold medicines	50	1,908	32	1,990	(64.1)	(64.9)	(55.2)	(64.7)	0.005
Antipyretic analgesics	53	1,854	30	1,937	(67.9)	(63.1)	(51.7)	(63.0)	0.002
Drugs for rhinitis (allergy drugs)	18	872	9	899	(23.1)	(29.7)	(15.5)	(29.2)	0.001
Motion sickness drugs	6	208	3	217	(7.7)	(7.1)	(5.2)	(7.1)	0.012
Gastrointestinal medicines	23	1,109	10	1,142	(29.5)	(37.7)	(17.2)	(37.1)	<0.001
Laxatives	7	315	5	327	(9.0)	(10.7)	(8.6)	(10.6)	0.012
Cough medicines	18	549	12	579	(23.1)	(18.7)	(20.7)	(18.8)	0.008
Chinese herbal medicines	8	447	7	462	(10.3)	(15.2)	(12.1)	(15.0)	0.007
Vitamin supplements	15	488	5	508	(19.2)	(16.6)	(8.6)	(16.5)	0.003
Other supplements	22	644	6	672	(28.2)	(21.9)	(10.3)	(21.8)	0.001
Other	6	250	6	262	(7.7)	(8.5)	(10.3)	(8.5)	0.012
No response/unknown	2	8	0	10	(2.6)	(.3)	(.0)	(.3)	0.002

For household medicines and drugs used within the past year, vitamin supplements are not included in “other supplements,” and “gastrointestinal medicines” include antifatulents and antidiarrheics.

Table 22. Analgesic Use by Residence area (n=3076)

	Residence area											
	Hokkaido		Tohoku		Kanto		Hokuriku		Tousan		Tokai	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Past-year analgesic use												
No	34	(26.0)	99	(39.6)	346	(36.5)	58	(37.7)	62	(41.3)	111	(33.8)
Yes	96	(73.3)	151	(60.4)	599	(63.2)	96	(62.3)	88	(58.7)	217	(66.2)
Frequency of the past-year analgesic use												
None	34	(26.0)	99	(39.6)	346	(36.5)	58	(37.7)	62	(41.3)	111	(33.8)
≤5 times a year	52	(39.7)	90	(36.0)	330	(34.8)	49	(31.8)	49	(32.7)	115	(35.1)
Approx. 6–11 times a year	7	(5.3)	15	(6.0)	76	(8.0)	11	(7.1)	9	(6.0)	27	(8.2)
Approx. 12–24 times a year	17	(13.0)	18	(7.2)	75	(7.9)	11	(7.1)	15	(10.0)	42	(12.8)
Approx. 25–51 times a year	13	(9.9)	8	(3.2)	47	(5.0)	9	(5.8)	8	(5.3)	16	(4.9)
Approx. 1–2 times a week	3	(2.3)	3	(1.2)	22	(2.3)	5	(3.2)	1	(.7)	5	(1.5)
Approx. 3–6 times a week	0	(.0)	3	(1.2)	7	(.7)	2	(1.3)	2	(1.3)	2	(.6)
Almost every day	2	(1.5)	4	(1.6)	19	(2.0)	4	(2.6)	2	(1.3)	3	(.9)
Frequency unknown	2	(1.5)	10	(4.0)	23	(2.4)	5	(3.2)	2	(1.3)	7	(2.1)
Chronic analgesic use												
No	126	(96.2)	233	(93.2)	896	(94.5)	143	(92.9)	144	(96.0)	316	(96.3)
Yes	2	(1.5)	7	(2.8)	26	(2.7)	6	(3.9)	4	(2.7)	5	(1.5)
Source of analgesics												
Never obtained	27	(20.6)	84	(33.6)	294	(31.0)	49	(31.8)	55	(36.7)	91	(27.7)
Household medicines	15	(11.5)	35	(14.0)	134	(14.1)	23	(14.9)	22	(14.7)	43	(13.1)
Family	10	(7.6)	8	(3.2)	39	(4.1)	4	(2.6)	5	(3.3)	15	(4.6)
Clinics/hospitals	43	(32.8)	57	(22.8)	228	(24.1)	35	(22.7)	35	(23.3)	95	(29.0)
Pharmacies/drugstores	58	(44.3)	81	(32.4)	388	(40.9)	60	(39.0)	57	(38.0)	145	(44.2)
Friends/acquaintances	0	(.0)	2	(.8)	12	(1.3)	1	(.6)	0	(.0)	1	(.3)
Romantic partners	0	(.0)	0	(.0)	1	(.1)	0	(.0)	0	(.0)	0	(.0)
Internet	1	(.8)	1	(.4)	2	(.2)	1	(.6)	0	(.0)	0	(.0)
Other	0	(.0)	0	(.0)	4	(.4)	0	(.0)	0	(.0)	0	(.0)
Source unknown	3	(2.3)	8	(3.2)	13	(1.4)	3	(1.9)	2	(1.3)	5	(1.5)
Reason for analgesic use												
None	34	(26.0)	99	(39.6)	346	(36.5)	58	(37.7)	62	(41.3)	111	(33.8)
Headache	59	(45.0)	76	(30.4)	377	(39.8)	54	(35.1)	60	(40.0)	137	(41.8)
Toothache	16	(12.2)	40	(16.0)	94	(9.9)	19	(12.3)	9	(6.0)	32	(9.8)
Low back pain	10	(7.6)	17	(6.8)	70	(7.4)	10	(6.5)	11	(7.3)	25	(7.6)
Menstrual pain	14	(10.7)	32	(12.8)	125	(13.2)	15	(9.7)	14	(9.3)	37	(11.3)
Stomachache	6	(4.6)	5	(2.0)	31	(3.3)	5	(3.2)	2	(1.3)	11	(3.4)
Stiff shoulder	4	(3.1)	7	(2.8)	46	(4.9)	5	(3.2)	6	(4.0)	18	(5.5)
Recreation (pleasure)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Other	14	(10.7)	22	(8.8)	101	(10.7)	17	(11.0)	19	(12.7)	32	(9.8)
Reason for use unknown	4	(3.1)	8	(3.2)	20	(2.1)	5	(3.2)	2	(1.3)	6	(1.8)
Past 30-day analgesic use												
No	90	(68.7)	202	(80.8)	682	(71.9)	114	(74.0)	113	(75.3)	230	(70.1)
Yes	40	(30.5)	48	(19.2)	261	(27.5)	38	(24.7)	36	(24.0)	98	(29.9)
Type of analgesics used												
Nonopioid analgesics	29	(100.0)	39	(100.0)	225	(97.4)	35	(100.0)	30	(100.0)	85	(97.7)
Opioid analgesics	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Co-analgesics	0	(.0)	1	(2.6)	5	(2.2)	1	(2.9)	0	(.0)	2	(2.3)
Other	0	(.0)	1	(2.6)	6	(2.6)	0	(.0)	0	(.0)	3	(3.4)

The number of analgesics used (average) and the type of analgesics used are based on the past 30-day use.

Table 22. Analgesic Use by Residence area (n=3076) continued

	Residence area											p-value	
	Kinki		Chugoku		Shikoku		Kita-Kyusyu		Minami-		Total		
	n=442		n=191		n=88		n=229		n=165		n=3076		
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	
Past-year analgesic use													0.097
No	185	(41.9)	78	(40.8)	25	(28.4)	81	(35.4)	55	(33.3)	1,134	(36.9)	
Yes	257	(58.1)	112	(58.6)	63	(71.6)	148	(64.6)	110	(66.7)	1,937	(63.0)	
Frequency of the past-year analgesic use													0.707
None	185	(41.9)	78	(40.8)	25	(28.4)	81	(35.4)	55	(33.3)	1,134	(36.9)	
≤5 times a year	140	(31.7)	62	(32.5)	32	(36.4)	82	(35.8)	63	(38.2)	1,064	(34.6)	
Approx. 6–11 times a year	31	(7.0)	15	(7.9)	7	(8.0)	18	(7.9)	16	(9.7)	232	(7.5)	
Approx. 12–24 times a year	37	(8.4)	19	(9.9)	8	(9.1)	18	(7.9)	13	(7.9)	273	(8.9)	
Approx. 25–51 times a year	21	(4.8)	9	(4.7)	10	(11.4)	14	(6.1)	8	(4.8)	163	(5.3)	
Approx. 1–2 times a week	6	(1.4)	1	(.5)	1	(1.1)	7	(3.1)	4	(2.4)	58	(1.9)	
Approx. 3–6 times a week	3	(.7)	2	(1.0)	2	(2.3)	1	(.4)	1	(.6)	25	(.8)	
Almost every day	7	(1.6)	2	(1.0)	2	(2.3)	5	(2.2)	2	(1.2)	52	(1.7)	
Frequency unknown	12	(2.7)	2	(1.0)	1	(1.1)	3	(1.3)	3	(1.8)	70	(2.3)	
Chronic analgesic use													0.893
No	420	(95.0)	184	(96.3)	83	(94.3)	220	(96.1)	159	(96.4)	2,924	(95.1)	
Yes	10	(2.3)	4	(2.1)	4	(4.5)	6	(2.6)	3	(1.8)	77	(2.5)	
Source of analgesics													
Never obtained	156	(35.3)	67	(35.1)	21	(23.9)	73	(31.9)	48	(29.1)	965	(31.4)	0.078
Household medicines	52	(11.8)	21	(11.0)	11	(12.5)	26	(11.4)	15	(9.1)	397	(12.9)	0.637
Family	20	(4.5)	9	(4.7)	3	(3.4)	6	(2.6)	12	(7.3)	131	(4.3)	0.329
Clinics/hospitals	94	(21.3)	59	(30.9)	37	(42.0)	65	(28.4)	44	(26.7)	792	(25.7)	0.004
Pharmacies/drugstores	171	(38.7)	53	(27.7)	30	(34.1)	95	(41.5)	70	(42.4)	1,208	(39.3)	0.031
Friends/acquaintances	4	(.9)	1	(.5)	1	(1.1)	1	(.4)	4	(2.4)	27	(.9)	0.362
Romantic partners	1	(.2)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	2	(.1)	0.840
Internet	0	(.0)	1	(.5)	0	(.0)	0	(.0)	0	(.0)	6	(.2)	0.526
Other	0	(.0)	1	(.5)	0	(.0)	1	(.4)	1	(.6)	7	(.2)	0.584
Source unknown	8	(1.8)	2	(1.0)	0	(.0)	2	(.9)	1	(.6)	47	(1.5)	0.532
Reason for analgesic use													
None	185	(41.9)	78	(40.8)	25	(28.4)	81	(35.4)	55	(33.3)	1,134	(36.9)	0.097
Headache	157	(35.5)	78	(40.8)	46	(52.3)	92	(40.2)	79	(47.9)	1,215	(39.5)	0.018
Toothache	30	(6.8)	12	(6.3)	9	(10.2)	26	(11.4)	18	(10.9)	305	(9.9)	0.045
Low back pain	20	(4.5)	8	(4.2)	9	(10.2)	14	(6.1)	13	(7.9)	207	(6.7)	0.607
Menstrual pain	43	(9.7)	9	(4.7)	5	(5.7)	28	(12.2)	13	(7.9)	335	(10.9)	0.108
Stomachache	19	(4.3)	5	(2.6)	1	(1.1)	7	(3.1)	6	(3.6)	98	(3.2)	0.730
Stiff shoulder	11	(2.5)	6	(3.1)	8	(9.1)	9	(3.9)	5	(3.0)	125	(4.1)	0.287
Recreation (pleasure)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.554
Other	39	(8.8)	19	(9.9)	8	(9.1)	31	(13.5)	10	(6.1)	312	(10.1)	0.605
Reason for use unknown	12	(2.7)	4	(2.1)	1	(1.1)	3	(1.3)	4		69	(2.2)	0.895
Past 30-day analgesic use													0.206
No	323	(73.1)	141	(73.8)	62	(70.5)	167	(72.9)	117	(70.9)	2,241	(72.9)	
Yes	116	(26.2)	47	(24.6)	26	(29.5)	62	(27.1)	48	(29.1)	820	(26.7)	
Type of analgesics used													
Nonopioid analgesics	99	(97.1)	41	(100.0)	20	(95.2)	57	(100.0)	40	(93.0)	700	(97.9)	0.331
Opioid analgesics	3	(2.9)	0	(.0)	1	(4.8)	0	(.0)	0	(.0)	4	(.6)	0.025
Co-analgesics	1	(1.0)	1	(2.4)	0	(.0)	1	(1.8)	0	(.0)	12	(1.7)	0.962
Other	5	(4.9)	0	(.0)	1	(4.8)	1	(1.8)	3	(7.0)	20	(2.8)	0.419

The number of analgesics used (average) and the type of analgesics used are based on the past 30-day use.

Table 23. Analgesic Use by Sex (n = 3076)

	Sex						P-value
	Men		Women		Total		
	n = 1466		n = 1610		n = 3076		
	n	(%)	n	(%)	n	(%)	
Past-year analgesic use							<0.001
No	685	(46.7)	449	(27.9)	1,134	(36.9)	
Yes	777	(53.0)	1,160	(72.0)	1,937	(63.0)	
Frequency of the past-year analgesic use							<0.001
None	685	(46.7)	449	(27.9)	1,134	(36.9)	
≤5 times a year	520	(35.5)	544	(33.8)	1,064	(34.6)	
Approx. 6–11 times a year	89	(6.1)	143	(8.9)	232	(7.5)	
Approx. 12–24 times a year	54	(3.7)	219	(13.6)	273	(8.9)	
Approx. 25–51 times a year	34	(2.3)	129	(8.0)	163	(5.3)	
Approx. 1–2 times a week	16	(1.1)	42	(2.6)	58	(1.9)	
Approx. 3–6 times a week	9	(.6)	16	(1.0)	25	(.8)	
Almost every day	20	(1.4)	32	(2.0)	52	(1.7)	
Frequency unknown	35	(2.4)	35	(2.2)	70	(2.3)	
Chronic analgesic use							0.159
No	1,398	(95.4)	1,526	(94.8)	2,924	(95.1)	
Yes	29	(2.0)	48	(3.0)	77	(2.5)	
Source of analgesics							
Never obtained	597	(40.7)	368	(22.9)	965	(31.4)	<0.001
Household medicines	168	(11.5)	229	(14.2)	397	(12.9)	0.002
Family	63	(4.3)	68	(4.2)	131	(4.3)	0.018
Clinics/hospitals	300	(20.5)	492	(30.6)	792	(25.7)	<0.001
Pharmacies/drugstores	457	(31.2)	751	(46.6)	1,208	(39.3)	<0.001
Friends/acquaintances	7	(.5)	20	(1.2)	27	(.9)	0.001
Romantic partners	1	(.1)	1	(.1)	2	(.1)	0.018
Internet	2	(.1)	4	(.2)	6	(.2)	0.014
Other	2	(.1)	5	(.3)	7	(.2)	0.011
Source unknown	25	(1.7)	22	(1.4)	47	(1.5)	0.444
Reason for analgesic use							
None	685	(46.7)	449	(27.9)	1,134	(36.9)	<0.001
Headache	433	(29.5)	782	(48.6)	1,215	(39.5)	<0.001
Toothache	160	(10.9)	145	(9.0)	305	(9.9)	0.071
Low back pain	98	(6.7)	109	(6.8)	207	(6.7)	0.349
Menstrual pain	0	(.0)	335	(20.8)	335	(10.9)	<0.001
Stomachache	38	(2.6)	60	(3.7)	98	(3.2)	0.072
Stiff shoulder	30	(2.0)	95	(5.9)	125	(4.1)	<0.001
Recreation (pleasure)	0	(.0)	0	(.0)	0	(.0)	0.147
Other	132	(9.0)	180	(11.2)	312	(10.1)	0.050
Reason for use unknown	41	(2.8)	28	(1.7)	69	(2.2)	0.048
Past 30-day analgesic use							<0.001
No	1,230	(83.9)	1,011	(62.8)	2,241	(72.9)	
Yes	226	(15.4)	594	(36.9)	820	(26.7)	
Type of analgesics used							
Nonopioid analgesics	178	(97.3)	522	(98.1)	700	(97.9)	<0.001
Opioid analgesics	1	(.5)	3	(.6)	4	(.6)	0.364
Co-analgesics	6	(3.3)	6	(1.1)	12	(1.7)	0.871
Other	4	(2.2)	16	(3.0)	20	(2.8)	0.013

For the source of analgesics, “pharmacies/drugstores” include external prescription.

The number of analgesics used (average) and the type of analgesics used are based on the past 30-day use.

Table 24. Analgesic Use by Age group (n=3076)

	Age group												p-value		
	10s		20s		30s		40s		50s		60s			Total	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)		n	(%)
Past-year analgesic use															
No	95	(42.8)	143	(37.4)	164	(29.7)	250	(33.3)	257	(37.0)	225	(47.6)	1,134	(36.9)	<0.001
Yes	127	(57.2)	239	(62.6)	389	(70.3)	499	(66.4)	438	(63.0)	245	(51.8)	1,937	(63.0)	
Frequency of the past-year analgesic use															
None	95	(42.8)	143	(37.4)	164	(29.7)	250	(33.3)	257	(37.0)	225	(47.6)	1,134	(36.9)	<0.001
≤5 times a year	63	(28.4)	119	(31.2)	192	(34.7)	273	(36.4)	250	(36.0)	167	(35.3)	1,064	(34.6)	
Approx. 6–11 times a year	14	(6.3)	32	(8.4)	41	(7.4)	67	(8.9)	60	(8.6)	18	(3.8)	232	(7.5)	
Approx. 12–24 times a year	34	(15.3)	44	(11.5)	72	(13.0)	68	(9.1)	41	(5.9)	14	(3.0)	273	(8.9)	
Approx. 25–51 times a year	9	(4.1)	26	(6.8)	44	(8.0)	40	(5.3)	30	(4.3)	14	(3.0)	163	(5.3)	
Approx. 1–2 times a week	1	(.5)	2	(.5)	19	(3.4)	17	(2.3)	15	(2.2)	4	(.8)	58	(1.9)	
Approx. 3–6 times a week	0	(.0)	4	(1.0)	3	(.5)	6	(.8)	10	(1.4)	2	(.4)	25	(.8)	
Almost every day	0	(.0)	3	(.8)	6	(1.1)	14	(1.9)	14	(2.0)	15	(3.2)	52	(1.7)	
Frequency unknown	6	(2.7)	9	(2.4)	12	(2.2)	14	(1.9)	18	(2.6)	11	(2.3)	70	(2.3)	
Chronic analgesic use															
No	216	(97.3)	366	(95.8)	532	(96.2)	715	(95.2)	653	(94.0)	442	(93.4)	2,924	(95.1)	0.159
Yes	0	(.0)	7	(1.8)	9	(1.6)	20	(2.7)	24	(3.5)	17	(3.6)	77	(2.5)	
Source of analgesics															
Never obtained	87	(39.2)	126	(33.0)	143	(25.9)	203	(27.0)	211	(30.4)	195	(41.2)	965	(31.4)	<0.001
Household medicines	27	(12.2)	51	(13.4)	73	(13.2)	96	(12.8)	100	(14.4)	50	(10.6)	397	(12.9)	0.459
Family	37	(16.7)	40	(10.5)	23	(4.2)	14	(1.9)	11	(1.6)	6	(1.3)	131	(4.3)	<0.001
Clinics/hospitals	36	(16.2)	93	(24.3)	150	(27.1)	200	(26.6)	192	(27.6)	121	(25.6)	792	(25.7)	0.033
Pharmacies/drugstores	54	(24.3)	154	(40.3)	269	(48.6)	328	(43.7)	259	(37.3)	144	(30.4)	1,208	(39.3)	<0.001
Friends/acquaintances	1	(.5)	9	(2.4)	8	(1.4)	4	(.5)	4	(.6)	1	(.2)	27	(.9)	0.013
Romantic partners	0	(.0)	1	(.3)	0	(.0)	1	(.1)	0	(.0)	0	(.0)	2	(.1)	0.420
Internet	0	(.0)	0	(.0)	1	(.2)	3	(.4)	1	(.1)	1	(.2)	6	(.2)	0.524
Other	0	(.0)	0	(.0)	3	(.5)	4	(.5)	0	(.0)	0	(.0)	7	(.2)	0.109
Source unknown	5	(2.3)	7	(1.8)	8	(1.4)	12	(1.6)	10	(1.4)	5	(1.1)	47	(1.5)	0.877
Reason for analgesic use															
None	95	(42.8)	143	(37.4)	164	(29.7)	250	(33.3)	257	(37.0)	225	(47.6)	1,134	(36.9)	<0.001
Headache	73	(32.9)	144	(37.7)	265	(47.9)	334	(44.5)	276	(39.7)	123	(26.0)	1,215	(39.5)	<0.001
Toothache	14	(6.3)	33	(8.6)	49	(8.9)	83	(11.1)	78	(11.2)	48	(10.1)	305	(9.9)	0.071
Low back pain	11	(5.0)	11	(2.9)	33	(6.0)	57	(7.6)	51	(7.3)	44	(9.3)	207	(6.7)	0.002
Menstrual pain	52	(23.4)	99	(25.9)	92	(16.6)	81	(10.8)	11	(1.6)	0	(.0)	335	(10.9)	<0.001
Stomachache	5	(2.3)	14	(3.7)	18	(3.3)	22	(2.9)	24	(3.5)	15	(3.2)	98	(3.2)	0.340
Stiff shoulder	4	(1.8)	8	(2.1)	32	(5.8)	36	(4.8)	29	(4.2)	16	(3.4)	125	(4.1)	0.013
Recreation (pleasure)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.075
Other	13	(5.9)	25	(6.5)	59	(10.7)	73	(9.7)	86	(12.4)	56	(11.8)	312	(10.1)	0.004
Reason for use unknown	8	(3.6)	11	(2.9)	11	(2.0)	17	(2.3)	11	(1.6)	11	(2.3)	69	(2.2)	0.529
Past 30-day analgesic use															
No	167	(75.2)	275	(72.0)	369	(66.7)	534	(71.1)	517	(74.4)	379	(80.1)	2,241	(72.9)	<0.001
Yes	55	(24.8)	107	(28.0)	181	(32.7)	215	(28.6)	176	(25.3)	86	(18.2)	820	(26.7)	
Type of analgesics used															
Nonopioid analgesics	47	(100.0)	97	(100.0)	164	(99.4)	181	(97.8)	145	(94.8)	66	(97.1)	700	(97.9)	<0.001
Opioid analgesics	0	(.0)	0	(.0)	0	(.0)	1	(.5)	3	(2.0)	0	(.0)	4	(.6)	0.221
Co-analgesics	0	(.0)	0	(.0)	2	(1.2)	3	(1.6)	1	(.7)	6	(8.8)	12	(1.7)	0.025
Other	0	(.0)	0	(.0)	4	(2.4)	4	(2.2)	10	(6.5)	2	(2.9)	20	(2.8)	0.047

“10s” refers to those aged 15 to 19, and “60s” refers to those aged 60 to 64.

The number of analgesics used (average) and the type of analgesics used are based on the past 30-day use.

Table 25. Analgesic Use by Occupation (n=3076)

	Occupation									
	Self-employed		Full-time		Non-full-time		Student		Housewife	
	n=248		n=1406		n=394		n=271		n=436	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Past-year analgesic use										
No	105	(42.3)	511	(36.3)	127	(32.2)	119	(43.9)	124	(28.4)
Yes	141	(56.9)	893	(63.5)	267	(67.8)	152	(56.1)	312	(71.6)
Frequency of the past-year analgesic use										
None	105	(42.3)	511	(36.3)	127	(32.2)	119	(43.9)	124	(28.4)
≤5 times a year	91	(36.7)	517	(36.8)	144	(36.5)	71	(26.2)	150	(34.4)
Approx. 6–11 times a year	15	(6.0)	114	(8.1)	29	(7.4)	17	(6.3)	37	(8.5)
Approx. 12–24 times a year	10	(4.0)	112	(8.0)	36	(9.1)	40	(14.8)	52	(11.9)
Approx. 25–51 times a year	7	(2.8)	63	(4.5)	26	(6.6)	16	(5.9)	41	(9.4)
Approx. 1–2 times a week	4	(1.6)	22	(1.6)	12	(3.0)	1	(.4)	11	(2.5)
Approx. 3–6 times a week	1	(.4)	10	(.7)	6	(1.5)	0	(.0)	5	(1.1)
Almost every day	4	(1.6)	22	(1.6)	7	(1.8)	0	(.0)	10	(2.3)
Frequency unknown	9	(3.6)	33	(2.3)	7	(1.8)	7	(2.6)	6	(1.4)
Chronic analgesic use										
No	232	(93.5)	1,339	(95.2)	374	(94.9)	264	(97.4)	415	(95.2)
Yes	5	(2.0)	32	(2.3)	13	(3.3)	0	(.0)	15	(3.4)
No response/unknown	11	(4.4)	35	(2.5)	7	(1.8)	7	(2.6)	6	(1.4)
Source of analgesics										
Never obtained	88	(35.5)	436	(31.0)	98	(24.9)	109	(40.2)	104	(23.9)
Household medicines	31	(12.5)	190	(13.5)	64	(16.2)	29	(10.7)	57	(13.1)
Family	9	(3.6)	54	(3.8)	11	(2.8)	40	(14.8)	8	(1.8)
Clinics/hospitals	67	(27.0)	355	(25.2)	109	(27.7)	45	(16.6)	140	(32.1)
Pharmacies/drugstores	74	(29.8)	560	(39.8)	180	(45.7)	71	(26.2)	211	(48.4)
Friends/acquaintances	2	(.8)	12	(.9)	3	(.8)	1	(.4)	2	(.5)
Romantic partners	0	(.0)	2	(.1)	0	(.0)	0	(.0)	0	(.0)
Internet	1	(.4)	2	(.1)	1	(.3)	0	(.0)	2	(.5)
Other	0	(.0)	5	(.4)	0	(.0)	2	(.7)	0	(.0)
Source unknown	5	(2.0)	22	(1.6)	7	(1.8)	6	(2.2)	5	(1.1)
Reason for analgesic use										
None	105	(42.3)	511	(36.3)	127	(32.2)	119	(43.9)	124	(28.4)
Headache	76	(30.6)	535	(38.1)	185	(47.0)	83	(30.6)	226	(51.8)
Toothache	32	(12.9)	158	(11.2)	39	(9.9)	15	(5.5)	33	(7.6)
Low back pain	22	(8.9)	101	(7.2)	17	(4.3)	13	(4.8)	32	(7.3)
Menstrual pain	6	(2.4)	126	(9.0)	61	(15.5)	68	(25.1)	52	(11.9)
Stomachache	11	(4.4)	43	(3.1)	18	(4.6)	6	(2.2)	11	(2.5)
Stiff shoulder	11	(4.4)	57	(4.1)	13	(3.3)	4	(1.5)	28	(6.4)
Recreation (pleasure)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Other	26	(10.5)	143	(10.2)	35	(8.9)	17	(6.3)	60	(13.8)
Reason for use unknown	7	(2.8)	35	(2.5)	6	(1.5)	8	(3.0)	5	(1.1)
Past 30-day analgesic use										
No	203	(81.9)	1,044	(74.3)	275	(69.8)	200	(73.8)	268	(61.5)
Yes	42	(16.9)	357	(25.4)	116	(29.4)	71	(26.2)	166	(38.1)
No response/unknown	3	(1.2)	5	(.4)	3	(.8)	0	(.0)	2	(.5)
Type of analgesics used										
Nonopioid analgesics	27	(90.0)	316	(99.4)	97	(97.0)	60	(100.0)	144	(98.0)
Opioid analgesics	1	(3.3)	2	(.6)	0	(.0)	0	(.0)	1	(.7)
Co-analgesics	1	(3.3)	4	(1.3)	1	(1.0)	0	(.0)	4	(2.7)
Other	2	(6.7)	5	(1.6)	3	(3.0)	0	(.0)	6	(4.1)

The number of analgesics used (average) and the type of analgesics used are based on the past 30-day use.

Table 25. Analgesic Use by Occupation (n=3076) continued

	Occupation								p-value
	Unemployed		Other		Unknown		Total		
	n	(%)	n	(%)	n	(%)	n	(%)	
Past-year analgesic use									<0.001
No	92	(51.4)	54	(39.1)	2	(50.0)	1,134	(36.9)	
Yes	86	(48.0)	84	(60.9)	2	(50.0)	1,937	(63.0)	
Frequency of the past-year analgesic use									<0.001
None	92	(51.4)	54	(39.1)	2	(50.0)	1,134	(36.9)	
≤5 times a year	47	(26.3)	43	(31.2)	1	(25.0)	1,064	(34.6)	
Approx. 6–11 times a year	9	(5.0)	11	(8.0)	0	(.0)	232	(7.5)	
Approx. 12–24 times a year	13	(7.3)	9	(6.5)	1	(25.0)	273	(8.9)	
Approx. 25–51 times a year	7	(3.9)	3	(2.2)	0	(.0)	163	(5.3)	
Approx. 1–2 times a week	2	(1.1)	6	(4.3)	0	(.0)	58	(1.9)	
Approx. 3–6 times a week	0	(.0)	3	(2.2)	0	(.0)	25	(.8)	
Almost every day	5	(2.8)	4	(2.9)	0	(.0)	52	(1.7)	
Frequency unknown	3	(1.7)	5	(3.6)	0	(.0)	70	(2.3)	
Chronic analgesic use									0.082
No	170	(95.0)	126	(91.3)	4	(100.0)	2,924	(95.1)	
Yes	5	(2.8)	7	(5.1)	0	(.0)	77	(2.5)	
No response/unknown	4	(2.2)	5	(3.6)	0	(.0)	75	(2.4)	
Source of analgesics									
Never obtained	83	(46.4)	45	(32.6)	2	(50.0)	965	(31.4)	<0.001
Household medicines	14	(7.8)	12	(8.7)	0	(.0)	397	(12.9)	0.216
Family	3	(1.7)	6	(4.3)	0	(.0)	131	(4.3)	<0.001
Clinics/hospitals	36	(20.1)	40	(29.0)	0	(.0)	792	(25.7)	0.003
Pharmacies/drugstores	58	(32.4)	52	(37.7)	2	(50.0)	1,208	(39.3)	<0.001
Friends/acquaintances	3	(1.7)	4	(2.9)	0	(.0)	27	(.9)	0.375
Romantic partners	0	(.0)	0	(.0)	0	(.0)	2	(.1)	0.900
Internet	0	(.0)	0	(.0)	0	(.0)	6	(.2)	0.834
Other	0	(.0)	0	(.0)	0	(.0)	7	(.2)	0.549
Source unknown	0	(.0)	2	(1.4)	0	(.0)	47	(1.5)	0.699
Reason for analgesic use									
None	92	(51.4)	54	(39.1)	2	(50.0)	1,134	(36.9)	<0.001
Headache	50	(27.9)	58	(42.0)	2	(50.0)	1,215	(39.5)	<0.001
Toothache	14	(7.8)	14	(10.1)	0	(.0)	305	(9.9)	0.031
Low back pain	13	(7.3)	9	(6.5)	0	(.0)	207	(6.7)	0.188
Menstrual pain	12	(6.7)	10	(7.2)	0	(.0)	335	(10.9)	<0.001
Stomachache	6	(3.4)	3	(2.2)	0	(.0)	98	(3.2)	0.313
Stiff shoulder	3	(1.7)	9	(6.5)	0	(.0)	125	(4.1)	0.022
Recreation (pleasure)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.182
Other	13	(7.3)	18	(13.0)	0	(.0)	312	(10.1)	0.036
Reason for use unknown	4	(2.2)	4	(2.9)	0	(.0)	69	(2.2)	0.651
Past 30-day analgesic use									<0.001
No	142	(79.3)	106	(76.8)	3	(75.0)	2,241	(72.9)	
Yes	36	(20.1)	31	(22.5)	1	(25.0)	820	(26.7)	
No response/unknown	1	(.6)	1	(.7)	0	(.0)	15	(.5)	
Type of analgesics used									
Nonopioid analgesics	28	(87.5)	28	(100.0)	0	(.0)	700	(97.9)	<0.001
Opioid analgesics	0	(.0)	0	(.0)	0	(.0)	4	(.6)	0.880
Co-analgesics	2	(6.3)	0	(.0)	0	(.0)	12	(1.7)	0.354
Other	3	(9.4)	1	(3.6)	0	(.0)	20	(2.8)	0.170

The number of analgesics used (average) and the type of analgesics used are based on the past 30-day use.

Table 26. Analgesic Use by Drug use experience (n=3076)

	Drug use experience								p-value
	Lifetime		No lifetime		Unknown		Total		
	n	(%)	n	(%)	n	(%)	n	(%)	
Past-year analgesic use									
No	25	(32.1)	1081	(36.8)	28	(48.3)	1134	(36.9)	0.373
Yes	53	(67.9)	1854	(63.1)	30	(51.7)	1937	(63.0)	
Frequency of the past-year analgesic use									
None	25	(32.1)	1081	(36.8)	28	(48.3)	1134	(36.9)	0.587
≤5 times a year	31	(39.7)	1018	(34.6)	15	(25.9)	1064	(34.6)	
Approx. 6–11 times a year	4	(5.1)	224	(7.6)	4	(6.9)	232	(7.5)	
Approx. 12–24 times a year	5	(6.4)	262	(8.9)	6	(10.3)	273	(8.9)	
Approx. 25–51 times a year	6	(7.7)	157	(5.3)	0	(.0)	163	(5.3)	
Approx. 1–2 times a week	2	(2.6)	56	(1.9)	0	(.0)	58	(1.9)	
Approx. 3–6 times a week	1	(1.3)	23	(.8)	1	(1.7)	25	(.8)	
Almost every day	3	(3.8)	47	(1.6)	2	(3.4)	52	(1.7)	
Frequency unknown	1	(1.3)	67	(2.3)	2	(3.4)	70	(2.3)	
No response/unknown	0	(.0)	5	(.2)	0	(.0)	5	(.2)	
Chronic analgesic use									
No	73	(93.6)	2798	(95.2)	53	(91.4)	2924	(95.1)	0.314
Yes	4	(5.1)	70	(2.4)	3	(5.2)	77	(2.5)	
Source of analgesics									
Never obtained	18	(23.1)	926	(31.5)	21	(36.2)	965	(31.4)	<0.001
Household medicines	10	(12.8)	386	(13.1)	1	(1.7)	397	(12.9)	<0.001
Family	2	(2.6)	125	(4.3)	4	(6.9)	131	(4.3)	<0.001
Clinics/hospitals	31	(39.7)	751	(25.5)	10	(17.2)	792	(25.7)	<0.001
Pharmacies/drugstores	30	(38.5)	1163	(39.6)	15	(25.9)	1208	(39.3)	<0.001
Friends/acquaintances	3	(3.8)	24	(.8)	0	(.0)	27	(.9)	<0.001
Romantic partners	0	(.0)	2	(.1)	0	(.0)	2	(.1)	<0.001
Internet	0	(.0)	6	(.2)	0	(.0)	6	(.2)	<0.001
Other	2	(2.6)	5	(.2)	0	(.0)	7	(.2)	<0.001
Source unknown	0	(.0)	44	(1.5)	3	(5.2)	47	(1.5)	0.042
Reason for analgesic use									
None	25	(32.1)	1081	(36.8)	28	(48.3)	1134	(36.9)	0.373
Headache	30	(38.5)	1174	(39.9)	11	(19.0)	1215	(39.5)	0.029
Toothache	12	(15.4)	288	(9.8)	5	(8.6)	305	(9.9)	0.560
Low back pain	7	(9.0)	195	(6.6)	5	(8.6)	207	(6.7)	0.874
Menstrual pain	4	(5.1)	330	(11.2)	1	(1.7)	335	(10.9)	0.081
Stomachache	3	(3.8)	94	(3.2)	1	(1.7)	98	(3.2)	0.946
Stiff shoulder	3	(3.8)	121	(4.1)	1	(1.7)	125	(4.1)	0.897
Recreation (pleasure)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.891
Other	13	(16.7)	293	(10.0)	6	(10.3)	312	(10.1)	0.412
Reason for use unknown	2	(2.6)	65	(2.2)	2	(3.4)	69	(2.2)	0.805
Past 30-day analgesic use									
No	52	(66.7)	2149	(73.1)	40	(69.0)	2241	(72.9)	<0.001
Yes	25	(32.1)	780	(26.5)	15	(25.9)	820	(26.7)	
No response/unknown	1	(1.3)	11	(.4)	3	(5.2)	15	(.5)	
Type of analgesics used									
Nonopioid analgesics	19	(95.0)	674	(98.1)	7	(87.5)	700	(97.9)	0.140
Opioid analgesics	0	(.0)	4	(.6)	0	(.0)	4	(.6)	0.912
Co-analgesics	1	(5.0)	10	(1.5)	1	(12.5)	12	(1.7)	0.108
Other	0	(.0)	20	(2.9)	0	(.0)	20	(2.8)	0.628

The number of analgesics used (average) and the type of analgesics used are based on the past 30-day use.

Table 27. Tranquilizer Use by Residence area (n=3076)

	Residence area											
	Hokkaido		Tohoku		Kanto		Hokuriku		Tousan		Tokai	
	n=131		n=250		n=948		n=154		n=150		n=328	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Past-year tranquilizer use												
No	120	(91.6)	235	(94.0)	877	(92.5)	149	(96.8)	142	(94.7)	315	(96.0)
Yes	11	(8.4)	15	(6.0)	68	(7.2)	5	(3.2)	8	(5.3)	13	(4.0)
No response/unknown	0	(.0)	0	(.0)	3	(.3)	0	(.0)	0	(.0)	0	(.0)
Frequency of the past-year tranquilizer use												
No	120	(91.6)	235	(94.0)	877	(92.5)	149	(96.8)	142	(94.7)	315	(96.0)
≤5 times a year	2	(1.5)	2	(.8)	9	(.9)	1	(.6)	3	(2.0)	3	(.9)
Approx. 6–11 times a year	0	(.0)	1	(.4)	7	(.7)	0	(.0)	1	(.7)	1	(.3)
Approx. 12–24 times a year	0	(.0)	2	(.8)	3	(.3)	1	(.6)	0	(.0)	0	(.0)
Approx. 25–51 times a year	1	(.8)	1	(.4)	4	(.4)	0	(.0)	1	(.7)	0	(.0)
Approx. 1–2 times a week	1	(.8)	0	(.0)	3	(.3)	1	(.6)	1	(.7)	2	(.6)
Approx. 3–6 times a week	0	(.0)	0	(.0)	1	(.1)	1	(.6)	0	(.0)	1	(.3)
Almost every day	6	(4.6)	7	(2.8)	37	(3.9)	1	(.6)	2	(1.3)	6	(1.8)
Frequency unknown	1	(.8)	2	(.8)	4	(.4)	0	(.0)	0	(.0)	0	(.0)
No response/unknown	0	(.0)	0	(.0)	3	(.3)	0	(.0)	0	(.0)	0	(.0)
Chronic tranquilizer use												
No	124	(94.7)	241	(96.4)	903	(95.3)	152	(98.7)	148	(98.7)	321	(97.9)
Yes	6	(4.6)	7	(2.8)	38	(4.0)	2	(1.3)	2	(1.3)	7	(2.1)
No response/unknown	1	(.8)	2	(.8)	7	(.7)	0	(.0)	0	(.0)	0	(.0)
Source of tranquilizers												
Never obtained	120	(91.6)	231	(92.4)	869	(91.7)	148	(96.1)	141	(94.0)	309	(94.2)
Household medicines	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Family	1	(.8)	1	(.4)	1	(.1)	1	(.6)	0	(.0)	0	(.0)
Clinics/hospitals	7	(5.3)	9	(3.6)	47	(5.0)	3	(1.9)	7	(4.7)	13	(4.0)
Pharmacies/drugstores	3	(2.3)	3	(1.2)	25	(2.6)	1	(.6)	1	(.7)	2	(.6)
Friends/acquaintances	0	(.0)	1	(.4)	2	(.2)	0	(.0)	0	(.0)	0	(.0)
Romantic partners	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Internet	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Other	0	(.0)	0	(.0)	1	(.1)	0	(.0)	0	(.0)	0	(.0)
Source unknown	0	(.0)	2	(.8)	0	(.0)	0	(.0)	1	(.7)	0	(.0)
No response/unknown	0	(.0)	4	(1.6)	9	(.9)	1	(.6)	1	(.7)	5	(1.5)
Reason for tranquilizer use												
None	120	(91.6)	235	(94.0)	877	(92.5)	149	(96.8)	142	(94.7)	315	(96.0)
To improve insomnia	3	(2.3)	5	(2.0)	27	(2.8)	1	(.6)	2	(1.3)	5	(1.5)
To eliminate anxiety	6	(4.6)	9	(3.6)	40	(4.2)	4	(2.6)	3	(2.0)	6	(1.8)
To reduce stress	2	(1.5)	2	(.8)	15	(1.6)	1	(.6)	2	(1.3)	5	(1.5)
To treat hypertension	1	(.8)	1	(.4)	3	(.3)	0	(.0)	0	(.0)	0	(.0)
Recreation (pleasure)	0	(.0)	1	(.4)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Other	3	(2.3)	4	(1.6)	16	(1.7)	0	(.0)	2	(1.3)	1	(.3)
Reason for use unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	1	(.7)	0	(.0)
No response/unknown	0	(.0)	0	(.0)	3	(.3)	0	(.0)	0	(.0)	0	(.0)
Past 30-day tranquilizer use												
No	121	(92.4)	235	(94.0)	887	(93.6)	151	(98.1)	145	(96.7)	315	(96.0)
Yes	10	(7.6)	13	(5.2)	52	(5.5)	3	(1.9)	4	(2.7)	11	(3.4)
No response/unknown	0	(.0)	2	(.8)	9	(.9)	0	(.0)	1	(.7)	2	(.6)

For the source of tranquilizers, “pharmacies/drugstores” include external prescription.

The number of tranquilizers used (average) and the type of tranquilizers used are based on the past 30-day use.

Table 27. Tranquilizer Use by Residence area (n=3076) continued

	Residence area										p-value		
	Kinki		Chugoku		Shikoku		Kita-Kyusyu		Minami-			Total	
	n=442		n=191		n=88		n=229		n=165			n=3076	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	
Past-year tranquilizer use													0.564
No	415	(93.9)	182	(95.3)	81	(92.0)	219	(95.6)	153	(92.7)	2888	(93.9)	
Yes	27	(6.1)	9	(4.7)	7	(8.0)	9	(3.9)	12	(7.3)	184	(6.0)	
No response/unknown	0	(.0)	0	(.0)	0	(.0)	1	(.4)	0	(.0)	4	(.1)	
Frequency of the past-year tranquilizer use													0.979
No	415	(93.9)	182	(95.3)	81	(92.0)	219	(95.6)	153	(92.7)	2888	(93.9)	
≤5 times a year	7	(1.6)	4	(2.1)	1	(1.1)	3	(1.3)	3	(1.8)	38	(1.2)	
Approx. 6–11 times a year	3	(.7)	0	(.0)	1	(1.1)	0	(.0)	1	(.6)	15	(.5)	
Approx. 12–24 times a year	1	(.2)	0	(.0)	0	(.0)	1	(.4)	0	(.0)	8	(.3)	
Approx. 25–51 times a year	1	(.2)	1	(.5)	0	(.0)	0	(.0)	1	(.6)	10	(.3)	
Approx. 1–2 times a week	1	(.2)	0	(.0)	0	(.0)	0	(.0)	1	(.6)	10	(.3)	
Approx. 3–6 times a week	2	(.5)	1	(.5)	0	(.0)	0	(.0)	1	(.6)	7	(.2)	
Almost every day	11	(2.5)	3	(1.6)	5	(5.7)	5	(2.2)	5	(3.0)	88	(2.9)	
Frequency unknown	1	(.2)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	8	(.3)	
No response/unknown	0	(.0)	0	(.0)	0	(.0)	1	(.4)	0	(.0)	4	(.1)	
Chronic tranquilizer use													0.426
No	428	(96.8)	187	(97.9)	83	(94.3)	223	(97.4)	159	(96.4)	2969	(96.5)	
Yes	13	(2.9)	4	(2.1)	5	(5.7)	5	(2.2)	6	(3.6)	95	(3.1)	
No response/unknown	1	(.2)	0	(.0)	0	(.0)	1	(.4)	0	(.0)	12	(.4)	
Source of tranquilizers													
Never obtained	408	(92.3)	180	(94.2)	81	(92.0)	217	(94.8)	153	(92.7)	2857	(92.9)	0.524
Household medicines	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.679
Family	0	(.0)	0	(.0)	0	(.0)	1	(.4)	0	(.0)	5	(.2)	0.655
Clinics/hospitals	19	(4.3)	8	(4.2)	5	(5.7)	8	(3.5)	8	(4.8)	134	(4.4)	0.914
Pharmacies/drugstores	10	(2.3)	2	(1.0)	2	(2.3)	0	(.0)	1	(.6)	50	(1.6)	0.214
Friends/acquaintances	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	3	(.1)	0.881
Romantic partners	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.679
Internet	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.679
Other	0	(.0)	0	(.0)	0	(.0)	0	(.0)	1	(.6)	2	(.1)	0.691
Source unknown	2	(.5)	0	(.0)	0	(.0)	0	(.0)	2	(1.2)	7	(.2)	0.062
No response/unknown	7	(1.6)	2	(1.0)	0	(.0)	3	(1.3)	0	(.0)	32	(1.0)	0.679
Reason for tranquilizer use													
None	415	(93.9)	182	(95.3)	81	(92.0)	219	(95.6)	153	(92.7)	2888	(93.9)	0.564
To improve insomnia	8	(1.8)	4	(2.1)	4	(4.5)	7	(3.1)	3	(1.8)	69	(2.2)	0.785
To eliminate anxiety	11	(2.5)	5	(2.6)	3	(3.4)	3	(1.3)	8	(4.8)	98	(3.2)	0.538
To reduce stress	9	(2.0)	3	(1.6)	1	(1.1)	4	(1.7)	2	(1.2)	46	(1.5)	0.977
To treat hypertension	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	5	(.2)	0.794
Recreation (pleasure)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	1	(0.03)	0.589
Other	4	(.9)	5	(2.6)	2	(2.3)	0	(.0)	2	(1.2)	39	(1.3)	0.419
Reason for use unknown	3	(.7)	0	(.0)	0	(.0)	0	(.0)	2	(1.2)	6	(.2)	0.026
No response/unknown	0	(.0)	0	(.0)	0	(.0)	1	(.4)	0	(.0)	4	(.1)	0.756
Past 30-day tranquilizer use													0.264
No	419	(94.8)	185	(96.9)	84	(95.5)	220	(96.1)	157	(95.2)	2919	(94.9)	
Yes	16	(3.6)	5	(2.6)	4	(4.5)	6	(2.6)	8	(4.8)	132	(4.3)	
No response/unknown	7	(1.6)	1	(.5)	0	(.0)	3	(1.3)	0	(.0)	25	(.8)	

For the source of tranquilizers, "pharmacies/drugstores" include external prescription.

The number of tranquilizers used (average) and the type of tranquilizers used are based on the past 30-day use.

Table 28. Tranquilizer Use by Sex (n = 3076)

	Sex						P-value
	Men		Women		Total		
	n = 1466		n = 1610		n = 3076		
	n	(%)	n	(%)	n	(%)	
Past-year tranquilizer use							0.007
No	1397	(95.3)	1491	(92.6)	2888	(93.9)	
Yes	68	(4.6)	116	(7.2)	184	(6.0)	
No response/unknown	1	(.1)	3	(.2)	4	(.1)	
Frequency of the past-year tranquilizer use							0.009
No	1397	(95.3)	1491	(92.6)	2888	(93.9)	
≤5 times a year	8	(.5)	30	(1.9)	38	(1.2)	
Approx. 6–11 times a year	5	(.3)	10	(.6)	15	(.5)	
Approx. 12–24 times a year	1	(.1)	7	(.4)	8	(.3)	
Approx. 25–51 times a year	3	(.2)	7	(.4)	10	(.3)	
Approx. 1–2 times a week	4	(.3)	6	(.4)	10	(.3)	
Approx. 3–6 times a week	3	(.2)	4	(.2)	7	(.2)	
Almost every day	38	(2.6)	50	(3.1)	88	(2.9)	
Frequency unknown	6	(.4)	2	(.1)	8	(.3)	
No response/unknown	1	(.1)	3	(.2)	4	(.1)	
Chronic tranquilizer use							0.514
No	1418	(96.7)	1551	(96.3)	2969	(96.5)	
Yes	41	(2.8)	54	(3.4)	95	(3.1)	
No response/unknown	7	(.5)	5	(.3)	12	(.4)	
Source of tranquilizers							
Never obtained	1386	(94.5)	1471	(91.4)	2857	(92.9)	0.003
Household medicines	0	(.0)	0	(.0)	0	(.0)	0.130
Family	2	(.1)	3	(.2)	5	(.2)	0.300
Clinics/hospitals	39	(2.7)	95	(5.9)	134	(4.4)	<0.001
Pharmacies/drugstores	25	(1.7)	25	(1.6)	50	(1.6)	0.303
Friends/acquaintances	2	(.1)	1	(.1)	3	(.1)	0.257
Romantic partners	0	(.0)	0	(.0)	0	(.0)	0.130
Internet	0	(.0)	0	(.0)	0	(.0)	0.130
Other	0	(.0)	2	(.1)	2	(.1)	0.127
Source unknown	4	(.3)	3	(.2)	7	(.2)	0.615
No response/unknown	11	(.8)	21	(1.3)	32	(1.0)	0.130
Reason for tranquilizer use							
None	1397	(95.3)	1491	(92.6)	2888	(93.9)	0.007
To improve insomnia	23	(1.6)	46	(2.9)	69	(2.2)	0.036
To eliminate anxiety	29	(2.0)	69	(4.3)	98	(3.2)	0.001
To reduce stress	14	(1.0)	32	(2.0)	46	(1.5)	0.041
To treat hypertension	3	(.2)	2	(.1)	5	(.2)	0.569
Recreation (pleasure)	1	(.1)	0	(.0)	1	(0.03)	0.383
Other	19	(1.3)	20	(1.2)	39	(1.3)	0.657
Reason for use unknown	3	(.2)	3	(.2)	6	(.2)	0.909
No response/unknown	1	(.1)	3	(.2)	4	(.1)	0.364
Past 30-day tranquilizer use							0.041
No	1406	(95.9)	1513	(94.0)	2919	(94.9)	
Yes	52	(3.5)	80	(5.0)	132	(4.3)	
No response/unknown	8	(.5)	17	(1.1)	25	(.8)	

For the source of tranquilizers, "pharmacies/drugstores" include external prescription.

The number of tranquilizers used (average) and the type of tranquilizers used are based on the past 30-day use.

Table 29. Tranquilizer Use by Age group(n=3076)

	Age group										p-value				
	10s		20s		30s		40s		50s			60s		Total	
	n=222	n=382	n=553	n=751	n=695	n=473	n=3076	n (%)	n (%)	n (%)		n (%)	n (%)	n (%)	n (%)
Past year tranquilizer use													0.002		
No	215	(96.8)	360	(94.2)	525	(94.9)	701	(93.3)	652	(93.8)	435	(92.0)	2888	(93.9)	
Yes	7	(3.2)	22	(5.8)	28	(5.1)	50	(6.7)	43	(6.2)	34	(7.2)	184	(6.0)	
No response/unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	4	(.8)	4	(.1)	
Frequency of the past-year tranquilizer use													0.097		
No	215	(96.8)	360	(94.2)	525	(94.9)	701	(93.3)	652	(93.8)	435	(92.0)	2888	(93.9)	
≤5 times a year	1	(.5)	6	(1.6)	7	(1.3)	9	(1.2)	10	(1.4)	5	(1.1)	38	(1.2)	
Approx. 6–11 times a year	1	(.5)	3	(.8)	2	(.4)	3	(.4)	2	(.3)	4	(.8)	15	(.5)	
Approx. 12–24 times a year	0	(.0)	1	(.3)	0	(.0)	5	(.7)	1	(.1)	1	(.2)	8	(.3)	
Approx. 25–51 times a year	0	(.0)	1	(.3)	2	(.4)	4	(.5)	1	(.1)	2	(.4)	10	(.3)	
Approx. 1–2 times a week	0	(.0)	1	(.3)	2	(.4)	1	(.1)	4	(.6)	2	(.4)	10	(.3)	
Approx. 3–6 times a week	0	(.0)	2	(.5)	1	(.2)	3	(.4)	1	(.1)	0	(.0)	7	(.2)	
Almost every day	3	(1.4)	6	(1.6)	14	(2.5)	23	(3.1)	23	(3.3)	19	(4.0)	88	(2.9)	
Frequency unknown	2	(.9)	2	(.5)	0	(.0)	2	(.3)	1	(.1)	1	(.2)	8	(.3)	
No response/unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	4	(.8)	4	(.1)	
Chronic tranquilizer use													0.088		
No	217	(97.7)	372	(97.4)	538	(97.3)	723	(96.3)	670	(96.4)	449	(94.9)	2969	(96.5)	
Yes	3	(1.4)	8	(2.1)	15	(2.7)	26	(3.5)	24	(3.5)	19	(4.0)	95	(3.1)	
No response/unknown	2	(.9)	2	(.5)	0	(.0)	2	(.3)	1	(.1)	5	(1.1)	12	(.4)	
Source of tranquilizers															
Never obtained	214	(96.4)	356	(93.2)	521	(94.2)	696	(92.7)	645	(92.8)	425	(89.9)	2857	(92.9)	0.010
Household medicines	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.006
Family	1	(.5)	2	(.5)	1	(.2)	0	(.0)	1	(.1)	0	(.0)	5	(.2)	0.012
Clinics/hospitals	3	(1.4)	13	(3.4)	18	(3.3)	40	(5.3)	33	(4.7)	27	(5.7)	134	(4.4)	0.002
Pharmacies/drugstores	2	(.9)	4	(1.0)	9	(1.6)	15	(2.0)	10	(1.4)	10	(2.1)	50	(1.6)	0.034
Friends/acquaintances	0	(.0)	0	(.0)	0	(.0)	2	(.3)	0	(.0)	1	(.2)	3	(.1)	0.021
Romantic partners	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.006
Internet	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.006
Other	0	(.0)	2	(.5)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	2	(.1)	0.001
Source unknown	1	(.5)	2	(.5)	0	(.0)	1	(.1)	2	(.3)	1	(.2)	7	(.2)	0.603
No response/unknown	1	(.5)	4	(1.0)	4	(.7)	5	(.7)	5	(.7)	13	(2.7)	32	(1.0)	0.006
Reason for tranquilizer use															
None	215	(96.8)	360	(94.2)	525	(94.9)	701	(93.3)	652	(93.8)	435	(92.0)	2888	(93.9)	0.002
To improve insomnia	0	(.0)	5	(1.3)	11	(2.0)	20	(2.7)	21	(3.0)	12	(2.5)	69	(2.2)	<0.001
To eliminate anxiety	4	(1.8)	15	(3.9)	14	(2.5)	29	(3.9)	20	(2.9)	16	(3.4)	98	(3.2)	0.003
To reduce stress	1	(.5)	6	(1.6)	5	(.9)	12	(1.6)	10	(1.4)	12	(2.5)	46	(1.5)	0.001
To treat hypertension	0	(.0)	1	(.3)	0	(.0)	1	(.1)	1	(.1)	2	(.4)	5	(.2)	0.004
Recreation (pleasure)	0	(.0)	1	(.3)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	1	(0.03)	0.001
Other	2	(.9)	5	(1.3)	6	(1.1)	12	(1.6)	6	(.9)	8	(1.7)	39	(1.3)	0.006
Reason for use unknown	1	(.5)	1	(.3)	1	(.2)	2	(.3)	1	(.1)	0	(.0)	6	(.2)	0.842
No response/unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	4	(.8)	4	(.1)	0.001
Past 30-day tranquilizer use													0.014		
No	217	(97.7)	368	(96.3)	529	(95.7)	715	(95.2)	656	(94.4)	434	(91.8)	2919	(94.9)	
Yes	4	(1.8)	13	(3.4)	20	(3.6)	32	(4.3)	34	(4.9)	29	(6.1)	132	(4.3)	
No response/unknown	1	(.5)	1	(.3)	4	(.7)	4	(.5)	5	(.7)	10	(2.1)	25	(.8)	

“10s” refers to those aged 15 to 19, and “60s” refers to those aged 60 to 64.

For the source of tranquilizers, “pharmacies/drugstores” include external prescription.

The number of tranquilizers used (average) and the type of tranquilizers used are based on the past 30-day use.

Table 30. Tranquilizer Use by Occupation (n=3076)

	Occupation									
	Self-employed		Full-time		Non-full-time		Student		Housewife	
	n=248		n=1406		n=394		n=271		n=436	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Past-year tranquilizer use										
No	235	(94.8)	1342	(95.4)	373	(94.7)	264	(97.4)	402	(92.2)
Yes	12	(4.8)	64	(4.6)	20	(5.1)	7	(2.6)	33	(7.6)
No response/unknown	1	(.4)	0	(.0)	1	(.3)	0	(.0)	1	(.2)
Frequency of the past-year tranquilizer use										
No	235	(94.8)	1342	(95.4)	373	(94.7)	264	(97.4)	402	(92.2)
≤5 times a year	1	(.4)	16	(1.1)	5	(1.3)	1	(.4)	11	(2.5)
Approx. 6–11 times a year	2	(.8)	4	(.3)	2	(.5)	1	(.4)	4	(.9)
Approx. 12–24 times a year	1	(.4)	2	(.1)	0	(.0)	1	(.4)	1	(.2)
Approx. 25–51 times a year	0	(.0)	4	(.3)	1	(.3)	0	(.0)	2	(.5)
Approx. 1–2 times a week	1	(.4)	5	(.4)	0	(.0)	0	(.0)	0	(.0)
Approx. 3–6 times a week	0	(.0)	4	(.3)	1	(.3)	0	(.0)	0	(.0)
Almost every day	7	(2.8)	24	(1.7)	11	(2.8)	2	(.7)	15	(3.4)
Frequency unknown	0	(.0)	5	(.4)	0	(.0)	2	(.7)	0	(.0)
No response/unknown	1	(.4)	0	(.0)	1	(.3)	0	(.0)	1	(.2)
Chronic tranquilizer use										
No	240	(96.8)	1373	(97.7)	381	(96.7)	267	(98.5)	420	(96.3)
Yes	7	(2.8)	28	(2.0)	12	(3.0)	2	(.7)	15	(3.4)
No response/unknown	1	(.4)	5	(.4)	1	(.3)	2	(.7)	1	(.2)
Source of tranquilizers										
Never obtained	232	(93.5)	1330	(94.6)	370	(93.9)	263	(97.0)	395	(90.6)
Household medicines	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Family	0	(.0)	3	(.2)	0	(.0)	2	(.7)	0	(.0)
Clinics/hospitals	6	(2.4)	45	(3.2)	16	(4.1)	2	(.7)	30	(6.9)
Pharmacies/drugstores	5	(2.0)	19	(1.4)	3	(.8)	2	(.7)	6	(1.4)
Friends/acquaintances	1	(.4)	1	(.1)	0	(.0)	0	(.0)	0	(.0)
Romantic partners	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Internet	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Other	0	(.0)	1	(.1)	1	(.3)	0	(.0)	0	(.0)
Source unknown	1	(.4)	2	(.1)	0	(.0)	1	(.4)	2	(.5)
No response/unknown	4	(1.6)	11	(.8)	4	(1.0)	1	(.4)	7	(1.6)
Reason for tranquilizer use										
None	235	(94.8)	1342	(95.4)	373	(94.7)	264	(97.4)	402	(92.2)
To improve insomnia	1	(.4)	27	(1.9)	6	(1.5)	0	(.0)	11	(2.5)
To eliminate anxiety	2	(.8)	34	(2.4)	12	(3.0)	4	(1.5)	18	(4.1)
To reduce stress	5	(2.0)	18	(1.3)	1	(.3)	0	(.0)	9	(2.1)
To treat hypertension	0	(.0)	2	(.1)	2	(.5)	0	(.0)	0	(.0)
Recreation (pleasure)	0	(.0)	1	(.1)	0	(.0)	0	(.0)	0	(.0)
Other	6	(2.4)	14	(1.0)	5	(1.3)	2	(.7)	3	(.7)
Reason for use unknown	0	(.0)	2	(.1)	0	(.0)	1	(.4)	1	(.2)
No response/unknown	1	(.4)	0	(.0)	1	(.3)	0	(.0)	1	(.2)
Past 30-day tranquilizer use										
No	236	(95.2)	1358	(96.6)	377	(95.7)	266	(98.2)	405	(92.9)
Yes	9	(3.6)	39	(2.8)	15	(3.8)	4	(1.5)	26	(6.0)
No response/unknown	3	(1.2)	9	(.6)	2	(.5)	1	(.4)	5	(1.1)

For the source of tranquilizers, “pharmacies/drugstores” include external prescription.

The number of tranquilizers used (average) and the type of tranquilizers used are based on the past 30-day use.

Table 30. Tranquilizer Use by Occupation (n=3076) continued

	Occupation								p-value
	Unemployed		Other		Unknown		Total		
	n=179		n=138		n=4		n=3076		
	n	(%)	n	(%)	n	(%)	n	(%)	
Past-year tranquilizer use									<0.001
No	143	(79.9)	126	(91.3)	3	(75.0)	2888	(93.9)	
Yes	35	(19.6)	12	(8.7)	1	(25.0)	184	(6.0)	
No response/unknown	1	(.6)	0	(.0)	0	(.0)	4	(.1)	
Frequency of the past-year tranquilizer use									<0.001
No	143	(79.9)	126	(91.3)	3	(75.0)	2888	(93.9)	
≤5 times a year	3	(1.7)	1	(.7)	0	(.0)	38	(1.2)	
Approx. 6–11 times a year	1	(.6)	1	(.7)	0	(.0)	15	(.5)	
Approx. 12–24 times a year	2	(1.1)	1	(.7)	0	(.0)	8	(.3)	
Approx. 25–51 times a year	2	(1.1)	1	(.7)	0	(.0)	10	(.3)	
Approx. 1–2 times a week	4	(2.2)	0	(.0)	0	(.0)	10	(.3)	
Approx. 3–6 times a week	1	(.6)	0	(.0)	1	(25.0)	7	(.2)	
Almost every day	21	(11.7)	8	(5.8)	0	(.0)	88	(2.9)	
Frequency unknown	1	(.6)	0	(.0)	0	(.0)	8	(.3)	
No response/unknown	1	(.6)	0	(.0)	0	(.0)	4	(.1)	
Chronic tranquilizer use									<0.001
No	155	(86.6)	130	(94.2)	3	(75.0)	2969	(96.5)	
Yes	22	(12.3)	8	(5.8)	1	(25.0)	95	(3.1)	
No response/unknown	2	(1.1)	0	(.0)	0	(.0)	12	(.4)	
Source of tranquilizers									
Never obtained	141	(78.8)	123	(89.1)	3	(75.0)	2857	(92.9)	<0.001
Household medicines	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.634
Family	0	(.0)	0	(.0)	0	(.0)	5	(.2)	0.511
Clinics/hospitals	25	(14.0)	9	(6.5)	1	(25.0)	134	(4.4)	<0.001
Pharmacies/drugstores	10	(5.6)	4	(2.9)	1	(25.0)	50	(1.6)	<0.001
Friends/acquaintances	1	(.6)	0	(.0)	0	(.0)	3	(.1)	0.540
Romantic partners	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.634
Internet	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.634
Other	0	(.0)	0	(.0)	0	(.0)	2	(.1)	0.879
Source unknown	1	(.6)	0	(.0)	0	(.0)	7	(.2)	0.764
No response/unknown	3	(1.7)	2	(1.4)	0	(.0)	32	(1.0)	0.634
Reason for tranquilizer use									
None	143	(79.9)	126	(91.3)	3	(75.0)	2888	(93.9)	<0.001
To improve insomnia	18	(10.1)	5	(3.6)	1	(25.0)	69	(2.2)	<0.001
To eliminate anxiety	20	(11.2)	8	(5.8)	0	(.0)	98	(3.2)	<0.001
To reduce stress	10	(5.6)	3	(2.2)	0	(.0)	46	(1.5)	<0.001
To treat hypertension	1	(.6)	0	(.0)	0	(.0)	5	(.2)	0.482
Recreation (pleasure)	0	(.0)	0	(.0)	0	(.0)	1	(0.03)	0.873
Other	8	(4.5)	1	(.7)	0	(.0)	39	(1.3)	0.017
Reason for use unknown	2	(1.1)	0	(.0)	0	(.0)	6	(.2)	0.188
No response/unknown	1	(.6)	0	(.0)	0	(.0)	4	(.1)	0.416
Past 30-day tranquilizer use									<0.001
No	147	(82.1)	127	(92.0)	3	(75.0)	2919	(94.9)	
Yes	28	(15.6)	10	(7.2)	1	(25.0)	132	(4.3)	
No response/unknown	4	(2.2)	1	(.7)	0	(.0)	25	(.8)	

For the source of tranquilizers, “pharmacies/drugstores” include external prescription.

The number of tranquilizers used (average) and the type of tranquilizers used are based on the past 30-day

Table 31. Tranquilizer Use by Drug use experience (n=3076)

	Drug use experience								p-value
	Lifetime		No lifetime		Unknown		Total		
	n=78	n=2940	n=58	n=3076	n	(%)	n	(%)	
Past-year tranquilizer use									0.869
No	72	(92.3)	2760	(93.9)	56	(96.6)	2888	(93.9)	
Yes	6	(7.7)	176	(6.0)	2	(3.4)	184	(6.0)	
No response/unknown	0	(.0)	4	(.1)	0	(.0)	4	(.1)	
Frequency of the past-year tranquilizer use									0.785
No	72	(92.3)	2760	(93.9)	56	(96.6)	2888	(93.9)	
≤5 times a year	0	(.0)	37	(1.3)	1	(1.7)	38	(1.2)	
Approx. 6–11 times a year	2	(2.6)	13	(.4)	0	(.0)	15	(.5)	
Approx. 12–24 times a year	0	(.0)	8	(.3)	0	(.0)	8	(.3)	
Approx. 25–51 times a year	0	(.0)	10	(.3)	0	(.0)	10	(.3)	
Approx. 1–2 times a week	1	(1.3)	9	(.3)	0	(.0)	10	(.3)	
Approx. 3–6 times a week	0	(.0)	7	(.2)	0	(.0)	7	(.2)	
Almost every day	3	(3.8)	84	(2.9)	1	(1.7)	88	(2.9)	
Frequency unknown	0	(.0)	8	(.3)	0	(.0)	8	(.3)	
No response/unknown	0	(.0)	4	(.1)	0	(.0)	4	(.1)	
Chronic tranquilizer use									0.899
No	75	(96.2)	2837	(96.5)	57	(98.3)	2969	(96.5)	
Yes	3	(3.8)	91	(3.1)	1	(1.7)	95	(3.1)	
No response/unknown	0	(.0)	12	(.4)	0	(.0)	12	(.4)	
Source of tranquilizers									
Never obtained	72	(92.3)	2732	(92.9)	53	(91.4)	2857	(92.9)	0.022
Household medicines	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.005
Family	0	(.0)	5	(.2)	0	(.0)	5	(.2)	0.030
Clinics/hospitals	3	(3.8)	130	(4.4)	1	(1.7)	134	(4.4)	0.022
Pharmacies/drugstores	2	(2.6)	48	(1.6)	0	(.0)	50	(1.6)	0.019
Friends/acquaintances	1	(1.3)	2	(.1)	0	(.0)	3	(.1)	<0.001
Romantic partners	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.005
Internet	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.005
Other	1	(1.3)	1	(0.03)	0	(.0)	2	(.1)	<0.001
Source unknown	0	(.0)	6	(.2)	1	(1.7)	7	(.2)	0.051
No response/unknown	0	(.0)	29	(1.0)	3	(5.2)	32	(1.0)	0.005
Reason for tranquilizer use									
None	72	(92.3)	2760	(93.9)	56	(96.6)	2888	(93.9)	0.869
To improve insomnia	2	(2.6)	67	(2.3)	0	(.0)	69	(2.2)	0.814
To eliminate anxiety	5	(6.4)	92	(3.1)	1	(1.7)	98	(3.2)	0.518
To reduce stress	1	(1.3)	44	(1.5)	1	(1.7)	46	(1.5)	0.994
To treat hypertension	1	(1.3)	4	(.1)	0	(.0)	5	(.2)	0.169
Recreation (pleasure)	0	(.0)	1	(0.03)	0	(.0)	1	(0.03)	0.994
Other	1	(1.3)	38	(1.3)	0	(.0)	39	(1.3)	0.918
Reason for use unknown	0	(.0)	5	(.2)	1	(1.7)	6	(.2)	0.027
No response/unknown	0	(.0)	4	(.1)	0	(.0)	4	(.1)	0.912
Past 30-day tranquilizer use									0.156
No	74	(94.9)	2790	(94.9)	55	(94.8)	2919	(94.9)	
Yes	4	(5.1)	127	(4.3)	1	(1.7)	132	(4.3)	
No response/unknown	0	(.0)	23	(.8)	2	(3.4)	25	(.8)	

For the source of tranquilizers, “pharmacies/drugstores” include external prescription.

The number of tranquilizers used (average) and the type of tranquilizers used are based on the past 30-day use.

Table 32. Hypnotic Use by Residence area (n=3076)

	Residence area											
	Hokkaido		Tohoku		Kanto		Hokuriku		Tousan		Tokai	
	n=131		n=250		n=948		n=154		n=150		n=328	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Past-year hypnotic use												
No	118	(90.1)	237	(94.8)	873	(92.1)	147	(95.5)	141	(94.0)	314	(95.7)
Yes	13	(9.9)	13	(5.2)	70	(7.4)	7	(4.5)	9	(6.0)	13	(4.0)
No response/unknown	0	(.0)	0	(.0)	5	(.5)	0	(.0)	0	(.0)	1	(.3)
Frequency of the past-year hypnotic use												
No	118	(90.1)	237	(94.8)	873	(92.1)	147	(95.5)	141	(94.0)	314	(95.7)
≤5 times a year	5	(3.8)	0	(.0)	23	(2.4)	3	(1.9)	2	(1.3)	5	(1.5)
Approx. 6–11 times a year	0	(.0)	1	(.4)	4	(.4)	1	(.6)	0	(.0)	0	(.0)
Approx. 12–24 times a year	1	(.8)	2	(.8)	3	(.3)	1	(.6)	1	(.7)	0	(.0)
Approx. 25–51 times a year	1	(.8)	0	(.0)	4	(.4)	1	(.6)	1	(.7)	0	(.0)
Approx. 1–2 times a week	1	(.8)	2	(.8)	3	(.3)	0	(.0)	0	(.0)	1	(.3)
Approx. 3–6 times a week	0	(.0)	2	(.8)	5	(.5)	1	(.6)	2	(1.3)	0	(.0)
Almost every day	5	(3.8)	5	(2.0)	27	(2.8)	0	(.0)	3	(2.0)	6	(1.8)
Frequency unknown	0	(.0)	1	(.4)	1	(.1)	0	(.0)	0	(.0)	1	(.3)
No response/unknown	0	(.0)	0	(.0)	5	(.5)	0	(.0)	0	(.0)	1	(.3)
Chronic hypnotic use												
No	126	(96.2)	242	(96.8)	910	(96.0)	153	(99.4)	145	(96.7)	320	(97.6)
Yes	5	(3.8)	7	(2.8)	32	(3.4)	1	(.6)	5	(3.3)	6	(1.8)
No response/unknown	0	(.0)	1	(.4)	6	(.6)	0	(.0)	0	(.0)	2	(.6)
Source of hypnotics												
Never obtained	118	(90.1)	235	(94.0)	868	(91.6)	145	(94.2)	140	(93.3)	311	(94.8)
Household medicines	0	(.0)	0	(.0)	1	(.1)	0	(.0)	0	(.0)	0	(.0)
Family	0	(.0)	0	(.0)	1	(.1)	0	(.0)	0	(.0)	0	(.0)
Clinics/hospitals	10	(7.6)	9	(3.6)	49	(5.2)	4	(2.6)	7	(4.7)	14	(4.3)
Pharmacies/drugstores	3	(2.3)	4	(1.6)	22	(2.3)	3	(1.9)	1	(.7)	1	(.3)
Friends/acquaintances	0	(.0)	0	(.0)	1	(.1)	0	(.0)	1	(.7)	0	(.0)
Romantic partners	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Internet	0	(.0)	0	(.0)	1	(.1)	1	(.6)	0	(.0)	0	(.0)
Other	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Source unknown	0	(.0)	0	(.0)	2	(.2)	0	(.0)	0	(.0)	0	(.0)
No response/unknown	0	(.0)	2	(.8)	10	(1.1)	1	(.6)	1	(.7)	3	(.9)
Reason for hypnotic use												
None	118	(90.1)	237	(94.8)	873	(92.1)	147	(95.5)	141	(94.0)	314	(95.7)
To improve insomnia	11	(8.4)	13	(5.2)	55	(5.8)	7	(4.5)	8	(5.3)	10	(3.0)
To eliminate anxiety	1	(.8)	0	(.0)	11	(1.2)	0	(.0)	2	(1.3)	1	(.3)
To reduce stress	0	(.0)	0	(.0)	5	(.5)	1	(.6)	1	(.7)	0	(.0)
To treat hypertension	0	(.0)	0	(.0)	0	(.0)	0	(.0)	1	(.7)	1	(.3)
Recreation (pleasure)	0	(.0)	0	(.0)	1	(.1)	0	(.0)	0	(.0)	0	(.0)
Other	3	(2.3)	0	(.0)	7	(.7)	0	(.0)	1	(.7)	3	(.9)
Reason for use unknown	0	(.0)	0	(.0)	2	(.2)	0	(.0)	0	(.0)	0	(.0)
No response/unknown	0	(.0)	0	(.0)	5	(.5)	0	(.0)	0	(.0)	1	(.3)
Past 30-day hypnotic use												
No	122	(93.1)	237	(94.8)	890	(93.9)	149	(96.8)	143	(95.3)	316	(96.3)
Yes	9	(6.9)	13	(5.2)	50	(5.3)	4	(2.6)	6	(4.0)	9	(2.7)
No response/unknown	0	(.0)	0	(.0)	8	(.8)	1	(.6)	1	(.7)	3	(.9)

For the source of hypnotics, “pharmacies/drugstores” include external prescription.

The number of hypnotics used (average) and the type of hypnotics used are based on the past 30-day use.

Benzodiazepine use: The proportion of respondents with at least one benzodiazepine included in tranquilizers and/or hypnotics used within the past 30 days.

Table 32. Hypnotic Use by Residence area (n=3076) continued

	Residence area										p-value		
	Kinki		Chugoku		Shikoku		Kita-Kyusyu		Minami-			Total	
	n=442		n=191		n=88		n=229		n=165			n=3076	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	
Past-year hypnotic use													0.581
No	415	(93.9)	181	(94.8)	82	(93.2)	216	(94.3)	155	(93.9)	2879	(93.6)	
Yes	27	(6.1)	10	(5.2)	6	(6.8)	12	(5.2)	10	(6.1)	190	(6.2)	
No response/unknown	0	(.0)	0	(.0)	0	(.0)	1	(.4)	0	(.0)	7	(.2)	
Frequency of the past-year hypnotic use													0.942
No	415	(93.9)	181	(94.8)	82	(93.2)	216	(94.3)	155	(93.9)	2879	(93.6)	
≤5 times a year	6	(1.4)	3	(1.6)	3	(3.4)	4	(1.7)	3	(1.8)	57	(1.9)	
Approx. 6–11 times a year	1	(.2)	0	(.0)	0	(.0)	1	(.4)	0	(.0)	8	(.3)	
Approx. 12–24 times a year	2	(.5)	0	(.0)	0	(.0)	1	(.4)	0	(.0)	11	(.4)	
Approx. 25–51 times a year	1	(.2)	3	(1.6)	0	(.0)	0	(.0)	0	(.0)	11	(.4)	
Approx. 1–2 times a week	1	(.2)	0	(.0)	0	(.0)	0	(.0)	1	(.6)	9	(.3)	
Approx. 3–6 times a week	5	(1.1)	1	(.5)	0	(.0)	1	(.4)	1	(.6)	18	(.6)	
Almost every day	10	(2.3)	3	(1.6)	3	(3.4)	5	(2.2)	4	(2.4)	71	(2.3)	
Frequency unknown	1	(.2)	0	(.0)	0	(.0)	0	(.0)	1	(.6)	5	(.2)	
No response/unknown	0	(.0)	0	(.0)	0	(.0)	1	(.4)	0	(.0)	7	(.2)	
Chronic hypnotic use													0.931
No	426	(96.4)	187	(97.9)	85	(96.6)	222	(96.9)	159	(96.4)	2975	(96.7)	
Yes	15	(3.4)	4	(2.1)	3	(3.4)	6	(2.6)	5	(3.0)	89	(2.9)	
No response/unknown	1	(.2)	0	(.0)	0	(.0)	1	(.4)	1	(.6)	12	(.4)	
Source of hypnotics													
Never obtained	408	(92.3)	179	(93.7)	82	(93.2)	213	(93.0)	155	(93.9)	2854	(92.8)	0.787
Household medicines	0	(.0)	0	(.0)	0	(.0)	0	(.0)	1	(.6)	2	(.1)	0.777
Family	4	(.9)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	5	(.2)	0.242
Clinics/hospitals	17	(3.8)	7	(3.7)	5	(5.7)	8	(3.5)	9	(5.5)	139	(4.5)	0.850
Pharmacies/drugstores	10	(2.3)	4	(2.1)	2	(2.3)	3	(1.3)	0	(.0)	53	(1.7)	0.620
Friends/acquaintances	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	2	(.1)	0.721
Romantic partners	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.811
Internet	1	(.2)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	3	(.1)	0.872
Other	1	(.2)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	1	(0.03)	0.915
Source unknown	0	(.0)	0	(.0)	0	(.0)	1	(.4)	0	(.0)	3	(.1)	0.831
No response/unknown	5	(1.1)	2	(1.0)	0	(.0)	4	(1.7)	0	(.0)	28	(.9)	0.811
Reason for hypnotic use													
None	415	(93.9)	181	(94.8)	82	(93.2)	216	(94.3)	155	(93.9)	2879	(93.6)	0.581
To improve insomnia	22	(5.0)	10	(5.2)	5	(5.7)	9	(3.9)	8	(4.8)	158	(5.1)	0.751
To eliminate anxiety	6	(1.4)	1	(.5)	0	(.0)	2	(.9)	4	(2.4)	28	(.9)	0.445
To reduce stress	1	(.2)	1	(.5)	0	(.0)	1	(.4)	2	(1.2)	12	(.4)	0.760
To treat hypertension	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	2	(.1)	0.408
Recreation (pleasure)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	1	(0.03)	0.966
Other	2	(.5)	0	(.0)	2	(2.3)	2	(.9)	1	(.6)	21	(.7)	0.395
Reason for use unknown	1	(.2)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	3	(.1)	0.962
No response/unknown	0	(.0)	0	(.0)	0	(.0)	1	(.4)	0	(.0)	7	(.2)	0.642
Past 30-day hypnotic use													0.719
No	417	(94.3)	184	(96.3)	85	(96.6)	217	(94.8)	159	(96.4)	2919	(94.9)	
Yes	20	(4.5)	6	(3.1)	3	(3.4)	9	(3.9)	6	(3.6)	135	(4.4)	
No response/unknown	5	(1.1)	1	(.5)	0	(.0)	3	(1.3)	0	(.0)	22	(.7)	

For the source of hypnotics, “pharmacies/drugstores” include external prescription.

The number of hypnotics used (average) and the type of hypnotics used are based on the past 30-day use.

Benzodiazepine use: The proportion of respondents with at least one benzodiazepine included in tranquilizers and/or hypnotics used within the past 30 days.

Table 33. Hypnotic Use by Sex (n = 3076)

	Sex						P-value
	Men		Women		Total		
	n = 1466		n = 1610		n = 3076		
	n	(%)	n	(%)	n	(%)	
Past-year hypnotic use							0.022
No	1387	(94.6)	1492	(92.7)	2879	(93.6)	
Yes	74	(5.0)	116	(7.2)	190	(6.2)	
No response/unknown	5	(.3)	2	(.1)	7	(.2)	
Frequency of the past-year hypnotic use							0.431
No	1387	(94.6)	1492	(92.7)	2879	(93.6)	
≤5 times a year	20	(1.4)	37	(2.3)	57	(1.9)	
Approx. 6–11 times a year	4	(.3)	4	(.2)	8	(.3)	
Approx. 12–24 times a year	5	(.3)	6	(.4)	11	(.4)	
Approx. 25–51 times a year	4	(.3)	7	(.4)	11	(.4)	
Approx. 1–2 times a week	4	(.3)	5	(.3)	9	(.3)	
Approx. 3–6 times a week	6	(.4)	12	(.7)	18	(.6)	
Almost every day	29	(2.0)	42	(2.6)	71	(2.3)	
Frequency unknown	2	(.1)	3	(.2)	5	(.2)	
No response/unknown	5	(.3)	2	(.1)	7	(.2)	
Chronic hypnotic use							0.215
No	1424	(97.1)	1551	(96.3)	2975	(96.7)	
Yes	35	(2.4)	54	(3.4)	89	(2.9)	
No response/unknown	7	(.5)	5	(.3)	12	(.4)	
Source of hypnotics							
Never obtained	1381	(94.2)	1473	(91.5)	2854	(92.8)	0.014
Household medicines	0	(.0)	2	(.1)	2	(.1)	0.178
Family	2	(.1)	3	(.2)	5	(.2)	0.419
Clinics/hospitals	44	(3.0)	95	(5.9)	139	(4.5)	<0.001
Pharmacies/drugstores	30	(2.0)	23	(1.4)	53	(1.7)	0.192
Friends/acquaintances	1	(.1)	1	(.1)	2	(.1)	0.445
Romantic partners	0	(.0)	0	(.0)	0	(.0)	0.204
Internet	1	(.1)	2	(.1)	3	(.1)	0.393
Other	0	(.0)	1	(.1)	1	(0.03)	0.282
Source unknown	0	(.0)	3	(.2)	3	(.1)	0.098
No response/unknown	10	(.7)	18	(1.1)	28	(.9)	0.204
Reason for hypnotic use							
None	1387	(94.6)	1492	(92.7)	2879	(93.6)	0.022
To improve insomnia	62	(4.2)	96	(6.0)	158	(5.1)	0.044
To eliminate anxiety	10	(.7)	18	(1.1)	28	(.9)	0.203
To reduce stress	7	(.5)	5	(.3)	12	(.4)	0.342
To treat hypertension	0	(.0)	2	(.1)	2	(.1)	0.182
Recreation (pleasure)	1	(.1)	0	(.0)	1	(0.03)	0.261
Other	6	(.4)	15	(.9)	21	(.7)	0.097
Reason for use unknown	0	(.0)	3	(.2)	3	(.1)	0.098
No response/unknown	5	(.3)	2	(.1)	7	(.2)	0.207
Past 30-day hypnotic use							0.104
No	1404	(95.8)	1515	(94.1)	2919	(94.9)	
Yes	54	(3.7)	81	(5.0)	135	(4.4)	
No response/unknown	8	(.5)	14	(.9)	22	(.7)	

For the source of hypnotics, “pharmacies/drugstores” include external prescription.

The number of hypnotics used (average) and the type of hypnotics used are based on the past 30-day use.

Benzodiazepine use: The proportion of respondents with at least one benzodiazepine included in tranquilizers and/or hypnotics used within the past 30 days.

Table 34. Hypnotic Use by Age group(n=3076)

	Age group												p-value		
	10s		20s		30s		40s		50s		60s			Total	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)		n	(%)
Past-year hypnotic use														0.002	
No	218	(98.2)	368	(96.3)	527	(95.3)	696	(92.7)	641	(92.2)	429	(90.7)	2879	(93.6)	
Yes	4	(1.8)	14	(3.7)	25	(4.5)	53	(7.1)	53	(7.6)	41	(8.7)	190	(6.2)	
No response/unknown	0	(.0)	0	(.0)	1	(.2)	2	(.3)	1	(.1)	3	(.6)	7	(.2)	
Frequency of the past-year hypnotic use														0.013	
No	218	(98.2)	368	(96.3)	527	(95.3)	696	(92.7)	641	(92.2)	429	(90.7)	2879	(93.6)	
≤5 times a year	3	(1.4)	5	(1.3)	7	(1.3)	16	(2.1)	17	(2.4)	9	(1.9)	57	(1.9)	
Approx. 6–11 times a year	0	(.0)	0	(.0)	0	(.0)	2	(.3)	3	(.4)	3	(.6)	8	(.3)	
Approx. 12–24 times a year	1	(.5)	2	(.5)	1	(.2)	6	(.8)	0	(.0)	1	(.2)	11	(.4)	
Approx. 25–51 times a year	0	(.0)	1	(.3)	0	(.0)	5	(.7)	2	(.3)	3	(.6)	11	(.4)	
Approx. 1–2 times a week	0	(.0)	1	(.3)	1	(.2)	2	(.3)	4	(.6)	1	(.2)	9	(.3)	
Approx. 3–6 times a week	0	(.0)	2	(.5)	1	(.2)	3	(.4)	4	(.6)	8	(1.7)	18	(.6)	
Almost every day	0	(.0)	3	(.8)	14	(2.5)	19	(2.5)	19	(2.7)	16	(3.4)	71	(2.3)	
Frequency unknown	0	(.0)	0	(.0)	1	(.2)	0	(.0)	4	(.6)	0	(.0)	5	(.2)	
No response/unknown	0	(.0)	0	(.0)	1	(.2)	2	(.3)	1	(.1)	3	(.6)	7	(.2)	
Chronic hypnotic use														0.007	
No	222	(100.0)	377	(98.7)	536	(96.9)	727	(96.8)	667	(96.0)	446	(94.3)	2975	(96.7)	
Yes	0	(.0)	5	(1.3)	15	(2.7)	22	(2.9)	23	(3.3)	24	(5.1)	89	(2.9)	
No response/unknown	0	(.0)	0	(.0)	2	(.4)	2	(.3)	5	(.7)	3	(.6)	12	(.4)	
Source of hypnotics															
Never obtained	216	(97.3)	366	(95.8)	523	(94.6)	692	(92.1)	637	(91.7)	420	(88.8)	2854	(92.8)	<0.001
Household medicines	1	(.5)	0	(.0)	1	(.2)	0	(.0)	0	(.0)	0	(.0)	2	(.1)	0.025
Family	0	(.0)	1	(.3)	0	(.0)	2	(.3)	1	(.1)	1	(.2)	5	(.2)	0.135
Clinics/hospitals	4	(1.8)	11	(2.9)	17	(3.1)	32	(4.3)	40	(5.8)	35	(7.4)	139	(4.5)	<0.001
Pharmacies/drugstores	0	(.0)	4	(1.0)	6	(1.1)	21	(2.8)	16	(2.3)	6	(1.3)	53	(1.7)	0.004
Friends/acquaintances	0	(.0)	0	(.0)	0	(.0)	1	(.1)	1	(.1)	0	(.0)	2	(.1)	0.129
Romantic partners	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.025
Internet	0	(.0)	0	(.0)	1	(.2)	2	(.3)	0	(.0)	0	(.0)	3	(.1)	0.071
Other	0	(.0)	0	(.0)	0	(.0)	0	(.0)	1	(.1)	0	(.0)	1	(0.03)	0.092
Source unknown	0	(.0)	0	(.0)	1	(.2)	1	(.1)	0	(.0)	1	(.2)	3	(.1)	0.793
No response/unknown	1	(.5)	2	(.5)	4	(.7)	6	(.8)	4	(.6)	11	(2.3)	28	(.9)	0.025
Reason for hypnotic use															
None	218	(98.2)	368	(96.3)	527	(95.3)	696	(92.7)	641	(92.2)	429	(90.7)	2879	(93.6)	0.002
To improve insomnia	3	(1.4)	10	(2.6)	16	(2.9)	45	(6.0)	46	(6.6)	38	(8.0)	158	(5.1)	<0.001
To eliminate anxiety	2	(.9)	2	(.5)	2	(.4)	10	(1.3)	6	(.9)	6	(1.3)	28	(.9)	0.457
To reduce stress	0	(.0)	2	(.5)	4	(.7)	2	(.3)	1	(.1)	3	(.6)	12	(.4)	0.451
To treat hypertension	0	(.0)	0	(.0)	0	(.0)	0	(.0)	1	(.1)	1	(.2)	2	(.1)	0.569
Recreation (pleasure)	0	(.0)	0	(.0)	0	(.0)	1	(.1)	0	(.0)	0	(.0)	1	(0.03)	0.606
Other	0	(.0)	1	(.3)	7	(1.3)	4	(.5)	5	(.7)	4	(.8)	21	(.7)	0.365
Reason for use unknown	0	(.0)	1	(.3)	1	(.2)	1	(.1)	0	(.0)	0	(.0)	3	(.1)	0.714
No response/unknown	0	(.0)	0	(.0)	1	(.2)	2	(.3)	1	(.1)	3	(.6)	7	(.2)	0.399
Past 30-day hypnotic use														<0.001	
No	220	(99.1)	372	(97.4)	532	(96.2)	711	(94.7)	652	(93.8)	432	(91.3)	2919	(94.9)	
Yes	1	(.5)	9	(2.4)	19	(3.4)	36	(4.8)	38	(5.5)	32	(6.8)	135	(4.4)	
No response/unknown	1	(.5)	1	(.3)	2	(.4)	4	(.5)	5	(.7)	9	(1.9)	22	(.7)	

“10s” refers to those aged 15 to 19, and “60s” refers to those aged 60 to 64.

For the source of hypnotics, “pharmacies/drugstores” include external prescription.

The number of hypnotics used (average) and the type of hypnotics used are based on the past 30-day use.

Benzodiazepine use: The proportion of respondents with at least one benzodiazepine included in tranquilizers and/or hypnotics used within the past 30 days.

Table 35. Hypnotic Use by Occupation (n=3076)

	Occupation									
	Self-employed		Full-time		Non-full-time		Student		Housewife	
	n=248		n=1406		n=394		n=271		n=436	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Past-year hypnotic use										
No	240	(96.8)	1329	(94.5)	375	(95.2)	267	(98.5)	397	(91.1)
Yes	7	(2.8)	73	(5.2)	18	(4.6)	4	(1.5)	39	(8.9)
No response/unknown	1	(.4)	4	(.3)	1	(.3)	0	(.0)	0	(.0)
Frequency of the past-year hypnotic use										
No	240	(96.8)	1,329	(94.5)	375	(95.2)	267	(98.5)	397	(91.1)
≤5 times a year	1	(.4)	22	(1.6)	6	(1.5)	3	(1.1)	15	(3.4)
Approx. 6–11 times a year	0	(.0)	5	(.4)	1	(.3)	0	(.0)	2	(.5)
Approx. 12–24 times a year	0	(.0)	5	(.4)	3	(.8)	1	(.4)	1	(.2)
Approx. 25–51 times a year	0	(.0)	8	(.6)	0	(.0)	0	(.0)	1	(.2)
Approx. 1–2 times a week	1	(.4)	3	(.2)	0	(.0)	0	(.0)	2	(.5)
Approx. 3–6 times a week	2	(.8)	6	(.4)	0	(.0)	0	(.0)	3	(.7)
Almost every day	3	(1.2)	22	(1.6)	8	(2.0)	0	(.0)	13	(3.0)
Frequency unknown	0	(.0)	2	(.1)	0	(.0)	0	(.0)	2	(.5)
No response/unknown	1	(.4)	4	(.3)	1	(.3)	0	(.0)	0	(.0)
Chronic hypnotic use										
No	242	(97.6)	1372	(97.6)	385	(97.7)	271	(100.0)	418	(95.9)
Yes	5	(2.0)	28	(2.0)	8	(2.0)	0	(.0)	16	(3.7)
No response/unknown	1	(.4)	6	(.4)	1	(.3)	0	(.0)	2	(.5)
Source of hypnotics										
Never obtained	237	(95.6)	1320	(93.9)	372	(94.4)	266	(98.2)	391	(89.7)
Household medicines	0	(.0)	0	(.0)	1	(.3)	1	(.4)	0	(.0)
Family	0	(.0)	1	(.1)	1	(.3)	0	(.0)	1	(.2)
Clinics/hospitals	6	(2.4)	49	(3.5)	14	(3.6)	3	(1.1)	32	(7.3)
Pharmacies/drugstores	2	(.8)	28	(2.0)	3	(.8)	0	(.0)	5	(1.1)
Friends/acquaintances	0	(.0)	0	(.0)	0	(.0)	0	(.0)	1	(.2)
Romantic partners	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Internet	0	(.0)	1	(.1)	0	(.0)	0	(.0)	2	(.5)
Other	0	(.0)	0	(.0)	0	(.0)	0	(.0)	1	(.2)
Source unknown	0	(.0)	0	(.0)	1	(.3)	0	(.0)	2	(.5)
No response/unknown	4	(1.6)	13	(.9)	3	(.8)	1	(.4)	3	(.7)
Reason for hypnotic use										
None	240	(96.8)	1329	(94.5)	375	(95.2)	267	(98.5)	397	(91.1)
To improve insomnia	6	(2.4)	63	(4.5)	15	(3.8)	2	(.7)	29	(6.7)
To eliminate anxiety	1	(.4)	8	(.6)	2	(.5)	1	(.4)	8	(1.8)
To reduce stress	0	(.0)	6	(.4)	1	(.3)	0	(.0)	2	(.5)
To treat hypertension	0	(.0)	0	(.0)	0	(.0)	0	(.0)	2	(.5)
Recreation (pleasure)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Other	1	(.4)	6	(.4)	2	(.5)	1	(.4)	8	(1.8)
Reason for use unknown	0	(.0)	1	(.1)	1	(.3)	0	(.0)	1	(.2)
No response/unknown	1	(.4)	4	(.3)	1	(.3)	0	(.0)	0	(.0)
Past 30-day hypnotic use										
No	238	(96.0)	1348	(95.9)	381	(96.7)	269	(99.3)	407	(93.3)
Yes	6	(2.4)	49	(3.5)	12	(3.0)	1	(.4)	26	(6.0)
No response/unknown	4	(1.6)	9	(.6)	1	(.3)	1	(.4)	3	(.7)

For the source of hypnotics, "pharmacies/drugstores" include external prescription.

The number of hypnotics used (average) and the type of hypnotics used are based on the past 30-day use.

Benzodiazepine use: The proportion of respondents with at least one benzodiazepine included in tranquilizers and/or hypnotics used within the past 30 days.

Table 35. Hypnotic Use by Occupation (n=3076) continued

	Occupation								p-value
	Unemployed		Other		Unknown		Total		
	n=179		n=138		n=4		n=3076		
	n	(%)	n	(%)	n	(%)	n	(%)	
Past-year hypnotic use									<0.001
No	147	(82.1)	121	(87.7)	3	(75.0)	2879	(93.6)	
Yes	31	(17.3)	17	(12.3)	1	(25.0)	190	(6.2)	
No response/unknown	1	(.6)	0	(.0)	0	(.0)	7	(.2)	
Frequency of the past-year hypnotic use									<0.001
No	147	(82.1)	121	(87.7)	3	(75.0)	2879	(93.6)	
≤5 times a year	7	(3.9)	3	(2.2)	0	(.0)	57	(1.9)	
Approx. 6–11 times a year	0	(.0)	0	(.0)	0	(.0)	8	(.3)	
Approx. 12–24 times a year	1	(.6)	0	(.0)	0	(.0)	11	(.4)	
Approx. 25–51 times a year	1	(.6)	1	(.7)	0	(.0)	11	(.4)	
Approx. 1–2 times a week	2	(1.1)	1	(.7)	0	(.0)	9	(.3)	
Approx. 3–6 times a week	3	(1.7)	3	(2.2)	1	(25.0)	18	(.6)	
Almost every day	17	(9.5)	8	(5.8)	0	(.0)	71	(2.3)	
Frequency unknown	0	(.0)	1	(.7)	0	(.0)	5	(.2)	
No response/unknown	1	(.6)	0	(.0)	0	(.0)	7	(.2)	
Chronic hypnotic use									<0.001
No	158	(88.3)	126	(91.3)	3	(75.0)	2975	(96.7)	
Yes	20	(11.2)	11	(8.0)	1	(25.0)	89	(2.9)	
No response/unknown	1	(.6)	1	(.7)	0	(.0)	12	(.4)	
Source of hypnotics									
Never obtained	146	(81.6)	119	(86.2)	3	(75.0)	2854	(92.8)	<0.001
Household medicines	0	(.0)	0	(.0)	0	(.0)	2	(.1)	0.708
Family	1	(.6)	1	(.7)	0	(.0)	5	(.2)	0.800
Clinics/hospitals	21	(11.7)	13	(9.4)	1	(25.0)	139	(4.5)	<0.001
Pharmacies/drugstores	9	(5.0)	5	(3.6)	1	(25.0)	53	(1.7)	<0.001
Friends/acquaintances	1	(.6)	0	(.0)	0	(.0)	2	(.1)	0.505
Romantic partners	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.872
Internet	0	(.0)	0	(.0)	0	(.0)	3	(.1)	0.742
Other	0	(.0)	0	(.0)	0	(.0)	1	(0.03)	0.818
Source unknown	0	(.0)	0	(.0)	0	(.0)	3	(.1)	0.251
No response/unknown	2	(1.1)	2	(1.4)	0	(.0)	28	(.9)	0.872
Reason for hypnotic use									
None	147	(82.1)	121	(87.7)	3	(75.0)	2879	(93.6)	<0.001
To improve insomnia	29	(16.2)	14	(10.1)	0	(.0)	158	(5.1)	<0.001
To eliminate anxiety	4	(2.2)	3	(2.2)	1	(25.0)	28	(.9)	<0.001
To reduce stress	2	(1.1)	1	(.7)	0	(.0)	12	(.4)	0.860
To treat hypertension	0	(.0)	0	(.0)	0	(.0)	2	(.1)	0.348
Recreation (pleasure)	1	(.6)	0	(.0)	0	(.0)	1	(0.03)	0.145
Other	2	(1.1)	1	(.7)	0	(.0)	21	(.7)	0.405
Reason for use unknown	0	(.0)	0	(.0)	0	(.0)	3	(.1)	0.912
No response/unknown	1	(.6)	0	(.0)	0	(.0)	7	(.2)	0.851
Past 30-day hypnotic use									<0.001
No	152	(84.9)	121	(87.7)	3	(75.0)	2919	(94.9)	
Yes	24	(13.4)	16	(11.6)	1	(25.0)	135	(4.4)	
No response/unknown	3	(1.7)	1	(.7)	0	(.0)	22	(.7)	

For the source of hypnotics, "pharmacies/drugstores" include external prescription.

The number of hypnotics used (average) and the type of hypnotics used are based on the past 30-day use.

Benzodiazepine use: The proportion of respondents with at least one benzodiazepine included in tranquilizers and/or hypnotics used within the past 30 days.

Table 36. Hypnotic Use by Drug use experience (n=3076)

	Drug use experience								p-value
	Lifetime		No lifetime		Unknown		Total		
	n=78		n=2940		n=58		n=3076		
	n	(%)	n	(%)	n	(%)	n	(%)	
Past-year hypnotic use									
									0.081
No	70	(89.7)	2755	(93.7)	54	(93.1)	2879	(93.6)	
Yes	8	(10.3)	179	(6.1)	3	(5.2)	190	(6.2)	
No response/unknown	0	(.0)	6	(.2)	1	(1.7)	7	(.2)	
Frequency of the past-year hypnotic use									
									0.012
No	70	(89.7)	2755	(93.7)	54	(93.1)	2879	(93.6)	
≤5 times a year	2	(2.6)	54	(1.8)	1	(1.7)	57	(1.9)	
Approx. 6–11 times a year	0	(.0)	7	(.2)	1	(1.7)	8	(.3)	
Approx. 12–24 times a year	0	(.0)	10	(.3)	1	(1.7)	11	(.4)	
Approx. 25–51 times a year	1	(1.3)	10	(.3)	0	(.0)	11	(.4)	
Approx. 1–2 times a week	2	(2.6)	7	(.2)	0	(.0)	9	(.3)	
Approx. 3–6 times a week	0	(.0)	18	(.6)	0	(.0)	18	(.6)	
Almost every day	3	(3.8)	68	(2.3)	0	(.0)	71	(2.3)	
Frequency unknown	0	(.0)	5	(.2)	0	(.0)	5	(.2)	
No response/unknown	0	(.0)	6	(.2)	1	(1.7)	7	(.2)	
Chronic hypnotic use									
									0.296
No	75	(96.2)	2843	(96.7)	57	(98.3)	2975	(96.7)	
Yes	3	(3.8)	86	(2.9)	0	(.0)	89	(2.9)	
No response/unknown	0	(.0)	11	(.4)	1	(1.7)	12	(.4)	
Source of hypnotics									
									<0.001
Never obtained	70	(89.7)	2733	(93.0)	51	(87.9)	2854	(92.8)	<0.001
Household medicines	0	(.0)	2	(.1)	0	(.0)	2	(.1)	<0.001
Family	1	(1.3)	4	(.1)	0	(.0)	5	(.2)	<0.001
Clinics/hospitals	3	(3.8)	134	(4.6)	2	(3.4)	139	(4.5)	<0.001
Pharmacies/drugstores	5	(6.4)	47	(1.6)	1	(1.7)	53	(1.7)	<0.001
Friends/acquaintances	1	(1.3)	1	(0.03)	0	(.0)	2	(.1)	<0.001
Romantic partners	0	(.0)	0	(.0)	0	(.0)	0	(.0)	<0.001
Internet	0	(.0)	3	(.1)	0	(.0)	3	(.1)	<0.001
Other	0	(.0)	1	(0.03)	0	(.0)	1	(0.03)	<0.001
Source unknown	0	(.0)	3	(.1)	0	(.0)	3	(.1)	0.933
No response/unknown	0	(.0)	24	(.8)	4	(6.9)	28	(.9)	<0.001
Reason for hypnotic use									
									0.081
None	70	(89.7)	2755	(93.7)	54	(93.1)	2879	(93.6)	0.081
To improve insomnia	6	(7.7)	150	(5.1)	2	(3.4)	158	(5.1)	0.120
To eliminate anxiety	0	(.0)	28	(1.0)	0	(.0)	28	(.9)	0.123
To reduce stress	0	(.0)	11	(.4)	1	(1.7)	12	(.4)	0.062
To treat hypertension	0	(.0)	2	(.1)	0	(.0)	2	(.1)	0.195
Recreation (pleasure)	1	(1.3)	0	(.0)	0	(.0)	1	(0.03)	<0.001
Other	0	(.0)	21	(.7)	0	(.0)	21	(.7)	0.139
Reason for use unknown	1	(1.3)	2	(.1)	0	(.0)	3	(.1)	0.003
No response/unknown	0	(.0)	6	(.2)	1	(1.7)	7	(.2)	0.051
Past 30-day hypnotic use									
									<0.001
No	71	(91.0)	2796	(95.1)	52	(89.7)	2919	(94.9)	
Yes	7	(9.0)	126	(4.3)	2	(3.4)	135	(4.4)	
No response/unknown	0	(.0)	18	(.6)	4	(6.9)	22	(.7)	

For the source of hypnotics, “pharmacies/drugstores” include external prescription.

The number of hypnotics used (average) and the type of hypnotics used are based on the past 30-day use.

Benzodiazepine use: The proportion of respondents with at least one benzodiazepine included in tranquilizers and/or hypnotics used within the past 30 days.

Table 37. Knowledge on and/or Awareness of Drug Abuse by Residence area (n=3076)

	Residence area											
	Hokkaido		Tohoku		Kanto		Hokuriku		Tousan		Tokai	
	n=131	n=250	n=948	n=154	n=150	n=328	n	(%)	n	(%)	n	(%)
[Knowledge] Drug dependence												
Know	128	(97.7)	245	(98.0)	933	(98.4)	150	(97.4)	146	(97.3)	320	(97.6)
Do not know	3	(2.3)	5	(2.0)	15	(1.6)	4	(2.6)	4	(2.7)	8	(2.4)
[Knowledge] Hallucination												
Know	125	(95.4)	243	(97.2)	917	(96.7)	148	(96.1)	144	(96.0)	313	(95.4)
Do not know	6	(4.6)	6	(2.4)	31	(3.3)	6	(3.9)	6	(4.0)	14	(4.3)
[Knowledge] Delusion												
Know	120	(91.6)	239	(95.6)	888	(93.7)	141	(91.6)	134	(89.3)	302	(92.1)
Do not know	10	(7.6)	10	(4.0)	60	(6.3)	12	(7.8)	16	(10.7)	25	(7.6)
[Knowledge] Flashback												
Know	100	(76.3)	202	(80.8)	746	(78.7)	127	(82.5)	121	(80.7)	259	(79.0)
Do not know	31	(23.7)	46	(18.4)	198	(20.9)	27	(17.5)	29	(19.3)	69	(21.0)
[Knowledge] Cannabis-induced hallucinations/delusion												
Know	100	(76.3)	195	(78.0)	739	(78.0)	121	(78.6)	118	(78.7)	254	(77.4)
Do not know	31	(23.7)	53	(21.2)	208	(21.9)	33	(21.4)	32	(21.3)	74	(22.6)
[Knowledge] Cannabis-induced amotivational syndrome												
Know	73	(55.7)	157	(62.8)	582	(61.4)	85	(55.2)	86	(57.3)	202	(61.6)
Do not know	58	(44.3)	92	(36.8)	365	(38.5)	69	(44.8)	63	(42.0)	126	(38.4)
View on cannabis use												
Under no situation should it be used, regardless of whether legally prohibited or not	108	(82.4)	202	(80.8)	771	(81.3)	134	(87.0)	123	(82.0)	270	(82.3)
It should not be used because it is legally prohibited	15	(11.5)	36	(14.4)	135	(14.2)	14	(9.1)	21	(14.0)	35	(10.7)
A little use should be allowed although legally prohibited	0	(.0)	0	(.0)	4	(.4)	0	(.0)	0	(.0)	2	(.6)
It is an individual freedom and should not be legally prohibited	1	(.8)	3	(1.2)	12	(1.3)	2	(1.3)	0	(.0)	5	(1.5)
Do not know/cannot decide	7	(5.3)	8	(3.2)	24	(2.5)	4	(2.6)	5	(3.3)	16	(4.9)
[Knowledge] Methamphetamine-induced hallucinations/delusion												
Know	117	(89.3)	224	(89.6)	859	(90.6)	140	(90.9)	139	(92.7)	299	(91.2)
Do not know	14	(10.7)	25	(10.0)	86	(9.1)	14	(9.1)	10	(6.7)	29	(8.8)
View on methamphetamine use												
Under no situation should it be used, regardless of whether legally prohibited or not	114	(87.0)	222	(88.8)	852	(89.9)	142	(92.2)	138	(92.0)	294	(89.6)
It should not be used because it is legally prohibited	11	(8.4)	18	(7.2)	68	(7.2)	8	(5.2)	10	(6.7)	20	(6.1)
A little use should be allowed although legally prohibited	0	(.0)	0	(.0)	1	(.1)	0	(.0)	0	(.0)	0	(.0)
It is an individual freedom and should not be legally prohibited	0	(.0)	2	(.8)	10	(1.1)	1	(.6)	0	(.0)	4	(1.2)
Do not know/cannot decide	5	(3.8)	8	(3.2)	16	(1.7)	2	(1.3)	2	(1.3)	9	(2.7)

“No response/unknown” are not included.

Table 37. Knowledge on and/or Awareness of Drug Abuse by Residence area (n=3076) continued

	Residence area										p-value		
	Kinki		Chugoku		Shikoku		Kita-Kyusyu		Minami-			Total	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)		n	(%)
[Knowledge] Drug dependence												0.879	
Know	429	(97.1)	189	(99.0)	87	(98.9)	223	(97.4)	161	(97.6)	3011	(97.9)	
Do not know	13	(2.9)	2	(1.0)	1	(1.1)	6	(2.6)	4	(2.4)	65	(2.1)	
[Knowledge] Hallucination												0.870	
Know	418	(94.6)	184	(96.3)	84	(95.5)	220	(96.1)	156	(94.5)	2952	(96.0)	
Do not know	23	(5.2)	7	(3.7)	4	(4.5)	9	(3.9)	8	(4.8)	120	(3.9)	
[Knowledge] Delusion												0.240	
Know	395	(89.4)	175	(91.6)	79	(89.8)	212	(92.6)	155	(93.9)	2840	(92.3)	
Do not know	44	(10.0)	15	(7.9)	9	(10.2)	17	(7.4)	10	(6.1)	228	(7.4)	
[Knowledge] Flashback												0.803	
Know	334	(75.6)	147	(77.0)	68	(77.3)	181	(79.0)	129	(78.2)	2414	(78.5)	
Do not know	107	(24.2)	44	(23.0)	20	(22.7)	48	(21.0)	36	(21.8)	655	(21.3)	
[Knowledge] Cannabis-induced hallucinations/delusion												0.816	
Know	343	(77.6)	147	(77.0)	67	(76.1)	186	(81.2)	130	(78.8)	2400	(78.0)	
Do not know	98	(22.2)	44	(23.0)	20	(22.7)	42	(18.3)	35	(21.2)	670	(21.8)	
[Knowledge] Cannabis-induced amotivational syndrome												0.419	
Know	256	(57.9)	117	(61.3)	57	(64.8)	144	(62.9)	112	(67.9)	1871	(60.8)	
Do not know	184	(41.6)	74	(38.7)	31	(35.2)	83	(36.2)	53	(32.1)	1198	(38.9)	
View on cannabis use												0.624	
Under no situation should it be used, regardless of whether legally prohibited or not	361	(81.7)	168	(88.0)	75	(85.2)	191	(83.4)	141	(85.5)	2544	(82.7)	
It should not be used because it is legally prohibited	56	(12.7)	12	(6.3)	11	(12.5)	26	(11.4)	13	(7.9)	374	(12.2)	
A little use should be allowed although legally prohibited	2	(.5)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	8	(.3)	
It is an individual freedom and should not be legally prohibited	3	(.7)	3	(1.6)	2	(2.3)	4	(1.7)	3	(1.8)	38	(1.2)	
Do not know/cannot decide	17	(3.8)	8	(4.2)	0	(.0)	8	(3.5)	7	(4.2)	104	(3.4)	
[Knowledge] Methamphetamine-induced hallucinations/delusion												0.763	
Know	384	(86.9)	171	(89.5)	78	(88.6)	206	(90.0)	147	(89.1)	2764	(89.9)	
Do not know	55	(12.4)	19	(9.9)	10	(11.4)	23	(10.0)	16	(9.7)	301	(9.8)	
View on methamphetamine use												0.744	
Under no situation should it be used, regardless of whether legally prohibited or not	395	(89.4)	176	(92.1)	79	(89.8)	203	(88.6)	150	(90.9)	2765	(89.9)	
It should not be used because it is legally prohibited	32	(7.2)	11	(5.8)	7	(8.0)	15	(6.6)	5	(3.0)	205	(6.7)	
A little use should be allowed although legally prohibited	1	(.2)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	2	(.1)	
It is an individual freedom and should not be legally prohibited	0	(.0)	0	(.0)	2	(2.3)	2	(.9)	1	(.6)	22	(.7)	
Do not know/cannot decide	12	(2.7)	4	(2.1)	0	(.0)	8	(3.5)	7	(4.2)	73	(2.4)	

“No response/unknown” are not included.

Table 38. Knowledge on and/or Awareness of Drug Abuse by Sex (n = 3076)

	Sex						P-value
	Men		Women		Total		
	n = 1466		n = 1610		n = 3076		
	n	(%)	n	(%)	n	(%)	
[Knowledge] Drug dependence							0.131
Know	1429	(97.5)	1582	(98.3)	3011	(97.9)	
Do not know	37	(2.5)	28	(1.7)	65	(2.1)	
[Knowledge] Hallucination							0.984
Know	1406	(95.9)	1546	(96.0)	2952	(96.0)	
Do not know	58	(4.0)	62	(3.9)	120	(3.9)	
[Knowledge] Delusion							0.302
Know	1343	(91.6)	1497	(93.0)	2840	(92.3)	
Do not know	118	(8.0)	110	(6.8)	228	(7.4)	
[Knowledge] Flashback							0.504
Know	1138	(77.6)	1276	(79.3)	2414	(78.5)	
Do not know	324	(22.1)	331	(20.6)	655	(21.3)	
[Knowledge] Cannabis-induced hallucinations/delusion							0.021
Know	1112	(75.9)	1288	(80.0)	2400	(78.0)	
Do not know	351	(23.9)	319	(19.8)	670	(21.8)	
[Knowledge] Cannabis-induced amotivational syndrome							0.533
Know	886	(60.4)	985	(61.2)	1871	(60.8)	
Do not know	578	(39.4)	620	(38.5)	1198	(38.9)	
View on cannabis use							<0.001
Under no situation should it be used, regardless of whether legally prohibited or not	1109	(75.6)	1435	(89.1)	2544	(82.7)	
It should not be used because it is legally prohibited	246	(16.8)	128	(8.0)	374	(12.2)	
A little use should be allowed although legally prohibited	6	(.4)	2	(.1)	8	(.3)	
It is an individual freedom and should not be legally prohibited	32	(2.2)	6	(.4)	38	(1.2)	
Do not know/cannot decide	71	(4.8)	33	(2.0)	104	(3.4)	
[Knowledge] Methamphetamine-induced hallucinations/delusion							0.032
Know	1296	(88.4)	1468	(91.2)	2764	(89.9)	
Do not know	163	(11.1)	138	(8.6)	301	(9.8)	
View on methamphetamine use							<0.001
Under no situation should it be used, regardless of whether legally prohibited or not	1256	(85.7)	1509	(93.7)	2765	(89.9)	
It should not be used because it is legally prohibited	143	(9.8)	62	(3.9)	205	(6.7)	
A little use should be allowed although legally prohibited	1	(.1)	1	(.1)	2	(.1)	
It is an individual freedom and should not be legally prohibited	16	(1.1)	6	(.4)	22	(.7)	
Do not know/cannot decide	49	(3.3)	24	(1.5)	73	(2.4)	

"No response/unknown" are not included.

Table 39. Knowledge on and/or Awareness of Drug Abuse by Age group (n=3076)

	Age group												p-value		
	10s		20s		30s		40s		50s		60s			Total	
	n=222	n=382	n=553	n=751	n=695	n=473	n=3076	n (%)	n (%)	n (%)	n (%)	n (%)		n (%)	
[Knowledge] Drug dependence													0.191		
Know	218	(98.2)	378	(99.0)	543	(98.2)	738	(98.3)	677	(97.4)	457	(96.6)	3011	(97.9)	
Do not know	4	(1.8)	4	(1.0)	10	(1.8)	13	(1.7)	18	(2.6)	16	(3.4)	65	(2.1)	
[Knowledge] Hallucination													0.082		
Know	217	(97.7)	373	(97.6)	532	(96.2)	725	(96.5)	663	(95.4)	442	(93.4)	2952	(96.0)	
Do not know	5	(2.3)	8	(2.1)	20	(3.6)	25	(3.3)	31	(4.5)	31	(6.6)	120	(3.9)	
[Knowledge] Delusion													0.511		
Know	204	(91.9)	361	(94.5)	506	(91.5)	698	(92.9)	643	(92.5)	428	(90.5)	2840	(92.3)	
Do not know	18	(8.1)	19	(5.0)	45	(8.1)	52	(6.9)	51	(7.3)	43	(9.1)	228	(7.4)	
[Knowledge] Flashback													0.082		
Know	182	(82.0)	320	(83.8)	441	(79.7)	570	(75.9)	534	(76.8)	367	(77.6)	2414	(78.5)	
Do not know	40	(18.0)	61	(16.0)	112	(20.3)	180	(24.0)	158	(22.7)	104	(22.0)	655	(21.3)	
[Knowledge] Cannabis-induced hallucinations/delusion													0.036		
Know	186	(83.8)	316	(82.7)	420	(75.9)	582	(77.5)	535	(77.0)	361	(76.3)	2400	(78.0)	
Do not know	36	(16.2)	64	(16.8)	133	(24.1)	168	(22.4)	157	(22.6)	112	(23.7)	670	(21.8)	
[Knowledge] Cannabis-induced amotivational syndrome													<0.001		
Know	163	(73.4)	255	(66.8)	300	(54.2)	432	(57.5)	431	(62.0)	290	(61.3)	1871	(60.8)	
Do not know	59	(26.6)	125	(32.7)	253	(45.8)	317	(42.2)	262	(37.7)	182	(38.5)	1198	(38.9)	
View on cannabis use													<0.001		
Under no situation should it be used, regardless of whether legally prohibited or not	178	(80.2)	311	(81.4)	423	(76.5)	611	(81.4)	601	(86.5)	420	(88.8)	2544	(82.7)	
It should not be used because it is legally prohibited	31	(14.0)	47	(12.3)	91	(16.5)	100	(13.3)	66	(9.5)	39	(8.2)	374	(12.2)	
A little use should be allowed although legally prohibited	0	(.0)	4	(1.0)	1	(.2)	1	(.1)	1	(.1)	1	(.2)	8	(.3)	
It is an individual freedom and should not be legally prohibited	3	(1.4)	8	(2.1)	9	(1.6)	11	(1.5)	4	(.6)	3	(.6)	38	(1.2)	
Do not know/cannot decide	10	(4.5)	11	(2.9)	29	(5.2)	27	(3.6)	21	(3.0)	6	(1.3)	104	(3.4)	
[Knowledge] Methamphetamine-induced hallucinations/delusion													0.053		
Know	202	(91.0)	361	(94.5)	498	(90.1)	675	(89.9)	612	(88.1)	416	(87.9)	2764	(89.9)	
Do not know	18	(8.1)	20	(5.2)	54	(9.8)	72	(9.6)	81	(11.7)	56	(11.8)	301	(9.8)	
View on methamphetamine use													<0.001		
Under no situation should it be used, regardless of whether legally prohibited or not	188	(84.7)	340	(89.0)	470	(85.0)	683	(90.9)	646	(92.9)	438	(92.6)	2765	(89.9)	
It should not be used because it is legally prohibited	19	(8.6)	27	(7.1)	56	(10.1)	46	(6.1)	30	(4.3)	27	(5.7)	205	(6.7)	
A little use should be allowed although legally prohibited	0	(.0)	0	(.0)	1	(.2)	1	(.1)	0	(.0)	0	(.0)	2	(.1)	
It is an individual freedom and should not be legally prohibited	4	(1.8)	5	(1.3)	6	(1.1)	6	(.8)	0	(.0)	1	(.2)	22	(.7)	
Do not know/cannot decide	11	(5.0)	9	(2.4)	20	(3.6)	13	(1.7)	17	(2.4)	3	(.6)	73	(2.4)	

"10s" refers to those aged 15 to 19, and "60s" refers to those aged 60 to 64.

"No response/unknown" are not included.

Table 40. Knowledge on and/or Awareness of Drug Abuse by Occupation (n=3076)

	Occupation									
	Self-employed		Full-time		Non-full-time		Student		Housewife	
	n=248	n=1406	n=394	n=271	n=436	n	(%)	n	(%)	
[Knowledge] Drug dependence										
Know	242	(97.6)	1388	(98.7)	385	(97.7)	267	(98.5)	426	(97.7)
Do not know	6	(2.4)	18	(1.3)	9	(2.3)	4	(1.5)	10	(2.3)
[Knowledge] Hallucination										
Know	235	(94.8)	1368	(97.3)	378	(95.9)	265	(97.8)	412	(94.5)
Do not know	13	(5.2)	35	(2.5)	15	(3.8)	6	(2.2)	24	(5.5)
[Knowledge] Delusion										
Know	231	(93.1)	1311	(93.2)	370	(93.9)	250	(92.3)	400	(91.7)
Do not know	16	(6.5)	90	(6.4)	23	(5.8)	21	(7.7)	36	(8.3)
[Knowledge] Flashback										
Know	187	(75.4)	1117	(79.4)	317	(80.5)	225	(83.0)	331	(75.9)
Do not know	60	(24.2)	287	(20.4)	75	(19.0)	46	(17.0)	104	(23.9)
[Knowledge] Cannabis-induced hallucinations/delusion										
Know	187	(75.4)	1102	(78.4)	317	(80.5)	227	(83.8)	341	(78.2)
Do not know	61	(24.6)	302	(21.5)	75	(19.0)	44	(16.2)	94	(21.6)
[Knowledge] Cannabis-induced amotivational syndrome										
Know	146	(58.9)	864	(61.5)	240	(60.9)	200	(73.8)	238	(54.6)
Do not know	102	(41.1)	541	(38.5)	150	(38.1)	71	(26.2)	197	(45.2)
View on cannabis use										
Under no situation should it be used, regardless of whether legally prohibited or not	196	(79.0)	1130	(80.4)	339	(86.0)	220	(81.2)	407	(93.3)
It should not be used because it is legally prohibited	34	(13.7)	201	(14.3)	40	(10.2)	37	(13.7)	24	(5.5)
A little use should be allowed although legally prohibited	0	(.0)	4	(.3)	2	(.5)	0	(.0)	0	(.0)
It is an individual freedom and should not be legally prohibited	4	(1.6)	20	(1.4)	3	(.8)	4	(1.5)	0	(.0)
Do not know/cannot decide	13	(5.2)	51	(3.6)	7	(1.8)	10	(3.7)	3	(.7)
[Knowledge] Methamphetamine-induced hallucinations/delusion										
Know	215	(86.7)	1283	(91.3)	356	(90.4)	249	(91.9)	389	(89.2)
Do not know	31	(12.5)	122	(8.7)	34	(8.6)	20	(7.4)	46	(10.6)
View on methamphetamine use										
Under no situation should it be used, regardless of whether legally prohibited or not	220	(88.7)	1251	(89.0)	364	(92.4)	233	(86.0)	422	(96.8)
It should not be used because it is legally prohibited	20	(8.1)	110	(7.8)	19	(4.8)	23	(8.5)	10	(2.3)
A little use should be allowed although legally prohibited	0	(.0)	2	(.1)	0	(.0)	0	(.0)	0	(.0)
It is an individual freedom and should not be legally prohibited	1	(.4)	9	(.6)	3	(.8)	4	(1.5)	0	(.0)
Do not know/cannot decide	6	(2.4)	31	(2.2)	6	(1.5)	11	(4.1)	3	(.7)

“No response/unknown” are not included.

Table 40. Knowledge on and/or Awareness of Drug Abuse by Occupation (n=3076) continued

	Occupation								p-value
	Unemployed		Other		Unknown		Total		
	n=179	n=138	n=4	n=3076	n	(%)	n	(%)	
[Knowledge] Drug dependence									<0.001
Know	171	(95.5)	128	(92.8)	4	(100.0)	3011	(97.9)	
Do not know	8	(4.5)	10	(7.2)	0	(.0)	65	(2.1)	
[Knowledge] Hallucination									0.002
Know	164	(91.6)	126	(91.3)	4	(100.0)	2952	(96.0)	
Do not know	15	(8.4)	12	(8.7)	0	(.0)	120	(3.9)	
[Knowledge] Delusion									0.038
Know	156	(87.2)	118	(85.5)	4	(100.0)	2840	(92.3)	
Do not know	23	(12.8)	19	(13.8)	0	(.0)	228	(7.4)	
[Knowledge] Flashback									0.319
Know	131	(73.2)	103	(74.6)	3	(75.0)	2414	(78.5)	
Do not know	47	(26.3)	35	(25.4)	1	(25.0)	655	(21.3)	
[Knowledge] Cannabis-induced hallucinations/delusion									0.049
Know	123	(68.7)	100	(72.5)	3	(75.0)	2400	(78.0)	
Do not know	55	(30.7)	38	(27.5)	1	(25.0)	670	(21.8)	
[Knowledge] Cannabis-induced amotivational syndrome									<0.001
Know	97	(54.2)	83	(60.1)	3	(75.0)	1871	(60.8)	
Do not know	82	(45.8)	54	(39.1)	1	(25.0)	1198	(38.9)	
View on cannabis use									<0.001
Under no situation should it be used, regardless of whether legally prohibited or not	137	(76.5)	112	(81.2)	3	(75.0)	2544	(82.7)	
It should not be used because it is legally prohibited	26	(14.5)	12	(8.7)	0	(.0)	374	(12.2)	
A little use should be allowed although legally prohibited	1	(.6)	1	(.7)	0	(.0)	8	(.3)	
It is an individual freedom and should not be legally prohibited	4	(2.2)	3	(2.2)	0	(.0)	38	(1.2)	
Do not know/cannot decide	10	(5.6)	9	(6.5)	1	(25.0)	104	(3.4)	
[Knowledge] Methamphetamine-induced hallucinations/delusion									0.009
Know	151	(84.4)	117	(84.8)	4	(100.0)	2764	(89.9)	
Do not know	28	(15.6)	20	(14.5)	0	(.0)	301	(9.8)	
View on methamphetamine use									0.001
Under no situation should it be used, regardless of whether legally prohibited or not	151	(84.4)	121	(87.7)	3	(75.0)	2765	(89.9)	
It should not be used because it is legally prohibited	15	(8.4)	8	(5.8)	0	(.0)	205	(6.7)	
A little use should be allowed although legally prohibited	0	(.0)	0	(.0)	0	(.0)	2	(.1)	
It is an individual freedom and should not be legally prohibited	3	(1.7)	2	(1.4)	0	(.0)	22	(.7)	
Do not know/cannot decide	8	(4.5)	7	(5.1)	1	(25.0)	73	(2.4)	

"No response/unknown" are not included.

Table 41. Knowledge on and/or Awareness of Drug Abuse by Drug use experience (n=3076)

	Drug use experience								p-value
	Lifetime experience n=78		No lifetime experience n=2940		Unknown n=58		Total n=3076		
	n	(%)	n	(%)	n	(%)	n	(%)	
[Knowledge] Drug dependence									<0.001
Know	74	(94.9)	2884	(98.1)	53	(91.4)	3011	(97.9)	
Do not know	4	(5.1)	56	(1.9)	5	(8.6)	65	(2.1)	
[Knowledge] Hallucination									0.001
Know	73	(93.6)	2828	(96.2)	51	(87.9)	2952	(96.0)	
Do not know	5	(6.4)	109	(3.7)	6	(10.3)	120	(3.9)	
[Knowledge] Delusion									<0.001
Know	72	(92.3)	2723	(92.6)	45	(77.6)	2840	(92.3)	
Do not know	6	(7.7)	210	(7.1)	12	(20.7)	228	(7.4)	
[Knowledge] Flashback									0.028
Know	68	(87.2)	2305	(78.4)	41	(70.7)	2414	(78.5)	
Do not know	10	(12.8)	629	(21.4)	16	(27.6)	655	(21.3)	
[Knowledge] Cannabis-induced hallucinations/delusion									0.023
Know	55	(70.5)	2304	(78.4)	41	(70.7)	2400	(78.0)	
Do not know	23	(29.5)	631	(21.5)	16	(27.6)	670	(21.8)	
[Knowledge] Cannabis-induced amotivational syndrome									0.188
Know	46	(59.0)	1791	(60.9)	34	(58.6)	1871	(60.8)	
Do not know	32	(41.0)	1143	(38.9)	23	(39.7)	1198	(38.9)	
View on cannabis use									<0.001
Under no situation should it be used, regardless of whether legally prohibited or not	43	(55.1)	2458	(83.6)	43	(74.1)	2544	(82.7)	
It should not be used because it is legally prohibited	21	(26.9)	348	(11.8)	5	(8.6)	374	(12.2)	
A little use should be allowed although legally prohibited	3	(3.8)	5	(.2)	0	(.0)	8	(.3)	
It is an individual freedom and should not be legally prohibited	9	(11.5)	28	(1.0)	1	(1.7)	38	(1.2)	
Do not know/cannot decide	2	(2.6)	94	(3.2)	8	(13.8)	104	(3.4)	
[Knowledge] Methamphetamine-induced hallucinations/delusion									0.039
Know	68	(87.2)	2650	(90.1)	46	(79.3)	2764	(89.9)	
Do not know	10	(12.8)	280	(9.5)	11	(19.0)	301	(9.8)	
View on methamphetamine use									<0.001
Under no situation should it be used, regardless of whether legally prohibited or not	60	(76.9)	2658	(90.4)	47	(81.0)	2765	(89.9)	
It should not be used because it is legally prohibited	8	(10.3)	192	(6.5)	5	(8.6)	205	(6.7)	
A little use should be allowed although legally prohibited	0	(.0)	2	(.1)	0	(.0)	2	(.1)	
It is an individual freedom and should not be legally prohibited	8	(10.3)	14	(.5)	0	(.0)	22	(.7)	
Do not know/cannot decide	2	(2.6)	65	(2.2)	6	(10.3)	73	(2.4)	

"No response/unknown" are not included.

Table 42. NPS Use and Other Related Items by Residence area (n=3076)

	Residence area											
	Hokkaido		Tohoku		Kanto		Hokuriku		Tousan		Tokai	
	n=131	n=250	n=948	n=154	n=150	n=328	n	(%)	n	(%)	n	(%)
Harmful effects of NPSs												
Know	112	(85.5)	206	(82.4)	829	(87.4)	124	(80.5)	125	(83.3)	287	(87.5)
Do not know	19	(14.5)	42	(16.8)	117	(12.3)	30	(19.5)	24	(16.0)	39	(11.9)
No response/unknown	0	(.0)	2	(.8)	2	(.2)	0	(.0)	1	(.7)	2	(.6)
Japan's regulation for designated substances												
Know	73	(55.7)	149	(59.6)	548	(57.8)	81	(52.6)	90	(60.0)	193	(58.8)
Do not know	58	(44.3)	100	(40.0)	398	(42.0)	72	(46.8)	60	(40.0)	134	(40.9)
No response/unknown	0	(.0)	1	(.4)	2	(.2)	1	(.6)	0	(.0)	1	(.3)
The perceived number of NPS users												
Increasing	70	(53.4)	145	(58.0)	561	(59.2)	79	(51.3)	91	(60.7)	188	(57.3)
Not changing	14	(10.7)	13	(5.2)	58	(6.1)	7	(4.5)	6	(4.0)	20	(6.1)
Decreasing	2	(1.5)	2	(.8)	9	(.9)	3	(1.9)	0	(.0)	9	(2.7)
Do not know	45	(34.4)	89	(35.6)	316	(33.3)	65	(42.2)	52	(34.7)	111	(33.8)
No response/unknown	0	(.0)	1	(.4)	4	(.4)	0	(.0)	1	(.7)	0	(.0)
Experience of NPS use (lifetime)												
Never used	126	(96.2)	246	(98.4)	935	(98.6)	152	(98.7)	146	(97.3)	324	(98.8)
Have used	2	(1.5)	0	(.0)	2	(.2)	0	(.0)	0	(.0)	1	(.3)
No response/unknown	3	(2.3)	4	(1.6)	11	(1.2)	2	(1.3)	4	(2.7)	3	(.9)
Experience of NPS use (within the past year)												
Never used	128	(97.7)	246	(98.4)	937	(98.8)	152	(98.7)	146	(97.3)	325	(99.1)
Have used	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
No response/unknown	3	(2.3)	4	(1.6)	11	(1.2)	2	(1.3)	4	(2.7)	3	(.9)
Type of NPSs used												
Never used	121	(92.4)	230	(92.0)	896	(94.5)	144	(93.5)	139	(92.7)	307	(93.6)
Herbal	2	(1.5)	0	(.0)	1	(.1)	0	(.0)	0	(.0)	0	(.0)
Liquid	2	(1.5)	0	(.0)	1	(.1)	0	(.0)	0	(.0)	1	(.3)
Powder	1	(.8)	0	(.0)	2	(.2)	0	(.0)	0	(.0)	1	(.3)
Other	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Form unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
No response/unknown	8	(6.1)	20	(8.0)	50	(5.3)	10	(6.5)	11	(7.3)	20	(6.1)
Hospital visit associated with NPS use												
None	126	(96.2)	242	(96.8)	929	(98.0)	150	(97.4)	146	(97.3)	320	(97.6)
Have used an NPS but no hospital visit associated with NPS use	2	(1.5)	0	(.0)	2	(.2)	0	(.0)	0	(.0)	1	(.3)
Used an NPS and was taken to hospital by ambulance	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Used an NPS and presented to a psychiatric department	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Used an NPS and presented to a department of internal medicine	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Used an NPS and presented to a trauma department	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Used an NPS and presented to any other department	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Have used an NPS but history of hospital visit is unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
No response/unknown	3	(2.3)	8	(3.2)	17	(1.8)	4	(2.6)	4	(2.7)	7	(2.1)

For the type of NPSs used, all the responses of "form unknown" fell under the category of "No response/unknown," and no test was therefore performed.

There were no respondents with a history of hospital visit associated with NPS use, and no test was therefore performed.

Table 42. NPS Use and Other Related Items by Residence area (n=3076) continued

	Residence area										p-value		
	Kinki		Chugoku		Shikoku		Kita-Kyusyu		Minami-			Total	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)		n	(%)
Harmful effects of NPSs													0.117
Know	377	(85.3)	171	(89.5)	72	(81.8)	200	(87.3)	136	(82.4)	2,639	(85.8)	
Do not know	62	(14.0)	20	(10.5)	16	(18.2)	29	(12.7)	26	(15.8)	424	(13.8)	
No response/unknown	3	(.7)	0	(.0)	0	(.0)	0	(.0)	3	(1.8)	13	(.4)	
Japan's regulation for designated substances													0.702
Know	229	(51.8)	109	(57.1)	44	(50.0)	139	(60.7)	94	(57.0)	1,749	(56.9)	
Do not know	210	(47.5)	82	(42.9)	43	(48.9)	89	(38.9)	70	(42.4)	1,316	(42.8)	
No response/unknown	3	(.7)	0	(.0)	1	(1.1)	1	(.4)	1	(.6)	11	(.4)	
The perceived number of NPS users													0.357
Increasing	250	(56.6)	105	(55.0)	51	(58.0)	138	(60.3)	83	(50.3)	1,761	(57.2)	
Not changing	25	(5.7)	7	(3.7)	8	(9.1)	10	(4.4)	11	(6.7)	179	(5.8)	
Decreasing	4	(.9)	2	(1.0)	1	(1.1)	1	(.4)	0	(.0)	33	(1.1)	
Do not know	160	(36.2)	76	(39.8)	28	(31.8)	80	(34.9)	70	(42.4)	1,092	(35.5)	
No response/unknown	3	(.7)	1	(.5)	0	(.0)	0	(.0)	1	(.6)	11	(.4)	
Experience of NPS use (lifetime)													0.829
Never used	434	(98.2)	186	(97.4)	86	(97.7)	225	(98.3)	162	(98.2)	3,022	(98.2)	
Have used	2	(.5)	1	(.5)	1	(1.1)	1	(.4)	1	(.6)	11	(.4)	
No response/unknown	6	(1.4)	4	(2.1)	1	(1.1)	3	(1.3)	2	(1.2)	43	(1.4)	
Experience of NPS use (within the past year)													0.932
Never used	436	(98.6)	187	(97.9)	87	(98.9)	226	(98.7)	163	(98.8)	3,033	(98.6)	
Have used	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
No response/unknown	6	(1.4)	4	(2.1)	1	(1.1)	3	(1.3)	2	(1.2)	43	(1.4)	
Type of NPSs used													
Never used	415	(93.9)	177	(92.7)	81	(92.0)	217	(94.8)	154	(93.3)	2,881	(93.7)	0.836
Herbal	2	(.5)	1	(.5)	1	(1.1)	1	(.4)	0	(.0)	8	(.3)	0.462
Liquid	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	4	(.1)	0.139
Powder	0	(.0)	1	(.5)	0	(.0)	0	(.0)	1	(.6)	6	(.2)	0.927
Other	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.937
Form unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	-
No response/unknown	25	(5.7)	13	(6.8)	6	(6.8)	11	(4.8)	10	(6.1)	184	(6.0)	0.937
Hospital visit associated with NPS use													
None	427	(96.6)	184	(96.3)	85	(96.6)	221	(96.5)	159	(96.4)	2,989	(97.2)	-
Have used an NPS but no hospital visit associated with NPS use	2	(.5)	1	(.5)	1	(1.1)	1	(.4)	1	(.6)	11	(.4)	-
Used an NPS and was taken to hospital by ambulance	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	-
Used an NPS and presented to a psychiatric department	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	-
Used an NPS and presented to a department of internal medicine	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	-
Used an NPS and presented to a trauma department	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	-
Used an NPS and presented to any other department	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	-
Have used an NPS but history of hospital visit is unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	-
No response/unknown	13	(2.9)	6	(3.1)	2	(2.3)	7	(3.1)	5	(3.0)	76	(2.5)	-

For the type of NPSs used, all the responses of "form unknown" fell under the category of "No response/unknown," and no test was therefore performed.

There were no respondents with a history of hospital visit associated with NPS use, and no test was therefore performed.

Table 43. NPS Use and Other Related Items by Sex (n = 3076)

	Sex						P-value
	Men		Women		Total		
	n = 1466		n = 1610		n = 3076		
	n	(%)	n	(%)	n	(%)	
Harmful effects of NPSs							0.532
Know	1,261	(86.0)	1,378	(85.6)	2,639	(85.8)	
Do not know	197	(13.4)	227	(14.1)	424	(13.8)	
No response/unknown	8	(.5)	5	(.3)	13	(.4)	
Japan's regulation for designated substances							<0.001
Know	907	(61.9)	842	(52.3)	1,749	(56.9)	
Do not know	553	(37.7)	763	(47.4)	1,316	(42.8)	
No response/unknown	6	(.4)	5	(.3)	11	(.4)	
The perceived number of NPS users							<0.001
Increasing	782	(53.3)	979	(60.8)	1,761	(57.2)	
Not changing	103	(7.0)	76	(4.7)	179	(5.8)	
Decreasing	28	(1.9)	5	(.3)	33	(1.1)	
Do not know	549	(37.4)	543	(33.7)	1,092	(35.5)	
No response/unknown	4	(.3)	7	(.4)	11	(.4)	
Experience of NPS use (lifetime)							0.137
Never used	1,434	(97.8)	1,588	(98.6)	3,022	(98.2)	
Have used	8	(.5)	3	(.2)	11	(.4)	
No response/unknown	24	(1.6)	19	(1.2)	43	(1.4)	
Experience of NPS use (within the past year)							0.281
Never used	1,442	(98.4)	1,591	(98.8)	3,033	(98.6)	
Have used	0	(.0)	0	(.0)	0	(.0)	
No response/unknown	24	(1.6)	19	(1.2)	43	(1.4)	
Type of NPSs used							
Never used	1,359	(92.7)	1,522	(94.5)	2,881	(93.7)	0.054
Herbal	5	(.3)	3	(.2)	8	(.3)	0.157
Liquid	3	(.2)	1	(.1)	4	(.1)	0.123
Powder	5	(.3)	1	(.1)	6	(.2)	0.047
Other	0	(.0)	0	(.0)	0	(.0)	0.085
Form unknown	0	(.0)	0	(.0)	0	(.0)	-
No response/unknown	99	(6.8)	85	(5.3)	184	(6.0)	0.085
Hospital visit associated with NPS use							
None	1,418	(96.7)	1,571	(97.6)	2,989	(97.2)	-
Have used an NPS but no hospital visit associated with NPS use	8	(.5)	3	(.2)	11	(.4)	-
Used an NPS and was taken to hospital by ambulance	0	(.0)	0	(.0)	0	(.0)	-
Used an NPS and presented to a psychiatric department	0	(.0)	0	(.0)	0	(.0)	-
Used an NPS and presented to a department of internal medicine	0	(.0)	0	(.0)	0	(.0)	-
Used an NPS and presented to a trauma department	0	(.0)	0	(.0)	0	(.0)	-
Used an NPS and presented to any other department	0	(.0)	0	(.0)	0	(.0)	-
Have used an NPS but history of hospital visit is unknown	0	(.0)	0	(.0)	0	(.0)	-
No response/unknown	40	(2.7)	36	(2.2)	76	(2.5)	-

For the type of NPSs used, all the responses of "form unknown" fell under the category of "No response/unknown," and no test was therefore performed.

There were no respondents with a history of hospital visit associated with NPS use, and no test was therefore performed.

Table 44. NPS Use and Other Related Items by Age group(n=3076)

	Age group												p-value		
	10s		20s		30s		40s		50s		60s			Total	
	n=222	n=382	n=553	n=751	n=695	n=473	n=3076	n (%)	n (%)	n (%)	n (%)	n (%)		n (%)	
Harmful effects of NPSs													0.898		
Know	189 (85.1)	334 (87.4)	471 (85.2)	650 (86.6)	599 (86.2)	396 (83.7)	2,639 (85.8)								
Do not know	33 (14.9)	47 (12.3)	79 (14.3)	97 (12.9)	93 (13.4)	75 (15.9)	424 (13.8)								
No response/unknown	0 (.0)	1 (.3)	3 (.5)	4 (.5)	3 (.4)	2 (.4)	13 (.4)								
Japan's regulation for designated substances													0.058		
Know	109 (49.1)	203 (53.1)	301 (54.4)	427 (56.9)	413 (59.4)	296 (62.6)	1,749 (56.9)								
Do not know	112 (50.5)	178 (46.6)	250 (45.2)	322 (42.9)	279 (40.1)	175 (37.0)	1,316 (42.8)								
No response/unknown	1 (.5)	1 (.3)	2 (.4)	2 (.3)	3 (.4)	2 (.4)	11 (.4)								
The perceived number of NPS users													<0.001		
Increasing	87 (39.2)	187 (49.0)	314 (56.8)	457 (60.9)	427 (61.4)	289 (61.1)	1,761 (57.2)								
Not changing	12 (5.4)	36 (9.4)	34 (6.1)	39 (5.2)	38 (5.5)	20 (4.2)	179 (5.8)								
Decreasing	4 (1.8)	5 (1.3)	6 (1.1)	10 (1.3)	5 (.7)	3 (.6)	33 (1.1)								
Do not know	119 (53.6)	154 (40.3)	195 (35.3)	243 (32.4)	221 (31.8)	160 (33.8)	1,092 (35.5)								
No response/unknown	0 (.0)	0 (.0)	4 (.7)	2 (.3)	4 (.6)	1 (.2)	11 (.4)								
Experience of NPS use (lifetime)													0.455		
Never used	219 (98.6)	375 (98.2)	544 (98.4)	741 (98.7)	681 (98.0)	462 (97.7)	3,022 (98.2)								
Have used	0 (.0)	2 (.5)	4 (.7)	2 (.3)	3 (.4)	0 (.0)	11 (.4)								
No response/unknown	3 (1.4)	5 (1.3)	5 (.9)	8 (1.1)	11 (1.6)	11 (2.3)	43 (1.4)								
Experience of NPS use (within the past year)													0.449		
Never used	219 (98.6)	377 (98.7)	548 (99.1)	743 (98.9)	684 (98.4)	462 (97.7)	3,033 (98.6)								
Have used	0 (.0)	0 (.0)	0 (.0)	0 (.0)	0 (.0)	0 (.0)	0 (.0)								
No response/unknown	3 (1.4)	5 (1.3)	5 (.9)	8 (1.1)	11 (1.6)	11 (2.3)	43 (1.4)								
Type of NPSs used													0.535		
Never used	211 (95.0)	362 (94.8)	509 (92.0)	700 (93.2)	654 (94.1)	445 (94.1)	2,881 (93.7)								
Herbal	0 (.0)	2 (.5)	4 (.7)	1 (.1)	1 (.1)	0 (.0)	8 (.3)						0.281		
Liquid	0 (.0)	0 (.0)	1 (.2)	2 (.3)	1 (.1)	0 (.0)	4 (.1)						0.780		
Powder	0 (.0)	0 (.0)	2 (.4)	2 (.3)	2 (.3)	0 (.0)	6 (.2)						0.704		
Other	0 (.0)	0 (.0)	0 (.0)	0 (.0)	0 (.0)	0 (.0)	0 (.0)						0.582		
Form unknown	0 (.0)	0 (.0)	0 (.0)	0 (.0)	0 (.0)	0 (.0)	0 (.0)						-		
No response/unknown	11 (5.0)	18 (4.7)	40 (7.2)	49 (6.5)	38 (5.5)	28 (5.9)	184 (6.0)						0.582		
Hospital visit associated with NPS use													-		
None	216 (97.3)	378 (99.0)	529 (95.7)	735 (97.9)	672 (96.7)	459 (97.0)	2,989 (97.2)								
Have used an NPS but no hospital visit associated with NPS use	0 (.0)	2 (.5)	4 (.7)	2 (.3)	3 (.4)	0 (.0)	11 (.4)								
Used an NPS and was taken to hospital by ambulance	0 (.0)	0 (.0)	0 (.0)	0 (.0)	0 (.0)	0 (.0)	0 (.0)								
Used an NPS and presented to a psychiatric department	0 (.0)	0 (.0)	0 (.0)	0 (.0)	0 (.0)	0 (.0)	0 (.0)								
Used an NPS and presented to a department of internal medicine	0 (.0)	0 (.0)	0 (.0)	0 (.0)	0 (.0)	0 (.0)	0 (.0)								
Used an NPS and presented to a trauma department	0 (.0)	0 (.0)	0 (.0)	0 (.0)	0 (.0)	0 (.0)	0 (.0)								
Used an NPS and presented to any other department	0 (.0)	0 (.0)	0 (.0)	0 (.0)	0 (.0)	0 (.0)	0 (.0)								
Have used an NPS but history of hospital visit is unknown	0 (.0)	0 (.0)	0 (.0)	0 (.0)	0 (.0)	0 (.0)	0 (.0)								
No response/unknown	6 (2.7)	2 (.5)	20 (3.6)	14 (1.9)	20 (2.9)	14 (3.0)	76 (2.5)								

"10s" refers to those aged 15 to 19, and "60s" refers to those aged 60 to 64.

For the type of NPSs used, all the responses of "form unknown" fell under the category of "No response/unknown," and no test was therefore performed.

Table 45. NPS Use and Other Related Items by Occupation (n=3076)

	Occupation									
	Self-employed		Full-time		Non-full-time		Student		Housewife	
	n=248		n=1406		n=394		n=271		n=436	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Harmful effects of NPSs										
Know	216	(87.1)	1,228	(87.3)	333	(84.5)	239	(88.2)	373	(85.6)
Do not know	32	(12.9)	171	(12.2)	59	(15.0)	32	(11.8)	61	(14.0)
No response/unknown	0	(.0)	7	(.5)	2	(.5)	0	(.0)	2	(.5)
Japan's regulation for designated substances										
Know	165	(66.5)	822	(58.5)	217	(55.1)	127	(46.9)	244	(56.0)
Do not know	83	(33.5)	579	(41.2)	174	(44.2)	142	(52.4)	192	(44.0)
No response/unknown	0	(.0)	5	(.4)	3	(.8)	2	(.7)	0	(.0)
The perceived number of NPS users										
Increasing	151	(60.9)	795	(56.5)	242	(61.4)	111	(41.0)	280	(64.2)
Not changing	15	(6.0)	90	(6.4)	19	(4.8)	21	(7.7)	16	(3.7)
Decreasing	3	(1.2)	18	(1.3)	2	(.5)	5	(1.8)	2	(.5)
Do not know	78	(31.5)	495	(35.2)	130	(33.0)	134	(49.4)	138	(31.7)
No response/unknown	1	(.4)	8	(.6)	1	(.3)	0	(.0)	0	(.0)
Experience of NPS use (lifetime)										
Never used	243	(98.0)	1,381	(98.2)	390	(99.0)	269	(99.3)	426	(97.7)
Have used	1	(.4)	7	(.5)	1	(.3)	0	(.0)	1	(.2)
No response/unknown	4	(1.6)	18	(1.3)	3	(.8)	2	(.7)	9	(2.1)
Experience of NPS use (within the past year)										
Never used	244	(98.4)	1,388	(98.7)	391	(99.2)	269	(99.3)	427	(97.9)
Have used	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
No response/unknown	4	(1.6)	18	(1.3)	3	(.8)	2	(.7)	9	(2.1)
Type of NPSs used										
Never used	226	(91.1)	1,320	(93.9)	371	(94.2)	258	(95.2)	408	(93.6)
Herbal	0	(.0)	5	(.4)	1	(.3)	0	(.0)	1	(.2)
Liquid	0	(.0)	4	(.3)	0	(.0)	0	(.0)	0	(.0)
Powder	1	(.4)	5	(.4)	0	(.0)	0	(.0)	0	(.0)
Other	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Form unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
No response/unknown	21	(8.5)	79	(5.6)	22	(5.6)	13	(4.8)	27	(6.2)
Hospital visit associated with NPS use										
None	237	(95.6)	1,368	(97.3)	382	(97.0)	265	(97.8)	425	(97.5)
Have used an NPS but no hospital visit associated with NPS use	1	(.4)	7	(.5)	1	(.3)	0	(.0)	1	(.2)
Used an NPS and was taken to hospital by ambulance	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Used an NPS and presented to a psychiatric department	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Used an NPS and presented to a department of internal medicine	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Used an NPS and presented to a trauma department	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Used an NPS and presented to any other department	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Have used an NPS but history of hospital visit is unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
No response/unknown	10	(4.0)	31	(2.2)	11	(2.8)	6	(2.2)	10	(2.3)

For the type of NPSs used, all the responses of "form unknown" fell under the category of "No response/unknown," and no test was therefore performed.

There were no respondents with a history of hospital visit associated with NPS use, and no test was therefore performed.

Table 45. NPS Use and Other Related Items by Occupation (n=3076) continued

	Occupation								p-value
	Unemployed		Other		Unknown		Total		
	n=179		n=138		n=4		n=3076		
	n	(%)	n	(%)	n	(%)	n	(%)	
Harmful effects of NPSs									0.007
Know	137	(76.5)	109	(79.0)	4	(100.0)	2,639	(85.8)	
Do not know	42	(23.5)	27	(19.6)	0	(.0)	424	(13.8)	
No response/unknown	0	(.0)	2	(1.4)	0	(.0)	13	(.4)	
Japan's regulation for designated substances									0.003
Know	97	(54.2)	73	(52.9)	4	(100.0)	1,749	(56.9)	
Do not know	82	(45.8)	64	(46.4)	0	(.0)	1,316	(42.8)	
No response/unknown	0	(.0)	1	(.7)	0	(.0)	11	(.4)	
The perceived number of NPS users									0.002
Increasing	100	(55.9)	79	(57.2)	3	(75.0)	1,761	(57.2)	
Not changing	10	(5.6)	8	(5.8)	0	(.0)	179	(5.8)	
Decreasing	2	(1.1)	1	(.7)	0	(.0)	33	(1.1)	
Do not know	66	(36.9)	50	(36.2)	1	(25.0)	1,092	(35.5)	
No response/unknown	1	(.6)	0	(.0)	0	(.0)	11	(.4)	
Experience of NPS use (lifetime)									0.809
Never used	176	(98.3)	133	(96.4)	4	(100.0)	3,022	(98.2)	
Have used	0	(.0)	1	(.7)	0	(.0)	11	(.4)	
No response/unknown	3	(1.7)	4	(2.9)	0	(.0)	43	(1.4)	
Experience of NPS use (within the past year)									0.533
Never used	176	(98.3)	134	(97.1)	4	(100.0)	3,033	(98.6)	
Have used	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
No response/unknown	3	(1.7)	4	(2.9)	0	(.0)	43	(1.4)	
Type of NPSs used									
Never used	165	(92.2)	130	(94.2)	3	(75.0)	2,881	(93.7)	0.688
Herbal	0	(.0)	1	(.7)	0	(.0)	8	(.3)	0.674
Liquid	0	(.0)	0	(.0)	0	(.0)	4	(.1)	0.570
Powder	0	(.0)	0	(.0)	0	(.0)	6	(.2)	0.531
Other	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.357
Form unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	-
No response/unknown	14	(7.8)	7	(5.1)	1	(25.0)	184	(6.0)	0.357
Hospital visit associated with NPS use									
None	175	(97.8)	134	(97.1)	3	(75.0)	2,989	(97.2)	-
Have used an NPS but no hospital visit associated with NPS use	0	(.0)	1	(.7)	0	(.0)	11	(.4)	-
Used an NPS and was taken to hospital by ambulance	0	(.0)	0	(.0)	0	(.0)	0	(.0)	-
Used an NPS and presented to a psychiatric department	0	(.0)	0	(.0)	0	(.0)	0	(.0)	-
Used an NPS and presented to a department of internal medicine	0	(.0)	0	(.0)	0	(.0)	0	(.0)	-
Used an NPS and presented to a trauma department	0	(.0)	0	(.0)	0	(.0)	0	(.0)	-
Used an NPS and presented to any other department	0	(.0)	0	(.0)	0	(.0)	0	(.0)	-
Have used an NPS but history of hospital visit is unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	-
No response/unknown	4	(2.2)	3	(2.2)	1	(25.0)	76	(2.5)	-

For the type of NPSs used, all the responses of "form unknown" fell under the category of "No response/unknown," and no test was therefore performed.

There were no respondents with a history of hospital visit associated with NPS use, and no test was therefore performed.

Table 46. NPS Use and Other Related Items by Drug use experience (n=3076)

	Drug use experience								p-value
	Lifetime		No lifetime		Unknown		Total		
	n=78	n=2940	n=58	n=3076	n	(%)	n	(%)	
Harmful effects of NPSs									0.005
Know	67	(85.9)	2,527	(86.0)	45	(77.6)	2,639	(85.8)	
Do not know	11	(14.1)	402	(13.7)	11	(19.0)	424	(13.8)	
No response/unknow	0	(.0)	11	(.4)	2	(3.4)	13	(.4)	
Japan's regulation for designated substances									0.246
Know	48	(61.5)	1,673	(56.9)	28	(48.3)	1,749	(56.9)	
Do not know	30	(38.5)	1,257	(42.8)	29	(50.0)	1,316	(42.8)	
No response/unknow	0	(.0)	10	(.3)	1	(1.7)	11	(.4)	
The perceived number of NPS users									0.009
Increasing	41	(52.6)	1,693	(57.6)	27	(46.6)	1,761	(57.2)	
Not changing	12	(15.4)	164	(5.6)	3	(5.2)	179	(5.8)	
Decreasing	1	(1.3)	32	(1.1)	0	(.0)	33	(1.1)	
Do not know	23	(29.5)	1,041	(35.4)	28	(48.3)	1,092	(35.5)	
No response/unknow	1	(1.3)	10	(.3)	0	(.0)	11	(.4)	
Experience of NPS use (lifetime)									<0.001
Never used	67	(85.9)	2,940	(100.0)	15	(25.9)	3,022	(98.2)	
Have used	11	(14.1)	0	(.0)	0	(.0)	11	(.4)	
No response/unknow	0	(.0)	0	(.0)	43	(74.1)	43	(1.4)	
Experience of NPS use (within the past year)									<0.001
Never used	78	(100.0)	2,940	(100.0)	15	(25.9)	3,033	(98.6)	
Have used	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
No response/unknow	0	(.0)	0	(.0)	43	(74.1)	43	(1.4)	
Type of NPSs used									
Never used	62	(79.5)	2,780	(94.6)	39	(67.2)	2,881	(93.7)	<0.001
Herbal	8	(10.3)	0	(.0)	0	(.0)	8	(.3)	<0.001
Liquid	4	(5.1)	0	(.0)	0	(.0)	4	(.1)	<0.001
Powder	6	(7.7)	0	(.0)	0	(.0)	6	(.2)	<0.001
Other	0	(.0)	0	(.0)	0	(.0)	0	(.0)	<0.001
Form unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	-
No response/unknow	5	(6.4)	160	(5.4)	19	(32.8)	184	(6.0)	<0.001
Hospital visit associated with NPS use									
None	63	(80.8)	2,881	(98.0)	45	(77.6)	2,989	(97.2)	-
Have used an NPS but no hospital visit associated with NPS use	11	(14.1)	0	(.0)	0	(.0)	11	(.4)	-
Used an NPS and was taken to hospital by ambulance	0	(.0)	0	(.0)	0	(.0)	0	(.0)	-
Used an NPS and presented to a psychiatric department	0	(.0)	0	(.0)	0	(.0)	0	(.0)	-
Used an NPS and presented to a department of internal medicine	0	(.0)	0	(.0)	0	(.0)	0	(.0)	-
Used an NPS and presented to a trauma department	0	(.0)	0	(.0)	0	(.0)	0	(.0)	-
Used an NPS and presented to any other department	0	(.0)	0	(.0)	0	(.0)	0	(.0)	-
Have used an NPS but history of hospital visit is unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	-
No response/unknown	4	(5.1)	59	(2.0)	13	(22.4)	76	(2.5)	-

For the type of NPSs used, all the responses of "form unknown" fell under the category of "No response/unknown," and no test was therefore performed.

There were no respondents with a history of hospital visit associated with NPS use, and no test was therefore performed.

Table 47. Presence of Close Drug Users and Experience of Ever Having Try to Tempt Illegal Drugs by Residence area

	Residence area											
	Hokkaido		Tohoku		Kanto		Hokuriku		Tousan		Tokai	
	n=131		n=250		n=948		n=154		n=150		n=328	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Close drug users (any drug)												
Absent	116	(88.5)	234	(93.6)	875	(92.3)	138	(89.6)	138	(92.0)	300	(91.5)
Present	11	(8.4)	12	(4.8)	56	(5.9)	9	(5.8)	7	(4.7)	25	(7.6)
Close drug users (organic solvents)												
Absent	124	(94.7)	236	(94.4)	890	(93.9)	142	(92.2)	141	(94.0)	306	(93.3)
Present	4	(3.1)	11	(4.4)	44	(4.6)	8	(5.2)	4	(2.7)	21	(6.4)
Close drug users (cannabis)												
Absent	119	(90.8)	240	(96.0)	909	(95.9)	145	(94.2)	139	(92.7)	313	(95.4)
Present	8	(6.1)	7	(2.8)	22	(2.3)	4	(2.6)	5	(3.3)	11	(3.4)
Close drug users (methamphetamine)												
Absent	122	(93.1)	240	(96.0)	915	(96.5)	146	(94.8)	138	(92.0)	314	(95.7)
Present	5	(3.8)	6	(2.4)	19	(2.0)	3	(1.9)	5	(3.3)	11	(3.4)
Close drug users (MDMA)												
Absent	123	(93.9)	245	(98.0)	930	(98.1)	148	(96.1)	140	(93.3)	316	(96.3)
Present	4	(3.1)	3	(1.2)	8	(.8)	2	(1.3)	4	(2.7)	8	(2.4)
Close drug users (cocaine)												
Absent	126	(96.2)	241	(96.4)	923	(97.4)	148	(96.1)	139	(92.7)	318	(97.0)
Present	1	(.8)	4	(1.6)	8	(.8)	1	(.6)	4	(2.7)	6	(1.8)
Close drug users (heroin)												
Absent	126	(96.2)	242	(96.8)	921	(97.2)	147	(95.5)	139	(92.7)	319	(97.3)
Present	1	(.8)	3	(1.2)	9	(.9)	1	(.6)	4	(2.7)	5	(1.5)
Close drug users (NPSs)												
Absent	126	(96.2)	240	(96.0)	925	(97.6)	147	(95.5)	140	(93.3)	319	(97.3)
Present	3	(2.3)	5	(2.0)	13	(1.4)	1	(.6)	4	(2.7)	6	(1.8)
Experience of ever having try to tempt illegal drugs (any drug)												
No	118	(90.1)	236	(94.4)	884	(93.2)	148	(96.1)	141	(94.0)	300	(91.5)
Yes	10	(7.6)	10	(4.0)	52	(5.5)	4	(2.6)	4	(2.7)	18	(5.5)
Experience of ever having try to tempt illegal drugs(organic solvents)												
No	126	(96.2)	242	(96.8)	915	(96.5)	148	(96.1)	145	(96.7)	309	(94.2)
Yes	4	(3.1)	6	(2.4)	29	(3.1)	4	(2.6)	2	(1.3)	14	(4.3)
Experience of ever having try to tempt illegal drugs (cannabis)												
No	125	(95.4)	242	(96.8)	910	(96.0)	152	(98.7)	143		316	(96.3)
Yes	5	(3.8)	6	(2.4)	29	(3.1)	0	(.0)	3	(2.0)	6	(1.8)
Experience of ever having try to tempt illegal drugs (methamphetamine)												
No	128	(97.7)	247	(98.8)	927	(97.8)	152	(98.7)	145	(96.7)	317	(96.6)
Yes	2	(1.5)	1	(.4)	13	(1.4)	0	(.0)	2	(1.3)	5	(1.5)
Experience of ever having try to tempt illegal drugs (MDMA)												
No	126	(96.2)	246	(98.4)	932	(98.3)	152	(98.7)	145	(96.7)	319	(97.3)
Yes	3	(2.3)	2	(.8)	7	(.7)	0	(.0)	0	(.0)	2	(.6)
Experience of ever having try to tempt illegal drugs (cocaine)												
No	128	(97.7)	248	(99.2)	933	(98.4)	152	(98.7)	145	(96.7)	321	(97.9)
Yes	1	(.8)	0	(.0)	5	(.5)	0	(.0)	0	(.0)	0	(.0)
Experience of ever having try to tempt illegal drugs (heroin)												
No	128	(97.7)	248	(99.2)	934	(98.5)	152	(98.7)	145	(96.7)	322	(98.2)
Yes	0	(.0)	0	(.0)	4	(.4)	0	(.0)	0	(.0)	0	(.0)
Experience of ever having try to tempt illegal drugs (NPSs)												
No	125	(95.4)	245	(98.0)	931	(98.2)	152	(98.7)	145	(96.7)	320	(97.6)
Yes	4	(3.1)	1	(.4)	7	(.7)	0	(.0)	0	(.0)	0	(.0)

Table 47. Presence of Close Drug Users and Experience of Ever Having Try to Tempt Illegal Drugs by Residence area (n=3076) continued

	Residence area										p-value		
	Kinki		Chugoku		Shikoku		Kita-Kyusyu		Minami-			Total	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)		n	(%)
Close drug users (any drug)												0.189	
Absent	409	(92.5)	174	(91.1)	77	(87.5)	218	(95.2)	154	(93.3)	2,833	(92.1)	
Present	24	(5.4)	15	(7.9)	10	(11.4)	9	(3.9)	7	(4.2)	185	(6.0)	
Close drug users (organic solvents)												0.184	
Absent	425	(96.2)	177	(92.7)	79	(89.8)	219	(95.6)	157	(95.2)	2,896	(94.1)	
Present	13	(2.9)	12	(6.3)	8	(9.1)	7	(3.1)	5	(3.0)	137	(4.5)	
Close drug users (cannabis)												0.561	
Absent	423	(95.7)	181	(94.8)	85	(96.6)	223	(97.4)	157	(95.2)	2,934	(95.4)	
Present	13	(2.9)	6	(3.1)	2	(2.3)	4	(1.7)	4	(2.4)	86	(2.8)	
Close drug users (methamphetamine)												0.312	
Absent	425	(96.2)	180	(94.2)	82	(93.2)	222	(96.9)	158	(95.8)	2,942	(95.6)	
Present	10	(2.3)	7	(3.7)	5	(5.7)	5	(2.2)	3	(1.8)	79	(2.6)	
Close drug users (MDMA)												0.193	
Absent	432	(97.7)	184	(96.3)	85	(96.6)	224	(97.8)	161	(97.6)	2,988	(97.1)	
Present	3	(.7)	4	(2.1)	2	(2.3)	2	(.9)	2	(1.2)	42	(1.4)	
Close drug users (cocaine)												0.358	
Absent	432	(97.7)	182	(95.3)	86	(97.7)	225	(98.3)	159	(96.4)	2,979	(96.8)	
Present	3	(.7)	5	(2.6)	1	(1.1)	1	(.4)	2	(1.2)	36	(1.2)	
Close drug users (heroin)												0.411	
Absent	432	(97.7)	182	(95.3)	86	(97.7)	224	(97.8)	160	(97.0)	2,978	(96.8)	
Present	3	(.7)	5	(2.6)	1	(1.1)	2	(.9)	1	(.6)	35	(1.1)	
Close drug users (NPSs)												0.098	
Absent	433	(98.0)	180	(94.2)	87	(98.9)	225	(98.3)	161	(97.6)	2,983	(97.0)	
Present	5	(1.1)	6	(3.1)	1	(1.1)	2	(.9)	1	(.6)	47	(1.5)	
Experience of ever having try to tempt illegal drugs (any drug)												0.154	
No	416	(94.1)	182	(95.3)	84	(95.5)	221	(96.5)	155	(93.9)	2,885	(93.8)	
Yes	14	(3.2)	5	(2.6)	4	(4.5)	4	(1.7)	6	(3.6)	131	(4.3)	
Experience of ever having try to tempt illegal drugs (organic solvents)												0.310	
No	425	(96.2)	188	(98.4)	84	(95.5)	222	(96.9)	160	(97.0)	2,964	(96.4)	
Yes	8	(1.8)	2	(1.0)	4	(4.5)	4	(1.7)	4	(2.4)	81	(2.6)	
Experience of ever having try to tempt illegal drugs (cannabis)												0.379	
No	425	(96.2)	187	(97.9)	87	(98.9)	224	(97.8)	161		2,972	(96.6)	
Yes	8	(1.8)	2	(1.0)	1	(1.1)	2	(.9)	2	(1.2)	64	(2.1)	
Experience of ever having try to tempt illegal drugs (methamphetamine)												0.777	
No	431	(97.5)	187	(97.9)	87	(98.9)	225	(98.3)	162	(98.2)	3,008	(97.8)	
Yes	2	(.5)	2	(1.0)	1	(1.1)	1	(.4)	2	(1.2)	31	(1.0)	
Experience of ever having try to tempt illegal drugs (MDMA)												0.321	
No	431	(97.5)	189	(99.0)	87	(98.9)	224	(97.8)	161	(97.6)	3,012	(97.9)	
Yes	1	(.2)	0	(.0)	1	(1.1)	2	(.9)	2	(1.2)	20	(.7)	
Experience of ever having try to tempt illegal drugs (cocaine)												0.447	
No	431	(97.5)	188	(98.4)	88	(100.0)	225	(98.3)	161	(97.6)	3,020	(98.2)	
Yes	0	(.0)	1	(.5)	0	(.0)	1	(.4)	0	(.0)	8	(.3)	
Experience of ever having try to tempt illegal drugs (heroin)												0.625	
No	432	(97.7)	188	(98.4)	88	(100.0)	225	(98.3)	162	(98.2)	3,024	(98.3)	
Yes	0	(.0)	1	(.5)	0	(.0)	1	(.4)	0	(.0)	6	(.2)	
Experience of ever having try to tempt illegal drugs (NPSs)												0.067	
No	432	(97.7)	186	(97.4)	88	(100.0)	224	(97.8)	162	(98.2)	3,010	(97.9)	
Yes	1	(.2)	1	(.5)	0	(.0)	1	(.4)	1	(.6)	16	(.5)	

Table 48. Presence of Close Drug Users and Experience of Ever Having Try to Tempt Illegal Drugs by Sex (n = 3076)

	Sex						P-value
	Men		Women		Total		
	n = 1466		n = 1610		n = 3076		
	n	(%)	n	(%)	n	(%)	
Close drug users (any drug)							0.003
Absent	1,331	(90.8)	1,502	(93.3)	2,833	(92.1)	
Present	110	(7.5)	75	(4.7)	185	(6.0)	
Close drug users (organic solvents)							0.005
Absent	1,366	(93.2)	1,530	(95.0)	2,896	(94.1)	
Present	83	(5.7)	54	(3.4)	137	(4.5)	
Close drug users (cannabis)							0.004
Absent	1,386	(94.5)	1,548	(96.1)	2,934	(95.4)	
Present	56	(3.8)	30	(1.9)	86	(2.8)	
Close drug users (methamphetamine)							0.297
Absent	1,398	(95.4)	1,544	(95.9)	2,942	(95.6)	
Present	44	(3.0)	35	(2.2)	79	(2.6)	
Close drug users (MDMA)							0.089
Absent	1,416	(96.6)	1,572	(97.6)	2,988	(97.1)	
Present	27	(1.8)	15	(.9)	42	(1.4)	
Close drug users (cocaine)							0.069
Absent	1,414	(96.5)	1,565	(97.2)	2,979	(96.8)	
Present	24	(1.6)	12	(.7)	36	(1.2)	
Close drug users (heroin)							0.194
Absent	1,414	(96.5)	1,564	(97.1)	2,978	(96.8)	
Present	22	(1.5)	13	(.8)	35	(1.1)	
Close drug users (NPSs)							0.033
Absent	1,411	(96.2)	1,572	(97.6)	2,983	(97.0)	
Present	31	(2.1)	16	(1.0)	47	(1.5)	
Experience of ever having try to tempt illegal drugs (any drug)							0.006
No	1,356	(92.5)	1,529	(95.0)	2,885	(93.8)	
Yes	80	(5.5)	51	(3.2)	131	(4.3)	
Experience of ever having try to tempt illegal drugs (organic solvents)							0.005
No	1,397	(95.3)	1,567	(97.3)	2,964	(96.4)	
Yes	53	(3.6)	28	(1.7)	81	(2.6)	
Experience of ever having try to tempt illegal drugs (cannabis)							0.005
No	1,402	(95.6)	1,570	(97.5)	2,972	(96.6)	
Yes	43	(2.9)	21	(1.3)	64	(2.1)	
Experience of ever having try to tempt illegal drugs (methamphetamine)							0.107
No	1,425	(97.2)	1,583	(98.3)	3,008	(97.8)	
Yes	19	(1.3)	12	(.7)	31	(1.0)	
Experience of ever having try to tempt illegal drugs (MDMA)							0.252
No	1,429	(97.5)	1,583	(98.3)	3,012	(97.9)	
Yes	12	(.8)	8	(.5)	20	(.7)	
Experience of ever having try to tempt illegal drugs (cocaine)							0.144
No	1,433	(97.7)	1,587	(98.6)	3,020	(98.2)	
Yes	6	(.4)	2	(.1)	8	(.3)	
Experience of ever having try to tempt illegal drugs (heroin)							0.068
No	1,434	(97.8)	1,590	(98.8)	3,024	(98.3)	
Yes	5	(.3)	1	(.1)	6	(.2)	
Experience of ever having try to tempt illegal drugs (NPSs)							0.634
No	1,432	(97.7)	1,578	(98.0)	3,010	(97.9)	
Yes	7	(.5)	9	(.6)	16	(.5)	

Table 49. Presence of Close Drug Users and Experience of Ever Having Try to Tempt Illegal Drugs by Age group(n=3076)

	Age group												p-value		
	10s		20s		30s		40s		50s		60s			Total	
	n=222		n=382		n=553		n=751		n=695		n=473			n=3076	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	
Close drug users (any drug)															<0.001
Absent	212	(95.5)	350	(91.6)	497	(89.9)	695	(92.5)	649	(93.4)	430	(90.9)	2,833	(92.1)	
Present	7	(3.2)	25	(6.5)	50	(9.0)	49	(6.5)	29	(4.2)	25	(5.3)	185	(6.0)	
Close drug users (organic solvents)															0.017
Absent	213	(95.9)	362	(94.8)	518	(93.7)	709	(94.4)	654	(94.1)	440	(93.0)	2,896	(94.1)	
Present	6	(2.7)	15	(3.9)	32	(5.8)	38	(5.1)	26	(3.7)	20	(4.2)	137	(4.5)	
Close drug users (cannabis)															<0.001
Absent	213	(95.9)	362	(94.8)	522	(94.4)	727	(96.8)	665	(95.7)	445	(94.1)	2,934	(95.4)	
Present	6	(2.7)	15	(3.9)	25	(4.5)	18	(2.4)	13	(1.9)	9	(1.9)	86	(2.8)	
Close drug users (methamphetamine)															0.004
Absent	214	(96.4)	369	(96.6)	533	(96.4)	718	(95.6)	661	(95.1)	447	(94.5)	2,942	(95.6)	
Present	5	(2.3)	8	(2.1)	15	(2.7)	27	(3.6)	16	(2.3)	8	(1.7)	79	(2.6)	
Close drug users (MDMA)															0.152
Absent	214	(96.4)	372	(97.4)	536	(96.9)	738	(98.3)	671	(96.5)	457	(96.6)	2,988	(97.1)	
Present	5	(2.3)	5	(1.3)	12	(2.2)	6	(.8)	10	(1.4)	4	(.8)	42	(1.4)	
Close drug users (cocaine)															0.014
Absent	214	(96.4)	372	(97.4)	539	(97.5)	738	(98.3)	667	(96.0)	449	(94.9)	2,979	(96.8)	
Present	5	(2.3)	5	(1.3)	7	(1.3)	5	(.7)	9	(1.3)	5	(1.1)	36	(1.2)	
Close drug users (heroin)															0.018
Absent	215	(96.8)	372	(97.4)	539	(97.5)	737	(98.1)	667	(96.0)	448	(94.7)	2,978	(96.8)	
Present	4	(1.8)	5	(1.3)	7	(1.3)	5	(.7)	9	(1.3)	5	(1.1)	35	(1.1)	
Close drug users (NPSs)															0.077
Absent	215	(96.8)	370	(96.9)	533	(96.4)	736	(98.0)	674	(97.0)	455	(96.2)	2,983	(97.0)	
Present	4	(1.8)	9	(2.4)	13	(2.4)	7	(.9)	10	(1.4)	4	(.8)	47	(1.5)	
Experience of ever having try to tempt illegal drugs (any drug)															<0.001
No	218	(98.2)	353	(92.4)	500	(90.4)	706	(94.0)	657	(94.5)	451	(95.3)	2,885	(93.8)	
Yes	0	(.0)	23	(6.0)	44	(8.0)	35	(4.7)	21	(3.0)	8	(1.7)	131	(4.3)	
Experience of ever having try to tempt illegal drugs (organic solvents)															<0.001
No	219	(98.6)	366	(95.8)	518	(93.7)	723	(96.3)	675	(97.1)	463	(97.9)	2,964	(96.4)	
Yes	0	(.0)	10	(2.6)	28	(5.1)	26	(3.5)	13	(1.9)	4	(.8)	81	(2.6)	
Experience of ever having try to tempt illegal drugs (cannabis)															<0.001
No	219	(98.6)	366	(95.8)	518	(93.7)	728	(96.9)	678		463	(97.9)	2,972	(96.6)	
Yes	0	(.0)	12	(3.1)	27	(4.9)	17	(2.3)	7	(1.0)	1	(.2)	64	(2.1)	
Experience of ever having try to tempt illegal drugs (methamphetamine)															0.035
No	220	(99.1)	374	(97.9)	531	(96.0)	739	(98.4)	681	(98.0)	463	(97.9)	3,008	(97.8)	
Yes	0	(.0)	2	(.5)	14	(2.5)	6	(.8)	6	(.9)	3	(.6)	31	(1.0)	
Experience of ever having try to tempt illegal drugs (MDMA)															0.006
No	219	(98.6)	374	(97.9)	534	(96.6)	740	(98.5)	683	(98.3)	462	(97.7)	3,012	(97.9)	
Yes	0	(.0)	2	(.5)	11	(2.0)	5	(.7)	1	(.1)	1	(.2)	20	(.7)	
Experience of ever having try to tempt illegal drugs (cocaine)															0.740
No	219	(98.6)	374	(97.9)	544	(98.4)	740	(98.5)	681	(98.0)	462	(97.7)	3,020	(98.2)	
Yes	0	(.0)	1	(.3)	1	(.2)	4	(.5)	1	(.1)	1	(.2)	8	(.3)	
Experience of ever having try to tempt illegal drugs (heroin)															0.514
No	219	(98.6)	376	(98.4)	544	(98.4)	739	(98.4)	684	(98.4)	462	(97.7)	3,024	(98.3)	
Yes	0	(.0)	0	(.0)	1	(.2)	4	(.5)	0	(.0)	1	(.2)	6	(.2)	
Experience of ever having try to tempt illegal drugs (NPSs)															0.051
No	218	(98.2)	373	(97.6)	538	(97.3)	740	(98.5)	679	(97.7)	462	(97.7)	3,010	(97.9)	
Yes	0	(.0)	3	(.8)	8	(1.4)	3	(.4)	2	(.3)	0	(.0)	16	(.5)	

"10s" refers to those aged 15 to 19, and "60s" refers to those aged 60 to 64.

Table 50. Presence of Close Drug Users and Experience of Ever Having Try to Tempt Illegal Drugs by Occupation (n=3076)

	Occupation									
	Self-employed		Full-time		Non-full-time		Student		Housewife	
	n=248		n=1406		n=394		n=271		n=436	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Close drug users (any drug)										
Absent	219	(88.3)	1,296	(92.2)	357	(90.6)	259	(95.6)	409	(93.8)
Present	27	(10.9)	89	(6.3)	26	(6.6)	10	(3.7)	17	(3.9)
Close drug users (organic solvents)										
Absent	224	(90.3)	1,324	(94.2)	367	(93.1)	261	(96.3)	417	(95.6)
Present	22	(8.9)	70	(5.0)	17	(4.3)	8	(3.0)	11	(2.5)
Close drug users (cannabis)										
Absent	228	(91.9)	1,351	(96.1)	371	(94.2)	260	(95.9)	423	(97.0)
Present	18	(7.3)	35	(2.5)	12	(3.0)	9	(3.3)	4	(.9)
Close drug users (methamphetamine)										
Absent	235	(94.8)	1,354	(96.3)	370	(93.9)	262	(96.7)	421	(96.6)
Present	10	(4.0)	33	(2.3)	12	(3.0)	7	(2.6)	7	(1.6)
Close drug users (MDMA)										
Absent	238	(96.0)	1,370	(97.4)	381	(96.7)	262	(96.7)	428	(98.2)
Present	7	(2.8)	18	(1.3)	5	(1.3)	7	(2.6)	3	(.7)
Close drug users (cocaine)										
Absent	239	(96.4)	1,370	(97.4)	377	(95.7)	262	(96.7)	425	(97.5)
Present	6	(2.4)	14	(1.0)	5	(1.3)	7	(2.6)	1	(.2)
Close drug users (heroin)										
Absent	240	(96.8)	1,369	(97.4)	375	(95.2)	263	(97.0)	425	(97.5)
Present	5	(2.0)	13	(.9)	7	(1.8)	6	(2.2)	1	(.2)
Close drug users (NPSs)										
Absent	241	(97.2)	1,362	(96.9)	381	(96.7)	263	(97.0)	425	(97.5)
Present	6	(2.4)	24	(1.7)	6	(1.5)	6	(2.2)	3	(.7)
Experience of ever having try to tempt illegal drugs (any drug)										
No	233	(94.0)	1,312	(93.3)	365	(92.6)	266	(98.2)	413	(94.7)
Yes	13	(5.2)	66	(4.7)	21	(5.3)	1	(.4)	14	(3.2)
Experience of ever having try to tempt illegal drugs (organic solvents)										
No	236	(95.2)	1,344	(95.6)	383	(97.2)	268	(98.9)	426	(97.7)
Yes	10	(4.0)	48	(3.4)	8	(2.0)	0	(.0)	5	(1.1)
Experience of ever having try to tempt illegal drugs (cannabis)										
No	238	(96.0)	1,356	(96.4)	376	(95.4)	267	(98.5)	427	
Yes	8	(3.2)	30	(2.1)	14	(3.6)	1	(.4)	4	(.9)
Experience of ever having try to tempt illegal drugs (methamphetamine)										
No	244	(98.4)	1,370	(97.4)	386	(98.0)	269	(99.3)	427	(97.9)
Yes	2	(.8)	18	(1.3)	4	(1.0)	0	(.0)	5	(1.1)
Experience of ever having try to tempt illegal drugs (MDMA)										
No	244	(98.4)	1,374	(97.7)	388	(98.5)	268	(98.9)	428	(98.2)
Yes	2	(.8)	12	(.9)	2	(.5)	0	(.0)	2	(.5)
Experience of ever having try to tempt illegal drugs (cocaine)										
No	244	(98.4)	1,381	(98.2)	386	(98.0)	268	(98.9)	430	(98.6)
Yes	2	(.8)	2	(.1)	3	(.8)	0	(.0)	0	(.0)
Experience of ever having try to tempt illegal drugs (heroin)										
No	244	(98.4)	1,382	(98.3)	388	(98.5)	268	(98.9)	430	(98.6)
Yes	2	(.8)	1	(.1)	2	(.5)	0	(.0)	0	(.0)
Experience of ever having try to tempt illegal drugs (NPSs)										
No	245	(98.8)	1,375	(97.8)	384	(97.5)	267	(98.5)	427	(97.9)
Yes	1	(.4)	8	(.6)	4	(1.0)	0	(.0)	2	(.5)

Table 50. Presence of Close Drug Users and Experience of Ever Having Try to Tempt Illegal Drugs by Occupation (n=3076) continued

	Occupation								p-value
	Unemployed		Other		Unknown		Total		
	n	(%)	n	(%)	n	(%)	n	(%)	
Close drug users (any drug)									0.002
Absent	163	(91.1)	127	(92.0)	3	(75.0)	2,833	(92.1)	
Present	10	(5.6)	5	(3.6)	1	(25.0)	185	(6.0)	
Close drug users (organic solvents)									<0.001
Absent	169	(94.4)	131	(94.9)	3	(75.0)	2,896	(94.1)	
Present	6	(3.4)	2	(1.4)	1	(25.0)	137	(4.5)	
Close drug users (cannabis)									<0.001
Absent	169	(94.4)	128	(92.8)	4	(100.0)	2,934	(95.4)	
Present	4	(2.2)	4	(2.9)	0	(.0)	86	(2.8)	
Close drug users (methamphetamine)									0.025
Absent	169	(94.4)	128	(92.8)	3	(75.0)	2,942	(95.6)	
Present	5	(2.8)	4	(2.9)	1	(25.0)	79	(2.6)	
Close drug users (MDMA)									0.107
Absent	174	(97.2)	131	(94.9)	4	(100.0)	2,988	(97.1)	
Present	1	(.6)	1	(.7)	0	(.0)	42	(1.4)	
Close drug users (cocaine)									0.022
Absent	173	(96.6)	129	(93.5)	4	(100.0)	2,979	(96.8)	
Present	1	(.6)	2	(1.4)	0	(.0)	36	(1.2)	
Close drug users (heroin)									0.056
Absent	173	(96.6)	129	(93.5)	4	(100.0)	2,978	(96.8)	
Present	1	(.6)	2	(1.4)	0	(.0)	35	(1.1)	
Close drug users (NPSs)									0.578
Absent	174	(97.2)	133	(96.4)	4	(100.0)	2,983	(97.0)	
Present	1	(.6)	1	(.7)	0	(.0)	47	(1.5)	
Experience of ever having try to tempt illegal drugs (any drug)									0.215
No	165	(92.2)	127	(92.0)	4	(100.0)	2,885	(93.8)	
Yes	9	(5.0)	7	(5.1)	0	(.0)	131	(4.3)	
Experience of ever having try to tempt illegal drugs (organic solvents)									0.200
No	171	(95.5)	132	(95.7)	4	(100.0)	2,964	(96.4)	
Yes	6	(3.4)	4	(2.9)	0	(.0)	81	(2.6)	
Experience of ever having try to tempt illegal drugs (cannabis)									0.391
No	172	(96.1)	132	(95.7)	4	(100.0)	2,972	(96.6)	
Yes	4	(2.2)	3	(2.2)	0	(.0)	64	(2.1)	
Experience of ever having try to tempt illegal drugs (methamphetamine)									0.726
No	174	(97.2)	134	(97.1)	4	(100.0)	3,008	(97.8)	
Yes	2	(1.1)	0	(.0)	0	(.0)	31	(1.0)	
Experience of ever having try to tempt illegal drugs (MDMA)									0.637
No	173	(96.6)	133	(96.4)	4	(100.0)	3,012	(97.9)	
Yes	2	(1.1)	0	(.0)	0	(.0)	20	(.7)	
Experience of ever having try to tempt illegal drugs (cocaine)									0.296
No	174	(97.2)	133	(96.4)	4	(100.0)	3,020	(98.2)	
Yes	1	(.6)	0	(.0)	0	(.0)	8	(.3)	
Experience of ever having try to tempt illegal drugs (heroin)									0.259
No	175	(97.8)	133	(96.4)	4	(100.0)	3,024	(98.3)	
Yes	1	(.6)	0	(.0)	0	(.0)	6	(.2)	
Experience of ever having try to tempt illegal drugs (NPSs)									0.914
No	175	(97.8)	133	(96.4)	4	(100.0)	3,010	(97.9)	
Yes	0	(.0)	1	(.7)	0	(.0)	16	(.5)	

Table 51. Presence of Close Drug Users and Experience of Ever Having Try to Tempt Illegal Drugs by Drug use experience (n=3076)

	Drug use experience								p-value
	Lifetime		No lifetime		Unknown		Total		
	n=78		n=2940		n=58		n=3076		
	n	(%)	n	(%)	n	(%)	n	(%)	
Close drug users (any drug)									<0.001
Absent	50	(64.1)	2,751	(93.6)	32	(55.2)	2,833	(92.1)	
Present	26	(33.3)	154	(5.2)	5	(8.6)	185	(6.0)	
Close drug users (organic solvents)									<0.001
Absent	59	(75.6)	2,799	(95.2)	38	(65.5)	2,896	(94.1)	
Present	16	(20.5)	116	(3.9)	5	(8.6)	137	(4.5)	
Close drug users (cannabis)									<0.001
Absent	59	(75.6)	2,840	(96.6)	35	(60.3)	2,934	(95.4)	
Present	17	(21.8)	69	(2.3)	0	(.0)	86	(2.8)	
Close drug users (methamphetamine)									<0.001
Absent	62	(79.5)	2,844	(96.7)	36	(62.1)	2,942	(95.6)	
Present	13	(16.7)	65	(2.2)	1	(1.7)	79	(2.6)	
Close drug users (MDMA)									<0.001
Absent	68	(87.2)	2,885	(98.1)	35	(60.3)	2,988	(97.1)	
Present	6	(7.7)	36	(1.2)	0	(.0)	42	(1.4)	
Close drug users (cocaine)									<0.001
Absent	69	(88.5)	2,875	(97.8)	35	(60.3)	2,979	(96.8)	
Present	5	(6.4)	31	(1.1)	0	(.0)	36	(1.2)	
Close drug users (heroin)									<0.001
Absent	69	(88.5)	2,874	(97.8)	35	(60.3)	2,978	(96.8)	
Present	5	(6.4)	30	(1.0)	0	(.0)	35	(1.1)	
Close drug users (NPSs)									<0.001
Absent	67	(85.9)	2,878	(97.9)	38	(65.5)	2,983	(97.0)	
Present	6	(7.7)	41	(1.4)	0	(.0)	47	(1.5)	
Experience of ever having try to tempt illegal drugs (any drug)									<0.001
No	27	(34.6)	2,831	(96.3)	27	(46.6)	2,885	(93.8)	
Yes	50	(64.1)	80	(2.7)	1	(1.7)	131	(4.3)	
Experience of ever having try to tempt illegal drugs (organic solvents)									<0.001
No	44	(56.4)	2,883	(98.1)	37	(63.8)	2,964	(96.4)	
Yes	33	(42.3)	47	(1.6)	1	(1.7)	81	(2.6)	
Experience of ever having try to tempt illegal drugs (cannabis)									<0.001
No	50	(64.1)	2,892	(98.4)	30	(51.7)	2,972	(96.6)	
Yes	28	(35.9)	36	(1.2)	0	(.0)	64	(2.1)	
Experience of ever having try to tempt illegal drugs (methamphetamine)									<0.001
No	59	(75.6)	2,919	(99.3)	30	(51.7)	3,008	(97.8)	
Yes	18	(23.1)	13	(.4)	0	(.0)	31	(1.0)	
Experience of ever having try to tempt illegal drugs (MDMA)									<0.001
No	67	(85.9)	2,917	(99.2)	28	(48.3)	3,012	(97.9)	
Yes	10	(12.8)	10	(.3)	0	(.0)	20	(.7)	
Experience of ever having try to tempt illegal drugs (cocaine)									<0.001
No	69	(88.5)	2,923	(99.4)	28	(48.3)	3,020	(98.2)	
Yes	8	(10.3)	0	(.0)	0	(.0)	8	(.3)	
Experience of ever having try to tempt illegal drugs (heroin)									<0.001
No	71	(91.0)	2,925	(99.5)	28	(48.3)	3,024	(98.3)	
Yes	6	(7.7)	0	(.0)	0	(.0)	6	(.2)	
Experience of ever having try to tempt illegal drugs (NPSs)									<0.001
No	69	(88.5)	2,911	(99.0)	30	(51.7)	3,010	(97.9)	
Yes	7	(9.0)	9	(.3)	0	(.0)	16	(.5)	

Table 52. Drug accessibility by Residence area (n=3076)

	Residence area											
	Hokkaido		Tohoku		Kanto		Hokuriku		Tousan		Tokai	
	n=131	n=250	n=948	n=154	n=150	n=328	n	(%)	n	(%)	n	(%)
Drug accessibility												
Any drug	60	(45.8)	124	(49.6)	540	(57.0)	77	(50.0)	70	(46.7)	172	(52.4)
Organic solvents	57	(43.5)	122	(48.8)	530	(55.9)	70	(45.5)	69	(46.0)	170	(51.8)
Cannabis	24	(18.3)	39	(15.6)	169	(17.8)	9	(5.8)	8	(5.3)	42	(12.8)
Methamphetamine	15	(11.5)	35	(14.0)	149	(15.7)	10	(6.5)	8	(5.3)	39	(11.9)
MDMA	16	(12.2)	35	(14.0)	147	(15.5)	10	(6.5)	10	(6.7)	42	(12.8)
Cocaine	13	(9.9)	28	(11.2)	134	(14.1)	8	(5.2)	7	(4.7)	34	(10.4)
Heroin	12	(9.2)	27	(10.8)	131	(13.8)	8	(5.2)	7	(4.7)	32	(9.8)
NPSs	27	(20.6)	47	(18.8)	237	(25.0)	24	(15.6)	12	(8.0)	72	(22.0)
Drug accessibility (organic solvents)												
Completely inaccessible	45	(34.4)	92	(36.8)	281	(29.6)	64	(41.6)	57	(38.0)	110	(33.5)
Almost inaccessible	22	(16.8)	24	(9.6)	113	(11.9)	13	(8.4)	19	(12.7)	31	(9.5)
Barely accessible	15	(11.5)	52	(20.8)	198	(20.9)	19	(12.3)	25	(16.7)	66	(20.1)
Easily accessible	42	(32.1)	70	(28.0)	332	(35.0)	51	(33.1)	44	(29.3)	104	(31.7)
Drug accessibility (cannabis)												
Completely inaccessible	84	(64.1)	166	(66.4)	559	(59.0)	108	(70.1)	108	(72.0)	204	(62.2)
Almost inaccessible	17	(13.0)	32	(12.8)	192	(20.3)	29	(18.8)	28	(18.7)	65	(19.8)
Barely accessible	19	(14.5)	31	(12.4)	136	(14.3)	6	(3.9)	6	(4.0)	32	(9.8)
Easily accessible	5	(3.8)	8	(3.2)	33	(3.5)	3	(1.9)	2	(1.3)	10	(3.0)
Drug accessibility (methamphetamine)												
Completely inaccessible	93	(71.0)	171	(68.4)	572	(60.3)	108	(70.1)	115	(76.7)	212	(64.6)
Almost inaccessible	17	(13.0)	32	(12.8)	200	(21.1)	27	(17.5)	21	(14.0)	59	(18.0)
Barely accessible	13	(9.9)	27	(10.8)	117	(12.3)	8	(5.2)	6	(4.0)	31	(9.5)
Easily accessible	2	(1.5)	8	(3.2)	32	(3.4)	2	(1.3)	2	(1.3)	8	(2.4)
Drug accessibility (MDMA)												
Completely inaccessible	93	(71.0)	173	(69.2)	577	(60.9)	105	(68.2)	112	(74.7)	204	(62.2)
Almost inaccessible	16	(12.2)	29	(11.6)	196	(20.7)	29	(18.8)	21	(14.0)	63	(19.2)
Barely accessible	15	(11.5)	29	(11.6)	119	(12.6)	7	(4.5)	10	(6.7)	33	(10.1)
Easily accessible	1	(.8)	6	(2.4)	28	(3.0)	3	(1.9)	0	(.0)	9	(2.7)
Drug accessibility (cocaine)												
Completely inaccessible	98	(74.8)	176	(70.4)	592	(62.4)	109	(70.8)	113	(75.3)	211	(64.3)
Almost inaccessible	14	(10.7)	33	(13.2)	197	(20.8)	28	(18.2)	24	(16.0)	65	(19.8)
Barely accessible	13	(9.9)	22	(8.8)	109	(11.5)	7	(4.5)	6	(4.0)	27	(8.2)
Easily accessible	0	(.0)	6	(2.4)	25	(2.6)	1	(.6)	1	(.7)	7	(2.1)
Drug accessibility (heroin)												
Completely inaccessible	98	(74.8)	178	(71.2)	595	(62.8)	109	(70.8)	117	(78.0)	212	(64.6)
Almost inaccessible	15	(11.5)	32	(12.8)	197	(20.8)	28	(18.2)	20		66	(20.1)
Barely accessible	12	(9.2)	20	(8.0)	110	(11.6)	7	(4.5)	6	(4.0)	27	(8.2)
Easily accessible	0	(.0)	7	(2.8)	21	(2.2)	1	(.6)	1	(.7)	5	(1.5)
Drug accessibility (NPSs)												
Completely inaccessible	75	(57.3)	164	(65.6)	493	(52.0)	95	(61.7)	98	(65.3)	172	(52.4)
Almost inaccessible	23	(17.6)	26	(10.4)	194	(20.5)	26	(16.9)	33	(22.0)	67	(20.4)
Barely accessible	18	(13.7)	33	(13.2)	165	(17.4)	19	(12.3)	11	(7.3)	50	(15.2)
Easily accessible	9	(6.9)	14	(5.6)	72	(7.6)	5	(3.2)	1	(.7)	22	(6.7)

Table 52. Drug accessibility by Residence area (n=3076) continued

	Residence area										p-value		
	Kinki		Chugoku		Shikoku		Kita-Kyusyu		Minami-			Total	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)		n	(%)
Drug accessibility													
Any drug	232	(52.5)	108	(56.5)	43	(48.9)	110	(48.0)	81	(49.1)	1,617	(52.6)	0.255
Organic solvents	228	(51.6)	107	(56.0)	43	(48.9)	109	(47.6)	79	(47.9)	1,584	(51.5)	0.119
Cannabis	56	(12.7)	24	(12.6)	11	(12.5)	33	(14.4)	18	(10.9)	433	(14.1)	0.003
Methamphetamine	50	(11.3)	27	(14.1)	10	(11.4)	31	(13.5)	17	(10.3)	391	(12.7)	0.049
MDMA	52	(11.8)	22	(11.5)	11	(12.5)	33	(14.4)	17	(10.3)	395	(12.8)	0.102
Cocaine	40	(9.0)	22	(11.5)	8	(9.1)	30	(13.1)	17	(10.3)	341	(11.1)	0.025
Heroin	36	(8.1)	20	(10.5)	8	(9.1)	28	(12.2)	15	(9.1)	324	(10.5)	0.020
NPSs	82	(18.6)	36	(18.8)	17	(19.3)	42	(18.3)	23	(13.9)	619	(20.1)	0.001
Drug accessibility (organic solvents)													0.019
Completely inaccessible	153	(34.6)	63	(33.0)	33	(37.5)	92	(40.2)	60	(36.4)	1,050	(34.1)	
Almost inaccessible	44	(10.0)	18	(9.4)	9	(10.2)	20	(8.7)	18	(10.9)	331	(10.8)	
Barely accessible	105	(23.8)	34	(17.8)	20	(22.7)	34	(14.8)	29	(17.6)	597	(19.4)	
Easily accessible	123	(27.8)	73	(38.2)	23	(26.1)	75	(32.8)	50	(30.3)	987	(32.1)	
Drug accessibility (cannabis)													0.022
Completely inaccessible	299	(67.6)	124	(64.9)	58	(65.9)	149	(65.1)	114	(69.1)	1,973	(64.1)	
Almost inaccessible	68	(15.4)	38	(19.9)	16	(18.2)	39	(17.0)	24	(14.5)	548	(17.8)	
Barely accessible	43	(9.7)	21	(11.0)	9	(10.2)	25	(10.9)	14	(8.5)	342	(11.1)	
Easily accessible	13	(2.9)	3	(1.6)	2	(2.3)	8	(3.5)	4	(2.4)	91	(3.0)	
Drug accessibility (methamphetamine)													0.045
Completely inaccessible	306	(69.2)	126	(66.0)	60	(68.2)	153	(66.8)	115	(69.7)	2,031	(66.0)	
Almost inaccessible	67	(15.2)	33	(17.3)	15	(17.0)	37	(16.2)	24	(14.5)	532	(17.3)	
Barely accessible	42	(9.5)	21	(11.0)	8	(9.1)	24	(10.5)	12	(7.3)	309	(10.0)	
Easily accessible	8	(1.8)	6	(3.1)	2	(2.3)	7	(3.1)	5	(3.0)	82	(2.7)	
Drug accessibility (MDMA)													0.052
Completely inaccessible	304	(68.8)	126	(66.0)	56	(63.6)	150	(65.5)	115	(69.7)	2,015	(65.5)	
Almost inaccessible	67	(15.2)	37	(19.4)	16	(18.2)	38	(16.6)	24	(14.5)	536	(17.4)	
Barely accessible	42	(9.5)	18	(9.4)	9	(10.2)	27	(11.8)	13	(7.9)	322	(10.5)	
Easily accessible	10	(2.3)	4	(2.1)	2	(2.3)	6	(2.6)	4	(2.4)	73	(2.4)	
Drug accessibility (cocaine)													0.024
Completely inaccessible	311	(70.4)	129	(67.5)	60	(68.2)	155	(67.7)	115	(69.7)	2,069	(67.3)	
Almost inaccessible	71	(16.1)	35	(18.3)	17	(19.3)	36	(15.7)	24	(14.5)	544	(17.7)	
Barely accessible	34	(7.7)	19	(9.9)	7	(8.0)	26	(11.4)	14	(8.5)	284	(9.2)	
Easily accessible	6	(1.4)	3	(1.6)	1	(1.1)	4	(1.7)	3	(1.8)	57	(1.9)	
Drug accessibility (heroin)													0.007
Completely inaccessible	314	(71.0)	129	(67.5)	60	(68.2)	156	(68.1)	116	(70.3)	2,084	(67.8)	
Almost inaccessible	70	(15.8)	36	(18.8)	17	(19.3)	37	(16.2)	25		543	(17.7)	
Barely accessible	32	(7.2)	18	(9.4)	8	(9.1)	24	(10.5)	12	(7.3)	276	(9.0)	
Easily accessible	4	(.9)	2	(1.0)	0	(.0)	4	(1.7)	3	(1.8)	48	(1.6)	
Drug accessibility (NPSs)													<0.001
Completely inaccessible	274	(62.0)	117	(61.3)	53	(60.2)	139	(60.7)	105	(63.6)	1,785	(58.0)	
Almost inaccessible	67	(15.2)	31	(16.2)	15	(17.0)	40	(17.5)	28	(17.0)	550	(17.9)	
Barely accessible	62	(14.0)	27	(14.1)	12	(13.6)	24	(10.5)	15	(9.1)	436	(14.2)	
Easily accessible	20	(4.5)	9	(4.7)	5	(5.7)	18	(7.9)	8	(4.8)	183	(5.9)	

Table 53. Drug accessibility by sex (n=3076)

	Sex						P-value
	Men		Women		Total		
	n = 1466		n = 1610		n = 3076		
	n	(%)	n	(%)	n	(%)	
Drug accessibility							
Any drug	920	(62.8)	697	(43.3)	1,617	(52.6)	<0.001
Organic solvents	906	(61.8)	678	(42.1)	1,584	(51.5)	<0.001
Cannabis	217	(14.8)	216	(13.4)	433	(14.1)	0.519
Methamphetamine	186	(12.7)	205	(12.7)	391	(12.7)	0.922
MDMA	192	(13.1)	203	(12.6)	395	(12.8)	0.813
Cocaine	162	(11.1)	179	(11.1)	341	(11.1)	0.975
Heroin	158	(10.8)	166	(10.3)	324	(10.5)	0.830
NPSs	326	(22.2)	293	(18.2)	619	(20.1)	0.020
Drug accessibility (organic solvents)							<0.001
Completely inaccessible	368	(25.1)	682	(42.4)	1,050	(34.1)	
Almost inaccessible	144	(9.8)	187	(11.6)	331	(10.8)	
Barely accessible	314	(21.4)	283	(17.6)	597	(19.4)	
Easily accessible	592	(40.4)	395	(24.5)	987	(32.1)	
Drug accessibility (cannabis)							<0.001
Completely inaccessible	853	(58.2)	1,120	(69.6)	1,973	(64.1)	
Almost inaccessible	340	(23.2)	208	(12.9)	548	(17.8)	
Barely accessible	173	(11.8)	169	(10.5)	342	(11.1)	
Easily accessible	44	(3.0)	47	(2.9)	91	(3.0)	
Drug accessibility (methamphetamine)							<0.001
Completely inaccessible	894	(61.0)	1,137	(70.6)	2,031	(66.0)	
Almost inaccessible	330	(22.5)	202	(12.5)	532	(17.3)	
Barely accessible	155	(10.6)	154	(9.6)	309	(10.0)	
Easily accessible	31	(2.1)	51	(3.2)	82	(2.7)	
Drug accessibility (MDMA)							<0.001
Completely inaccessible	885	(60.4)	1,130	(70.2)	2,015	(65.5)	
Almost inaccessible	330	(22.5)	206	(12.8)	536	(17.4)	
Barely accessible	163	(11.1)	159	(9.9)	322	(10.5)	
Easily accessible	29	(2.0)	44	(2.7)	73	(2.4)	
Drug accessibility (cocaine)							<0.001
Completely inaccessible	911	(62.1)	1,158	(71.9)	2,069	(67.3)	
Almost inaccessible	336	(22.9)	208	(12.9)	544	(17.7)	
Barely accessible	137	(9.3)	147	(9.1)	284	(9.2)	
Easily accessible	25	(1.7)	32	(2.0)	57	(1.9)	
Drug accessibility (heroin)							<0.001
Completely inaccessible	919	(62.7)	1,165	(72.4)	2,084	(67.8)	
Almost inaccessible	332	(22.6)	211	(13.1)	543	(17.7)	
Barely accessible	137	(9.3)	139	(8.6)	276	(9.0)	
Easily accessible	21	(1.4)	27	(1.7)	48	(1.6)	
Drug accessibility (NPSs)							<0.001
Completely inaccessible	756	(51.6)	1,029	(63.9)	1,785	(58.0)	
Almost inaccessible	327	(22.3)	223	(13.9)	550	(17.9)	
Barely accessible	245	(16.7)	191	(11.9)	436	(14.2)	
Easily accessible	81	(5.5)	102	(6.3)	183	(5.9)	

Table 54. Drug accessibility by Age group(n=3076)

	Age group										p-value				
	10s		20s		30s		40s		50s			60s		Total	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)		n	(%)	n	(%)
Drug accessibility															
Any drug	75	(33.8)	173	(45.3)	292	(52.8)	447	(59.5)	393	(56.5)	237	(50.1)	1,617	(52.6)	<0.001
Organic solvents	72	(32.4)	166	(43.5)	284	(51.4)	440	(58.6)	386	(55.5)	236	(49.9)	1,584	(51.5)	<0.001
Cannabis	41	(18.5)	78	(20.4)	105	(19.0)	102	(13.6)	74	(10.6)	33	(7.0)	433	(14.1)	<0.001
Methamphetamine	39	(17.6)	68	(17.8)	91	(16.5)	95	(12.6)	70	(10.1)	28	(5.9)	391	(12.7)	<0.001
MDMA	34	(15.3)	61	(16.0)	95	(17.2)	106	(14.1)	71	(10.2)	28	(5.9)	395	(12.8)	<0.001
Cocaine	36	(16.2)	62	(16.2)	76	(13.7)	82	(10.9)	62	(8.9)	23	(4.9)	341	(11.1)	<0.001
Heroin	35	(15.8)	58	(15.2)	73	(13.2)	79	(10.5)	56	(8.1)	23	(4.9)	324	(10.5)	<0.001
NPSs	45	(20.3)	88	(23.0)	133	(24.1)	168	(22.4)	132	(19.0)	53	(11.2)	619	(20.1)	<0.001
Drug accessibility (organic solvents)															
Completely inaccessible	117	(52.7)	169	(44.2)	192	(34.7)	215	(28.6)	205	(29.5)	152	(32.1)	1,050	(34.1)	<0.001
Almost inaccessible	25	(11.3)	36	(9.4)	56	(10.1)	79	(10.5)	75	(10.8)	60	(12.7)	331	(10.8)	<0.001
Barely accessible	38	(17.1)	50	(13.1)	109	(19.7)	147	(19.6)	157	(22.6)	96	(20.3)	597	(19.4)	<0.001
Easily accessible	34	(15.3)	116	(30.4)	175	(31.6)	293	(39.0)	229	(32.9)	140	(29.6)	987	(32.1)	<0.001
Drug accessibility (cannabis)															
Completely inaccessible	145	(65.3)	230	(60.2)	327	(59.1)	471	(62.7)	467	(67.2)	333	(70.4)	1,973	(64.1)	<0.001
Almost inaccessible	28	(12.6)	61	(16.0)	98	(17.7)	156	(20.8)	125	(18.0)	80	(16.9)	548	(17.8)	<0.001
Barely accessible	30	(13.5)	57	(14.9)	86	(15.6)	80	(10.7)	62	(8.9)	27	(5.7)	342	(11.1)	<0.001
Easily accessible	11	(5.0)	21	(5.5)	19	(3.4)	22	(2.9)	12	(1.7)	6	(1.3)	91	(3.0)	<0.001
Drug accessibility (methamphetamine)															
Completely inaccessible	147	(66.2)	238	(62.3)	339	(61.3)	491	(65.4)	480	(69.1)	336	(71.0)	2,031	(66.0)	<0.001
Almost inaccessible	28	(12.6)	61	(16.0)	99	(17.9)	143	(19.0)	120	(17.3)	81	(17.1)	532	(17.3)	<0.001
Barely accessible	29	(13.1)	47	(12.3)	78	(14.1)	74	(9.9)	58	(8.3)	23	(4.9)	309	(10.0)	<0.001
Easily accessible	10	(4.5)	21	(5.5)	13	(2.4)	21	(2.8)	12	(1.7)	5	(1.1)	82	(2.7)	<0.001
Drug accessibility (MDMA)															
Completely inaccessible	146	(65.8)	244	(63.9)	338	(61.1)	476	(63.4)	474	(68.2)	337	(71.2)	2,015	(65.5)	<0.001
Almost inaccessible	34	(15.3)	63	(16.5)	97	(17.5)	142	(18.9)	119	(17.1)	81	(17.1)	536	(17.4)	<0.001
Barely accessible	28	(12.6)	46	(12.0)	83	(15.0)	81	(10.8)	60	(8.6)	24	(5.1)	322	(10.5)	<0.001
Easily accessible	6	(2.7)	15	(3.9)	12	(2.2)	25	(3.3)	11	(1.6)	4	(.8)	73	(2.4)	<0.001
Drug accessibility (cocaine)															
Completely inaccessible	147	(66.2)	242	(63.4)	349	(63.1)	502	(66.8)	490	(70.5)	339	(71.7)	2,069	(67.3)	<0.001
Almost inaccessible	31	(14.0)	64	(16.8)	104	(18.8)	145	(19.3)	117	(16.8)	83	(17.5)	544	(17.7)	<0.001
Barely accessible	29	(13.1)	49	(12.8)	66	(11.9)	67	(8.9)	53	(7.6)	20	(4.2)	284	(9.2)	<0.001
Easily accessible	7	(3.2)	13	(3.4)	10	(1.8)	15	(2.0)	9	(1.3)	3	(.6)	57	(1.9)	<0.001
Drug accessibility (heroin)															
Completely inaccessible	148	(66.7)	245	(64.1)	352	(63.7)	503	(67.0)	492	(70.8)	344	(72.7)	2,084	(67.8)	<0.001
Almost inaccessible	31	(14.0)	65	(17.0)	104	(18.8)	147	(19.6)	118	(16.8)	78	(16.5)	543	(17.7)	<0.001
Barely accessible	29	(13.1)	45	(11.8)	62	(11.2)	68	(9.1)	51	(7.3)	21	(4.4)	276	(9.0)	<0.001
Easily accessible	6	(2.7)	13	(3.4)	11	(2.0)	11	(1.5)	5	(.7)	2	(.4)	48	(1.6)	<0.001
Drug accessibility (NPSs)															
Completely inaccessible	139	(62.6)	224	(58.6)	303	(54.8)	399	(53.1)	409	(58.8)	311	(65.8)	1,785	(58.0)	<0.001
Almost inaccessible	30	(13.5)	56	(14.7)	94	(17.0)	161	(21.4)	127	(18.3)	82	(17.3)	550	(17.9)	<0.001
Barely accessible	31	(14.0)	56	(14.7)	97	(17.5)	112	(14.9)	99	(14.2)	41	(8.7)	436	(14.2)	<0.001
Easily accessible	14	(6.3)	32	(8.4)	36	(6.5)	56	(7.5)	33	(4.7)	12	(2.5)	183	(5.9)	<0.001

"10s" refers to those aged 15 to 19, and "60s" refers to those aged 60 to 64.

Table 55. Drug accessibility by Occupation (n=3076)

	Occupation									
	Self-		Full-time		Non-full-		Student		Housewife	
	n=248		n=1406		n=394		n=271		n=436	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Drug accessibility										
Any drug	160	(64.5)	827	(58.8)	196	(49.7)	101	(37.3)	186	(42.7)
Organic solvents	159	(64.1)	813	(57.8)	189	(48.0)	97	(35.8)	182	(41.7)
Cannabis	32	(12.9)	205	(14.6)	66	(16.8)	54	(19.9)	41	(9.4)
Methamphetamine	29	(11.7)	174	(12.4)	63	(16.0)	51	(18.8)	38	(8.7)
MDMA	32	(12.9)	179	(12.7)	67	(17.0)	44	(16.2)	40	(9.2)
Cocaine	25	(10.1)	153	(10.9)	53	(13.5)	49	(18.1)	30	(6.9)
Heroin	25	(10.1)	146	(10.4)	51	(12.9)	47	(17.3)	26	(6.0)
NPSs	51	(20.6)	305	(21.7)	91	(23.1)	63	(23.2)	59	(13.5)
Drug accessibility (organic solvents)										
Completely inaccessible	63	(25.4)	406	(28.9)	141	(35.8)	134	(49.4)	180	(41.3)
Almost inaccessible	18	(7.3)	142	(10.1)	50	(12.7)	31	(11.4)	54	(12.4)
Barely accessible	61	(24.6)	291	(20.7)	73	(18.5)	43	(15.9)	77	(17.7)
Easily accessible	98	(39.5)	522	(37.1)	116	(29.4)	54	(19.9)	105	(24.1)
Drug accessibility (cannabis)										
Completely inaccessible	149	(60.1)	867	(61.7)	242	(61.4)	171	(63.1)	325	(74.5)
Almost inaccessible	58	(23.4)	285	(20.3)	69	(17.5)	37	(13.7)	50	(11.5)
Barely accessible	18	(7.3)	171	(12.2)	54	(13.7)	37	(13.7)	32	(7.3)
Easily accessible	14	(5.6)	34	(2.4)	12	(3.0)	17	(6.3)	9	(2.1)
Drug accessibility (methamphetamine)										
Completely inaccessible	159	(64.1)	898	(63.9)	246	(62.4)	173	(63.8)	331	(75.9)
Almost inaccessible	51	(20.6)	284	(20.2)	66	(16.8)	38	(14.0)	48	(11.0)
Barely accessible	20	(8.1)	143	(10.2)	54	(13.7)	35	(12.9)	29	(6.7)
Easily accessible	9	(3.6)	31	(2.2)	9	(2.3)	16	(5.9)	9	(2.1)
Drug accessibility (MDMA)										
Completely inaccessible	155	(62.5)	892	(63.4)	248	(62.9)	173	(63.8)	327	(75.0)
Almost inaccessible	51	(20.6)	280	(19.9)	61	(15.5)	45	(16.6)	50	(11.5)
Barely accessible	23	(9.3)	152	(10.8)	58	(14.7)	32	(11.8)	31	(7.1)
Easily accessible	9	(3.6)	27	(1.9)	9	(2.3)	12	(4.4)	9	(2.1)
Drug accessibility (cocaine)										
Completely inaccessible	162	(65.3)	920	(65.4)	256	(65.0)	173	(63.8)	332	(76.1)
Almost inaccessible	52	(21.0)	283	(20.1)	67	(17.0)	40	(14.8)	55	(12.6)
Barely accessible	19	(7.7)	132	(9.4)	46	(11.7)	37	(13.7)	22	(5.0)
Easily accessible	6	(2.4)	21	(1.5)	7	(1.8)	12	(4.4)	8	(1.8)
Drug accessibility (heroin)										
Completely inaccessible	164	(66.1)	925	(65.8)	259	(65.7)	175	(64.6)	333	(76.4)
Almost inaccessible	50	(20.2)	285	(20.3)	65	(16.5)	40	(14.8)	56	
Barely accessible	19	(7.7)	128	(9.1)	46	(11.7)	37	(13.7)	20	(4.6)
Easily accessible	6	(2.4)	18	(1.3)	5	(1.3)	10	(3.7)	6	(1.4)
Drug accessibility (NPSs)										
Completely inaccessible	139	(56.0)	761	(54.1)	223	(56.6)	163	(60.1)	293	(67.2)
Almost inaccessible	49	(19.8)	289	(20.6)	61	(15.5)	36	(13.3)	66	(15.1)
Barely accessible	36	(14.5)	219	(15.6)	65	(16.5)	41	(15.1)	39	(8.9)
Easily accessible	15	(6.0)	86	(6.1)	26	(6.6)	22	(8.1)	20	(4.6)

Table 55. Drug accessibility by Occupation (n=3076) continued

	Occupation						p-value	
	Unemployed		Other		Unknown			Total
	n=179		n=138		n=4			n=3076
	(%)	n	(%)	n	(%)	n	(%)	
Drug accessibility								
Any drug	82 (45.8)	63 (45.7)	2 (50.0)	1,617 (52.6)	<0.001			
Organic solvents	80 (44.7)	62 (44.9)	2 (50.0)	1,584 (51.5)	<0.001			
Cannabis	18 (10.1)	17 (12.3)	0 (.0)	433 (14.1)	<0.001			
Methamphetamine	19 (10.6)	16 (11.6)	1 (25.0)	391 (12.7)	0.010			
MDMA	17 (9.5)	16 (11.6)	0 (.0)	395 (12.8)	<0.001			
Cocaine	15 (8.4)	16 (11.6)	0 (.0)	341 (11.1)	<0.001			
Heroin	14 (7.8)	15 (10.9)	0 (.0)	324 (10.5)	<0.001			
NPSs	24 (13.4)	26 (18.8)	0 (.0)	619 (20.1)	<0.001			
Drug accessibility (organic solvents)								
Completely inaccessible	68 (38.0)	57 (41.3)	1 (25.0)	1,050 (34.1)	<0.001			
Almost inaccessible	25 (14.0)	11 (8.0)	0 (.0)	331 (10.8)				
Barely accessible	27 (15.1)	25 (18.1)	0 (.0)	597 (19.4)				
Easily accessible	53 (29.6)	37 (26.8)	2 (50.0)	987 (32.1)				
Drug accessibility (cannabis)								
Completely inaccessible	120 (67.0)	98 (71.0)	1 (25.0)	1,973 (64.1)	<0.001			
Almost inaccessible	32 (17.9)	16 (11.6)	1 (25.0)	548 (17.8)				
Barely accessible	15 (8.4)	15 (10.9)	0 (.0)	342 (11.1)				
Easily accessible	3 (1.7)	2 (1.4)	0 (.0)	91 (3.0)				
Drug accessibility (methamphetamine)								
Completely inaccessible	123 (68.7)	100 (72.5)	1 (25.0)	2,031 (66.0)	<0.001			
Almost inaccessible	30 (16.8)	14 (10.1)	1 (25.0)	532 (17.3)				
Barely accessible	14 (7.8)	13 (9.4)	1 (25.0)	309 (10.0)				
Easily accessible	5 (2.8)	3 (2.2)	0 (.0)	82 (2.7)				
Drug accessibility (MDMA)								
Completely inaccessible	120 (67.0)	99 (71.7)	1 (25.0)	2,015 (65.5)	<0.001			
Almost inaccessible	32 (17.9)	16 (11.6)	1 (25.0)	536 (17.4)				
Barely accessible	13 (7.3)	13 (9.4)	0 (.0)	322 (10.5)				
Easily accessible	4 (2.2)	3 (2.2)	0 (.0)	73 (2.4)				
Drug accessibility (cocaine)								
Completely inaccessible	122 (68.2)	103 (74.6)	1 (25.0)	2,069 (67.3)	<0.001			
Almost inaccessible	34 (19.0)	12 (8.7)	1 (25.0)	544 (17.7)				
Barely accessible	13 (7.3)	15 (10.9)	0 (.0)	284 (9.2)				
Easily accessible	2 (1.1)	1 (.7)	0 (.0)	57 (1.9)				
Drug accessibility (heroin)								
Completely inaccessible	123 (68.7)	104 (75.4)	1 (25.0)	2,084 (67.8)	<0.001			
Almost inaccessible	34 (19.0)	12 (8.7)	1 (25.0)	543 (17.7)				
Barely accessible	12 (6.7)	14 (10.1)	0 (.0)	276 (9.0)				
Easily accessible	2 (1.1)	1 (.7)	0 (.0)	48 (1.6)				
Drug accessibility (NPSs)								
Completely inaccessible	113 (63.1)	92 (66.7)	1 (25.0)	1,785 (58.0)	<0.001			
Almost inaccessible	34 (19.0)	14 (10.1)	1 (25.0)	550 (17.9)				
Barely accessible	18 (10.1)	18 (13.0)	0 (.0)	436 (14.2)				
Easily accessible	6 (3.4)	8 (5.8)	0 (.0)	183 (5.9)				

Table 56. Drug accessibility by Drug use experience (n=3076)

	Drug use experience								p-value
	Lifetime		No lifetime		Unknown		Total		
	n=78	n=2940	n=58	n=3076	n	(%)	n	(%)	
	n	(%)	n	(%)	n	(%)	n	(%)	
Drug accessibility									
Any drug	67	(85.9)	1,534	(52.2)	16	(27.6)	1,617	(52.6)	<0.001
Organic solvents	65	(83.3)	1,504	(51.2)	15	(25.9)	1,584	(51.5)	<0.001
Cannabis	36	(46.2)	394	(13.4)	3	(5.2)	433	(14.1)	<0.001
Methamphetamine	33	(42.3)	355	(12.1)	3	(5.2)	391	(12.7)	<0.001
MDMA	34	(43.6)	358	(12.2)	3	(5.2)	395	(12.8)	<0.001
Cocaine	25	(32.1)	313	(10.6)	3	(5.2)	341	(11.1)	<0.001
Heroin	23	(29.5)	298	(10.1)	3	(5.2)	324	(10.5)	<0.001
NPSs	39	(50.0)	576	(19.6)	4	(6.9)	619	(20.1)	<0.001
Drug accessibility (organic solvents) <0.001									
Completely inaccessible	5	(6.4)	1,030	(35.0)	15	(25.9)	1,050	(34.1)	
Almost inaccessible	7	(9.0)	318	(10.8)	6	(10.3)	331	(10.8)	
Barely accessible	18	(23.1)	574	(19.5)	5	(8.6)	597	(19.4)	
Easily accessible	47	(60.3)	930	(31.6)	10	(17.2)	987	(32.1)	
Drug accessibility (cannabis) <0.001									
Completely inaccessible	20	(25.6)	1,931	(65.7)	22	(37.9)	1,973	(64.1)	
Almost inaccessible	20	(25.6)	524	(17.8)	4	(6.9)	548	(17.8)	
Barely accessible	27	(34.6)	312	(10.6)	3	(5.2)	342	(11.1)	
Easily accessible	9	(11.5)	82	(2.8)	0	(.0)	91	(3.0)	
Drug accessibility (methamphetamine) <0.001									
Completely inaccessible	23	(29.5)	1,986	(67.6)	22	(37.9)	2,031	(66.0)	
Almost inaccessible	20	(25.6)	509	(17.3)	3	(5.2)	532	(17.3)	
Barely accessible	23	(29.5)	283	(9.6)	3	(5.2)	309	(10.0)	
Easily accessible	10	(12.8)	72	(2.4)	0	(.0)	82	(2.7)	
Drug accessibility (MDMA) <0.001									
Completely inaccessible	23	(29.5)	1,970	(67.0)	22	(37.9)	2,015	(65.5)	
Almost inaccessible	19	(24.4)	513	(17.4)	4	(6.9)	536	(17.4)	
Barely accessible	26	(33.3)	293	(10.0)	3	(5.2)	322	(10.5)	
Easily accessible	8	(10.3)	65	(2.2)	0	(.0)	73	(2.4)	
Drug accessibility (cocaine) <0.001									
Completely inaccessible	24	(30.8)	2,024	(68.8)	21	(36.2)	2,069	(67.3)	
Almost inaccessible	27	(34.6)	514	(17.5)	3	(5.2)	544	(17.7)	
Barely accessible	20	(25.6)	261	(8.9)	3	(5.2)	284	(9.2)	
Easily accessible	5	(6.4)	52	(1.8)	0	(.0)	57	(1.9)	
Drug accessibility (heroin) <0.001									
Completely inaccessible	26	(33.3)	2,036	(69.3)	22	(37.9)	2,084	(67.8)	
Almost inaccessible	27	(34.6)	514	(17.5)	2	(3.4)	543	(17.7)	
Barely accessible	19	(24.4)	254	(8.6)	3	(5.2)	276	(9.0)	
Easily accessible	4	(5.1)	44	(1.5)	0	(.0)	48	(1.6)	
Drug accessibility (NPSs) <0.001									
Completely inaccessible	17	(21.8)	1,746	(59.4)	22	(37.9)	1,785	(58.0)	
Almost inaccessible	20	(25.6)	526	(17.9)	4	(6.9)	550	(17.9)	
Barely accessible	27	(34.6)	405	(13.8)	4	(6.9)	436	(14.2)	
Easily accessible	12	(15.4)	171	(5.8)	0	(.0)	183	(5.9)	

Table 57. Drug Use Experience by Residence area (n = 3076)

	Residence area											
	Hokkaido		Tohoku		Kanto		Hokuriku		Tousan		Tokai	
	n=131		n=250		n=948		n=154		n=150		n=328	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Lifetime experience (any drug)												
No	120	(91.6)	239	(95.6)	909	(95.9)	149	(96.8)	144	(96.0)	312	(95.1)
Yes	6	(4.6)	4	(1.6)	25	(2.6)	3	(1.9)	2	(1.3)	10	(3.0)
Lifetime experience (organic solvents)												
No	128	(97.7)	244	(97.6)	930	(98.1)	149	(96.8)	147	(98.0)	317	(96.6)
Yes	2	(1.5)	3	(1.2)	14	(1.5)	3	(1.9)	1	(.7)	9	(2.7)
Lifetime experience (cannabis)												
No	126	(96.2)	246	(98.4)	925	(97.6)	152	(98.7)	145	(96.7)	319	(97.3)
Yes	4	(3.1)	1	(.4)	15	(1.6)	0	(.0)	2	(1.3)	4	(1.2)
Lifetime experience (methamphetamine)												
No	128	(97.7)	247	(98.8)	934	(98.5)	152	(98.7)	146	(97.3)	321	(97.9)
Yes	2	(1.5)	0	(.0)	7	(.7)	0	(.0)	1	(.7)	3	(.9)
Lifetime experience (MDMA)												
No	129	(98.5)	247	(98.8)	938	(98.9)	152	(98.7)	146	(97.3)	324	(98.8)
Yes	1	(.8)	0	(.0)	1	(.1)	0	(.0)	0	(.0)	0	(.0)
Lifetime experience (cocaine)												
No	128	(97.7)	247	(98.8)	935	(98.6)	152	(98.7)	146	(97.3)	323	(98.5)
Yes	1	(.8)	0	(.0)	3	(.3)	0	(.0)	0	(.0)	1	(.3)
Lifetime experience (heroin)												
No	129	(98.5)	244	(97.6)	933	(98.4)	152	(98.7)	146	(97.3)	323	(98.5)
Yes	0	(.0)	0	(.0)	3	(.3)	0	(.0)	0	(.0)	0	(.0)
Lifetime experience (NPSs)												
No	126	(96.2)	246	(98.4)	935	(98.6)	152	(98.7)	146	(97.3)	324	(98.8)
Yes	2	(1.5)	0	(.0)	2	(.2)	0	(.0)	0	(.0)	1	(.3)
Past-year experience (any drug)												
No	126	(96.2)	242	(96.8)	932	(98.3)	152	(98.7)	146	(97.3)	321	(97.9)
Yes	0	(.0)	1	(.4)	2	(.2)	0	(.0)	0	(.0)	1	(.3)
Past-year experience (organic solvents)												
No	130	(99.2)	246	(98.4)	943	(99.5)	152	(98.7)	148	(98.7)	326	(99.4)
Yes	0	(.0)	1	(.4)	1	(.1)	0	(.0)	0	(.0)	0	(.0)
Past-year experience (cannabis)												
No	130	(99.2)	247	(98.8)	939	(99.1)	152	(98.7)	147		322	(98.2)
Yes	0	(.0)	0	(.0)	1	(.1)	0	(.0)	0	(.0)	1	(.3)
Past-year experience (methamphetamine)												
No	130	(99.2)	247	(98.8)	941	(99.3)	152	(98.7)	147	(98.0)	324	(98.8)
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Past-year experience (MDMA)												
No	130	(99.2)	247	(98.8)	939	(99.1)	152	(98.7)	146	(97.3)	324	(98.8)
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Past-year experience (cocaine)												
No	129	(98.5)	247	(98.8)	938	(98.9)	152	(98.7)	146	(97.3)	324	(98.8)
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Past-year experience (heroin)												
No	129	(98.5)	244	(97.6)	936	(98.7)	152	(98.7)	146	(97.3)	323	(98.5)
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Past-year experience (NPSs)												
No	128	(97.7)	246	(98.4)	937	(98.8)	152	(98.7)	146	(97.3)	325	(99.1)
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)

Table 57. Drug Use Experience by Residence area (n = 3076) continued

	Residence area										p-value		
	Kinki		Chugoku		Shikoku		Kita-Kyusyu		Minami-			Total	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)		n	(%)
Lifetime experience (any drug)												0.798	
No	420	(95.0)	180	(94.2)	86	(97.7)	223	(97.4)	158	(95.8)	2,940	(95.6)	
Yes	13	(2.9)	6	(3.1)	1	(1.1)	3	(1.3)	5	(3.0)	78	(2.5)	
Lifetime experience (organic solvents)												0.894	
No	431	(97.5)	186	(97.4)	88	(100.0)	223	(97.4)	160	(97.0)	3,003	(97.6)	
Yes	6	(1.4)	4	(2.1)	0	(.0)	3	(1.3)	4	(2.4)	49	(1.6)	
Lifetime experience (cannabis)												0.660	
No	432	(97.7)	187	(97.9)	88	(100.0)	224	(97.8)	163	(98.8)	3,007	(97.8)	
Yes	6	(1.4)	1	(.5)	0	(.0)	2	(.9)	0	(.0)	35	(1.1)	
Lifetime experience (methamphetamine)												0.831	
No	436	(98.6)	186	(97.4)	88	(100.0)	225	(98.3)	163	(98.8)	3,026	(98.4)	
Yes	1	(.2)	1	(.5)	0	(.0)	1	(.4)	0	(.0)	16	(.5)	
Lifetime experience (MDMA)												0.870	
No	433	(98.0)	187	(97.9)	88	(100.0)	225	(98.3)	163	(98.8)	3,032	(98.6)	
Yes	2	(.5)	1	(.5)	0	(.0)	1	(.4)	0	(.0)	6	(.2)	
Lifetime experience (cocaine)												0.911	
No	434	(98.2)	188	(98.4)	88	(100.0)	226	(98.7)	163	(98.8)	3,030	(98.5)	
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	5	(.2)	
Lifetime experience (heroin)												0.925	
No	435	(98.4)	187	(97.9)	88	(100.0)	226	(98.7)	163	(98.8)	3,026	(98.4)	
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	3	(.1)	
Lifetime experience (NPSs)												0.829	
No	434	(98.2)	186	(97.4)	86	(97.7)	225	(98.3)	162	(98.2)	3,022	(98.2)	
Yes	2	(.5)	1	(.5)	1	(1.1)	1	(.4)	1	(.6)	11	(.4)	
Past-year experience (any drug)												0.919	
No	432	(97.7)	186	(97.4)	87	(98.9)	226	(98.7)	163	(98.8)	3,013	(98.0)	
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	4	(.1)	
Past-year experience (organic solvents)												0.928	
No	437	(98.9)	190	(99.5)	88	(100.0)	226	(98.7)	164	(99.4)	3,050	(99.2)	
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	2	(.1)	
Past-year experience (cannabis)												0.989	
No	438	(99.1)	188	(98.4)	88	(100.0)	226	(98.7)	163		3,040	(98.8)	
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	2	(.1)	
Past-year experience (methamphetamine)												0.869	
No	437	(98.9)	187	(97.9)	88	(100.0)	226	(98.7)	163	(98.8)	3,042	(98.9)	
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
Past-year experience (MDMA)												0.882	
No	435	(98.4)	188	(98.4)	88	(100.0)	226	(98.7)	163	(98.8)	3,038	(98.8)	
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
Past-year experience (cocaine)												0.908	
No	434	(98.2)	188	(98.4)	88	(100.0)	226	(98.7)	163	(98.8)	3,035	(98.7)	
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
Past-year experience (heroin)												0.891	
No	435	(98.4)	187	(97.9)	88	(100.0)	226	(98.7)	163	(98.8)	3,029	(98.5)	
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
Past-year experience (NPSs)												0.932	
No	436	(98.6)	187	(97.9)	87	(98.9)	226	(98.7)	163	(98.8)	3,033	(98.6)	
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	

Table 58. Drug Use Experience by Sex (n = 3076)

	Sex						P-value
	Men		Women		Total		
	n = 1466		n = 1610		n = 3076		
	n	(%)	n	(%)	n	(%)	
Lifetime experience (any drug)							<0.001
No	1,374	(93.7)	1,566	(97.3)	2,940	(95.6)	
Yes	58	(4.0)	20	(1.2)	78	(2.5)	
Lifetime experience (organic solvents)							0.003
No	1,417	(96.7)	1,586	(98.5)	3,003	(97.6)	
Yes	34	(2.3)	15	(.9)	49	(1.6)	
Lifetime experience (cannabis)							<0.001
No	1,416	(96.6)	1,591	(98.8)	3,007	(97.8)	
Yes	28	(1.9)	7	(.4)	35	(1.1)	
Lifetime experience (methamphetamine)							<0.001
No	1,429	(97.5)	1,597	(99.2)	3,026	(98.4)	
Yes	14	(1.0)	2	(.1)	16	(.5)	
Lifetime experience (MDMA)							0.059
No	1,438	(98.1)	1,594	(99.0)	3,032	(98.6)	
Yes	5	(.3)	1	(.1)	6	(.2)	
Lifetime experience (cocaine)							0.023
No	1,437	(98.0)	1,593	(98.9)	3,030	(98.5)	
Yes	5	(.3)	0	(.0)	5	(.2)	
Lifetime experience (heroin)							0.016
No	1,433	(97.7)	1,593	(98.9)	3,026	(98.4)	
Yes	3	(.2)	0	(.0)	3	(.1)	
Lifetime experience (NPSs)							0.137
No	1,434	(97.8)	1,588	(98.6)	3,022	(98.2)	
Yes	8	(.5)	3	(.2)	11	(.4)	
Past-year experience (any drug)							0.193
No	1,429	(97.5)	1,584	(98.4)	3,013	(98.0)	
Yes	2	(.1)	2	(.1)	4	(.1)	
Past-year experience (organic solvents)							0.114
No	1,449	(98.8)	1,601	(99.4)	3,050	(99.2)	
Yes	2	(.1)	0	(.0)	2	(.1)	
Past-year experience (cannabis)							0.055
No	1,444	(98.5)	1,596	(99.1)	3,040	(98.8)	
Yes	0	(.0)	2	(.1)	2	(.1)	
Past-year experience (methamphetamine)							0.019
No	1,443	(98.4)	1,599	(99.3)	3,042	(98.9)	
Yes	0	(.0)	0	(.0)	0	(.0)	
Past-year experience (MDMA)							0.110
No	1,443	(98.4)	1,595	(99.1)	3,038	(98.8)	
Yes	0	(.0)	0	(.0)	0	(.0)	
Past-year experience (cocaine)							0.160
No	1,442	(98.4)	1,593	(98.9)	3,035	(98.7)	
Yes	0	(.0)	0	(.0)	0	(.0)	
Past-year experience (heroin)							0.025
No	1,436	(98.0)	1,593	(98.9)	3,029	(98.5)	
Yes	0	(.0)	0	(.0)	0	(.0)	
Past-year experience (NPSs)							0.281
No	1,442	(98.4)	1,591	(98.8)	3,033	(98.6)	
Yes	0	(.0)	0	(.0)	0	(.0)	

Table 59. Drug Use Experience by Age group (n = 3076)

	Age group							p-value							
	10s		20s		30s		40s		50s		60s		Total		
	n	(%)	n	(%)	n	(%)	n		(%)	n	(%)	n	(%)	n	(%)
Lifetime experience (any drug)															0.101
No	219	(98.6)	368	(96.3)	530	(95.8)	718	(95.6)	655	(94.2)	450	(95.1)	2,940	(95.6)	
Yes	0	(.0)	8	(2.1)	15	(2.7)	23	(3.1)	23	(3.3)	9	(1.9)	78	(2.5)	
Lifetime experience (organic solvents)															0.058
No	219	(98.6)	376	(98.4)	544	(98.4)	732	(97.5)	674	(97.0)	458	(96.8)	3,003	(97.6)	
Yes	0	(.0)	3	(.8)	6	(1.1)	18	(2.4)	13	(1.9)	9	(1.9)	49	(1.6)	
Lifetime experience (cannabis)															0.044
No	219	(98.6)	375	(98.2)	537	(97.1)	736	(98.0)	676	(97.3)	464	(98.1)	3,007	(97.8)	
Yes	0	(.0)	4	(1.0)	11	(2.0)	11	(1.5)	9	(1.3)	0	(.0)	35	(1.1)	
Lifetime experience (methamphetamine)															0.266
No	219	(98.6)	378	(99.0)	543	(98.2)	741	(98.7)	682	(98.1)	463	(97.9)	3,026	(98.4)	
Yes	0	(.0)	0	(.0)	5	(.9)	6	(.8)	4	(.6)	1	(.2)	16	(.5)	
Lifetime experience (MDMA)															0.221
No	219	(98.6)	377	(98.7)	545	(98.6)	745	(99.2)	683	(98.3)	463	(97.9)	3,032	(98.6)	
Yes	0	(.0)	0	(.0)	3	(.5)	2	(.3)	1	(.1)	0	(.0)	6	(.2)	
Lifetime experience (cocaine)															0.371
No	219	(98.6)	376	(98.4)	547	(98.9)	743	(98.9)	682	(98.1)	463	(97.9)	3,030	(98.5)	
Yes	0	(.0)	0	(.0)	1	(.2)	3	(.4)	1	(.1)	0	(.0)	5	(.2)	
Lifetime experience (heroin)															0.038
No	219	(98.6)	377	(98.7)	546	(98.7)	743	(98.9)	681	(98.0)	460	(97.3)	3,026	(98.4)	
Yes	0	(.0)	0	(.0)	0	(.0)	3	(.4)	0	(.0)	0	(.0)	3	(.1)	
Lifetime experience (NPSs)															0.455
No	219	(98.6)	375	(98.2)	544	(98.4)	741	(98.7)	681	(98.0)	462	(97.7)	3,022	(98.2)	
Yes	0	(.0)	2	(.5)	4	(.7)	2	(.3)	3	(.4)	0	(.0)	11	(.4)	
Past-year experience (any drug)															0.606
No	219	(98.6)	374	(97.9)	544	(98.4)	740	(98.5)	678	(97.6)	458	(96.8)	3,013	(98.0)	
Yes	0	(.0)	1	(.3)	1	(.2)	1	(.1)	0	(.0)	1	(.2)	4	(.1)	
Past-year experience (organic solvents)															0.328
No	219	(98.6)	379	(99.2)	550	(99.5)	749	(99.7)	687	(98.8)	466	(98.5)	3,050	(99.2)	
Yes	0	(.0)	0	(.0)	0	(.0)	1	(.1)	0	(.0)	1	(.2)	2	(.1)	
Past-year experience (cannabis)															0.342
No	219	(98.6)	378	(99.0)	547	(98.9)	747	(99.5)	685		464	(98.1)	3,040	(98.8)	
Yes	0	(.0)	1	(.3)	1	(.2)	0	(.0)	0	(.0)	0	(.0)	2	(.1)	
Past-year experience (methamphetamine)															0.350
No	219	(98.6)	378	(99.0)	548	(99.1)	747	(99.5)	686	(98.7)	464	(98.1)	3,042	(98.9)	
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
Past-year experience (MDMA)															0.202
No	219	(98.6)	377	(98.7)	548	(99.1)	747	(99.5)	684	(98.4)	463	(97.9)	3,038	(98.8)	
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
Past-year experience (cocaine)															0.261
No	219	(98.6)	376	(98.4)	548	(99.1)	746	(99.3)	683	(98.3)	463	(97.9)	3,035	(98.7)	
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
Past-year experience (heroin)															0.078
No	219	(98.6)	377	(98.7)	546	(98.7)	746	(99.3)	681	(98.0)	460	(97.3)	3,029	(98.5)	
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
Past-year experience (NPSs)															0.449
No	219	(98.6)	377	(98.7)	548	(99.1)	743	(98.9)	684	(98.4)	462	(97.7)	3,033	(98.6)	
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	

"10s" refers to those aged 15 to 19, and "60s" refers to those aged 60 to 64.

Table 60 Drug Use Experience by Occupation (n = 3076)

	Occupation									
	Self-		Full-time		Non-full-		Student		Housewife	
	n=248		n=1406		n=394		n=271		n=436	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Lifetime experience (any drug)										
No	227	(91.5)	1,345	(95.7)	375	(95.2)	268	(98.9)	422	(96.8)
Yes	14	(5.6)	36	(2.6)	14	(3.6)	0	(.0)	5	(1.1)
Lifetime experience (organic solvents)										
No	236	(95.2)	1,375	(97.8)	385	(97.7)	269	(99.3)	429	(98.4)
Yes	7	(2.8)	23	(1.6)	8	(2.0)	0	(.0)	3	(.7)
Lifetime experience (cannabis)										
No	236	(95.2)	1,376	(97.9)	383	(97.2)	269	(99.3)	431	(98.9)
Yes	7	(2.8)	15	(1.1)	8	(2.0)	0	(.0)	0	(.0)
Lifetime experience (methamphetamine)										
No	241	(97.2)	1,381	(98.2)	391	(99.2)	269	(99.3)	432	(99.1)
Yes	3	(1.2)	9	(.6)	0	(.0)	0	(.0)	0	(.0)
Lifetime experience (MDMA)										
No	243	(98.0)	1,389	(98.8)	392	(99.5)	269	(99.3)	428	(98.2)
Yes	1	(.4)	2	(.1)	0	(.0)	0	(.0)	1	(.2)
Lifetime experience (cocaine)										
No	243	(98.0)	1,387	(98.6)	391	(99.2)	268	(98.9)	429	(98.4)
Yes	1	(.4)	3	(.2)	0	(.0)	0	(.0)	0	(.0)
Lifetime experience (heroin)										
No	242	(97.6)	1,385	(98.5)	390	(99.0)	269	(99.3)	429	(98.4)
Yes	1	(.4)	1	(.1)	0	(.0)	0	(.0)	0	(.0)
Lifetime experience (NPSs)										
No	243	(98.0)	1,381	(98.2)	390	(99.0)	269	(99.3)	426	(97.7)
Yes	1	(.4)	7	(.5)	1	(.3)	0	(.0)	1	(.2)
Past-year experience (any drug)										
No	241	(97.2)	1,380	(98.2)	388	(98.5)	268	(98.9)	427	(97.9)
Yes	0	(.0)	1	(.1)	1	(.3)	0	(.0)	0	(.0)
Past-year experience (organic solvents)										
No	243	(98.0)	1,397	(99.4)	393	(99.7)	269	(99.3)	432	(99.1)
Yes	0	(.0)	1	(.1)	0	(.0)	0	(.0)	0	(.0)
Past-year experience (cannabis)										
No	243	(98.0)	1,391	(98.9)	390	(99.0)	269	(99.3)	431	
Yes	0	(.0)	0	(.0)	1	(.3)	0	(.0)	0	(.0)
Past-year experience (methamphetamine)										
No	244	(98.4)	1,390	(98.9)	391	(99.2)	269	(99.3)	432	(99.1)
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Past-year experience (MDMA)										
No	244	(98.4)	1,391	(98.9)	392	(99.5)	269	(99.3)	429	(98.4)
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Past-year experience (cocaine)										
No	244	(98.4)	1,390	(98.9)	391	(99.2)	268	(98.9)	429	(98.4)
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Past-year experience (heroin)										
No	243	(98.0)	1,386	(98.6)	390	(99.0)	269	(99.3)	429	(98.4)
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Past-year experience (NPSs)										
No	244	(98.4)	1,388	(98.7)	391	(99.2)	269	(99.3)	427	(97.9)
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)

Table 60. Drug Use Experience by Occupation (n = 3076) continued

	Occupation						p-value		
	Unemployed		Other		Unknown			Total	
	n=179		n=138		n=4			n=3076	
	n	(%)	n	(%)	n	(%)	n	(%)	
Lifetime experience (any drug)								0.014	
No	169	(94.4)	130	(94.2)	4	(100.0)	2,940	(95.6)	
Yes	6	(3.4)	3	(2.2)	0	(.0)	78	(2.5)	
Lifetime experience (organic solvents)								0.088	
No	171	(95.5)	134	(97.1)	4	(100.0)	3,003	(97.6)	
Yes	6	(3.4)	2	(1.4)	0	(.0)	49	(1.6)	
Lifetime experience (cannabis)								0.106	
No	174	(97.2)	134	(97.1)	4	(100.0)	3,007	(97.8)	
Yes	3	(1.7)	2	(1.4)	0	(.0)	35	(1.1)	
Lifetime experience (methamphetamine)								0.300	
No	174	(97.2)	134	(97.1)	4	(100.0)	3,026	(98.4)	
Yes	3	(1.7)	1	(.7)	0	(.0)	16	(.5)	
Lifetime experience (MDMA)								0.344	
No	175	(97.8)	132	(95.7)	4	(100.0)	3,032	(98.6)	
Yes	1	(.6)	1	(.7)	0	(.0)	6	(.2)	
Lifetime experience (cocaine)								0.569	
No	175	(97.8)	133	(96.4)	4	(100.0)	3,030	(98.5)	
Yes	1	(.6)	0	(.0)	0	(.0)	5	(.2)	
Lifetime experience (heroin)								0.404	
No	174	(97.2)	133	(96.4)	4	(100.0)	3,026	(98.4)	
Yes	1	(.6)	0	(.0)	0	(.0)	3	(.1)	
Lifetime experience (NPSs)								0.809	
No	176	(98.3)	133	(96.4)	4	(100.0)	3,022	(98.2)	
Yes	0	(.0)	1	(.7)	0	(.0)	11	(.4)	
Past-year experience (any drug)								0.055	
No	173	(96.6)	132	(95.7)	4	(100.0)	3,013	(98.0)	
Yes	2	(1.1)	0	(.0)	0	(.0)	4	(.1)	
Past-year experience (organic solvents)								0.313	
No	176	(98.3)	136	(98.6)	4	(100.0)	3,050	(99.2)	
Yes	1	(.6)	0	(.0)	0	(.0)	2	(.1)	
Past-year experience (cannabis)								0.498	
No	176	(98.3)	136	(98.6)	4	(100.0)	3,040	(98.8)	
Yes	1	(.6)	0	(.0)	0	(.0)	2	(.1)	
Past-year experience (methamphetamine)								0.886	
No	177	(98.9)	135	(97.8)	4	(100.0)	3,042	(98.9)	
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
Past-year experience (MDMA)								0.180	
No	176	(98.3)	133	(96.4)	4	(100.0)	3,038	(98.8)	
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
Past-year experience (cocaine)								0.369	
No	176	(98.3)	133	(96.4)	4	(100.0)	3,035	(98.7)	
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
Past-year experience (heroin)								0.428	
No	175	(97.8)	133	(96.4)	4	(100.0)	3,029	(98.5)	
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
Past-year experience (NPSs)								0.533	
No	176	(98.3)	134	(97.1)	4	(100.0)	3,033	(98.6)	
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	

Table 61. Drug Use Experience by Drug use experience(n = 3076)

	Drug use experience						p-value		
	Lifetime n=78		No lifetime n=2940		Unknown n=58			Total n=3076	
	n	(%)	n	(%)	n	(%)		n	(%)
Lifetime experience (organic solvents)							<0.001		
No	28	(35.9)	2,940	(100.0)	35	(60.3)	3,003	(97.6)	
Yes	49	(62.8)	0	(.0)	0	(.0)	49	(1.6)	
Lifetime experience (cannabis)							<0.001		
No	43	(55.1)	2,940	(100.0)	24	(41.4)	3,007	(97.8)	
Yes	35	(44.9)	0	(.0)	0	(.0)	35	(1.1)	
Lifetime experience (methamphetamine)							<0.001		
No	61	(78.2)	2,940	(100.0)	25	(43.1)	3,026	(98.4)	
Yes	16	(20.5)	0	(.0)	0	(.0)	16	(.5)	
Lifetime experience (MDMA)							<0.001		
No	71	(91.0)	2,940	(100.0)	21	(36.2)	3,032	(98.6)	
Yes	6	(7.7)	0	(.0)	0	(.0)	6	(.2)	
Lifetime experience (cocaine)							<0.001		
No	72	(92.3)	2,940	(100.0)	18	(31.0)	3,030	(98.5)	
Yes	5	(6.4)	0	(.0)	0	(.0)	5	(.2)	
Lifetime experience (heroin)							<0.001		
No	74	(94.9)	2,940	(100.0)	12	(20.7)	3,026	(98.4)	
Yes	3	(3.8)	0	(.0)	0	(.0)	3	(.1)	
Lifetime experience (NPSs)							<0.001		
No	67	(85.9)	2,940	(100.0)	15	(25.9)	3,022	(98.2)	
Yes	11	(14.1)	0	(.0)	0	(.0)	11	(.4)	
Past-year experience (any drug)							<0.001		
No	73	(93.6)	2,940	(100.0)	0	(.0)	3,013	(98.0)	
Yes	4	(5.1)	0	(.0)	0	(.0)	4	(.1)	
Past-year experience (organic solvents)							<0.001		
No	75	(96.2)	2,940	(100.0)	35	(60.3)	3,050	(99.2)	
Yes	2	(2.6)	0	(.0)	0	(.0)	2	(.1)	
Past-year experience (cannabis)							<0.001		
No	76	(97.4)	2,940	(100.0)	24	(41.4)	3,040	(98.8)	
Yes	2	(2.6)	0	(.0)	0	(.0)	2	(.1)	
Past-year experience (methamphetamine)							<0.001		
No	77	(98.7)	2,940	(100.0)	25	(43.1)	3,042	(98.9)	
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
Past-year experience (MDMA)							<0.001		
No	77	(98.7)	2,940	(100.0)	21	(36.2)	3,038	(98.8)	
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
Past-year experience (cocaine)							<0.001		
No	77	(98.7)	2,940	(100.0)	18	(31.0)	3,035	(98.7)	
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
Past-year experience (heroin)							<0.001		
No	77	(98.7)	2,940	(100.0)	12	(20.7)	3,029	(98.5)	
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
Past-year experience (NPSs)							<0.001		
No	78	(100.0)	2,940	(100.0)	15	(25.9)	3,033	(98.6)	
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	




Fig.2 Changes in the Past-Year Prevalence of Alcohol Use (Overall:2005-2015)




Fig.3 Changes in the Past-Year Prevalence of Alcohol Use by Age Group (2005-2015)




Fig.4 Changes in the Lifetime Prevalence of Tobacco Use (Overall: 1999-2015)




Fig.5 Changes in the Lifetime Prevalence of Tobacco Use Over Time by Age Group (1999-2015)




Fig.6 Changes in the Past-Year Prevalence of Tobacco Use (Overall:2001-2015)




Fig.7 Changes in the Past-Year Prevalence of Tobacco Use by Age Group (2001-2015)

Table 62 Estimated Past-Year Prevalence of Alcohol/Tobacco Use by Sex (%)

	Alcohol use			Tobacco use		
	Overall	Men	Women	Overall	Men	Women
2003	85.1 (84.5)	89.2 (89.0)	81.3 (80.3)	32.8 (32.9)	49.5 (49.2)	17.2 (17.5)
2005	84.2 (84.0)	88.9 (88.9)	79.9 (79.2)	33.3 (34.6)	48.3 (49.1)	19.5 (20.3)
2007	83.8 (83.6)	88.8 (88.5)	79.3 (79.1)	30.4 (30.3)	44.6 (44.8)	17.3 (17.0)
2009	83.7 (83.8)	88.5 (88.5)	79.2 (79.4)	32.1 (32.2)	48.9 (48.9)	16.1 (16.4)
2011	85.3 (85.0)	88.9 (88.6)	81.9 (81.7)	29.3 (29.1)	43.4 (43.5)	16.2 (15.8)
2013	82.2 (81.9)	85.7 (85.5)	79.1 (78.7)	27.2 (28.0)	39.4 (40.9)	16.5 (16.6)
2015	80.2 (79.8)	84.6 (84.4)	76.1 (75.6)	26.2 (26.9)	40.2 (40.9)	13.3 (14.1)

The values in the parentheses are unadjusted.

Table 63 Estimated Past-Year Prevalence of Analgesic/Tranquilizer/Hypnotic Use by Sex (%)

	Analgesics		
	Overall	Men	Women
2003	55.2	47.1	62.8
2005	55.1	48.9	60.8
2007	55.3	47.0	63.0
2009	58.1	49.0	66.8
2011	58.6	46.4	69.9
2013	61.4	50.6	70.9
2015	62.9	53.1	71.9
	Tranquilizers		
	Overall	Men	Women
2003	7.4	5.6	9.1
2005	8.1	6.4	9.7
2007	8.1	6.2	9.9
2009	7.1	6.1	8.1
2011	5.6	4.8	6.3
2013	6.2	5.7	6.6
2015	5.6	4.2	6.9
	Hypnotics		
	Overall	Men	Women
2003	6.2	6.0	6.3
2005	6.2	4.7	7.6
2007	7.7	6.5	8.7
2009	6.5	5.5	7.4
2011	5.6	4.9	6.3
2013	5.6	5.6	5.6
2015	6.1	5.2	7.0




Fig.8 Changes in the Past-Year Prevalence of Analgesic Use (1995-2015)




Fig.9 Changes in the Chronic use of Analgesic (1999-2015)

Chronic use: defined as \geq three times a week




Fig.10 Changes in the Past-Year Prevalence of Tranquilizer Use (1995-2015)




Fig.11 Changes in the Chronic use of Tranquilizer (1999-2015)

Chronic use: defined as \geq three times a week




Fig.12 Changes in the Past-Year Prevalence of Hypnotic Use (1995-2015)




Fig.13 Changes in the Chronic use of Hypnotic (1999-2015)

Chronic use: defined as \geq three times a week




Fig.14 Changes in views on cannabis use (Overall: 1999-2015)
Sum of "Individual Freedom" + "A Little Use Should Be Allowed"




Fig.15 Changes in views on cannabis use (by age group: 1999-2015)
Sum of "Individual Freedom" + "A Little Use Should Be Allowed"



Fig.16 Changes in views on methamphetamine use (Overall: 1999-2015)
Sum of “Individual Freedom” + “A Little Use Should Be Allowed”




Fig.17 Changes in views on methamphetamine use (by age group: 1999-2015)
Sum of “Individual Freedom” + “A Little Use Should Be Allowed”




Fig.18 Changes in the proportion of respondents with a peer drug abuser within the past year (1995-2015)




Fig.19 Changes in drug accessibility (1999-2015)
Sum of "Easily Accessible" + "Barely Accessible"




Fig.20 Changes in drug accessibility (Organic solvents: 1999-2015)
Sum of “Easily Accessible” + “Barely Accessible”




Fig.21 Changes in drug accessibility by age group (Organic solvents: 1999-2015)
Sum of “Easily Accessible” + “Barely Accessible”




Fig.22 Changes in drug accessibility (Cannabis: 1999-2015)
Sum of “Easily Accessible” + “Barely Accessible”




Fig.23 Changes in drug accessibility by age group (Cannabis: 1999-2015)
Sum of “Easily Accessible” + “Barely Accessible”




Fig.24 Changes in drug accessibility (Methamphetamine: 1999-2015)
Sum of “Easily Accessible” + “Barely Accessible”




Fig.25 Changes in drug accessibility by age group (Methamphetamine: 1999-2015)
Sum of “Easily Accessible” + “Barely Accessible”




Fig.26 Changes in drug accessibility (Heroin: 1999-2015)
Sum of “Easily Accessible” + “Barely Accessible”




Fig.27 Changes in drug accessibility by age group (Heroin: 1999-2015)
Sum of “Easily Accessible” + “Barely Accessible”




Fig.28 Changes in drug accessibility (Cocaine: 1999-2015)
Sum of “Easily Accessible” + “Barely Accessible”




Fig.29 Changes in drug accessibility by age group (Cocaine: 1999-2015)
Sum of “Easily Accessible” + “Barely Accessible”




Fig.30 Changes in drug accessibility (MDMA: 1999-2015)
Sum of “Easily Accessible” + “Barely Accessible”




Fig.31 Changes in drug accessibility by age group (MDMA: 1999-2015)
Sum of “Easily Accessible” + “Barely Accessible”

Table 64 Estimated Prevalence of Experience of Ever Having Try to Tempt Illegal Drugs (1995–2015)

(%)

	Organic solvents	Cannabis	Methamp hetamine	Cocaine	Heroin	MDMA	NPSs	Any drug
1995	2.0	1.3	0.7	0.2	0.2	-	-	2.9
1997	1.7	1.6	0.4	0.1	0.2	-	-	3.2
1999	2.9	1.6	1.0	0.5	0.2	-	-	4.1
2001	3.9	2.1	1.1	0.3	0.2	-	-	5.0
2003	2.7	1.4	0.9	0.3	0.2	0.2	-	3.8
2005	2.7	2.0	0.9	0.4	0.2	0.2	-	4.0
2007	3.0	1.8	1.0	0.3	0.2	0.4	-	4.4
2009	3.6	2.8	1.2	0.4	0.1	0.6	-	6.4
2011	2.9	2.0	0.9	0.2	0.2	0.2	-	4.6
2013	2.6	2.7	0.9	0.3	*	0.4	-	4.8
2015	2.4	2.0	1.0	0.2	0.2	0.6	0.6	4.1

*:Within the range of statistical errors




Fig.32 Estimated Lifetime Prevalence of Experience of Ever Having Try to Tempt Illegal Drugs (1995-2015)

Table 65 Estimated Number of Individuals with Lifetime Experience of Ever Having Try to Tempt Illegal Drugs (Lower Limit–Upper Limit)

	Overall			Men			Women		
	Number of individuals with lifetime experience of ever having try to tempt illegal	Lower limit	Upper limit	Number of individuals with lifetime experience of ever having try to tempt illegal	Lower limit	Upper limit	Number of individuals with lifetime experience of ever having try to tempt illegal	Lower limit	Upper limit
Organic solvents									
2003	3,226,949	2,558,285	3,895,612	2,102,885	1,612,304	2,593,467	1,124,063	690,698	1,557,429
2005	3,327,335	2,575,055	4,079,615	1,880,665	1,306,516	2,454,813	1,446,670	946,809	1,946,532
2007	3,578,721	2,814,702	4,342,740	2,489,324	1,855,080	3,123,568	1,089,397	645,159	1,533,636
2009	3,410,271	2,749,052	4,071,491	2,379,363	1,828,276	2,930,449	1,030,909	649,260	1,412,557
2011	2,707,312	2,111,043	3,303,580	1,971,377	1,450,806	2,491,948	735,935	449,695	1,022,174
2013	2,510,411	1,909,630	3,111,191	1,652,457	1,181,965	2,122,950	857,953	497,656	1,218,250
2015	2,288,535	1,759,576	2,817,493	1,525,320	1,092,509	1,958,131	763,215	452,575	1,073,854
Cannabis									
2003	1,625,669	1,110,178	2,141,161	844,844	509,544	1,180,144	780,825	376,074	1,185,577
2005	2,469,019	1,821,518	3,116,520	1,567,729	1,044,808	2,090,649	901,290	473,796	1,328,784
2007	2,160,162	1,562,619	2,757,704	1,407,150	904,006	1,910,294	753,012	407,905	1,098,118
2009	2,683,957	2,033,104	3,334,810	1,795,410	1,286,427	2,304,392	888,547	548,116	1,228,978
2011	1,907,924	1,361,705	2,454,144	1,254,092	820,903	1,687,281	653,832	357,972	949,693
2013	2,671,872	1,625,383	3,718,361	2,014,082	1,006,378	3,021,787	657,790	338,947	976,633
2015	1,912,065	1,332,664	2,491,466	1,311,413	847,271	1,775,555	600,652	316,949	884,355
Methamphetamine									
2003	1,036,408	630,743	1,442,074	461,636	225,078	698,195	574,772	224,185	925,358
2005	1,078,081	588,153	1,568,008	503,991	223,707	784,275	574,090	253,558	894,622
2007	1,203,439	753,289	1,653,590	861,915	488,901	1,234,930	341,524	109,808	573,240
2009	1,171,001.0	734,182	1,607,821	602,661	321,784	883,538	568,340	244,158	892,523
2011	830,029	505,108	1,154,950	526,470	249,257	803,683	303,558	125,956	481,161
2013	928,581	549,479	1,307,682	582,003	271,613	892,393	346,578	118,935	574,220
2015	937,384	527,874	1,346,894	529,487	250,999	807,975	407,897	144,120	671,674
Heroin									
2003	250,292	46,103	454,481	*	*	*	*	*	*
2005	187,947	32,663	343,230	*	*	*	*	*	*
2007	245,514	24,782	466,245	203,468	35,570	371,367	*	*	*
2009	139,300	13,092	265,509	99,561	502	198,621	*	*	*
2011	148,309	26,256	270,363	*	*	*	117,023	8,842	225,204
2013	*	*	*	*	*	*	*	*	*
2015	156,910	21,955	291,864	143,305	11,033	275,577	*	*	*
Cocaine									
2003	343,025	101,546	584,504	227,511	47,742	407,280	*	*	*
2005	445,093	163,654	726,532	298,031	56,370	539,693	147,062	1,406	292,717
2007	408,925	127,275	690,575	249,214	38,013	460,415	*	*	*
2009	425,567	138,889	712,245	171,807	21,630	321,984	253,760	39,906	467,614
2011	228,319	79,568	377,070	*	*	*	160,824	34,994	286,654
2013	319,198	116,423	521,973	168,863	19,550	318,176	150,335	12,551	288,120
2015	204,813	53,320	356,305	173,398	28,470	318,326	*	*	*
MDMA									
2003	284,157	89,892	478,422	*	*	*	156,659	10,259	303,058
2005	199,470	21,993	376,947	*	*	*	*	*	*
2007	500,445	213,622	787,269	337,088	97,954	576,222	*	*	*
2009	571,689	269,053	874,324	169,461	18,247	320,676	402,227	165,065	639,390
2011	226,187	73,289	379,086	120,739	10,157	231,320	105,449	7,335	203,563
2013	421,940	161,430	682,449	246,878	61,407	432,350	*	*	*
2015	583,660	275,375	891,946	323,954	126,794	521,114	259,707	68,133	451,280
NPSs									
2015	520,545	190,934	850,155	294,740	972	588,508	225,804	70,100	381,509
Any drug									
2003	4,496,271	3,685,964	5,306,577	2,686,630	2,157,971	3,215,290	1,809,640	1,219,391	2,399,890
2005	4,854,569	3,934,099	5,775,039	2,737,955	2,058,196	3,417,714	2,116,614	1,496,584	2,736,644
2007	5,299,142	4,372,991	6,225,293	3,455,308	2,694,445	4,216,170	1,843,834	1,297,620	2,390,048
2009	6,114,892	5,211,889	7,017,894	3,912,521	3,228,707	4,596,336	2,202,371	1,587,472	2,817,269
2011	4,345,720	3,537,799	5,153,642	2,947,843	2,272,755	3,622,931	1,397,877	969,168	1,826,587
2013	4,644,870	3,461,837	5,827,904	3,145,687	2,061,827	4,229,548	1,499,183	1,039,005	1,959,362
2015	3,827,374	3,062,422	4,592,327	2,329,736	1,771,897	2,887,574	1,497,638	1,039,739	1,955,537

*:Within the range of statistical errors: The lower limit of confidence interval is <0.

Table 66 Changes in the Past-Year Prevalence of Experience of Ever Having Try to Tempt Illegal Drugs (1995–2015) No data for 2013

	Organic solvents	Cannabis	Methamphetamine	Heroin	Cocaine	MDMA	NPSs	Any drug
1995	0.16%	0.25%	0.07%	0.00%	0.05%	-	-	0.43%
1997	0.09%	0.26%	0.00%	0.13%	0.03%	-	-	0.42%
1999	0.04%	0.12%	0.10%	0.03%	0.03%	-	-	0.20%
2001	0.03%	0.30%	0.07%	0.03%	0.03%	-	-	0.30%
2003	0.04%	0.12%	0.07%	0.00%	0.00%	0.00%	-	0.23%
2005	0.06%	0.15%	0.00%	0.00%	0.00%	0.06%	-	0.20%
2007	0.07%	0.20%	0.18%	0.03%	0.07%	0.13%	-	0.47%
2009	0.00%	0.12%	0.03%	0.03%	0.00%	0.03%	-	0.19%
2011	0.00%	0.10%	0.00%	0.00%	0.00%	0.00%	-	0.20%
2015	0.10%	0.03%	0.00%	0.00%	0.03%	0.00%	0.07%	0.20%

Table 67 Changes in the Lifetime Prevalence of Drug Use (1995–2015)

	Organic solvents	Cannabis	Methamphetamine	Cocaine	Heroin	MDMA	NPSs	Any drug
1995	1.7%	0.5%	0.3%	*	*	-	-	2.2%
1997	1.9%	0.6%	0.3%	*	*	-	-	2.5%
1999	1.7%	1.0%	0.4%	0.2%	*	-	-	2.6%
2001	2.0%	1.1%	0.3%	0.1%	*	-	-	2.7%
2003	1.5%	0.5%	0.4%	0.1%	*	*	-	2.0%
2005	1.3%	1.2%	0.3%	*	*	*	-	2.2%
2007	2.0%	0.8%	0.4%	*	*	0.2%	-	2.6%
2009	1.9%	1.4%	0.3%	*	*	0.2%	-	2.9%
2011	1.6%	1.2%	0.4%	*	*	0.1%	-	2.7%
2013	1.9%	1.1%	0.5%	*	*	0.3%	0.4%	2.5%
2015	1.5%	1.0%	0.5%	0.1%	*	0.1%	0.3%	2.4%

*:Within the range of statistical errors




Fig.33 Estimated Lifetime Prevalence of Drug use (1995-2015)

Table 68 Estimated Number of Individuals with Lifetime Experience of Drug Use (Lower Limit–Upper Limit)

	Overall			Men			Women		
	Number of individuals with lifetime experience	Lower limit	Upper limit	Number of individuals with lifetime experience	Lower limit	Upper limit	Number of individuals with lifetime experience	Lower limit	Upper limit
Organic solvents									
2003	1,764,691	1,260,296	2,269,087	1,206,730	799,180	1,614,281	557,960	279,227	836,694
2005	1,560,170	1,047,149	2,073,191	896,139	514,780	1,277,498	664,031	306,047	1,022,015
2007	2,444,351	1,822,901	3,065,802	1,770,256	1,243,471	2,297,040	674,095	323,374	1,024,817
2009	1,798,329	1,299,177	2,297,482	1,412,115	983,657	1,840,572	386,214	146,849	625,580
2011	1,477,421	1,022,845	1,931,998	1,104,593	677,149	1,532,036	372,828	197,859	547,798
2013	1,825,432	1,279,188	2,371,675	1,217,329	799,429	1,635,229	608,103	283,883	932,322
2015	1,381,847	936,570	1,827,123	967,540	591,199	1,343,881	414,307	190,067	638,546
Cannabis									
2003	550,303	271,190	829,416	382,189	142,014	622,363	168,114	6,863	329,366
2005	1,416,593	892,019	1,941,167	972,618	523,460	1,421,775	443,975	140,755	747,195
2007	1,014,207	590,083	1,438,330	789,408	411,682	1,167,135	224,798	41,207	408,390
2009	1,363,965	909,827	1,818,102	1,070,441	705,209	1,435,672	293,524	92,566	494,482
2011	1,138,402	691,848	1,584,956	758,359	379,513	1,137,204	380,043	145,730	614,356
2013	1,073,212	667,074	1,479,350	787,970	442,245	1,133,695	285,242	69,470	501,014
2015	945,024	586,147	1,303,901	736,455	445,759	1,027,152	208,569	36,546	380,592
Methamphetamine									
2003	498,948	233,751	764,145	337,899	110,421	565,378	161,049	4,956	31,714
2005	315,282	20,842	609,722	*	*	*	203,513	4,814	402,211
2007	527,409	206,178	848,640	341,883	79,828	603,939	*	*	*
2009	323,006	122,634	523,378	212,023	46,391	377,655	*	*	*
2011	381,272	145,917	616,627	211,714	17,687	405,741	169,558	34,937	304,178
2013	519,721	236,800	802,642	318,376	107,899	528,853	201,346	10,516	392,175
2015	501,556	235,566	767,545	438,853	195,452	682,255	*	*	*
Heroin									
2003	*	*	*	*	*	*	180,206	16,296	344,116
2005	*	*	*	*	*	*	#	#	#
2007	*	*	*	*	*	*	#	#	#
2009	#	#	#	#	#	#	#	#	#
2011	#	#	#	#	#	#	#	#	#
2013	*	*	*	*	*	*	*	*	*
2015	*	*	*	*	*	*	#	#	#
Cocaine									
2003	*	*	*	*	*	*	#	#	#
2005	*	*	*	*	*	*	#	#	#
2007	*	*	*	*	*	*	*	*	*
2009	215,032	13,751	416,312	*	*	*	*	*	*
2011	*	*	*	*	*	*	#	#	#
2013	*	*	*	*	*	*	*	*	*
2015	118,177	11,248	225,106	118,177	11,248	225,106	#	#	#
MDMA									
2003	*	*	*	#	#	#	*	*	*
2005	*	*	*	*	*	*	*	*	*
2007	232,984	24,111	441,857	*	*	*	*	*	*
2009	207,868	35,795	379,942	*	*	*	138,278	1,844	274,711
2011	140,042	18,831	261,252	*	*	*	*	*	*
2013	260,762	45,744	475,780	160,167	5,822	314,511	*	*	*
2015	117,550	17,683	217,417	88,694	6,551	170,838	*	*	*
NPSs									
2013	399,773	168,771	630,774	299,080	91,609	506,551	*	*	*
2015	309,735	109,761	509,709	216,976	52,866	381,087	*	*	*
Any drug									
2003	2,373,965	1,769,084	2,978,845	1,552,576	1,081,467	2,023,685	821,389	462,480	1,180,298
2005	2,663,656	1,929,692	3,397,619	1,600,222	1,036,384	2,164,059	1,063,434	603,972	1,522,896
2007	3,086,607	2,400,434	3,772,780	2,114,588	1,544,277	2,684,899	972,019	571,793	1,372,245
2009	2,768,501	2,127,456	3,409,546	2,081,449	1,573,077	2,589,522	687,052	358,204	1,015,899
2011	2,510,211	1,896,082	3,124,340	1,830,861	1,280,232	2,381,489	679,350	398,721	959,980
2013	2,489,112	1,830,464	3,147,760	1,699,196	1,186,374	2,212,018	789,916	440,585	1,139,246
2015	2,225,266	1,652,598	2,797,934	1,636,768	1,164,391	2,109,145	588,498	313,346	863,649

*:Within the range of statistical errors: The lower limit of confidence interval is <0.

#:No respondent: No estimates could be calculated due to the absence of respondents.

Table 69 Changes in the Past-Year Prevalence of Drug Use (1995–2015)

	Organic solvents	Cannabis	Methamphetamine	Heroin	Cocaine	MDMA	NPSs	Any drug
1995	0.08%	0.07%	0.06%	0.00%	0.06%	-	-	0.16%
1997	0.02%	0.10%	0.06%	0.02%	0.02%	-	-	0.14%
1999	0.04%	0.04%	0.07%	0.03%	0.03%	-	-	0.13%
2001	0.00%	0.11%	0.00%	0.00%	0.03%	-	-	0.16%
2003	0.07%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.07%
2005	0.00%	0.04%	0.00%	0.00%	0.00%	0.00%	-	0.04%
2007	0.00%	0.04%	0.00%	0.00%	0.00%	0.00%	-	0.04%
2009	0.00%	0.03%	0.00%	0.00%	0.00%	0.00%	-	0.03%
2011	0.00%	0.10%	0.00%	0.00%	0.00%	0.00%	-	0.10%
2013	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.10%	0.10%
2015	0.07%	0.07%	0.00%	0.00%	0.00%	0.00%	0.00%	0.13%

Table E Number and Age (mean, SD) of Individuals with Lifetime Experience of Drug Use

drugs	2015			2013		
	number	age(mean)	SD	number	age(mean)	SD
Organic solvents	49	47.9	10.5	54	43.8	9.4
Cannabis	35	41.3	9.8	30	40.7	9.5
Methamphetamine	16	44.1	8.9	14	40.1	9.0
MDMA	6	40.0	9.4	6	40.5	8.1
Cocaine	5	45.4	6.7	2	36.5	
Heroin	3	45.7	4.9	2	43.0	
NPSs	11	40.8	10.4	12	33.8	8.1
Any drug	78	45.5	11.1	72	42.5	9.8

